CONTENTS

CROI FOUNDATION .......................................................... 2
IAS—USA ....................................................................... 2
CROI 2015 PROGRAM COMMITTEE ...................................... 3
Scientific Program Committee ........................................... 3
Community Liaison Subcommittee .................................... 4
EXTERNAL REVIEWERS ...................................................... 5
COMMERCIAL SUPPORT ................................................ 6
CONTINUING MEDICAL EDUCATION ................................. 7
  Accreditation Statement .................................................. 7
  Objectives ....................................................................... 7
  Statement of Need .......................................................... 7
  CME Credit Information ................................................... 7
  Claiming CME Credits or a Certificate of Participation ......... 7
  Faculty Financial Disclosure .......................................... 7
  Drug and Product Disclaimer .......................................... 7
GENERAL INFORMATION .................................................. 8
  Overview ....................................................................... 8
  Americans with Disabilities Act ........................................ 8
  Ebola Precautions ......................................................... 8
  Welcome Reception ....................................................... 8
  Meals ........................................................................... 8
  Overflow Accommodations for Session Rooms ................. 9
  USB Flash Drive .......................................................... 9
  Website ....................................................................... 9
  Webcasts and Podcasts ................................................... 9
  Mobile App .................................................................. 9
  Wi-Fi Access at the Conference ...................................... 9
  Badges ....................................................................... 9
  Child Care ................................................................... 9
  Conference Etiquette .................................................... 9
CONFERENCE SERVICES .................................................. 10
HOTEL INFORMATION .................................................... 11
ORAL SESSIONS ................................................................ 13
POSTER SESSIONS, BY CATEGORY .................................... 41
POSTER LISTINGS, BY CATEGORY ...................................... 44
CONFERENCE SCHEDULE OVERVIEW ............................. 126
CONVENTION CENTER FLOOR PLANS ......................... 127
CROI FOUNDATION

The CROI Foundation operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

Roles and Responsibilities of the CROI Foundation Board of Directors

- Works closely with the CROI Scientific Program Committee (CROI PC) and the CROI Secretariat to accomplish the mission of CROI
- Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs
- Ensures that the CROI PC is responsible for the scientific program content of CROI
- Enters into and oversees the partner agreement with the CROI Secretariat
- Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed to be taken by the CROI PC or the CROI Secretariat that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification
- Oversees the long-term financial and administrative integrity of CROI

Composition of the CROI Foundation Board of Directors

The Board of Directors comprises current and previous CROI Chairs and Vice Chairs and selected members of the CROI PC.

CROI Foundation Board Members

Constance A. Benson, MD, President
University of California San Diego
San Diego, CA, US

John M. Coffin, PhD, Secretary-Treasurer
Tufts University
Boston, MA, US

Elaine J. Abrams, MD
International Center for AIDS Care and Treatment Programs
Columbia University
New York, NY, US

Susan P. Buchbinder, MD
San Francisco Department of Public Health
University of California San Francisco
San Francisco, CA, US

Judith S. Currier, MD, MsC
University of California Los Angeles
Los Angeles, CA, US

Kevin M. De Cock, MD
Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD
Columbia University Medical Center/New York—Presbyterian Hospital
New York, NY, US

John W. Mellors, MD
University of Pittsburgh
Pittsburgh, PA, US

Julie M. Overbaugh, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA, US

Robert T. Schooley, MD
University of California San Diego
San Diego, CA, US

Mario Stevenson, PhD
University of Miami
Miami, FL, US

IAS–USA

The International Antiviral Society–USA is a 501(c)(3) not-for-profit professional education organization. The IAS–USA serves as the Conference Secretariat for CROI.

The mission of the IAS–USA is to improve the treatment, care, and quality of life for people with HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

Executive Director: Donna M. Jacobsen
Address: 425 California Street, Suite 1450
San Francisco, CA 94104-2120
Phone: 415-544-9400
Website: www.iasusa.org
CROI 2015 PROGRAM COMMITTEE

The Scientific Program Committee (PC) is a team of experts in their given field who volunteer to organize the scientific program for CROI. Members are selected based on their area of scientific expertise and their commitment to the mission of the conference. Initial terms are 3 years; subsequent terms are based on previous participation and interest level. Members are nominated by the PC and approved by the CROI Foundation Board of Directors. The “goodwill ambassadors” of CROI, PC members are also responsible for identifying topics and speakers that will ensure innovative programming; strategic planning; abstract review and program development; and organizing, conducting, and convening workshops, symposia, and special sessions.

**Scientific Program Committee**

**Scott M. Hammer, MD**  
CROI 2015 Chair  
Columbia University Medical Center/New York–Presbyterian Hospital  
New York, NY, US

**Julie M. Overbaugh, PhD**  
CROI 2015 Vice Chair  
Fred Hutchinson Cancer Research Center  
Seattle, WA, US

**Susan P. Buchbinder, MD**  
CROI 2015 Vice Chair  
San Francisco Department of Public Health  
University of California San Francisco  
San Francisco, CA, US

**Elaine J. Abrams, MD**  
ICAP at Columbia University  
New York, NY, US

**Galit Alter, PhD**  
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University  
Boston, MA, US

**Constance A. Benson, MD**  
University of California San Diego  
San Diego, CA, US

**Bruce J. Brew, MD, MBBS**  
St. Vincent's Hospital  
Sydney, Australia

**Ellen G. Chadwick, MD**  
Northwestern University  
Ann and Robert J. Lurie Children's Hospital of Chicago  
Chicago, IL, US

**Richard E. Chaisson, MD**  
The Johns Hopkins University  
Baltimore, MD, US

**John M. Coffin, PhD**  
Tufts University  
Boston, MA, US

**Judith S. Currier, MD, MSc**  
University of California Los Angeles  
Los Angeles, CA, US

**Kevin M. De Cock, MD**  
Centers for Disease Control and Prevention  
Nairobi, Kenya

**Wafaa M. El-Sadr, MD, MPH**  
ICAP at Columbia University  
New York, NY, US

**Courtney V. Fletcher, PharmD**  
University of Nebraska Medical Center College of Pharmacy  
Omaha, NE, US

**Dana H. Gabuzda, MD**  
Dana-Farber Cancer Institute and Harvard University  
Boston, MA, US

**Sharon L. Hillier, PhD**  
Magee-Womens Hospital of UPMC  
University of Pittsburgh  
Pittsburgh, PA, US

**James A. Hoxie, MD**  
University of Pennsylvania  
Philadelphia, PA, US

**Peter W. Hunt, MD**  
University of California San Francisco  
San Francisco, CA, US

**Harold W. Jaffe, MD**  
Centers for Disease Control and Prevention  
Atlanta, GA, US

**Ilesh V. Jani, MD, PhD**  
Instituto Nacional de Saúde  
Maputo, Mozambique

**Frank Kirchhoff, PhD**  
Institute of Molecular Virology  
Ulm, Germany

**Dennis L. Kolson, MD, PhD**  
University of Pennsylvania  
Philadelphia, PA, US

**Richard A. Koup, MD**  
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health  
Bethesda, MD, US

**Hermione Lyall, MD**  
Imperial College Healthcare National Health Service Trust  
London, England
Community Liaison Subcommittee

The Community Liaison Subcommittee is a group of community educators and advocates that provides feedback to the PC about the content and structure of the scientific program in general and specifically related to scientific topics of interest to the HIV/AIDS-affected community.

Heidi M. Nass, JD
AIDS Treatment Activists Coalition
Madison, WI, US

Jeff Taylor
AIDS Treatment Activists Coalition
Palm Springs, CA, US

Robert T. Schooley, MD
University of California San Diego
La Jolla, CA, US

Guido Silvestri, MD
Emory University and Yerkes National Primate Research Center
Atlanta, GA, US

Papa Salif Sow, MD, MSc
Bill and Melinda Gates Foundation
Seattle, WA, US
University of Dakar
Dakar, Senegal

Mario Stevenson, PhD
University of Miami
Miami, FL, US

Amalio Telenti, MD, PhD
The J. Craig Venter Institute
La Jolla, CA, US

David L. Thomas, MD
The Johns Hopkins University
Baltimore, MD, US

Alexandra Trkola, PhD
University of Zurich
Zurich, Switzerland

Morenike Ukpong, FWACS, MBA, BChD
Obafemi Awolowo University
Ife-Ife, Nigeria

Steven F. Wakefield
HIV Vaccine Trials Network
Fred Hutchinson Cancer Research Center
Seattle, WA, US
EXTERNAL REVIEWERS

We gratefully acknowledge the contributions of the following, who served as volunteer external reviewers of abstracts for CROI 2015.

Edward P. Acosta, PharmD
University of Alabama at Birmingham
Birmingham, AL, US

Peter L. Anderson, PharmD
University of Colorado
Aurora, CO, US

Till Bärnighausen, MD, PhD, ScD, MSc
Harvard University
Boston, MA, US

John M. Blandford, PhD
Centers for Disease Control and Prevention
Atlanta, GA, US

Marta Boffito, MD, PhD
Chelsea and Westminster Hospital and National Health Service Foundation Trust
London, United Kingdom

William Borkowsky, MD
New York University School of Medicine
New York, NY, US

Corey Casper, MD
Fred Hutchinson Cancer Research Center
Seattle, WA, US

Nicolas Chomont, PhD
Vaccine and Gene Therapy Institute of Florida
Port St Lucie, FL, US

David B. Clifford, MD
Washington University School of Medicine
Saint Louis, MO, US

Susan E. Cohn, MD
Northwestern University
Chicago, IL, US

Eric S. Daar, MD
Harbor–University of California Los Angeles Medical Center
Torrance, CA, US

Charles W. Flexner, MD
The Johns Hopkins University
Baltimore, MD, US

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, US

Monica Gandhi, MD, MPH
University of California San Francisco
San Francisco, CA, US

J. Gerardo García-Lerma, PhD
Centers for Disease Control and Prevention
Atlanta, GA, US

Carlo Giaquinto, MD
University of Padova
Padova, Italy

Francisco Gonzalez-Scarano, MD
University of Texas
San Antonio, TX, US

Steven K. Grinspoon, MD
Massachusetts General Hospital and Harvard University
Boston, MA, US

Huldrych F. Gunthard, MD
University Hospital Zurich
Zurich, Switzerland

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, US

James G. Hakim, MD
University of Zimbabwe
Harare, Zimbabwe

Timothy B. Hallett, PhD
Imperial College London
London, United Kingdom

P. Richard Harrigan, MD
British Columbia Centre for Excellence in HIV/AIDS
Vancouver, BC, Canada

Diane V. Havlir, MD
University of California San Francisco
San Francisco, CA, US

Priscilla Y. Hsue, MD
University of California San Francisco
San Francisco, CA, US

Susan E. Krown, MD
AIDS Malignancy Consortium
New York, NY, US

Scott L. Letendre, MD
University of California San Diego
San Diego, CA, US

Sharon R. Lewin, MD
The Doherty Institute for Infection and Immunity
Melbourne, Australia

Susanna Naggie, MD, MHS
Duke Clinical Research Institute
Durham, NC, US

Jean-Michel Pawlotsky, MD, PhD
Henri Mondor University Hospital
Creteil, France

Sharon A. Riddler, MD
University of Pittsburgh
Pittsburgh, PA, US

Kenneth E. Sherman, MD
University of Cincinnati
Cincinnati, OH, US

Serena S. Spudich, MD, MA
Yale University
Guilford, CT, US

David L. Wyles, MD
University of California San Diego
San Diego, CA, US

Robert Yarchoan, MD
National Cancer Institute
Bethesda, MD, US
COMMERCIAL SUPPORT

The Conference on Retroviruses and Opportunistic Infections (CROI) is largely supported by the registration fees of participants. In addition, the organizers seek grants from commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations.

CROI 2015 has, to date, received grant support commitments from the following commercial companies:

**Platinum**

- Gilead Sciences, Inc
- Merck & Co, Inc
- ViiV Healthcare

**Gold**

- Bristol-Myers Squibb
- Janssen Therapeutics, Division of Janssen Products, LP

**Silver**

- AbbVie

Additional support has been provided by Mylan, Inc
CONTINUING MEDICAL EDUCATION

Accreditation Statement
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 28 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Since 2006, the IAS–USA has held Accreditation with Commendation. In so doing, the IAS–USA belongs to an elite group of organizations in the United States that have been awarded this prestigious status, which, in the words of the ACCME, is “reserved for programs that are truly exceptional.”

Objectives
After participating in CROI 2015, learners will be able to:

• Describe current basic science research on the pathogenesis of HIV and on advances toward a cure
• Discuss the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies
• Review current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide, and discuss the implications of these data for public-health program planning

Statement of Need
Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications.

CME Credit Information
Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI 2015. Other practitioners and clinicians can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA).

Claiming CME Credits or a Certificate of Participation
During the conference, daily evaluations will be e-mailed to all CROI participants to the e-mail account they used to register for the conference. On Thursday, February 26, 2015, all CROI participants will receive a final e-mail that will contain their registration confirmation number and a link to the overall CROI evaluation. To obtain CME credits or a Certificate of Participation for CROI, this final evaluation must be completed by Tuesday, March 31, 2015. Once the evaluation is submitted, participants will receive the link to claim and print their certificate.

To determine the number of CME credits or hours that you can claim, calculate your time spent attending the conference, including plenary sessions, symposia, themed discussions, etc. For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), a themed discussion (1:30 PM to 2:30 PM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 4 hours to apply toward CME credits for that day.

At the end of CROI, please add the total hours you attended for your certificate. You may claim a maximum of 28 AMA PRA Category 1 Credits™ for this activity.


Faculty Financial Disclosure
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make the IAS–USA audience aware of author and contributor interests and commitments with commercial companies or other entities, enabling the audience members to form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be included with the Program and Abstracts eBook on the web.

Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
Overview
The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) will take place at the Washington State Convention Center in Seattle, WA, from February 23 to February 26, 2015. CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and attracts more than 4000 HIV and AIDS research leaders internationally. The goal of the conference is to help researchers translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.

Americans with Disabilities Act
CROI 2015 endeavors to comply fully with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance on-site, please visit the Seattle Visitor Center and Concierge Services in the Upper Pike Street Lobby during the conference.

Ebola Precautions
Attendees who have recently returned from an Ebola-prevalent area are expected to follow the guidance of their institutions, local health departments, or the Centers for Disease Control and Prevention (CDC) as applicable with respect to monitoring and travel. CDC guidance can be found online: http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html.

Welcome Reception
All registered CROI attendees are invited to join us for a Welcome Reception immediately following the Opening Reception on February 23, 2015. This will be a private event hosted at Nordstrom's Flagship store in Downtown Seattle just a minutes walk from the Convention Center at Sixth and Pine Streets (enter using the Sixth Avenue entrance).

This unique Welcome Reception will offer attendees the opportunity to network with colleagues and experience a private shopping environment while enjoying passed hors d'oeuvres and beverages in a beautiful and unique setting.

Please join us for this exclusive event!

Meals
Morning coffee and light continental breakfast will be available to conference registrants from 9:30 AM to 10:00 AM, Tuesday, Wednesday, and Thursday, on the 6th floor. An afternoon snack break will be available at 2:30 PM in the Poster Hall and before the special session on Tuesday evening. Attendees are on their own for lunch each day. Below is a list of food service options located in the Convention Center or within a short walking distance.

At the Convention Center
820 Pike Street — Pan Asian Cuisine
Crêpes Voilá
Cyber Dogs — Internet Café
Espresso Caffé Dior
Goldberg's Deli
Subway Sandwiches
Taco Del Mar
The Juicy Café
Tully's Coffee
Wild Rye Café Bakery

Within 4 Blocks of the Convention Center
Benihana
Blueacre Seafood
Blue C Sushi
Daily Grill
Dragonfish Asian Cafe
FareStart
FOX Sports Grill
Gameworks
Gordon Biersch Brewery Restaurant
Il Fornaio
MOD Superfast Pizza
Morton's The Steakhouse
Ebar (Nordstrom Downtown Seattle)
Marketplace Café (Nordstrom Downtown Seattle)
The Grill (Nordstrom Downtown Seattle)
NYC Hyatt Deli Market
P.F. Chang's China Bistro — Seattle
Palomino
Pike Place Chowder — Pacific Place
Potbelly Sandwich Shop
RN74
Rock Bottom Restaurant & Brewery
Ruth’s Chris Steak House
Soup’s On!
Starbucks Coffee Company
Sullivan’s Steakhouse
Tango Restaurant & Lounge
Tap House Grill
Thai Ginger
The Capital Grille
The Cheesecake Factory
The Elephant and Castle Pub & Restaurant
Toss’d Custom Salads
Urbane Northwest (Hyatt at Olive 8)

Overflow Accommodations for Session Rooms
The 4AB Auditorium is the designated overflow area. Headsets and up to 4 screens will provide live audio and video feed throughout the conference.

USB Flash Drive
Each participant is supplied a USB flash drive at badge pickup with a copy of the eAbstract book. The Program at a Glance and Program and Abstracts eBook are also available online to be loaded onto the USB flash drive. Downloads can be completed at the Cyber Cafe or directly from the conference website.

Website
For additional information about the conference please visit the website at www.CROIconference.org.

Mobile App
CROI 2015 has a mobile App to enhance your conference experience. The App enables you to schedule sessions, view abstracts, e-mail session notes, receive announcements, and more. Search “CROI 2015” in your mobile device App store, and download the conference App. The mobile App supports iOS and Android devices. Access is restricted to registered attendees only. Your log-in information and password will be provided to you on site with your registration materials.

Wi-Fi Access at the Conference
Complimentary Wi-Fi access is provided at the Washington State Convention Center. Network information is as follows:
Network name: CROI 2015
Password: iasusa2015

Badges
Badge pickup will be available at the registration lobby; please bring government-issued photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. DO NOT LOSE YOUR BADGE. Unfortunately, payment of an additional registration fee ($730) will be required to replace a lost badge. Also, if you notice that your affiliation or the affiliations of other attendees are incorrect, please inform conference staff in the office of the Conference Secretariat.

Child Care
Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel or the Visitor Information Center on Level One at the Washington State Convention Center.

Conference Etiquette
Please ensure all cell phones and pagers are off or are placed in SILENT mode. No flash photography is permitted in session rooms.

Webcasts and Podcasts
Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions will be webcast and podcast. Webcasts are also available as streaming video for the Apple iPad and iPhone. Visit www.CROIconference.org or www.CROIwebcasts.org to access the CROI 2015 webcasts and podcasts. Webcasts will be available within 24 hours of the end of the relevant session.
# CONFERENCE SERVICES
## AT THE WASHINGTON STATE CONVENTION CENTER

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seattle Visitor Center and Concierge Services</td>
<td>Upper Pike Street Lobby Level 1</td>
<td>Monday to Friday 9:00 AM–5:00 PM</td>
<td>Full-service concierge assistance, including maps, guides, tickets, restaurant reservations, tours, ground transportation, and personal services</td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Monday 7:00 AM–7:30 PM, Tuesday 7:00 AM–8:00 PM, Wednesday to Thursday 7:30 AM–6:30 PM</td>
<td>Bag and coat check are free of charge.</td>
</tr>
<tr>
<td>Cyber Cafe</td>
<td>4D Skybridge Level 4</td>
<td>Sunday 3:00 PM–5:00 PM, Monday to Wednesday 7:00 AM–7:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>Computers with Internet access available for webcasts, abstract searches, and messages</td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 400 Level 4</td>
<td>Monday 9:00 AM–7:00 PM, Tuesday to Thursday 8:00 AM–6:00 PM</td>
<td>There is no on-site press registration. Registered press can pick up press kits and obtain location for press conferences.</td>
</tr>
<tr>
<td>Badge Pickup Attendee Services Housing Information Scholarship Badge Pickup Media Badge Pickup</td>
<td>Hall 4C-3, 4 Level 4</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 8:00 AM–12:00 PM</td>
<td>Location to pick up badges and conference materials</td>
</tr>
<tr>
<td>Speaker Ready Room and Electronic Poster Drop-off</td>
<td>Room 620 Level 6</td>
<td>Sunday 3:00 PM–6:00 PM, Monday to Thursday 7:30 AM–6:00 PM</td>
<td>Oral abstract, invited, and themed discussion session speakers must drop off presentations at least 24 hours before their presentation. Poster presenters must submit an electronic version of their poster for placement on the CROI website before their assigned session.</td>
</tr>
<tr>
<td>Personal Considerations Room</td>
<td>Room 507 Level 5</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>The Personal Considerations Room is a room set aside for those who require a short-term private space for personal health needs. Use of this room is on a first-come, first-served basis.</td>
</tr>
<tr>
<td>New Mother's Room</td>
<td>Room 416 Level 4</td>
<td>Sunday 3:00 PM–6:00 PM, Monday 7:00 AM–7:00 PM, Tuesday 7:00 AM–6:00 PM, Wednesday 8:00 AM–6:00 PM, Thursday 7:00 AM–6:00 PM</td>
<td>The New Mother's Room is a room set aside for nursing mothers who require a short-term private room. Use of this room is on a first-come, first-served basis.</td>
</tr>
</tbody>
</table>
HOTEL INFORMATION

CROI 2015 hotels are listed below. For more detailed housing information, please visit the CROI 2015 conference website: www.CROI2015.org/housing. Conference attendees are required to stay in one of the official conference hotels. The few exceptions to this include registrants who live in the Seattle area (ie, within a 50-mile radius of the Washington State Convention Center) and registrants who are sharing a room with an approved CROI attendee with accommodations booked via the CROI housing system.

Sheraton Seattle Hotel
1400 Sixth Avenue
Seattle, WA 98101
PH: +1 206 621 9000

Crowne Plaza Seattle Downtown
1113 6th Avenue
Seattle, WA 98101
PH: +1 206 464 1980

The Fairmont Olympic Hotel
411 University Street
Seattle, WA 98101
PH: +1 206 621 1700

Hilton Seattle
1301 6th Avenue S
Seattle, WA 98101
PH: +1 206 460 7456

Grand Hyatt Seattle
721 Pine Street
Seattle, WA 98101
PH: +1 206 774 1234

Hyatt at Olive 8
1635 8th Avenue
Seattle, WA 98101
PH: +1 206 695 1234

Mayflower Park Hotel
405 Olive Way
Seattle, WA 98101
PH: +1 206 623 8700

Motif Seattle
1415 Fifth Avenue
Seattle, WA 98101
PH: +1 206 971 8000

Renaissance Seattle Hotel
515 Madison Street
Seattle, WA 98104
PH: +1 206 583 0300

W Seattle
1112 4th Avenue
Seattle, WA 98101
PH: +1 206 264 6000

The Westin Seattle
1900 5th Avenue
Seattle, WA 98101
PH: +1 206 728 1000
ORAL SESSIONS

MONDAY, FEBRUARY 23, 2015

Session W1 Workshop
9:00 am – 12:30 pm
Room 6E

Program Committee Workshop for New Investigators and Trainees

Target audience: This workshop is directed toward new trainees (e.g., undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic).

Level of knowledge: It is assumed that participants have been conducting active research in the field for less than 3 years.

Objectives: At the completion of the session, participants will be able to:

• Describe the major areas of HIV investigation being presented at the conference.
• Identify the top 3 to 5 research questions in the field of retroviruses and opportunistic infections today.
• Describe some of the proposed solutions for addressing the challenges presented globally by a variety of retroviruses and opportunistic infections.

Workshop Conveners
Scott M. Hammer, Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY, US
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, US

1 A Path to an HIV Vaccine
Galit Alter
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

2 Animal Models of HIV Prevention and Cure
Guido Silvestri
Emory University, Decatur, GA, US

3 HIV Prevention 2.0: What’s Next?
Susan P. Buchbinder
San Francisco Department of Public Health, San Francisco, CA, US

4 Pathogenesis of HIV Complications
Peter W. Hunt
University of California San Francisco, San Francisco, CA, US

5 HIV Cure Research
John M. Coffin
Tufts University, Boston, MA, US

Session MD Presentation
1:00 pm – 2:00 pm
Room 6E

Martin Delaney Presentation: How to End the HIV Epidemic: Community Perspectives

6 Martin Delaney Presentation: How to End the HIV Epidemic: Community Perspectives

Moderator
Steven F. Wakefield, HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, US

Panelists
Connie Celum, University of Washington, Seattle, WA, US
Damon L. Jacobs, Private Practice Psychologist, Brooklyn, NY, US
Matthew V. Sharp, Shanti Project, Berkeley, CA, US

Session W2 Workshop
Room 6E
2:30 pm – 4:30 pm

Clinical Trial Design and Analysis

Target audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical trial results.

Level of knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical studies.

Objectives: At the completion of the session, participants will be able to:

• Describe strategies for evaluating the effectiveness of interventions.
• Interpret adherence measures.
• Evaluate study design with infrequent endpoints.

Workshop Conveners
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, US
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, US

7 Getting SMART About Innovative Designs for Studying Effectiveness: The Case of Adaptive Implementation Interventions
Daniel Almirall
University of Michigan, Ann Arbor, MI, US

8 The Clinical Pharmacology of Medication Adherence
Terrence Blaschke
Stanford University, Stanford, CA, US

9 Epidemiological and Biostatistical Issues in Studying Rare Events in HIV
Stephen J. Gange
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US
Session W3 Workshop  
**Room 6D**  
2:30 pm – 4:30 pm  
Frontiers in Laboratory Science  

**Target audience:** This session is directed to investigators and clinicians interested in learning about the main technological and conceptual developments in life sciences that are influencing HIV research or hold a significant potential for research.

**Level of knowledge:** It is assumed that participants are familiar with the main technological and data analysis approaches used in HIV research.

**Objectives:** At the completion of the session, participants will be able to:
- Recognize the potential of and directions in the field of big data analysis.
- Describe developments in immunophenotyping and in single-cell analyses.
- Use the basic concepts of integration site analysis to understand current directions in HIV latency research.

**Workshop Conveners**
- **Galit Alter**, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, US
- **Amalio Telenti**, The J. Craig Venter Institute, La Jolla, CA, US

1. **Measuring Immunity 1 Cell at a Time**  
   **Mario Roederer**  
   Vaccine Research Center, NIAID, NIH, Bethesda, MD, US

11. **Studying Heterogeneity With Single Cell RNA-Sequencing**  
    **Simon Quenneville**  
    Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

12. **Integration-Site Analysis**  
    **Frederic D. Bushman**  
    University of Pennsylvania School of Medicine, Philadelphia, PA, US

13. **Discovery and Modeling of Genomic Regulatory Networks With Big Data**  
    **Hamid Bolouri**  
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

Opening Session  
**4AB Auditorium**  
5:00 pm – 7:00 pm  
Welcome: Opening Session

**Opening Session Hosts**
- **Scott M. Hammer**, Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY, US
- **Julie M. Overbaugh**, Fred Hutchinson Cancer Research Center, Seattle, WA, US
- **Susan P. Buchbinder**, San Francisco Department of Public Health, San Francisco, CA, US

Session NL1 Lecture  
**4AB Auditorium**  
Bernard Fields Lecture

18. **Hepatitis C: Light at the End of the Tunnel**  
    **Charles M. Rice**  
    The Rockefeller University, New York, NY, US

Session NL2 Lecture  
**4AB Auditorium**  
N’Galy-Mann Lecture

19. **Antiretroviral Therapy: Past, Present, and Future**  
    **David A. Cooper**  
    Kirby Institute, University of New South Wales, Sydney, Australia
TUESDAY, FEBRUARY 24, 2015

Session PL-1 Plenary  4AB Auditorium  8:30 am – 9:00 am
PrEP for HIV Prevention: What We Know and What We Still Need to Know for Implementation

Raphael J. Landovitz
University of California Los Angeles, Los Angeles, CA, US

Session PL-2 Plenary  4AB Auditorium  9:00 am – 9:30 am
Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells

Stephen H. Hughes
National Cancer Institute, Frederick, MD, US

Session O-1 Oral Abstracts  Room 6AB  10:00 am – 12:15 pm
Preventing HIV and HSV-2: What Will It Take?

Moderators
Sharon L. Hillier, Magee-Womens Hospital of UPMC, University of Pittsburgh, Pittsburgh, PA, US
Jorge Sanchez, Impacta Peru CTU, Barranco, Peru

10:00  22LB Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study
Sheena McCormack; David Dunn
On behalf of the PROUD Study Group
MRC Clinical Trials Unit at University College London, London, United Kingdom

10:15  23LB On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial
Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Christian Chilila; Isabelle Charreau; Cecile Tremblay; Laurence Meyer; Jean-Francois Delfraissy
On behalf of the ANRS Ipergay Study Group
1University of Paris Diderot, Paris, France; 2Kenya Medical Research Institute, Nairobi, Kenya; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Kabwohe Clinical Research Centre, Kabwohe, Uganda; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 6Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

10:30  24 Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
Jared Baeten; Renee Heffron; Lara Kidgoguchi; Nelly Mugo; Elly Katafiri; Elizabeth Bukusi; Stephen Asimwe; Jessica Haberer; Deborah Donnell; Connie Celum
1University of Washington, Seattle, WA, US; 2Kenya Medical Research Institute, Nairobi, Kenya; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Kabwohe Clinical Research Centre, Kabwohe, Uganda; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 6Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

10:45  25 Scale-Up of Preexposure Prophylaxis in San Francisco to Impact HIV Incidence
Robert M. Grant; Albert Liu; Jen Hecht; Susan P. Buchbinder; Shannon Weber; Pierre-Cedric Crouch; Steven Gibson; Stephanie Cohen; David Glidden

11:00  26LB FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
Helen Rees; Sineda A. Delany-Morettwe; Carl Lombard; Deborah Baron; Ravindra Panchia; Landon Myer; Jill L. Schwartz; Gustavo F. Doncel; Glenda Gray
On behalf of the FACTS 001 Study Team
1Wits Reproductive Health and HIV Institute, Johannesburg, South Africa; 2South African Medical Research Council, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa; 4Perinatal HIV Research Unit, Soweto, South Africa; 5CONRAD, Arlington, VA, US

11:15  27 Effect of Oral and Gel Tenofovir on Genital HSV Shedding in Immunocompetent Women
Rachel A. Bender Ignacio; Tara Pertl; Amalia S. Magaret; Sharanya Rajagopal; Mee-Lee W. Huang; Christine M. Johnston; Stacy Selke; Jeanne M. Marrazza; Anna Wald
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kalisizo, Uganda; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5Johns Hopkins University, Baltimore, MD, US

11:30  28 Injectable Hormonal Contraception Use and Women’s Risk for HSV-2 Acquisition
Mary K. Grabowski; Ronald H. Gray; Fred Makumbi; Joseph Kagaayi; Andrew D. Redd; Fred Nalugoda; Maria J. Wawer; David Serwadda; Thomas C. Quinn; Aaron A. Tobian
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kalisizo, Uganda; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5Johns Hopkins University, Baltimore, MD, US
11:45 29  Effect of Financial Incentives on Linkage to Care and Viral Suppression: HPTN 065  
Wafaa M. El-Sadr1; Bernard M. Branson2; Gheettha Beauchamp1; H. Irene Hall1; Lucia V. Torian3; Barry S. Zingman1; Garrett Lum4; Rick Elion5; Theresa Gamble6; Deborah Donnell1; Julie A. Nelson1; Carrie Ziemniak3; Michael Max Kroon2; Lorna Dunning2; Landon Myer2; Helena Huerga1; Irene Mukui4; Benson Ronald H. Gray2; Maria J. Wawer2; Fred Elisabeth Szmulimil3; Thomas Ermann4; Jean-François Eard1; 1ICAP at Columbia University, New York, NY, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 3SCHARP, Fred Hutchinson Cancer Research Center, Seattle, WA, US; 4New York City Department of Health and Mental Hygiene, New York, NY, US; 5Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, New York, NY, US; 6District of Columbia Department of Health, Washington, DC, US; 7Whitman-Walker Health, Washington, DC, US; 8FHI360, Durham, NC, US  

12:00 30  Medical Male Circumcision of HIV-Infected Men Reduces Long-Term Penile HIV Shedding  
Jordyn L. Manucci1; Godfrey Kigozi1; Mary K. Grabowski1; David Serwadda1; Ronald H. Gray2; Maria J. Wawer2; Fred Nalugoda3; Andrew D. Redd4; Thomas C. Quinn4; Aaron A. Tobian1; 1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Makerere University College of Health Sciences, Kampala, Uganda; 4National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US  

Session 0-2 Oral Abstracts  
Room 613  
10:00 am – 12:00 pm  
Prevention, Diagnosis, and Treatment of Pediatric HIV Infection  
Moderators  
Carey Farquhar, University of Washington, Seattle, WA, US  
Annette H. Sohn, TREAT Asia/amfAR – The Foundation for AIDS Research, Bangkok, Thailand  

10:00 31LB  PROMISE: Efficacy and Safety of 2 Strategies to Prevent Perinatal HIV Transmission  
Mary Glenn Fowler1; Min Qin2; Susan A. Fiscus2; Judith S. Currier2; Bonus Makanani3; Francis Martinson4; Tsungai Chipato5; Renee Browning5; David Shapiro5; Lynne Mofenson*; 1On behalf of the IMPAACT PROMISE Team; 2Johns Hopkins University School of Medicine/Makerere University, Baltimore, MD, US; 3Harvard School of Public Health, Boston, MA, US; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 5University of California Los Angeles, Los Angeles, CA, US; 6Univ of Malawi, Blantyre, Malawi; 7University of North Carolina Project—Malawi, Lilongwe, Malawi; 8Univ of Zimbabwe, Harare, Zimbabwe; 9NIAID/NIH, Bethesda, MD, US; 10National Institute of Child Health and Human Development, Bethesda, MD, US  

10:15 32  Most Breastfeeding Women With High Viral Load Are Still Undiagnosed in Sub-Saharan Africa  
David Maman1; Helena Huerga1; Irene Mukui2; Benson Chilima3; Beatrice Kirubi4; Gilles Van Cutsem5; Charles Masiku6; Elisabeth Szmulimil3; Thomas Ermann4; Jean-François Eard1; 1L’Episcopale/Médecins Sans Frontières, Paris, France; 2Ministry of Health, Lilongwe, Malawi; 3Medecins Sans Frontieres, Cape Town, South Africa; 4National AIDS and STDs Control Program, Nairobi, Kenya; 5Médecins Sans Frontières, Nairobi, Kenya; 6Médecins Sans Frontières, Cape Town, South Africa; 7Médecins Sans Frontières, Lilongwe, Malawi; 8Médecins Sans Frontières, Paris, France  

10:30 33  Delayed HIV Detection in Infants Exposed to ARV Prophylaxis During Breastfeeding  
Caroline C. King1; Julie A. Nelson1; Carrie Ziemniak1; Michael G. Hudgens2; Gerald Tega3; Charles S. Chasela4; Denise J. Jamieson4; Deborah Persaud5; Charles M. van der Horst6; Athena P. Kourtis1; 1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 3Johns Hopkins University, Baltimore, MD, US; 4UNC Project, Lilongwe, Malawi; 5University of Witwatersrand, Johannesburg, South Africa; 6Medical Research Council, London, UK  

10:45 34  Evaluation of the Alere q for Point-of-Care Early Infant HIV Diagnosis in South Africa  
Nie-Yuan Hsiao1; Max Kroon2; Lorna Dunning2; Landon Myer2; 1University of Cape Town, Cape Town, South Africa; 2University of Cape Town, Cape Town, South Africa  

11:00 35  Early ART and Sustained Virological Suppression Limits HIV Provaliral DNA Reservoir: CHER Evidence  
Helen A. Payne1; Sarah Waters2; Marvin Hsiao3; Robin Callard4; Abdel Babiker5; Mark F. Cotton5; Kenneth Otswome6; Avy沃尔7; Diana M. Gibb7; Nigel J. Klein1; 1University College London, London, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa; 4National Institutes of Health, Bethesda, MD, US; 5National AIDS and STDs Control Program, New Delhi, India; 6District of Columbia Department of Health, Washington, DC, US; 7Médecins Sans Frontières, Paris, France  

11:15 36  Long-Term Outcomes of HIV-Infected Children Initiating NVP vs LPV/r-Based Treatment  
Linda Barlow-Mosha1; Konstantia Angelidou2; Mohendran Archary3; Avy Wol1; Jane Lindsey4; Lynne Mofenson5; Patrick Jean-Philippe6; Paul E Palumbo7; Benjamin Chi7; 1On behalf of the IMPAACT P1060 Protocol Team; 2Makerere University—Johns Hopkins University Research Collaboration, Kampala, Uganda; 3Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 4National Institutes of Health, Bethesda, MD, US; 5Geisel School of Medicine at Dartmouth, Lebanon, NH, US; 6Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, US; 7University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 8University of Witwatersrand, Johannesburg, South Africa; 9University of KwaZulu-Natal, Durban, South Africa; 10IMPAACT, SilverSpring, MD, US
11:30 37 Structural Cardiovascular Changes Are Reversible in HIV-Infected Children in Zambia and Uganda.
Julia M. Kenny1; Adrian Cook1; Grace Mirembe2; Dorica Masaku1; Priscilla Wavamunno1; Florence Odongo1; Alicia Rapala1; John Deanfield1; Diana M. Gibb1; Nigel J. Klein1
1University College London, London, United Kingdom; 2Joint Clinical Research Centre, Kampala, Uganda; 3University Teaching Hospital, Lusaka, Zambia

11:45 38LB ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI
Karina M. Butler
On behalf of the BREATHER Trial Team
Our Lady's Children's Hospital, Dublin, Ireland

11:30 44 Mucosal HIV-1 Transmission Specifically Selects for Type 1 Interferon-Resistant Viruses
Shilpa Iyer1; Frederic Bibollet-Ruche1; Christiana M. Shaw2; Weiyu Zhang1; Yingying Li1; Timothy Decker1; George M. Shaw1; Persephone Borrow1; Beatrice H. Hahn2
1University of Pennsylvania, Philadelphia, PA, US; 2University of Oxford, London, United Kingdom

11:30 45 The Dynamics of HIV-1 RNA Near the Plasma Membrane During Virus Assembly
Luca Sardo; Steven C. Hatch; Jianbo Chen; Olga A. Nikolaitchik; Ryan C. Burdick; De Chen; Christopher J. Westlake; Stephen Lockett; Vinay K. Pathak; Wei-Shau Hu
Frederick National Laboratory for Cancer Research, Frederick, MD, US

11:15 47 Inflammation Persists Despite Early Initiation of ART in Acute HIV Infection
Netanya S. Utay1; Jintanat Ananworanich2; Suteera Pinyakorn1; Adam Rupert5; Duanghathai Sutthichom3; Suwanna Puttasamwis1; Bonnie M. Slike1; Nelson L. Michael1; Daniel C. Douek1; Irini Sereti4
1University of Texas Medical Branch at Galveston, Galveston, TX, US; 2US Military HIV Research Program, Silver Spring, MD, US; 3South East Asia Research Collaboration with Hawaii, Bangkok, Thailand; 4National Institutes of Health (NIH), Frederick, MD, US; 5Leidos Biomedical Research, Inc, Frederick, MD, US
10:15  48  HIV Burden and Biomarker Associations With Colonic HIV RNA During Acute HIV Infection
James L. Fletcher; Trevor A. Crowell; Robin Dewar; Irini Sereti; Bonnie Slike; Nitiya Cheomche; Rungsun Rerknimit; Nelson L. Michael; Nicolas Chomont; Jintanat Ananworanich
On behalf of the RV254/SEARCH010 Study Group
1US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, US; 2SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Virus Isolation and Serological Lab, National Cancer Institute at Frederick, Frederick, MD, US; 4National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, US; 5Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 6Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL, US

10:30  49  Identification and Characterization of Individual HIV-Infected CD4 T Cells Ex Vivo
Joseph Casazza; Irene Primmer; David Ambrozak; Constantinos Petrovas; Sara Ferrando-Martinez; Perla Del Rio-Estrada; Gustavo Reyes-Teran; Ezequiel Ruiz-Mateos; John Mascola; Richard A. Koup
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 2Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 3HU Virgen del Rocia/IBIS, Sevilla, Spain

10:45  50  Efficacy of HIV-1 Monoclonal Antibody Immunotherapy in Acute SHIV-Infected Macaques
Diane L. Bolton; Amarendra Pegu; Keyun Wang; Kathleen McGinniss; Kathryn Foulds; Sinivas Rao; Merlin L. Robb; Nelson L. Michael; John Mascola; Richard A. Koup
1US Military HIV Research Program, Silver Spring, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

11:00  51  HIV-1 Infections With Multiple Founders Are Associated With Higher Viral Loads
Holly Janes; Sodsai Tovanabutra; Joshua Herbeck; Supachai Rerk-Ngam; Merlin L. Robb; Nelson L. Michael; Peter Gilbert; Jerome H. Kim; Morgane Rolland
On behalf of the Step/HVTN502 and RV144 study teams
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2US Military HIV Research Program, Silver Spring, MD, US; 3Instituto de Infectology y Medicina Tropical, Universidad Autonoma de Madrid, Spain; 4Thai Ministry of Public Health, Bangkok, Thailand

11:15  52  Post-Treatment Controllers Have Particular NK Cells With High Anti-HIV Capacity: VISCOUNTI Study
Daniel Scott-Algara; Céline Didier; Vincent Arnold; Jean-Saville Cummings; Faroudy Boufassa; Olivier Lambotte; Laurent Hocqueloux; Asier Sáez-Cirión; Christine Rouzouxi
1Institut Pasteur, Paris, France; 2CEESP U1018 Inserm, Le Kremlin-Bicêtre, France; 3Laboratoire de Virologie, EA 3620—Université Paris Descartes Hôpital Necker, Paris, France; 4Service des Maladies Infectieuses et Tropicales CHR d’Orléans—La Source, Orléans, France; 5Hôpital Bicêtre, Le Kremlin-Bicêtre, France

11:30  53  Antiretroviral Therapy Preserves Polyfunctional HIV-1—Specific CD8 T Cells With Stem-Cell—Like Properties
Selena Vignano; Jordi J. Negron; Eric S. Rosenberg; Bruce D. Walker; Mathias Lichtenfeld; Xu G. Yu
1The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

11:45  54LB In Vitro Replication and Interferon-Alpha Resistance of Transmitted HIV-1 Variants
Zachary Enke; Martin Demeyer; Anghard Fenton-May; Daniel T. Caiborne; William Kilembé; Susan Allen; Persephone Borrow; Eric Hunter
1Emory University, Atlanta, GA, US; 2Oxford University, Oxfordshire, United Kingdom; 3Zambia Emory HIV Research Project, Lusaka, Zambia

12:00  55LB HVTN505 Breakthrough Sequences Show HIV Vaccine-Associated Differences in Env-gp120
Morgane Rolland; Allan deCamp; Breana M. Hall; Sodsai Tovanabutra; Mario Roederer; Scott M. Hammer; Magdalena E. Sobieszczuk; Peter B. Gilbert; Jerome H. Kim; James Mullins
On behalf of the HVTN505 Sieve Analysis Group

Session TD-B Themed Discussion

Room 615
1:30 pm – 2:30 pm
Next Generation of Next-Generation Sequencing

Themed Discussion Leader
Davey M. Smith, University of California San Diego, San Diego, CA, US

258  PCR-Free Full Genome Characterization of Diverse HIV-1 Strains by Nextgen Sequencing
Viswanath Ragupathy; Feng Gao; Ana Sanchez; Marco Schito; Thomas Denny; Michael Busch; Jianguin Zhao; Christelle Mbonjdi; SaiWikram Venmula; Indira Hewlett
1US Food and Drug Administration, Silver Spring, MD, US; 2Duke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC, US; 3Henry Jackson Foundation, DAIDS, NIAID, Bethesda, MD, US; 4Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US

257  Pan-HIV Next-Gen Sequencing Strategy for Viral Surveillance
Michael G. Berg; Julie Yamaguchi; Elodie Alessandri-Gradit; Jean-Christophe Plantier; Catherine Brennan
1Abbott Laboratories, Abbott Park, IL, US; 2Virology Unit, National Reference for HIV, Rouen, France

256  Near Full Length HIV-1 Sequencing to Understand HIV Phylodynamics in Africa in Real Time
Siva Danaviah; Justen Manasa; Eduan Wilkinson; Sureshnee Pillay; Zandile Sibisi; Sthembiso Mswele; Deenan Pillay; Tulio de Oliveira
University of KwaZulu-Natal, Durban, South Africa
254 Present Applications of a High-Throughput, Single Measure HIV Genomic Incidence Assay
Sung Yong Park1; Tanzy Love1; Nolan Goeken1; Robert Bolan1; Alan S Perelson1; Michael Dube1; Ha Youn Lee1
1Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 2University of Rochester School of Medicine and Dentistry, Rochester, CA, US; 3Los Angeles Gay and Lesbian Center, Los Angeles, CA, US; 4Los Alamos National Laboratory, Los Alamos, CA, US

A Comprehensive Analysis of Primer IDs to Study Heterogeneous HIV-1 Populations
David Seifert1; Armin Töpfer1; Francesca Di Giallonardo1; Stefan Schmutz2; Huldrych G. Günthard2; Volker Roth3; Niko Beeremewinkel1; Karin J. Metzner1
1ETH Zurich, Basel, Switzerland; 2University Hospital Zurich, Zurich, Switzerland; 3University of Basel, Basel, Switzerland

Analysis of Resistance Haplotypes Using Primer IDs and Next Gen Sequencing of HIV RNA
Valerie F. Boltz1; Jason Rausch1; Wei Sha2; Charles Coomer1; John W. Mellors1; Mary Kearney1; John M. Coffin1
1Infectious Diseases, Bethesda, MD, US; 2Leidos Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 3University Hospital of Southern California Keck School of Medicine, Los Angeles, CA, US; 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 5National Institute of Child Health and Human Development, Bethesda, MD, US

255

300 Effect of CMV and HIV Replication on T-Cell Exhaustion and Senescence During ART
Jennifer M. Dan1; Marta Massanella1; David M. Smith1; Eric S. Daar1; Michael P. Dube1; Richard Haubrich1; Sheldon Morris1; Sara Gianella Weibel1
1University of California San Diego, La Jolla, CA, US; 2Harbor–University of California Los Angeles Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US

HIV Myeloid Derived Suppressor Cells Control Cytomegalovirus Inflammation by IL-27
Ankita Garg1; Stephen Spector1
1University of California San Diego, La Jolla, CA, US

255

302 Persistent Elevation of Inflammation Markers in HIV+ Persons With CMV Disease
Melissa Schechter1; Bruno Andrade2; Eleanor M. Wilson1; Virginia Sheikh1; Sonya Krishman1; Margaret Caplan1; Gregg Roby2; Adam Rupert1; Peter Burbelo1; Irini Sereti1
1NIADC, Fredrick, MD, US; 2National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 3NIADC, Leidos Biomedical Inc., Fredrick, MD, US; 4National Institute of Dental and Craniofacial Research, Bethesda, MD, US

303 sCD163 Increase in HIV/CMV-Coinfected Subjects Included in ICONA Cohort
Serena Vita1; Miriam Lichtner1; Giulia Marchetti1; Claudia Mascia1; Esther Merlini1; Paola Cicconi1; Vincenzo Vullo1; Pier Luigi Viale1; Alberto Costantini1; Antonella d’Arminio Monforte1
On behalf of the ICONA Foundation Study
1University of Rome La Sapienza, Polo Pontino, Latina, Italy; 2San Paolo Hospital, Milano, Italy; 3University of Rome La Sapienza, Rome, Italy; 4University of Ancona, Ancona, Italy; 5University of Bologna, Bologna, Italy

Genital CMV Shedding Predicts Syphilis Acquisition in HIV-infected MSM on ART
Sara Gianella Weibel1; David M. Smith1; Eric Daar1; Michael Dube2; Andrea Lisco3; Christophe Vanpouille3; Richard Haubrich1; Sheldon Morris1
1University of California San Diego, La Jolla, CA, US; 2University of Rome La Sapienza, Polo Pontino, Latina, Italy; 3University Hospital Zurich, Zurich, Switzerland; 4University of Basel, Basel, Switzerland

Session TD-F Themed Discussion

Themed Discussion Leader
Monique Nijhuis, University Medical Center Utrecht, Utrecht, Netherlands

Defective HIV-1 Proviruses Can Be Transcribed Upon Activation
Ya-Chi Ho1; Ross Pollack1; Patrick Yong2; Robert F. Siliciano1
1Johns Hopkins University School of Medicine, Baltimore, MD, US

Influenza Vaccination Increases HIV-1 Transcription During Antiretroviral Therapy
Christina C. Yek1; Sara Gianella1; Montserrat Plana2; Pedro Castro2; Felipe Garcia2; Marta Massanella1; David M. Smith1
1University of California San Diego, La Jolla, CA, US; 2University Hospital Zurich, Zurich, Switzerland; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US

Measurement of Viral Transcription in Elite Suppressor CD4+ T Cells
Christopher W. Pohlmeyer1; C. Corin Bullen2; Greg Laird2; Alyssa R. Martin1; Victoria Walker-Sperling1; Stanley U. Chioma1; Robert F. Siliciano1; Joel Blankson1
1Johns Hopkins University School of Medicine, Baltimore, MD, US

Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA
Alexander Pasternak1; Una O’Doherty1; Ben Berkhout1
1Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2University of Pennsylvania, Philadelphia, PA, US

Characterizing the Active HIV Reservoir on ART: Cell-Associated HIV RNA and Viremia
Feiyu Hong1; Elizabeth Fyne2; Anthony R. Cillo2; Margaret A. Bedison1; Dianna Koontz1; John W. Mellors1
1University of Pittsburgh, Pittsburgh, PA, US

Session TD-C Themed Discussion

Themed Discussion Leader
Victor Appay, Institut National de la Santé et de la Recherche Médicale, Paris, France

Effect of CMV and HIV Replication on T-Cell Exhaustion and Senescence During ART
Jennifer M. Dan1; Marta Massanella1; David M. Smith1; Eric S. Daar1; Michael P. Dube1; Richard Haubrich1; Sheldon Morris1; Sara Gianella Weibel1
1University of California San Diego, La Jolla, CA, US; 2Harbor–University of California Los Angeles Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US

HIV Myeloid Derived Suppressor Cells Control Cytomegalovirus Inflammation by IL-27
Ankita Garg1; Stephen Spector1
1University of California San Diego, La Jolla, CA, US

Persistent Elevation of Inflammation Markers in HIV+ Persons With CMV Disease
Melissa Schechter1; Bruno Andrade2; Eleanor M. Wilson1; Virginia Sheikh1; Sonya Krishman1; Margaret Caplan1; Gregg Roby2; Adam Rupert1; Peter Burbelo1; Irini Sereti1
1NIADC, Fredrick, MD, US; 2National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 3NIADC, Leidos Biomedical Inc., Fredrick, MD, US; 4National Institute of Dental and Craniofacial Research, Bethesda, MD, US

Measurements of Viral Transcription in Elite Suppressor CD4+ T Cells
Christopher W. Pohlmeyer1; C. Corin Bullen2; Greg Laird2; Alyssa R. Martin1; Victoria Walker-Sperling1; Stanley U. Chioma1; Robert F. Siliciano1; Joel Blankson1
1Johns Hopkins University School of Medicine, Baltimore, MD, US

Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA
Alexander Pasternak1; Una O’Doherty1; Ben Berkhout1
1Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2University of Pennsylvania, Philadelphia, PA, US

Characterizing the Active HIV Reservoir on ART: Cell-Associated HIV RNA and Viremia
Feiyu Hong1; Elizabeth Fyne2; Anthony R. Cillo2; Margaret A. Bedison1; Dianna Koontz1; John W. Mellors1
1University of Pittsburgh, Pittsburgh, PA, US
778 Obesity and Inflammation in Resource-Diverse Settings of ART Initiation
Kristine M. Erlandson1; Nikhil Gupta2; Javier R. Lama3; Patcharaphan Sugandhavese4; Thando Mwelase5; Ashwin Balagopal6; David Asmuth7; Thomas B. Campbell7; Amita Gupta8
On behalf of the A5175 and INCS319 study team
1University of Colorado, Aurora, CO, US; 2Johns Hopkins University, Baltimore, MD, US; 3Impacta Peru Clinical Trials Unit, Lima, Peru; 4Chiang Mai University, Chiang Mai, Thailand; 5University of Witwatersrand, Johannesburg, South Africa; 6University of California Davis, Sacramento, CA, US

779 Body Composition Outcomes at 96 Weeks in the SECOND-LINE RCT DXA Substudy
Mark A. Boyd1; Janaki Amin2; Patrick W. Mallon3; Jennifer F. Hoy4; Samuel Ferret5; Waldo Belloso6; Praphan Phanuphak7; Sean Emery8; David A. Cooper9
On behalf of the SECOND-LINE study group
1University of New South Wales Australia, Sydney, Australia; 2University College Dublin, Dublin, Ireland; 3Monash University/Alfred Hospital, Melbourne, Australia; 4Hôpital Saint Louis, Paris, France; 5Hospital Italiano, Buenos Aires, Argentina; 6Thai Red Cross AIDS Research Centre, Bangkok, Thailand

780 Bone Quality by Quantitative Ultrasound at the Radius Does Not Differ in ART-Naïve HIV+ and HIV- Rwandan Women
Eugene Mutimura1; Qiuhu Shi2; Donald R. Hoover3; Kathryn Anastas4; Emmanuel Rudakemwa5; Jean Claude Dusingize2; Jean D’Amour6; Sinayobye7; Michael T Yin8
1Regional Alliance for Sustainable Development, Kigali, Rwanda; 2School of Health Sciences and Practice, New York Medical College, New York, NY, US; 3State University of New Jersey, New Brunswick, NJ, US; 4Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, US; 5University of the Witwatersrand, Johannesburg, South Africa; 6University of Colorado Davis, Sacramento, CA, US; 7University of Arkansas for Medical Sciences, Little Rock, AR, US; 8Fred Hutchinson Cancer Research Center, Seattle, WA, US; 9National Institutes of Health, Bethesda, MD, US

781 Predictors and Outcomes of Incident High Cholesterol in Adults on ART in South Africa
Denise Evans1; Alana T. Brennan2; Faith Moyo1; David Spencer1; Kay Mahomed1; Mhairi Maskew3; Lawrence Long1; Sydney Rosen4; Matt P. Fox3
1University of the Witwatersrand, Johannesburg, South Africa; 2Boston University, Boston, MA, US; 3Right to Care, Johannesburg, South Africa

782 Metabolic Changes and Second-Line ART in Africa (2LADY/ANRS 12169 Trial)
Amandine Cournil1; Assane Diouf2; Sabrina Eymard-Duvernay3; Adrien Savadogo4; Liliane Ayangma5; Louise Fortes-Dequenoumo6; Jean-Marc Mben7; Eric Delaporte8; Laura Ciaffi9; Sinata Koulla-Shiro10
1IRD/UM 1, Montpellier, France; 2CHU Sourou Sanou, Bobo Dioulasso, Burkina Faso; 3CRF, Dakar, Senegal; 4Yaounde Military Hospital, Yaounde, Cameroon; 5FMSB/University Yaounde 1, Yaounde, Cameroon; 6ANRS Research Center, Yaounde, Cameroon

Program and Agenda

Session TD-Q Themed Discussion Room 6AB
1:30 pm – 2:30 pm
Fat Without Borders: Metabolic Complications in Resource-Limited Settings
Themed Discussion Leader
Miriam Rabkin, Columbia University Mailman School of Public Health, Chapel Hill, NC, US

Session TD-S Themed Discussion Room 6C
1:30 pm – 2:30 pm
Hormonal Contraceptives: Enduring Controversy
Themed Discussion Leader
Betsy Herold, Albert Einstein College of Medicine, Bronx, NY, US

859 Estrogen Replacement in Healthy Postmenopausal Women Reduces %CCR5+ CD4+ T Cells
Amie Meditz1; Samantha MalWhinney2; Kemie Moreau2; Kelsey Melander2; Joy Folkvord2; Wendy Kohrt3; Margaret Wieman4; Elizabeth Connick5
1Boulder Community Health, Boulder, CO, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

858 CCR5 Expression in HIV-Uninfected Women Receiving Hormonal Contraception
Atie Tisbiros1; Gaia Sciaranghella2; Cuimei Wang3; Kerry Murphy4; Zaher Mehr2; Ruth M. Grenblatt4; Mardge Cohen5; Elizabeth Golub6; Heather Watts7; Mary A. Young8
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3Georgetown University Medical Center, Washington, DC, US; 4Albert Einstein College of Medicine, Bronx, NY, US; 5University of Vermont College of Medicine, Burlington, VT, US; 6University of California San Francisco, San Francisco, CA, US; 7Stroger Hospital and Rush University and CORE Center, Chicago, IL, US; 8Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 9The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US

860 Progesterone Increases Are Associated With HIV Susceptibility Factors in Women
Alison Y. Sways1; Tammy Evans-Strickfaden2; L Davis Lupo3; Alfredo Aguiri1; Anandi Sheth1; Igbo Ofoekon1; Clyde E. Hart1; Richard E. Haaland2
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Emory University School of Medicine, Atlanta, GA, US

861 Changes in Vaginal Microbiota and Cytokines in HIV-1-Seronegative Women Initiating DMPA
Alison C. Roxby1; David N. Fredricks2; Katherine Odem-Davis1; Kristjana H. Asbjörnsdóttir1; Linnet Masese3; Tina L. Fiedler1; Walter Jaoko1; James N. Kiarie1; Julie M. Overbaugh4; R Scott McClure5
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya
Session TD-Y Themed Discussion
1:30 pm – 2:30 pm
Circumcision: Evolving Knowledge and Practice
Themed Discussion Leader

1086 Mobile VMMC Teams in Tanzania See Older Clients and Have Higher Followup Rates
Augustino M. Hellar1; Dorica Boyee1; Hally Mahler1; Marya Plotkin1; Touma Ng’wanakilala1; Kelly Curran1; TsigiAsthengo1; Hawa Mziray1; Erick Mlanga1; Sifumi Yoshuma1
1Jhpiego, Dar es Salaam, United Republic of Tanzania; 2Jhpiego, Baltimore, MD, US; US Agency for International Development, Dar es Salaam, United Republic of Tanzania; 3Ministry of Health and Social Welfare, Iringa, United Republic of Tanzania

1087 High Acceptability of PrePex™ Device in Routine Programmatic Settings in Rwanda
Eugene Rugwizungo1; Beata Mukarugwino1; Jovite Sinzahera1; Alphonse Mutabarka1; Gioriose Abayisenga1; J.D. Ntakakirabose1; Ngeruka Leon4; Eugene Zimulinda3; Kelly Curran1; TsigiAsthengo1
1Jhpiego/Rwanda, Kigali, Rwanda; 2Jhpiego, an Affiliate of Johns Hopkins University, Washington, DC, US; 3US Department of Defense, Rwanda, Kigali, Rwanda; 4Rwanda Military Hospital, Kigali, Rwanda

1089 Potential Protection From HIV Transmission by Penile Cuttings in Papua New Guinea
Ivy H. Shih1; Lester Asugeni2; Matthew David5; Paul Horwood5; Parana Hewage Mangalasir1; David Mc Laren1; Rachael Tomsme1; Andrew Vallely1; Arnold Wainie1; Stuart G. Turville1
1The Kirby Institute, Sydney, Australia; 2Pacific Adventist University, Port Moresby, Papua New Guinea; 3James Cook University, Cairns, Australia; 4University of Papua New Guinea, Port Moresby, Papua New Guinea; 5Papua New Guinea Institute of Medical Health, Goroka, Papua New Guinea

1084 HSV-2 Shedding From Male Circumcision Wounds Among HIV-Infected Men
Mary K. Grabowski1; Godfrey Kigozi2; Ronald H. Gray3; Jordyn L. Manucci1; David Serwadda4; Ethan U. Patel1; Fred Nalugoda1; Maria J. Wawer1; Thomas C. Quinn1; Aaron A. Tobian1
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kailisizo, Uganda; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

1088 Self-Selection of Circumcision Acceptors, Risk Compensation and Effectiveness of Circumcision Among Service Recipients, Rakai Uganda
Joseph Kagaayi1; Xiangrong Kong1; Godfrey Kigozi1; Fred Nalugoda1; Steven J. Reynolds1; David Serwadda1; Nelson K. Sewankambo1; Maria J. Wawer1; Ronald H. Gray2
1Rakai Health Sciences Program, Entebbe, Uganda; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 4Makerere University School of Public Health, Kampala, Uganda; 5Makerere University College of Health Sciences, Kampala, Uganda

Session 0-5 Oral Abstracts
4:00 pm – 6:00 pm
NeuroAIDS Pathogenesis and Antiretroviral Therapy
Moderators
Lucette A. Cysique, NeuRA, University of New South Wales Australia, Randwick, NSW, Australia
Alan Winston, Imperial College London, London, United Kingdom

4:00 56 Randomized Clinical Trial of Antiretroviral Therapy for Prevention of HAND
Fujie Zhang1; Robert Heaton2; Hao Wu3; Hua Jin3; Hongxin Zhao2; Xin Yu; Donald Franklin1; Weiwai Mu1; Florin Vaida3; Scott Letendre1
1Chinese Center for Disease Control and Prevention, Beijing, China; 2University of California San Diego (UCSD), San Diego, CA, US; 3Capital Medical University, Beijing You’an Hospital, Beijing, China; 4Capital Medical University Beijing Ditan Hospital, Beijing, China; 5Peking University, Beijing, China

4:15 57 Neurocognitive Function in Africans Failing First-Line ART and Responses to Second Line
Andrew D. Kambugu1; Jennifer Thompson1; James Hakim1; Dinah Tumukunde6; Joep van Oosterhout2; Anne Hoppe2; Charles Kwobah2; Sarah Walker3; Nicholas Baton4 On behalf of the EARNEST Trial Team
1Infectious Diseases Institute, Makerere University Kampala, Kampala, Uganda; 2University College London, London, United Kingdom; 3Joint Clinical Research Centre, Kampala, Uganda; 4Queen Elizabeth Central Hospital, Malawi, Blantyre, Malawi; 5Africssi, Kenya, Eldoret, Kenya; 6University of Zimbabwe, Harare, Zimbabwe; 7Dignitas International, Zomba, Malawi; 8National University of Singapore, Singapore, Singapore; 9Moi University College of Health Sciences, Eldoret, Kenya; 10Joint Clinical Research Centre, Kampala, Uganda

4:30 58 Compartamentalized HIV Rebound in the CNS After ART Interruption
Sara Gianella Weibel1; Michelia Faria de Oliveira; Konrad Scheffler; Matt Strain; Antonio De la Torre; Scott Letendre; David M. Smith; Sergei L. Kosakovsky Pond1; Ronald J. Ellis; Fuhie Zhang1; Scott Letendre1
1University, Innsbruck, Austria, Inssbruck, Austria; 2University of Gothenburg, Gothenburg, Sweden; 3Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden, Gothenburg, Sweden; 4University of New South Wales, Sydney, Australia; 5Division of Biological Chemistry, Biocenter, Medical University, Innsbruck, Austria, Innsbruck, Austria; 6University of California San Francisco, San Francisco, CA, US

4:45 559 Impaired Blood-Brain Barrier Integrity Is Associated With Neuronal Injury in HIV
Birgitta Anesten1; Lars Hagberg1; Henrik Zetterberg2; Staffan Nilsson1; Bruce J. Brew4; Dietmar Fuchs3; Richard Price6; Magnus Gisslen1
1University of Gothenburg, Gothenburg, Sweden; 2University of Gothenburg, Gothenburg, Sweden; 3Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden, Gothenburg, Sweden; 4University of New South Wales, Sydney, Australia; 5Division of Biological Chemistry, Biocenter, Medical University, Innsbruck, Austria, Innsbruck, Austria; 6University of California San Francisco, San Francisco, CA, US
5:00  
60  
**Cortical and Subcortical Brain Volumes in Primary HIV Infection**  
*Patrick W. Wright; Ashmit Pyakurel; Kevin Robertson; Julia Peterson; Henrik Zetterberg; Dietmar Fuchs; Richard Price; Dieter Meyerhoff; Serena Spudich; Beau Ances*  
1Washington University School of Medicine, Saint Louis, MO, US; 2Yale University School of Medicine, New Haven, CT, US; 3University of California San Francisco, San Francisco, CA, US; 4Innsbruck Medical University, Innsbruck, Austria; 5University of Gothenburg, Gothenburg, Sweden  

5:15  
61  
**IRF4 Transcription Factor Associated With Integrated HIV DNA in Brain Macrophages**  
*Benjamin B. Gelman; Joshua G. Lisinicchia; Tetyana P. Buzhdyan; Vipulkumar Patel; Tyler Clement; Samantha A. Trevino; Kristofer R. Jennings; Dennis L. Kolson*  
1University of Texas Medical Branch, Galveston, TX, US; 2University of North Carolina, Chapel Hill, NC, US; 3University of California San Francisco, San Francisco, CA, US; 4Innsbruck Medical University, Innsbruck, Austria; 5University of Gothenburg, Gothenburg, Sweden  

5:30  
62  
**Longitudinal Assessment of Blood Brain Barrier Disruption in Primary HIV Infection**  
*Elham Rahimi; Fang-yong Li; Alex Russell; Julia Peterson; Lars Hagberg; Henrik Zetterberg; Richard Price; Magnus Gisslén; Serena Spudich*  
1Yale University School of Medicine, New Haven, CT, US; 2Yale Center for Analytical Sciences, Yale University, New Haven, CT, US; 3University of Gothenburg, Gothenburg, Sweden; 4University of California San Francisco, San Francisco, CA, US  

5:45  
63  
**Declining Prevalence of HIV-Associated Neurocognitive Disorders in More Recent Years**  
*Carmela Pinnetti; Raffaella Libertone; Pietro Balestra; Patrizia Lorenzini; Martina Ricottini; Samanta Menichetti; Carmela Pinnetti; Mauro Zaccarelli; Adriana Ammassari; Andrea Antinori*  
National Institute for Infectious Diseases, La zzer O Spallanzani, Rome, Italy  

**Session S-1 Symposium**  
**Room 6C**  
**4:00 pm – 6:00 pm**  
**Harnessing Antibodies for Prevention and Therapeutics**  
**Target audience:** This session is directed to scientists and clinicians interested in the potential therapeutic and prophylactic applications of anti-HIV antibodies.  
**Level of knowledge:** It is assumed that participants are familiar with basic immunologic principles, antibody structure, and HIV envelope variability.  
**Objectives:** At the completion of the session, participants will be able to:  
- List cutting-edge approaches for the delivery of protective and curative antibodies.  
- Describe emerging approaches to enhance monoclonal antibody activity against virus.  
- Describe new advances in the ability to elicit antibodies that resemble neutralizing antibodies through vaccination.  

**Symposium Conveners**  
*Leonidas Stamatatos, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US*  
*Susan Zolla-Pazner, New York University, Langone Medical Center, New York, NY, US*  

4:00  
64  
**Potentiating Protective Antibody Activity: A Systems Serology Approach**  
*Margaret E. Ackerman*  
Thayer School of Engineering, Dartmouth College, Hanover, NH, US  

4:30  
65  
**Impact of Repetitive Protein Boosting on RV305 HIV-1 Vaccine-Induced Antibodies**  
*Georgia D. Tomaras*  
Duke University Medical Center, Durham, NC, US  

5:00  
66  
**Immunoprophylaxis by Gene Transfer: Shortcut to an HIV Vaccine**  
*Phil Johnson*  
Children’s Hospital of Philadelphia, Philadelphia, PA, US  

5:30  
67  
**Broadly Neutralizing Antibodies for HIV-1 Eradication Strategies**  
*Dan H. Barouch*  
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US  

**Session S-2 Symposium**  
**Room 6D**  
**4:00 pm – 6:00 pm**  
**Current Issues in HIV-Related Malignancies**  
**Target audience:** This session is directed to those interested in development and management of cancers in HIV.  
**Level of knowledge:** It is assumed that participants have some basic knowledge of types of cancers seen in HIV.  
**Objectives:** At the completion of the session, participants will be able to:  
- Discuss differences in malignancy incidence and presentation, including in resource-limited settings around the world.  
- Describe new concepts in viral-induced oncogenesis.  
- Describe new therapies for lymphoma in HIV-infected individuals.  
- Examine major barriers for treatment of cancers in resource-limited settings.  

**Symposium Conveners**  
*Margaret Z. Borok, University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe*  
*Robert Yarchoan, National Cancer Institute, Bethesda, MD, US*  

4:00  
68  
**HIV-Associated Malignancies: The Worldwide Epidemic**  
*James J. Goedert*  
National Cancer Institute, Bethesda, MD, US  

4:30  
69  
**Viral Oncogenesis: Evolving Concepts**  
*Shannon C. Kenney*  
University of Wisconsin, Madison, WI, US
5:00  70  AIDS Lymphoma: Advances and Existing Challenges  
Ariela Noy  
Memorial Sloan Kettering Cancer Center, New York, NY, US

5:30  71  HIV Malignancies in Low- and Middle-Income Countries: A Double Burden of Disease  
Jackson Orem  
Uganda Cancer Institute, Kampala, Uganda

Session S-3 Symposium  
Room 6AB
4:00 pm – 6:00 pm

Current Imperatives in HIV Prevention and Treatment

Target audience: This session is directed to researchers, public health professionals, and educators interested in global HIV and public health.

Level of knowledge: It is assumed that participants are familiar with HIV program scale-up and global disease burden.

Objectives: At the completion of the session, participants will be able to:

- Define trends in HIV/AIDS and sexually transmitted infection epidemiology among different groups.
- Describe the epidemiology of HIV among men who have sex with men in Africa, and associated challenges.
- Assess broader impact on health programs and behavioral science of HIV/AIDS service scale-up.

Symposium Conveners
Wafaa M. El-Sadr, ICAP at Columbia University, New York, NY, US  
Lucy Ng’ang’a, CDC Center for Global Health, Division of Global AIDS/HIV, Nairobi, Kenya

4:00  72  How Has HIV Prevention Affected the Spread of Other Sexually Transmitted Infections?  
Marie Laga  
Institute of Tropical Medicine, Antwerp, Belgium

4:30  73  HIV Risks and Vulnerabilities Among Gay Men and Other Men Who Have Sex With Men Across Sub-Saharan Africa  
Stefan Baral  
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

5:00  74  An Expanded Behavioral Paradigm for Treatment and Prevention of HIV-1  
Thomas J. Coates  
University of California Los Angeles, Los Angeles, CA, US

5:30  75  Social Protection, Financial Incentives, and Prevention of HIV  
David Wilson  
World Bank, Washington, DC, US

Special Session  
Room 6E
6:30 pm – 7:30 pm

Special Session: Ebola Virus Disease: Responding to the Challenge

Moderators  
Kevin M. De Cock, Centers for Disease Control and Prevention, Nairobi, Kenya  
Wafaa M. El-Sadr, ICAP at Columbia University, New York, NY, US

6:30  76  The Médecins Sans Frontières Experience With the Current Ebola Outbreaks  
Gilles Van Cutsem  
Médecins Sans Frontières, Mowbray, Cape Town, South Africa

7:00  77  Ebola Vaccines, Passive Immunotherapy, and Antiviral Treatment  
H. Clifford Lane  
National Institute of Allergy and Infectious Diseases, Bethesda, MD, US
WEDNESDAY, FEBRUARY 25, 2015

Session PL-1 Plenary 4AB Auditorium
8:30 am – 9:00 am

Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now and Where Are We Going?

78 Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now, and Where Are We Going?
Diana M. Gibb
University College London, London, United Kingdom

Session PL-2 Plenary 4AB Auditorium
9:00 am – 9:30 am

Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses

79 Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses
Michael Gale
University of Washington, Center for Innate Immunity and Immune Disease, Seattle, WA, US

Session O-6 Scientific Overview and Oral Abstracts Room 615
10:00 am – 12:00 pm

Intracellular and Clinical Pharmacology, Drug Interactions, and Adherence

Moderators
Reina Bendayan, University of Toronto, Toronto, ON, Canada
Marta Boffito, Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom

10:00 80 Scientific Overview: The Clinical Pharmacology of HIV Prevention
Marta Boffito
Chelsea and Westminster Hospital, NHS Foundation Trust/Imperial College, London, United Kingdom

10:30 81 Intracellular Pharmacokinetics of Sofosbuvir In Vivo
Joseph Rower1; Ariel Hodara1; Jacob A. Langness1; Sarah Tise1; Greg Everson1; Aimee Truesdale1; Fafa Baouchi-Mokrane2; Lane Bushman1; Peter L. Anderson1; Jennifer J. Kiser1
1University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US; 2Denver Health and Hospital Authority, Denver, CO, US; 3University of Colorado Health, Aurora, CO, US; 4University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, US

10:45 82 Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals
Polina German; Kimberly Garrison; Phillip S. Pang; Luisa M. Stamm; Adrian S. Ray; Gong Shen; Marc Baucharet; Anita Mathias
Gilead Sciences, Inc., Foster City, CA, US

11:00 83 Emtricitabine-Triphosphate in Dried Blood Spots (DBS) as a Marker of Recent Dosing
Jose R. Castillo-Mancilla1; Lane R. Bushman1; Amie Meditz2; Sharon M. Seifert1; Jia-Hua Zheng1; L Anthony Guida1; Edward M. Gardner1; David V. Glidden1; Robert M. Grant1; Peter L. Anderson1
1University of Colorado-AMC, Aurora, CO, US; 2Beacon Center for Infectious Diseases, Boulder, CO, US; 3Denver Health and Hospital Authority, Denver, CO, US; 4University of California San Francisco, San Francisco, CA, US

11:15 84 Impact of EFV PK/PG on Neuropsychological Performance in Older HIV+ Patients
Uriel S. Sandkovsky1; Anthony T. Podany1; Courtney Fletcher1; Andrew Owen2; Angela Felton-Coleman1; Kevin Robertson1; Susan Swindells1
1University of Nebraska Medical Center, Omaha, NE, US; 2University of Liverpool, Liverpool, United Kingdom; 3University of North Carolina, Chapel Hill, NC, US

11:30 85LB Levonorgestrel Implant + EFV-Based ART: Unintended Pregnancies and Associated PK Data
Kimberly K. Scarsi1; Kristin M. Darin1; Shadia Nakalema2; David Back2; Pauline Byakika-Kibwika2; Laura Else3; Sujan Dilly-Penchala1; Susan Cohn1; Concepta Merry1; Mohammed Lamorde2
1University of Nebraska Medical Center, Omaha, NE, US; 2Infectious Diseases Institute, Kampala, Uganda; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4University of Liverpool, Liverpool, United Kingdom; 5Trinity College Dublin, Dublin, Ireland

11:45 86LB A Phase IV PrEP Study Reveals Limited Ex Vivo Potency of Oral Maraviroc Against HIV-1
Julie Fox1; Carolina Herrera2; Juan Manuel Tiraboschi3; Akil Jackson1; Laura Else4; Natalia Olejniczak2; Saye Khoo4; David Back4; Robin Shattock4; Marta Boffito1
On behalf of KCL Infectious Diseases Biobank
1Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom; 2Imperial College London, London, United Kingdom; 3Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 4University of Liverpool, Liverpool, United Kingdom
Majority of XDR TB Cases Are Due to Transmission in a High-HIV-Prevalence Setting
N. Sarita Shah1; James C. Brust2; Barun Mathema1; Thuli Mthiyane3; Nazir Ismail4; Pravi Moodley5; Koleka Misina4; Salim Allana1; Jonathan Smith1; Neel R. Gandhi7
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, NY, US; 3Columbia University Mailman School of Public Health, New York, NY, US; 4University of KwaZulu-Natal, Durban, South Africa; 5National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 6University of KwaZulu-Natal & National Health Laboratory System, Durban, South Africa; 7Emory University Rollins School of Public Health, Atlanta, GA, US; 8University of KwaZulu-Natal & National Health Laboratory Service, Durban, South Africa

Linkage to HIV/TB Care in South Africa: A Randomized Trial of Health Navigators
Ingrid V. Bassett1; Sharon M. Coleman1; Janet Giddy1; Laura M. Bogart2; Christine E. Chaisson1; Douglas Ross3; Tessa Persing4; David Alland5; Mark N. Polizzotto1; Jeffrey Martin1
1National Cancer Institute (NCI), Bethesda, MD, US; 2National Institutes of Health (NIH), Bethesda, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4National Cancer Institute (NCI), Bethesda, MD, US; 5Celgene Corporation, Summit, NJ, US

Is It Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Noninferiority RCT
Paula Munderi1; Jonathan B. Levin2; Zacchaeus Anywaine1; Ronnie Kasire1; Anatoli Kamali1; Andrew J. Nunn1; Heiner Grosskurth1
1High-Dose Rifampin, SQ109 and Moxifloxacin for Treating TB: The PanACEA MAMS-TB Trial
Martin J. Boeree1; Michael Hoelscher2
On behalf of the PanACEA consortium
1Radboudumc, Nijmegen, Netherlands; 2University of Munich, Munich, Germany

High Rate of HSIL on HRA in HIV+ Women Not Meeting Criteria for Anal Cancer Screening
Michael M. Gaisa1; Fanny Ita-Nagy1; Gabriela Rodriguez Caprio1; Michael Mullen1; Judith Aberg1; Michelle Cespedes1
1MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 2University College London, London, United Kingdom; 3London School of Hygiene and Tropical Medicine, London, United Kingdom

High Rate of HSIL on HRA in HIV+ Women Not Meeting Criteria for Anal Cancer Screening
Michael M. Gaisa1; Fanny Ita-Nagy1; Gabriela Rodriguez Caprio1; Michael Mullen1; Judith Aberg1; Michelle Cespedes1
1MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 2University College London, London, United Kingdom; 3London School of Hygiene and Tropical Medicine, London, United Kingdom

Xpert MTB/RIF Ultra: A New Near-Patient TB Test With Sensitivity Equal to Culture
David Alland1; Mazhgan Rowneki1; Laura Smith1; Jamie Ryan1; Mitchell Chancellor1; Ann Marie Simmons1; David Persing2; Robert Kwiatkowski3; Martin Jones1; Soumitesh Chakravorty1
1Rutgers New Jersey Medical School, Newark, NJ, US; 2Cepheid, Sunnyvale, CA, US

KS and Cervical/Anal Dysplasia: Tale of 2 Tumors, and TB and Other Os
Moderators
Corey Casper, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US
Timothy Sterling, Vanderbilt University, Nashville, TN, US

Pomalidomide for Kaposi Sarcoma in People With and Without HIV: A Phase I/II Study
Mark N. Polizzotto1; Thomas S. Uldrick1; Kathleen M. Wynn1; Karen Aleman1; Margaret Bevans2; Cody Peer3; Douglas Figg4; Seth Steinberg5; Jerome B. Zeldis6; Robert Yarchoon1
1National Cancer Institute (NCI), Bethesda, MD, US; 2National Institutes of Health (NIH), Bethesda, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4National Cancer Institute (NCI), Bethesda, MD, US; 5Celgene Corporation, Summit, NJ, US
10:30 97 Joint Estimation of HIV Progression and Survival: A Pooled Analysis of 25 Countries
Tara D. Mangal
On behalf of the UNAIDS Working Group on CD4 Progression and Mortality Among HIV Serocollectors including the CASCADE Collaboration in EuroCoord
Imperial College London, London, United Kingdom

10:45 98 Impact of Emergency Department HIV Testing and Linkage to Care: 25 Years’ Experience
Gabor Kelen1; Eshan U. Patel2; Yu-Hsiang Hsieh3; Oliver B. Laeyendecker4; Judy Shahani; William Clarke5; Jordyn L. Manucci6; Richard Rothman7; Thomas C. Quinn2
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US

11:00 99 Linkage to Care and Viral Suppression Among New HIV Diagnoses, New York City, 2006-13
Ellen W. Wiewel; Lucia V. Torian; Qiang Xia; Sarah L. Braunstein
New York City Department of Health and Mental Hygiene, Long Island City, NY, US

11:15 100 Care and Viral Suppression Among Women, 18 US Jurisdictions
Ndidi Ike1; Angela L. Hernandez; Qian An; Taoying Huang; H. Irene Hall
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

11:30 101 Time Above 1500 Copies/ml: A Viral-Load Measure for Assessing Transmission Risk of HIV-Positive Patients in Care
Lytt I. Gardner1; Gary Marks2; Charles Rose3; Meg Sullivan4; Susan Holman1; Jeanne Keruly5; Anne Zinski6; Allan Rodriguez7; Thomas Giordano8
1Centers for Disease Control and Prevention, Atlanta, GA, US; 2Boston University School of Medicine, Boston, MA, US; 3Colleges of Medicine and Nursing, SUNY Downstate Medical Center, Brooklyn, NY, US; 4Johns Hopkins University School of Medicine, Baltimore, MD, US; 5University of Alabama at Birmingham, Birmingham, AL, US; 6University of Miami, Miami, FL, US; 7Baylor College of Medicine, Houston, TX, US

11:45 102 Incidence and Risk Factors for Sexual Assault Among MSM and Young Women in Coastal Kenya
Adrian D. Smith1; Sam Rogers2; Elizabeth Wahome3; Marianne Darwinkel4; Susan M. Graham5; Eduard J. Sanders6
1Nuffield Department of Population Health, Oxford, United Kingdom; 2Centre for Geographic Medicine Research – Coast, Kilifi, Kenya; 3University of Washington, Seattle, WA, US

12:00 103LB Impact of the Ebola Epidemic on HIV Care in Macenta, Forest Guinea, 2014
David Leuenberger1; Jean Hébélamou2; Stefan Strahm3; Gilles Wandel4; Nathalie de Rekeneire; François Dabis1
On behalf of International Epidemiological Databases to Evaluate AIDS - West Africa
1Mission Philiafricaine, Conakry, Guinea; 2Department of Infectious Diseases, University Hospital Bern, Bern, Switzerland; 3Université Bordeaux, ISJED, Centre Inserm U987 – Epidémiologie-Biostatistique, Bordeaux, France

12:15 103-ALB Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea
Daouda Sissoko1; Elin Folkesson2; M’lebing Abdou3; Abdoul Habib Beavogui4; Stephanie Gunther1; Susan Shepherd5; Christine Danel1; Xavier Anglaret1; Denis Malvy1
1Inserm U987, Université de Bordeaux, Bordeaux, France; 2Médecins Sans Frontières, Bruxelles, Belgium; 3ALIMA, Montreuil, France; 4Centre de Formation et de Recherche en Santé Rurale de Maférynhay, Conakry, Guinée; 5Inserm U738, Université Paris Diderot, Paris, France; 6Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Germany

Session 0-9 Oral Abstracts
Room 6D
10:00 am – 12:15 pm

New Insights Into HIV Persistence, Latency Reversal, and Viremia Rebound

Moderators
Françoise Barré-Sinoussi, Institut Pasteur, Paris, France
Celsa A. Spina, University of California San Diego, La Jolla, CA, US

10:00 104LB Durable Control of Viral Rebound in Humanized Mice by ABX464 Targeting Rev Functions
Noelie Campos1; Renier Myburgh2; Aude Garcel3; Audrey Vautrin4; Laure Lapasset5; Katjana Tantale6; Mark Wainberg7; Roberto Speck2; Didier Scherrer2; Jamal Tazi2
1ABIVAX, Montpellier, France; 2University of Montpellier, Montpellier, France; 3University of Zurich, Zurich, Switzerland; 4McGill AIDS Center, Montréal, Canada

10:15 105 Residual Viremia Caused by Clonally Expanded Tumor-Infiltrating CD4+ Cells
Francesco R. Simonetti1; Michele D. Sobolowski2; Shawn Hill3; Wei Shao4; Elizabeth Fyne5; Xiaolin Wu6; John M. Coffin7; Stephen H. Hughes7; John W. Mellors2; Frank Maldairelli8
1National Cancer Institute (NCI), Frederick, MD, US; 2University of Pittsburgh, Pittsburgh, PA, US; 3Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4Tufts University, Boston, MA, US; 5National Cancer Institute (NCI), Frederick, MD, US;
10:30  106  Analysis of HIV RNA in Single Cells Reveals Clonal Expansions and Defective Genomes
Ann Wiegand1; Jonathan Spindler1; Wei Shao2; Feiyu Hong3; Anthony R. Cillo4; Elias Halvs3; Elizabeth Fyne5; John M. Coffin6; John W. Mellors7; Mary F. Kearney1
1National Cancer Institute, Frederick, MD, MD, US; 2Leidos, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US

10:45  107  Low-Level HIV Viremias Originate in Part From Infected Proliferating Cells
Marta E. Bull1; Sherry McLaughlin1; Tiffany L. Barnes2; Peter T. Hraber3; Thomas A. Rasmussen2; Romas Geleziunas2; Joseph Hesselgesser2
1University of Washington, Seattle, WA, US; 2Seattle Children's Research Institute, Seattle, WA, US; 3Hospital Nacional dos de Mayo, Lima, Peru; 4Investigaciones Médicas en Salud (INMENSA), Lima, Peru; 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 6University of Washington, Seattle, WA, US

11:00  108  Treatment With a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys
James B. Whitney1; So-Yon Lim1; Christa E. Osuna1; Srisowmya Sanisetty1; Nora Ramirez1; Gregory Gibson2; Simon Watkins2; Michael Emerman3; Alejandro Martinez2; Rodney Phillips3; Mary F. Kearney1
1University of North Carolina, Chapel Hill, NC, US; 2Drexel University, Philadelphia, PA, US; 3University of Pittsburgh, Pittsburgh, PA, US

11:15  109  Panobinostat Broadly Activates Latent HIV-1 Proviruses in Patients
Kirsten M. Barton1; Thomas A. Rasmussen2; Martin Tolstrup1; Wei Shao2; Bonnie Hiener3; Anjatha Solomon3; Lars Østergaard4; Sharon R. Lewin5; Ole Søgaard6; Sarah E. Palmer7
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 2Gilead Sciences, Inc., Foster City, CA, US; 3Los Alamos National Laboratories, Los Alamos, NM, US; 4University College of Medicine, Philadelphia, PA, US; 5University of North Carolina, Durham, NC, US; 6Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 7University of Oxford, Oxford, United Kingdom

11:30  110LB  The Size of the Active HIV Reservoir Predicts Timing of Viral Rebound
Behzad Etemadi1; Hayat Ahmed2; Evgenia Aga3; Ronald Bosch2; John W. Mellors4; Daniel Kuritzkes5; Michael Para5; Rajesh T. Gandhi6; Jonathan Li7
1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Ohio State University, Columbus, OH, US; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

11:45  111LB  Biomarkers to Predict Viral Rebound at Antiretroviral Therapy Interruption in SPARTAC
Jacob Hurst1; James Williams1; John P. Thornhill2; Matthew Pace1; Chris Willberg3; Elizabeth Hamlyn4; Abdel Babiker5; Rodney Phillips6; Sarah Fidler7; John Frater8
1On behalf of the SPARTAC Trial Investigators; 2University of Oxford, Oxford, United Kingdom; 3St Mary's Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 4King's College London, London, United Kingdom; 5Medical Research Council Clinical Trials Unit, London, United Kingdom

12:00  112LB  HIV-1 Diversity and Tropism of Rebound Virus After Treatment Discontinuation
Maria M. Bednar1; Blake Hauser2; Jeffrey M. Jacobson3; Ian Frank4; Joseph J. Eron1; Ronald Swanstrom4
1University of North Carolina, Durham, NC, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4University of Pennsylvania, Philadelphia, PA, US

Session TD-A Themed Discussion

Room 615

1:30 pm – 2:30 pm

Interferon: Triggers and Effectors

Themed Discussion Leader
Martin R. Jakobsen, Aarhus University, Aarhus C, Denmark

188  HIV-1 Exploits CD169 to Evade IFNα-Induced Antiviral State in Myeloid Cells
Hisashi Akiyama1; Nora Ramirez1; Gregory Gibson2; Simon Watkins2; Zandra Ambrose2; Rahim Gummel2
1Boston University School of Medicine, Boston, MA, US; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, US

192  HIV and SIV Inhibition by RNA-Associated Early Stage Antiviral Factor (REAF)
Aine McKnight
Queen Mary University of London, London, United Kingdom

194  Regulation of the Innate Immune Sensing of HIV by the Viral Capsid and the Cytosolic DNA Sensor cGAS
Nicolas Manel
Institut Curie, Paris, France

203  Mapping Vpx and Vpr Specificity in Antagonism of SAMHD1
Chelsea Spragg; Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, US

202  A Surprising New Function of SAMHD1 as a Pro-Pathogenic Factor in HIV Infection
Gild Doitsh; Nicole Galloway; Xin Geng; Isa Monus Arias; Zhiyuan Yang; Warner C. Greene
The J. David Gladstone Institute, University of California San Francisco, San Francisco, CA, US
191 Characterization of the Activity of an Innate Immunity Protein, the Apolipoprotein L6
Nitisha Pyndiah1; Angela Ciuffi1; Amalio Telenti2
1Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 2I Craig Venter Institute, San Diego, CA, US

Session TD-H Themed Discussion
Room 613
1:30 pm – 2:30 pm
New Technologies in Assessing Drug Interactions and Systemic and Intracellular Pharmacology

Themed Discussion Leader
Tim R. Cressey. Harvard School of Public Health / Chiang Mai University, Chiang Mai, Thailand

531 Pharmacokinetic Interactions Between Antidiabetics and Efavirenz Using PBPK Modeling
Catia Marzolini1; Rajith Rajoli2; Luigia Elzī2; Manuel Battegay2; David Back2; Marco Siccardi2
1University Hospital Basel, Basel, Switzerland; 2Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

532 In Silico Simulation of Interaction Between Rifampicin and Boosted Darunavir
Marco Siccardi; Owain Roberts; Rajith Rajoli; Laura Dickinson; Saye Khoo; Andrew Owen; David Back
University of Liverpool, Liverpool, United Kingdom

533 Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics
Adeniyi Olagunj1; Oluseye Bolaji1; Alieu Amara1; Laura Else1; Ogechi Okafor1; Ebunoluwa Adejuyigbe1; Oyigboja Johnson1; David Back2; Saye Khoo1; Andrew Owen1
1University of Liverpool, Liverpool, United Kingdom; 2Obafemi Awolowo University, Ile-Ife, Nigeria; 3Bishop Murray Medical Centre, Makurdi, Nigeria; 4Catholic Caritas Foundation of Nigeria, Makurdi, Nigeria

534 Antiretroviral Drug Transporters and Metabolic Enzymes in Human Testicular Tissue
Billy Huang1; Md. Tozammel Hoque1; Mohammad-Ali Jenabian1; Kishanda Vyboh1; Nancy Sheehan1; Pierre Brassard1; Maud Bélanger1; Nicolas Chomont1; Jean-Pierre Routy1; Reina Bendayan1
1University of Toronto, Toronto, Canada; 2McGill University, Montréal, Canada; 3Université du Québec à Montréal, Montréal, Canada; 4Metropolitan Centre of Plastic Surgery, Montréal, Canada; 5Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL, US

535 Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs
Elias P. Rosen1; Corbin G. Thompson3; Mark T. Bokhart4; Craig Sykes5; Yuri Fedorov6; Paul Luciw6; David C. Muddiman1; Angela D.M. Kashuba2; Owain Roberts2; Rajith Rajoli2; Luigia Elzī2; Manuel Battegay2; David Back2; Marco Siccardi2
1University of North Carolina, Chapel Hill, NC, US; 2Université de Montréal, Montréal, Canada; 3Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; 4Obafemi Awolowo University, Ile-Ife, Nigeria; 5Bishop Murray Medical Centre, Makurdi, Nigeria; 6Obafemi Awolowo University, Ile-Ife, Nigeria

Session TD-O Themed Discussion
Room 6D
1:30 pm – 2:30 pm
Cancers in Young and Old, and Lung Cancer in HIV

Themed Discussion Leader
Eric A. Engels, National Cancer Institute, Bethesda, MD, US

724 Cancer in HIV-Infected Children: Record Linkage Study in South Africa
Julia Bohlius1; Nicky Maxwell1; Brian Eley1; Hans Prozesky1; Shobna Sawry1; Karl-Günter Technau1; Alan Davidson1; Cristina Stefan1; Matthias Egger2 on behalf of the iDeA Southern Africa
1University of the Witwatersrand, Johannesburg, South Africa; 2University of Cape Town, Cape Town, South Africa; 3Red Cross War Memorial Children's Hospital, Cape Town, South Africa; 4University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; 5Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; 6University of Bern, Bern, Switzerland

725 High Cancer Risk Among the HIV-Infected Elderly in the United States
Elizabeth L. Yanik1; Hornuzd A. Katki2; Eric A. Engels3 National Cancer Institute (NCI), Rockville, MD, US

726 Smoking Outweighs HIV-Related Risk Factors for Non–AIDS-Defining Cancers
Keri N. Althoff1; Stephen J. Gange1; Chad Achenbach1; Lisa P. Jacobson1; Angel M. Mayor2; Michael J. Silverberg3; Amy Justice3; Richard Moore1; Yuezhou Jing1; Kelly Gebo1 On behalf of the North American AIDS Cohort Collaboration on Research and Design
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3University Central del Caribe, Bayamon, US; 4Kaiser Permanente Northern California, Oakland, CA, US; 5Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, CT, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US

727 High Frequency of Early Lung Cancer Diagnosis With Chest CT in HIV-Infected Smokers
Alain Makinson1; Sabrina Eymard-Duveryre2; François Raffi3; Fabrice Bonnet4; Laurence Thirard4; Pierre Tattevin4; Sophie Abgrall4; Jacques Reynes5; Vincent Le Moing6 on behalf of the ANRS EP48 HIV CHEST Study Team
1University Hospital Montpellier, UMI233, Montpellier, France; 2UMI 233, IRD, University Montpellier 1, Montpellier, France; 3Nantes University Hospital, Nantes, France; 4University Hospital Bordeaux, Inserm U897, Bordeaux, France; 5Tourcoing University Hospital, Tourcoing, France; 6Pontchaillou University Hospital, Rennes, France; 7University Hospital Avicenne, Bobigny, France; 8ANRS, Paris, France
Session TD-R Themed Discussion  Room 6E
1:30 pm – 2:30 pm
Cryptococcal Meningitis: Host Response, Treatment, and Outcomes

Themed Discussion Leader
Judith A. Aberg, Icahn School of Medicine at Mount Sinai, New York, NY, US

834 Local and Systemic Humoral Responses to Cryptococcal Meningitis in Patients With AIDS
Erin E. Finn1; Jordan Janoff1; Jeremy Rahkola1; David B. Meya1; Samuel Okurut1; Andrew D. Kambuugu1; Paul Bohjanen1; Kirsten Nielsen1; David R. Boulware1; Edward N. Janoff1
1Mucosal and Vaccine Research Colorado, Aurora, CO, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3University of Minnesota, Minneapolis, MN, US

835 Antiretroviral Therapy Alters the CSF Immune Response in Cryptococcal Meningitis
James E. Scriven1; Britta Urban1; Lisa Graham1; Charlotte Schutz2; Robert J. Wilkinson1; David R. Boulware1; David Lalloo1; Graeme Meintjes3
1Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, United Kingdom; 4University of Minnesota, Minneapolis, MN, US

836 Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
Joshua Rhein1; Katherine H. Hullsiek1; Nathan C. Bahr1; Reuben Kiggundu1; Darlisha Williams2; Henry W. Nabeta1; Abdu Musubire1; David B. Meya1; David R. Boulware1
1University of Minnesota, Minneapolis, MN, US; 2University of Minnesota, Minneapolis, MN, US; 3Makerere University College of Health Sciences, Kampala, Uganda

Session TD-W Themed Discussion  Room 6AB
1:30 pm – 2:30 pm
Serosorting and Seroadaptive Behavior: What’s Your Position?

Themed Discussion Leader
Andrew E. Grulich, University of New South Wales, Sydney, NSW, Australia

1060 Trends in Sexual Behaviors Among Men Who Have Sex With Men in the United States, the Role of Antiretroviral Therapy and Seroadaptive Strategies
Gabriela Paz-Bailey1; Maria Mendoza1; Binh Le1; Charles E. Rose1; Teresa Finlayson1; Cyprian Wejnert1; Henry F. Raymond2; Joseph Prejean1
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2San Francisco Department of Public Health, San Francisco, CA, US

1061 Changes in Condomless Sex and Serosorting Among MSM After HIV Diagnosis
Christine M. Khosropour2; Julia C. Dombrowski2; David A. Katz2; Matthew R. Golden2
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US

1062 Serosorting and Sexual Risk Behavior Influenced by Perceived HIV Serostatus Among MSM
Kathleen A. Brady1; Jennifer Shinfield; Catherine Mezzacappa
1Philadelphia Department of Public Health, Philadelphia, PA, US
1063 Use of the Seroadaptive Strategies of Sexual Positioning and Serosorting by MSM in Nigeria
Cristina M. Rodriguez-Hart1; Hongjie Liu2; Hieany K. Orazulike3; Sam Zorowitz2; Sylvia Adebajo3; Lindsay Hughes1; Stefan Baral1; Merlin L. Robb1; William Blattner1; Manhattan Charurat1
1University of Maryland School of Medicine, Baltimore, MD, US; 2University of Maryland School of Public Health, College Park, MD, US; 3International Center on Advocacy and Rights to Health, Abuja, Nigeria; 4Massachusetts General Hospital and Harvard Medical School, Boston, MA, US; 5Population Council, Abuja, Nigeria; 6US Military HIV Research Program, Bethesda, MD, US; 7Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

Session TD-Z Themed Discussion
1:30 pm – 2:30 pm
Economic Implications of ART

Themed Discussion Leader
John Blandford, US Centers for Disease Control and Prevention, Atlanta, GA, US

1104 The Lifetime Medical Cost Savings From Preventing HIV in the United States
Bruce R. Schackman1; John Fleishman2; Amanda Su3; Richard Moore1; Rochelle Walensky2; David Patil2; Milton Weinstein1; Kenneth Freedberg1; Kelly Gebo3; Elena Losina2
1Weill Cornell Medical College, New York, NY, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Harvard School of Public Health, Boston, MA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Agency for Healthcare Research and Quality, Rockville, MD, US

1119 Survival Benefits Attributable to the Brazilian National ART Policy
Paula M. Luz1; Michael P. Girouard2; Beatriz Grinsztejn1; Kenneth Freedberg1; Valdilea Veloso1; Elena Losina2; Claudio Struchiner1; Robert Parker1; David Patil2; Rochelle Walensky2
1Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Harvard School of Public Health, Boston, MA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Agency for Healthcare Research and Quality, Rockville, MD, US

1110 The Cost-Effectiveness of Early ART Initiation in South Africa: A Quasi-Experiment
Jacob Bor1; Ellen Moscoe1; Natsayi Chimbindi1; Kobus Herbst1; Kevindra K. Naidu1; Frank Tanser1; Deenan Pillay1; Till Barnighausen1
1Boston University School of Public Health, Boston, MA, US; 2Charité Research Institute, Berlin, Germany; 3Yale School of Public Health, New Haven, CT, US; 4Wellcome Trust Africa Centre for Health and Population Studies, Soweto, South Africa

1111 Community-Based Strategies to Strengthen the Continuum of HIV Care Are Cost-Effective
Jennifer A. Smith1; Monisha Sharma2; Carol Levin2; Jared Baeten3; Heidi van Rooyen1; Connie Celum1; Timothy Hallett2; Ruamne V. Barnabas3
1Imperial College London, London, United Kingdom; 2University of Washington, Seattle, WA, US; 3Human Sciences Research Council, Sweetwaters, South Africa

1114 Global Fund Cost Projections for Implementing WHO 2013 Guidelines
Obinna Onyekwena1; Ade Fakoya1; Michael Johnson1; Michael Olszak-Olszewski1; Mark Dybul2
1The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland

Session 0-10 Oral Abstracts
Room 6C
4:00 pm – 6:15 pm
New Antiretroviral Agents, Strategies, and HIV Drug Resistance

Moderators
Constance Delaugerre, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France
Richard Harrigan, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

113LB Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy
David Wohl1; Anton Pozniak2; Melanie Thompson1; Edwin DeJesus1; Daniel Podzamczer2; Jean-Michel Molina3; Gordon Crofoot2; Christian Callebaut4; Hal Martin5; Scott McCallister6

114LB Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor
Carey Hwang1; Dirk Schürmann2; Christian Sobotha3; Heather Sevinsky4; Palanikumar Ravindran5; Hong Xiao6; Neelanjan Ray7; Mark Krystal1; Ira B. Dicker2; Max La Cattle3
1Bristol-Myers Squibb, Princeton, NJ, US; 2Charité Research Organisation, Berlin, Germany; 3Bristol-Myers Squibb, Wallingford, CT, US

115LB Early ART and IPT in HIV-Infected African Adults With High CD4 Count (Temprano Trial)
Christine Daniel1; Raoul Moh2; Delphine Gabillard1; Anani Badje3; Jerome Le Carrou1; Gerard M. Kouame4; Jean Baptiste Ntakpe1; Hervé Ménan5; Serge Eholie2; Xavier Anglaret1
1Inserm, Bordeaux, France; 2Université Felix Houphouët-Boigny, Abidjan, Côte d’Ivoire; 3Université Gabriel Péri, Abidjan, Côte d’Ivoire; 4Programme PACCI, Abidjan, Côte d’Ivoire; 5CHU de Treichville, Abidjan, Côte d’Ivoire
4:45 116 Antiretroviral Drug Screening Provides Key Insights Into HIV Drug Resistance
Iris Chen1; Matthew B. Connor2; William Clarke1; Mark A. Marzinke1; Vanessa Cummings1; Sheldon D. Fields3; Darrell P. Wheeler4; Kenneth H. Mayer1; Beryl A. Koblin5; Susan H. Eshleman6
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3Florida International University, Miami, FL, US; 4Loyola University Chicago, Chicago, IL, US; 5Fenway Health, Boston, MA, US; 6New York Blood Center, New York, NY, US

5:00 117 Untimed Drug Levels and Resistance in Patients Experiencing Low-Level HIV Viremia
Alejandro Gonzalez-Serna; Luke C. Swenson; Adriana Nohpal; Birgit Watson; Kate Auyeung; Julio Montaner; Richard Harrigan
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

5:15 118 Pretreatment HIV Drug Resistance Increases Regimen Switch in Sub-Saharan Africa
Tamara Sonia Boender1; Bernice M. Hoenderboom1; Kim C. Sigaloff2; Maureen Wellington3; Margaret Siwale4; Cissy M. Kityo5; Aliani Sulaimon Akanmu6; Mariette E. Botes7; Tobias F. Rinke de Wit8
1On behalf of the PASER Study Group; 2Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 3Newlands Clinic, Harare, Zimbabwe; 4Lusaka Trust Hospital, Lusaka, Zambia; 5Joint Clinical Research Centre, Kampala, Uganda; 6Lagos University Teaching Hospital, Lagos, Nigeria; 7Muelmed Hospital, Pretoria, South Africa

5:30 119 Impact of NRTI Cross-Resistance on Second-Line PI + NRTI Therapy Outcomes in Africa
Nicholas Paton1; Cissy Kityo2; Jennifer Thompson3; Leonard Bagenda2; James Hakim4; Joep van Oosterhout4; Andrew D. Kambuqu4; Anne Hoppe5; Sarah Walker6
On behalf of the EARNEST Trial Team
1National University of Singapore, Singapore, Singapore; 2Joint Clinical Research Centre, Kampala, Uganda; 3Infectious Diseases Institute, Kampala, Uganda; 4University of Malawi, Blantyre, Malawi; 5MRC Clinical Trials Unit at University College London, London, United Kingdom; 6University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe

5:45 120 Fitness Effects of Drug-Resistant Strains Across the United States HIV-1 Transmission Network
Joel O. Wertheim1; Alexandra M. Oster2; Neeraja Saduvala2; Walid Heneine3; Jeffrey A. Johnson4; William M. Switzer5; Angela L. Hernandez6; H. Irene Hall7
1University of California San Diego, San Diego, CA, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

6:00 121 Dolutegravir Resistance Requires Multiple Primary Mutations in HIV-1 Integrase
Arne Frantzell; Christos J Petropoulos; Wei Huang
Monogram Biosciences, South San Francisco, CA, US

Session S-4 Symposium Room 613
4:00 pm – 6:00 pm
Making Sense of Sensing: Innate Immunity and HIV Infection

Target audience: This session is directed to clinicians and scientists interested in innate immune defenses against HIV, viral countermeasures, and the relevance of the ongoing arms race between both of these for the pathogenesis and spread of AIDS.

Level of knowledge: It is assumed that participants are familiar with the basics of HIV replication.

Objectives: At the completion of the session, participants will be able to:
• Describe the most current understanding of how the human host senses, responds to, and restricts HIV infection, and how the virus evades or counteracts host defense mechanisms.
• Appreciate the role of innate immunity in the pathogenesis and spread of HIV disease.

Symposium Conveners
Nathaniel Landau, NYU School of Medicine, New York, NY, US
Jairam R. Lingappa, University of Washington, Seattle, WA, US

4:00 122 Role of Tetherin in the Evolution and Spread of HIV-1
Daniel Sauter
Ulm University Medical Center, Ulm, Germany

4:30 123-A Innate Sensing of HIV-1 in Macrophages
Martin R. Jakobsen
Aarhus University, Aarhus C, Denmark

5:00 124 Innate Sensing and Signaling to HIV-1 in Dendritic Cells
Teunis Geijtenbeek
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

5:30 125 How HIV-1 Evades DNA Sensors
Vineet KewalRamani
National Cancer Institute, Frederick, MD, US
Session S-5 Symposium
Room 6D
4:00 pm – 6:00 pm
Advancing HIV Prevention: Lessons from Biology, Medicine, and Public Health Law

Target audience: This session is directed to clinicians, scientists, and policy makers who are interested in developing or implementing HIV prevention programs for maximal benefit.

Level of knowledge: It is assumed that participants are familiar with basic HIV epidemiology and transmission, and the effect of antiretroviral drugs for preexposure prophylaxis and treatment as prevention.

Objectives: At the completion of the session, participants will be able to:

- Determine how new insights into HIV transmission can assist prevention programs.
- Describe the barriers to scale up of test-and-treat approaches and how the law can help (or inhibit) prevention efforts.

Symposium Conveners
Meg C. Doherty, World Health Organization, Geneva, Switzerland
Jeanne M. Marrazzo, University of Washington, Seattle, WA, US

4:00 126 The Biology of HIV Transmission: What We Think Know and How We Know It
Julie M. Overbaugh
Fred Hutchinson Cancer Research Center, Seattle, WA, US

4:30 127 HIV Phylogenetics: Lessons for HIV Prevention
Christophe Fraser
Imperial College London, London, United Kingdom

5:00 128 Optimizing ART: Treatment as Prevention in the US: Will It Be Enough?
Richard A. Elion
Whitman-Walker Health, Washington, DC, US

5:30 129 Criminalizing HIV: Recent Experience in the United States and Africa to Update Laws and Policies to Promote the Public Health
Jeffrey Crowley
Georgetown University, Washington, DC, US

Session S-6 Symposium
Room 6E
4:00 pm – 6:00 pm
Tuberculosis: Magic Bullets and Moving Targets

Target audience: This session is directed to clinicians and scientists interested in the pathogenesis, clinical manifestations, treatment, and prevention of tuberculosis (TB).

Level of knowledge: It is assumed that participants are familiar with basic TB epidemiology, clinical features, and treatment.

Objectives: At the completion of the session, participants will be able to:

- List new techniques for TB diagnosis.
- Describe new investigational TB treatment options and strategies.
- Describe the unique situation of children and pregnant women infected with TB.

Symposium Conveners
Alison Grant, London School of Hygiene and Tropical Medicine, London, United Kingdom
Ilesh V. Jani, Instituto Nacional de Saúde, Maputo, Mozambique

4:00 130 Advances in Mycobacterial Diagnostics
Mark P. Nicol
University of Cape Town, Cape Town, South Africa

4:30 131 New Medications, Innovative Approaches: Accelerate the TB Regimen Development Pipeline
Michael Hoelscher
University of Munich, Munich, Germany

5:00 132 Tuberculosis in Pregnancy
Amita Gupta
Johns Hopkins University School of Medicine, Baltimore, MD, US

5:30 133 Tuberculosis in Children
Anneke C. Hesseling
Stellenbosch University, Cape Town, South Africa
Thursday, February 26, 2015 • Oral Sessions

10:00 136 Statin Therapy Reduces Coronary Noncalcified Plaque Volume in HIV Patients: A Randomized Controlled Trial
Janet Lo1; Michael Lu2; Ezinne Ihenachor1; Jeffrey Wei1; Sara Looby2; Kathleen Fitch1; Suhyb Abbara3; Gregory Robbins1; Udo Hoffmann4; Steven Grinspoon5
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2University of Texas Southwestern Medical Center, Dallas, TX, US; 3University of Alabama at Birmingham, Birmingham, AL, US; 4University of California Los Angeles, Los Angeles, CA, US; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

10:15 137 Rosuvastatin Arrests Progression of Carotid Intima-Media Thickness in Treated HIV
Chris T. Longenecker1; Ying Jiang1; Sara M. Debanne1; Danielle Labbato2; Bruce Kinley3; Norma Storer4; Grace A. McComsey5
1Case Western Reserve University, Cleveland, OH, US; 2University of Alabama at Birmingham, Birmingham, AL, US; 3University of Southern California, Los Angeles, CA, US; 4University of Texas, Dallas, TX, US; 5Massachusetts General Hospital, Boston, MA, US

10:30 138 Calcified Plaque Burden Is Associated With Serum Gut Microbiota-Generated TMA in HIV
Suman Srinivasa1; Kathleen V. Fitch1; Janet Lo1; Hanane Kadar2; Kimberly Wong1; Suhyb Abbara3; Dominique Gaugquier4; Jacqueline Capeau1; Franck Boccara1; Steven K. Grinspoon5
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2University of Texas Southwestern Medical Center, Dallas, TX, US; 3University of Alabama at Birmingham, Birmingham, AL, US; 4University of Southern California, Los Angeles, CA, US; 5Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

10:45 139 Varenicline vs Placebo for Smoking Cessation: ANRS 144 Inter-ACTIV Randomized Trial
Patrick Merdji1; Caroline Roussillon2; Christine Katlama3; Aurélie Beuscart1; Samuel Ferret1; Nathalie Wirth1; David Zucman1; Xavier Duval1; Geneviève Chene1
On behalf of the ANRS 144 inter-ACTIV study group
1Inserm U897, Bordeaux, France; 2Hosp. Saint-Louis, Paris, France; 3Hosp. Saint-André, Bordeaux, France; 4Hosp. La Pitié-Salpêtrière, Paris, France; 5Hosp. De Brabois, Vandœuvre les Nancy, France; 6Hosp. Foch, Suresnes, France; 7CIC 1425, Paris, France

11:00 140 Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors
Grace A. McComsey1; Carlee Moser2; Judith S. Currier2; Heather Ribaudo2; Pawel Paczuski3; Michael P. Dube3; Robert L. Murphy3; Jennifer Rothenberg4; James H. Stein4; Todd T. Brown1
1Case Western Reserve University, Cleveland, OH, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4University of Wisconsin School of Medicine and Public Health, Madison, WI, US; 5University of Southern California, Los Angeles, CA, US; 6Northwestern University, Chicago, IL, US; 7Social & Scientific Systems, Inc., Silver Spring, MD, US; 8University of California Los Angeles, Los Angeles, CA, US

11:15 141 Fracture Prediction With Modified FRAX in Older HIV+ and HIV- Men
Michael T. Yin1; Melissa Skanderson1; Stephanie Shiu2; Katherine Harwood1; Josh Aschheim1; David Rimland2; Cynthia Gibert3; Maria Rodriguez-Barradas4; Roger Bedimo5; Julie Womack1
1Columbia University Medical Center, New York, NY, US; 2VAMC and Emory School of Medicine, Atlanta, GA, US; 3Arcadia Healthcare Solutions, New York, NY, US; 4Baylor College of Medicine, Houston, TX, US; 5VA Medical Center, George Washington University, Washington, DC, US; 6University of Texas, Dallas, TX, US; 7VA Connecticut Healthcare System, West Haven, CT, US

11:30 142 Exposure to Antiretrovirals (ARVs) and Development of Chronic Kidney Disease (CKD)
Amanda Mocroft1; Jens D. Lundgren1; Michael Ross2; Christoph Fux3; Peter Reiss4; Olivier Moranne5; Philippe Morlat6; Antonella d’Arminio Monforte1; Ole Kirk2; Lene Ryom2; 1University College London, London, United Kingdom; 2Copenhagen HIV Programme, Centre for Health and Infectious Diseases Network, University of Copenhagen, Denmark, Denmark; 3Division of Nephrology, Mount Sinai School of Medicine, New York, NY, US; 4Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 5Academic Medical Center, Div. of Infectious Diseases and Dept. of Global Health, University of Amsterdam, Amsterdam, Netherlands; 6Université de Bordeaux, Inserm U 897, Bordeaux, France; 7Public Health Department, Nice, France; 8Istituto Di Clinica Malattie Infettive e Tropicale, Milan, Italy
11:45    143LB    Renal and Bone Safety of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate
Paul E. Sax; Michael S. Saag; Michael T. Yin; Frank A. Post; Shinichi Oka; Ellen Koenig; Benoit Trotter; Jaime Andrade-Villanueva; Huyen Cao; Marshall W. Fordyce
1Gilead Sciences Inc, Foster City, CA, US; 2University of Alabama at Birmingham, Birmingham, AL, US; 3College of Physicians and Surgeons, Columbia University, New York, NY, US; 4King’s College Hospital, London, United Kingdom; 5Dominican Institute for Virologic Studies, Santo Domingo, Dominican Republic; 6Unidad de VIH del Hospital Civil de Guadalajara, Guadalajara, Mexico; 7Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, US; 8National Center for Global Health and Medicine, Japan, Tokyo, Japan; 9Clinique Medica1 l’Actuel, Montreal, Canada

10:45    148 The Paradox of Highly Effective Sofosbuvir Combo Therapy Despite Slow Viral Decline
Thi Huyen Tram Nguyen; Jérémie Guedj; Laetitia Canini; Anu Osinusi; Phillip S. Pang; John McHutchison; Henry Masur; Anita Kohli; Shayam Kotttil; Alan S Perelson
1IAME, UMR 1137, Inserm, F-75018 Paris, France; Univ Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France, France; 2Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, US; 3Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, US; 5Gilead Sciences Inc, Foster City, MD, US; 6NIH Clinical Center, Bethesda, MD, US

12:00    144 Special Presentation: Update on National Heart, Lung, and Blood Institute High-Impact AIDS Research
Monica Shah
National Heart, Lung, and Blood Institute, Bethesda, MD, US

Session 0-12 Oral Abstracts    Room 6AB
10:00 am – 12:00 pm
Curing HCV: Mission Accomplished

Moderators
Karine Lacombe, Saint Antoine Hospital, AP-HP, Paris, France
John W. Ward, Centers for Disease Control and Prevention, Atlanta, GA, US

10:00    145 The Burden of Liver Disease Among Persons With Hepatitis C in the United States
Monina Klevens; Xiaohua Huang; Anthony E. Yeo; Mounee Odeh; Rick L. Pesano; John W. Ward
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2Quest Diagnostics, Madison, NJ, US

10:15    146 High Efficacy of Daclatasvir/Asunaprevir/PR in HIV/HCV1-4 Null Responders (ANRS HC30)
Lionel Piroth; Hubert Paniez; Corinne Vincent; Karine Lacombe; David Rey; Didier Neau; Jacques Izopet; Alpha Diallo; Laurence Meyer; Jean-Michel Molina
1CHU Dijon, Dijon, France; 2Inserm, Paris, France; 3Hôpital Saint-Antoine, Paris, France; 4Strasbourg University Hospital, Strasbourg, France; 5CHU, Bordeaux, France; 6CHU, Toulouse, France; 7Inserm-ANRS, Paris, France; 8CHU Saint Louis, Paris, France

10:30    147 High SVR Regardless of Time to Suppression With ABT-450/OMBRATIVIR+RBV
David Wyles; Joseph J. Eron; Roger Trinh; Jay Lalezari; Chia Wang; Laveezza Bhatti; Peter Gillick; Barbara McGovern; Linda Fredrick; Mark Sulkowski

10:45    148 The Paradox of Highly Effective Sofosbuvir Combo Therapy Despite Slow Viral Decline
Thi Huyen Tram Nguyen; Jérémie Guedj; Laetitia Canini; Anu Osinusi; Phillip S. Pang; John McHutchison; Henry Masur; Anita Kohli; Shayam Kotttil; Alan S Perelson
1IAME, UMR 1137, Inserm, F-75018 Paris, France; Univ Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France, France; 2Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, US; 3Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, US; 4Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, US; 5Gilead Sciences Inc, Foster City, MD, US; 6NIH Clinical Center, Bethesda, MD, US

11:00    149 Real-World Pharmaceutical Costs in the Sofosbuvir Era: $164,485 per SVR4
Kian Bichoupan; Neeta Tandon; Rachana Vlamanchill; Neal M. Patel; Sweta Chekuri; Alyson Hardy; Thomas Schiano; Pooni V. Perumalswami; Douglas Dieterich; Andrea D. Branch
1Mount Sinai School of Medicine, New York, NY, US; 2Janssen Scientific Affairs, Titusville, NJ, US

11:15    150 Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients
Cindy Zahnd; Luisa P. Salazar-Vizcaya; Jean-François Dufour; Beat Müllhäupt; Gilles Wandeler; Roger Koyos; Barbara Bertisch; Andri Rauch; Olivia Keiser
On behalf of the Swiss HIV and Hepatitis C Cohort Studies
1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 2University Hospital Bern, Bern, Switzerland; 3University Hospital Zurich, Zurich, Switzerland

11:30    151LB Daclatasvir in Combination With Sofosbuvir For HCV/HIV Coinfection: ALLY-2 Study
David Wyles; Peter Ruane; Mark Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy Morgan; Kenneth E. Sherman; Zhaozhi Liu; Stephanie Noviello; Peter Ackerman
1University of California San Diego, La Jolla, CA, US; 2Ruane Medical and Liver Health Institute, Los Angeles, CA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Icahn School of Medicine at Mount Sinai, New York, NY, US; 5University of California and San Francisco General Hospital, San Francisco, CA, US; 6VA Long Beach Healthcare System, Long Beach, CA, US; 7University of Cincinnati College of Medicine, Cincinnati, OH, US; 8Bristol-Myers Squibb Co, Princeton, NJ, US

11:45    152LB Ledipasvir/Sofosbuvir for 12 Weeks in Patients Cofected With HCV and HIV-1
Susanna Naggie; Curtis Cooper; Michael S. Saag; Jenny C. Yang; Luisa M. Stamm; Phillip S. Pang; John McHutchison; Douglas Dieterich; Mark Sulkowski
On behalf of the ION-4 Study Team
1Duke Clinical Research Institute, Durham, NC, US; 2University of Ottawa, Ottawa, Canada; 3University of Alabama at Birmingham, Birmingham, AL, US; 4Gilead Sciences, Inc, Foster City, CA, US; 5Mount Sinai Health System, New York, NY, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US
Session 0-13 Oral Abstracts
10:00 am – 12:15 pm
Reaching Populations: Demonstrating Impact

Moderators
Sarah Fidler, Imperial College and Imperial College NHS Trust, London, United Kingdom
Jessica E. Justman, Columbia University Medical Center, New York, NY, US

10:00 153 Population Viral Load in Three High HIV Prevalence Settings in Sub-Saharan Africa
David Maman1; Helena Huerga1; Gilles Van Cutsem2; Irene Mukui1; Benson Chilima4; Beatrice Kirubi2; Ruggero G. Giuliani3; Elisabeth Szumilin4; Charles Masiku2; Jean-François Etard4
1Epicentre/Médecins Sans Frontières, Paris, France; 2National AIDS and STDS Control Program, Nairobi, Kenya; 3Ministry of Health, Lilongwe, Malawi; 4Médecins Sans Frontières, Nairobi, Kenya; 5Médecins Sans Frontières, Paris, France; 6Médecins Sans Frontières, Malawi

10:15 154 Disparities in Engagement Within HIV Care in South Africa
Simbarashe Takuva1; Alison Brown2; William Macleod4; Yogan Pillay4; Valerie Delpech2; Adrian J. Puren1
1National Institute for Communicable Diseases, NHLS, Johannesburg, South Africa; 2Centre for Infectious Diseases Surveillance, Public Health England, London, United Kingdom; 3Boston University, Boston, MA, US; 4National Department of Health, Pretoria, South Africa

10:30 155 Decentralizing Access to Antiretroviral Therapy Services for Adults in Swaziland
Andrew F. Auld1; Harrison Kamiru1; Charles Azih1; Andrew L. Baughman1; Harriet Nuwagaba-Biribonwoha4; Peter Ehrenkranz4; Simon Agolory5; Tedd V. Ellerbrock6; Velephi Okello7; George Bicego1
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2ICAP, Columbia University, New York, NY, US; 3Ministry of Health, Mbabane, Swaziland

10:45 156 Who Are the 10-Year AIDS Survivors on Antiretroviral Therapy in Haiti?
Samuel Pierre1; Ashita Batavia1; Patrice Severe1; Vanessa Rouzier1; Benedict Charles1; Jean Pape1; Warren Johnson1; Daniel Fitzgerald1; Margaret L. McNairy2
1On behalf of Les Centres GESKIO CTU; 2Les Centres GESKIO, Port-au-Prince, Haiti; 3Weill Cornell Medical College, New York, NY, US

11:00 157 Nationwide Evaluation of Antiretroviral Therapy Coverage on Prevention in Rwanda: A Multisectional Time-Trend Analysis
Sabin Nsanzima1; Eric Remera1; Steve Kanters1; Eric Dusuzzle2; Adeline Dukuzze2; Till Barnighausen1; Eran Bendavid2; Julio Montaner1; Edward Mills2
On behalf of the Rwanda Treatment as Prevention Working Group
1Stanford University, Vancouver, Canada; 2Rwanda Biomedical Centre, Kigali, Rwanda; 3Harvard School of Public Health, Boston, MA, US; 4BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

11:15 158 Impact of Male Circumcision Scale-Up on Community-Level HIV Incidence in Rakai, Uganda
Xiangrong Kong1; Godfrey Kigozi1; Fred Kalungu2; David Serwadda3; Maria J. Wawer1; Ronald H. Gray1
On behalf of the Rakai Health Sciences Program
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Entebbe, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda

11:30 159 Effects of Antiretroviral Treatment on Health Care Utilization in Rural South Africa
Jan A. Hontelez1; Frank Tanser2; Sake J. de Vlas1; Kevindra K. Naidu2; Rob Baltussen3; Deenan Pillay4; Till Barnighausen1
1On behalf of the Rakai Health Sciences Program
2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Rakai Health Sciences Program, Entebbe, Uganda; 4Makerere University College of Health Sciences, Kampala, Uganda

11:45 160 The Impact of PEPFAR Abstinence and Faithfulness Funding Upon HIV Risk Behaviors in Sub-Saharan Africa
Nathan C. Lo1; Anita Lowe2; Eran Bendavid3
1Stanford University School of Medicine, Stanford, CA, US
2Vanderbilt University, Nashville, TN, US; 3Stanford University, Vancouver, Canada

12:00 161 The Impact of Antiretroviral Therapy on Adult Life Expectancy in Sub-Saharan Africa
Georges Reniers1; Jeffrey Eaton1; Jessica Nakayingi-Miio1; Amelia C. Campin1; Chodziwadzwa Kabudula2; Kuous Herbst1; Mark Urassa3; Amek Nyaguara6; Emma Slamaxkaya7
On behalf of the ALPHA Network
1Imperial College London, London, United Kingdom; 2MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 3Africa Centre for Health and Population Studies, Muthatuba, South Africa; 4Karonga Prevention Study, Chilumba, Malawi; 5University of the Witwatersrand, Johannesburg, South Africa; 6National Institute for Medical Research, Mwanza, United Republic of Tanzania; 7Kenya Medical Research Institute-Centers for Disease Control, Kisumu, Kenya; 8London School of Hygiene and Tropical Medicine, London, United Kingdom
Session 0-14 Oral Abstracts
Program and Agenda

Room 613
10:00 am – 12:15 pm

Immune Mechanisms: The Road to Protection

Moderators
Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, US
Bruce Walker, Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US

10:00 162  Passively Acquired ADCC Activity in HIV-Infected Infants Correlates With Survival
Caitlin Milligan1; Barbra A. Richardson1; Grace John-Stewart1; Ruth W. Ndubui1; Julie M. Overbaugh1
1Fed Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya

10:15 163  AAV-Expressed eCD4-Ig Protects Rhesus Macaques From Multiple SHIV-AD8 Challenges
Michael Farzan
The Scripps Research Institute, Jupiter, FL, US

10:30 164LB  HIV Neutralizing Antibodies Induced by Native-Like Envelope Trimers
Rogier Sanders
The WCMC/Scripps/AMC HIVRAD team
Academic Medical Center University of Amsterdam, Amsterdam, Netherlands

10:45 165  Efficacy Loss of BnAbs During HIV-1 Cell-Cell Spread Is Strain- and Epitope-Dependent
Lucia Reh; Carsten Magnus; Merle Schanz; Jacqueline Weber; Therese Uhr; Peter Rüser; Alexandra Trkola
University of Zurich, Zurich, Switzerland

11:00 166  Peripheral T Follicular Helper Cells With Universal Helper Activity in HIV Infection
Bruce Schultz; Alexander Oster; Franco Pissani; Jeffrey E. Teigler; Michael A. Eller; Merlin L. Robb; Jerome H. Kim; Nelson L. Michael; Diane Bolton; Hendrik Streeck
US Military HIV Research Program, Silver Spring, MD, US

11:15 167  Redirected Killing of HIV-Infected T Cells by Germinal Center CD8 T Cells
Constantinos Petrovas1; Sara Ferrando-Martinez1; Michael Gerner1; Amarendra Pegu1; Perla Del Rio-Estrada1; Kristin Boswell1; Manuel Leal1; Gustavo Reyes-Teran1; Ronald Germair1; Richard A. Koup1
1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2NIAID-NIH, Bethesda, MD, US; 3Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 4Instituto de Biomedicina de Sevilla, Sevilla, Spain

11:30 168  IL-21 Reduces Inflammation and Virus Persistence in ART-Treated SIV-Infected Macaques
Luca Micci1; Emily Ryan2; Colleen McGary3; Sara Paganini1; Guido Silvestri1; Mike Piatak2; Jeffrey Lifson2; Francois Villinger1; Jason M. Brenchley2; Mirko Paiardini1
1Yerkes National Primate Research Center, Emory University, Atlanta, GA, US; 2Leidos Biomedical Research, Inc, Frederick, MD, US; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

11:45 169  Discovery of CD8+ T Cell Epitope Epitopes Encoded by the HIV 5' Leader Sequence
Edward Kreider1; Katja J. Pfafferott2; Thomas Partridge2; Hui Li1; Ranjit Warrier1; Benedikt M. Kessler1; Andrew J. McMichael1; Persephone Borrow2; Beatrice H. Hahn1; George M. Shaw1
1University of Pennsylvania, Philadelphia, PA, US; 2University of Oxford, Headington, United Kingdom

12:00 170LB  Neutralizing Antibodies Differ Between HIV-1—Infected RV144 Vaccines and Placebos
Shelly J. Krebs1; Morgane Rolland2; Sodasi Tvanabutra2; Ivelin Georgiev3; Agnes-Laurence Chene1; Victoria R. Polonis3; Supachai Reks-Ngarm3; Peter D. Kwong2; Nelson L. Michael1; Jerome H. Kim1
On behalf of the RV152 Study Group
1US Military HIV Research Program, Silver Spring, MD, US; 2Vaccine Research Center, NIAID-NIH, Bethesda, MD, US; 3Ministry of Public Health, Bangkok, Thailand

Session TD-M Themed Discussion

Room 615
1:30 pm – 2:30 pm

Identifying Recent Infections: Issues of False Recency

Themed Discussion Leader
Michael Busch, Blood Systems Research Institute, San Francisco, CA, US

612  A Generalized Entropy Measure of Viral Diversity for Identifying Recent HIV-1 Infections
Julia W. Wu; Oscar Patterson-Lomba; Marcello Pagano
Harvard School of Public Health, Boston, MA, US

626  Viral Load is Critical in Limiting False-Recent Results From HIV Incidence Assays
Reshma Kassanjee1; Shelley Facente2; Sheila Keating1; Elaine McKinnie3; Kara Marson1; Christopher D. Pilcher2; Michael Busch3; Gary Murphy4; Alex Welte1
On behalf of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
1South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), University of Stellenbosch, Stellenbosch, South Africa; 2University of California San Francisco, San Francisco, CA, US; 3Public Health England, London, United Kingdom
625 False Recent Rates for Two Recent Infection Testing Algorithms, South Nyanza, Kenya
Clement Zeh1; David Maman; Harrison Omondi2; Alex Morwabe1; Collins Odhiambo1; Beatrice Kirubi3; Irene Mukuli1; Martinus W. Borgdorff4; Jean-François Etard1; Andrea A. Kim1
1US Centers for Disease Control and Prevention, Kisumu, Kenya; 2Kenya Medical Research Institute, Kisumu, Kenya; 3National AIDS and STI Control and Prevention, Nairobi, Kenya; 4 Médecins Sans Frontières, Paris, France

622 The Effect of HIV-1 Subtype A, C and D on Cross-Sectional Incidence Assay Performance
Andrew F. Longoza1; Mary Grabowski1; Charles S. Morrison1; Ronald H. Gray2; Connie Celum3; Quarraisha Abdo1; Karim1; Hilmarie Brand4; Thomas C. Quinn5; Susan H. Eshleman6; Oliver B. Laeyendecker7
1National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3FHI 360, Durham, NC, US; 4University of Washington, Seattle, WA, US; 5CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 6SACEMA, Stellenbosch University, Stellenbosch, South Africa

Session TD-N Themed Discussion
Room 6AB
1:30 pm – 2:30 pm
Next-Generation HCV Therapeutics: From Clinical Trials to the Clinic

Themed Discussion Leader
Debika Bhattacharya, University of California Los Angeles CARE Center, Los Angeles, CA, US

646 German Cohort on Sofosbuvir-Based Therapy for HIV/ HCV and HCV Infection (GECOSO)
Stefan Christensen1; Ingiliz Patrick1; Dietrich Hueppe2; Thomas Lutz3; Karl Georg Simon4; Knud Schewe5; Heiner Busch6; Axel Baumgarten7; Guenther Schmutz1; Stefan Mauss1
1Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; 2CIM Infectious Diseases, Muenster, Germany; 3Medizinisches Infektiologisches Zentrum Berlin, Berlin, Germany; 4Institut für Infektiologie, Frankfurt, Germany; 5Infektiomsmedizinisches Zentrum Hamburg, Hamburg, Germany; 6Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7Practice for Gastroenterology Herne, Herne, Germany

649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients
Jennifer L. Grant1; Valentina Stosor1; Frank J. Palella1; Richard M. Green1; Guajira Thomas1; Donna V. McGregor1; Milena M. McLaughlin2; Sudhir Penugonda1; Michael Angarone1; Stefan Mauss1; Claudia Hawkins1
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Midwestern University, Chicago, IL, US

645 Effectiveness of Sofosbuvir/Simeprevir for HCV/HIV Patients in Clinical Practice
Jody Gilmour1; Kenneth Lynn2; Delisha Breen3; Stacey Trooskin4; Jihad Slim5; Nancy Scangarelli6; Alvin Kingcade7; Katie Hunykh8; Vincent Lo Re9; Jay R. Kostman1
1Perelman School of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Philadelphia Health Management Corporation, Philadelphia, PA, US

648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs
Ponni V. Perumalswami1; Kian Bichoupan2; Lawrence Ku3; Neal M. Patel1; Rachana Yalamanchili1; Thomas Schiano1; Mark Woodward1; Douglas Dieterich1; Andrea A. Kim1
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2George Institute for Health at the University of Oxford, Oxford, United Kingdom

651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir
Rebecca Cope1; Aaron Pickering2; Thomas Glowa3; Samantha Faulds4; Peter Veldkamp1; Ramakrishna Prasad1
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Maryland, Glen Burnie, MD, US

644 Sofosbuvir, Simeprevir, +/- Ribavirin in HCV Protease Inhibitor-Experience Patients
Kristen M. Marks1; Ethan M. Weinberg2; Sonal Kumar3; Carrie Down4; Ype P. de Jong5; Lea A. Burke6; Mary C. Olson7; Ira M. Jacobson8
Weill Cornell Medical College, New York, NY, US

Session TD-P Themed Discussion
Room 6E
1:30 pm – 2:30 pm
Cardiovascular Risk Prediction: Can We Do Better?

Themed Discussion Leader
Nina Friis-Møller, Odense University Hospital, Odense, Denmark

746 Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction
Jorge L. Salinas1; Christopher T. Rentsch1; Vincent C. Marconi1; Janet Tate1; Adeel A. Butt2; Matthew S. Freiberg2; Matthew B. Goetz3; Maria Rodriguez-Barradas3; Amy Justice4; David Rimland1
1Emory University, Atlanta, GA, US; 2Atlanta VA Hospital, Decatur, GA, US; 3Yale University, New Haven, CT, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 6Baylor College of Medicine, Houston, TX, US

747 Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS)
Angela M. Thompson-Paul1; Kenneth A. Lichtenstein2; Carl Armon3; Kate Buchacz4; Rachel Debes5; Joan S. Chmiel6; Frank J. Palella7; Stanley C. Wei1; Jacek Skarbinski1; John T. Brooks1
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2National Jewish Health, Denver, CO, US; 3Cerner Corporation, Vienna, VA, US; 4Northwestern University, Feinberg School of Medicine, Chicago, IL, US

748 Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD
Daniel R. Drozd1; Mari M. Kitahata2; Keri N. Althoff2; Jinbing Zhang1; Susan R. Heckbert1; Matthew J. Budoff1; Frank J. Palella1; Daniel B. Klein1; Richard D. Moore1; Heidi M. Crane1
Program and Agenda

Oral Sessions • Thursday, February 26, 2015

750 HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins?  
Meredith E. Clement1; Lawrence Park2; Ann Marie Navar-Boggan3; 
Nwora L. Okeke4; Michael Pencina5; Pamela Douglas4; Susanna Naggie1  
1Duke University, Durham, NC, US; 2Duke University, Durham, NC, US; 
3Duke University, Durham, NC, US

751 Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients  
Susan Regan1; James B. Meigs2; Joseph Massaro3; Ralph B. D’Agostino4; 
Steven Grinspoon3; Virginia A. Trimian1  
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Boston University, Boston, MA, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Session TD-T Themed Discussion  
Room 6D  
1:30 pm – 2:30 pm  
Keys to the Kingdom: Viral Suppression in Pregnant and Postpartum Women

Themed Discussion Leader  
Laurent Mandelbrot, Hospital Louis Mourier, Colombes, France

863 Specific Effects of ZDV, 3TC and LPV/r on HIV-1 RNA Viral Load During Pregnancy  
Patumrat Sripan1; Sophie Le Coeur2; Lily Ingsrisawang3; Tim R. Cressey4; Jean-Marc Tréluyer5; Naim Bouazza6; Frantz Foissac7; Gonzague Jourdain8; Marc G. Lallemand9; Saïk Urien10  
1ED420, University of Paris Sud 11, Paris Descartes, Paris, France; 2PHPT-IRD UMI 174, Chiang Mai, Thailand/Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 3Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 4PHPT-IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University; 5Harvard School of Public Health, Chiang Mai, Thailand; 6EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Paris, France; 7Institut d’Études Démographiques, Institut de Recherche Pour le Développement (UMR 196 CEPED), Paris, France/Harvard School of Public Health, Boston, MA, USA/Faculty of Associated Medical Science, Chiang Mai University, Chiang Mai, Thailand; 8EA 08 UniversitéParis Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, Service de Pharmacologie Clinique, AP-HP, Groupe Hospitalier Paris Centre, CIC-0901 Inserm, Cochin-Necker, Paris, France; 9EA 08 UniversitéParis Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP, Hôpital Tarnier, CIC-0901 Inserm, Cochin-Necker, Paris, France

865 Maternal Viral Load in the Context of PMTCT B+ Within the Kabeho Study in Kigali  
Emily A. Bobrov1; Placidie Mugwaneza2; Gilles F. Ndjayisaba2; Dieudonne Ndahimana3; Michelle Gill4; Heather J. Hoffman5; Cyprien Baribwira6; Laura Guay7; Anita Asiimwe8  
On behalf of the Kabeho Study Team  
1Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 2Ministry of Health, Kigali, Rwanda; 3Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda; 4George Washington University Milken Institute School of Public Health, Washington, DC, US; 5University of Maryland, School of Medicine, Kigali, Rwanda; 6Rwanda University Teaching Hospitals, Kigali, Rwanda

Session TD-V Themed Discussion  
Room 6C  
1:30 pm – 2:30 pm  
PEP: Remember Me?  

Themed Discussion Leader  
Kenneth H. Mayer, Fenway Health, Boston, MA, US

959 Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials  
Lorna Leal1; Agathe Leon2; Berta Torres3; Alexy Inciarte1; Constanza Lucero4; Josep Mallolas5; Maria Martinez-Reboll6; Ana González-Cordon1; Jose M. Gatell7; Felipe Garcia8  
1Hospital Clinic Barcelona, Barcelona, Spain; 2Ministry of Health, Kigali, Rwanda; 3Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 4Weerawat Manosuthi1; Varaporn Thientong1; Patama Sutha1; Surasak Wiboonchutikul2; Boonchai Rowadisai4; Weerawat Manosuthi1

958 Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis  
Rosalind Foster1; John McAllister2; Tim R. Read3; Anna Pierce4; Robyn Richardson1; Anna McNulty1; Andrew Carr2  
On behalf of the EPEP Study Researchers  
1Sydney Sexual Health Centre, Sydney, Australia; 2St Vincent’s Centre for Applied Medical Research, Sydney, Australia; 3Melbourne Sexual Health Centre, Melbourne, Australia; 4The Alfred Hospital, Melbourne, Australia

957 Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis  
Surasak Wiboonchutikul1; Varaporn Thientong2; Patama Sutha3; Boonchai Rowadisai4; Weerawat Manosuthi1  
1Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand; 2Bangkok Hospital, Bangkok, Thailand
Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learned

Goli Haidari; Naomi Fitzgerald; Sonia Raffe; Nneka Nwokolo; Olamide Dosekun; Mark D. Lawton; Nickie Mackie; Julie Fox; Martin Fisher; Sarah Fidler

1St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 2Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 4Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 5The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 6St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 7Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 8Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 9St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom

Symposium Conveners

Steven Bosinger, Emory University, Yerkes National Primate Research Center, Atlanta, GA, US
Raphael Gottardo, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

4:00  171 Using Systems Approaches to Study Pathogenesis: Bridging Networks and Mechanisms
Nevan Krogan
University of California San Francisco, San Francisco, CA, US

4:30  172 Molecular Basis of T-Cell Exhaustion
E. John Wherry
University of Pennsylvania, Philadelphia, PA, US

5:00  173 A Systems Biology Approach to Identify Targets and Mechanisms of HIV Latency and HIV Eradication
Rafick P. Sekaly
Case Western Reserve University, Cleveland, OH, US

5:30  174 Translating Anti–HIV-1 Immune Mechanisms Into Clinical Interventions
Sallie R. Permar
Duke University, Durham, NC, US

Session S-7 Symposium

Room 613

4:00 pm – 6:00 pm

From Pathways to Paradigms: Applications of Systems Biology to HIV/Host Interactions

Target audience: This session is directed to scientists and clinicians who are interested in recent advances in the use of RNA profiling, transcriptomic analyses, microarrays, and other state-of-the-art methodologies in an integrated approach (ie, systems biology) to probe new insights and hypotheses in HIV and SIV pathogenesis, prevention, and treatment.

Level of knowledge: It is assumed that participants are familiar with the basic concepts and challenges in the fields of HIV pathogenesis, prevention, and treatment and have some familiarity with the cellular processes that underlie the molecular biology of viral–host interactions.

Objectives: At the completion of the session, participants will be able to:

• Recognize how integrative approaches to profiling RNA transcription can be applied to provide new interpretations of relevant problems in HIV pathogenesis research.
• Appreciate how a systems-biology approach can generate new hypotheses for developing novel interventions for HIV prevention and therapy.
• Discuss emerging technologies and bioinformatics analyses that have enabled molecular signatures and networks to be identified and applied to relevant questions for HIV and other infectious pathogens.

Session S-8 Symposium

Room 6D

4:00 pm – 6:00 pm

Scale-Up of Interventions

Target audience: This session is directed to researchers and programmers interested in the scale-up of HIV programs around the world.

Level of knowledge: It is assumed that participants are familiar with HIV prevention methods, the impact of HIV on key populations, HIV testing approaches, laboratory assays in support of HIV prevention, and HIV care and treatment.

Objectives: At the completion of the session, participants will be able to:

• Describe scientific evidence relating to male circumcision and its programmatic scale-up for HIV prevention.
• Describe scientific bases for interventions for people who inject drugs.
• Describe recent evidence and trends concerning scale-up of HIV testing.
• Describe the role of laboratory infrastructure and systems required to support HIV/AIDS program scale-up.

Symposium Conveners

Linda-Gail Bekker, Desmond Tutu HIV Foundation, Cape Town, South Africa
Kevin M. De Cock, Centers for Disease Control and Prevention, Nairobi, Kenya

4:00  175 From Equipoise to Efficacy to Millions Reached With Voluntary Medical Male Circumcision for HIV Prevention
Jason B. Reed
US Department of State, Office of the Global AIDS Coordinator, Washington, DC, US
4:30  176  Scale-Up of HIV Interventions for People Who Inject Drugs: Quality and Coverage
Anna Deryabina
ICAP at Columbia University, Almaty, Kazakhstan

5:00  177  HIV Testing and Counseling: Emerging Issues, New Directions
Rachel C. Baggaley
World Health Organization, Geneva, Switzerland

5:30  178  Ten Years of Strengthening Laboratory Services and Systems: Then, Now, and the Future
John Nkengasong
US Centers for Disease Control and Prevention, Atlanta, GA, US

Session S-9 Symposium  Room 6E
4:00 pm – 6:00 pm
HCV: New Frontiers and Controversies

Target audience: This session is directed to persons who are interested in the basic science, public health impact, and management of hepatitis C virus (HCV) infections.

Level of knowledge: It is assumed that participants are familiar with general concepts of virology and medicine.

Objectives: At the completion of the session, participants will be able to:
• Describe the mechanisms by which HCV affects the liver.
• Recognize the cells that HIV infects within the liver.
• Describe the impact of HCV eradication on HCV transmission, and the pitfalls.

Symposium Conveners
Chloe M. Orkin, Barts Health NHS Trust, London, United Kingdom
David L. Wyles, University of California San Diego, La Jolla, CA, US

4:00  179  Pathogenesis of Acute HCV Infection
Ashwin Balagopal
Johns Hopkins University School of Medicine, Baltimore, MD, US

4:30  180  HCV Treatment as Prevention: Challenges and Opportunities
Gregory Dore
University of New South Wales, Sydney, Australia

5:00  181  HCV Therapeutics: It's the Virus, Stupid
Mark S. Sulkowski
Johns Hopkins University School of Medicine, Baltimore, MD, US

5:30  182  HCV Therapeutics: Big Sticks With Big Stickers
Marion G. Peters
University of California San Francisco, San Francisco, CA, US
POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in the Poster Hall from 2:30 PM to 4:00 PM on the scheduled day.

A: Virology
P-A1: Cellular Innate Immunity: Tuesday, 2/24/2015
P-A2: Nucleus Entry, Integration, and Export: Wednesday, 2/25/2015
P-A3: SAMHD1: Tuesday, 2/24/2015
P-A4: Enhancers and Inhibitors of Viral Infectivity and Entry: Thursday, 2/26/2015
P-A5: Envelopes, Receptors, and Tropism: Wednesday, 2/25/2015
P-A6: Nef Functions: Thursday, 2/26/2015

B: Molecular Epidemiology and HIV/SIV Evolution
P-B1: Viral Origins and Recombinant Forms: Thursday, 2/26/2015
P-B2: Defining Epidemiologically Linked Transmission: Tuesday, 2/24/2015
P-B3: Transmission Clusters: Wednesday, 2/25/2015
P-B4: Transmission Networks: MSM: Tuesday, 2/24/2015
P-B5: Next Generation of Next-Generation Sequencing: Thursday, 2/26/2015

C: Pathogenesis—Human Studies and Animal Models
P-C1: The Gut Microbiome: Tuesday, 2/24/2015
P-C2: The Mucosa in HIV/SIV Pathogenesis: Tuesday, 2/24/2015
P-C3: Innate and Unconventional T-Cell Responses: Wednesday, 2/25/2015
P-C4: Monocytes, Dendritic Cells, and Neutrophils: Wednesday, 2/25/2015
P-C5: Studies of HIV-Exposed Uninfected Individuals: Tuesday, 2/24/2015
P-C6: Host Factors in HIV Pathogenesis: Tuesday, 2/24/2015
P-C7: HIV/CMV Interactions in Transmission and Pathogenesis: Thursday, 2/26/2015
P-C8: Aging and Immune Senescence: Thursday, 2/26/2015
P-C9: Immune Pathogenesis of IRIS: Tuesday, 2/24/2015
P-C10: Cellular Factors of Latency: Thursday, 2/26/2015
P-C11: Manipulating Immune Activation: Wednesday, 2/25/2015
P-C12: Pathogenesis in Lymph Nodes: Thursday, 2/26/2015
P-C13: Dissecting Pathogenesis Through In Vitro Studies: Thursday, 2/26/2015
P-C14: Dissecting Pathogenesis Through In Vivo Studies: Thursday, 2/26/2015

E: Host Immune Responses to Infection, Vaccines, and Immunotherapy
P-E1: The Effect of HIV Infection on B Cells: Tuesday, 2/24/2015
P-E2: The Envelope/Antibody Dynamic: Tuesday, 2/24/2015
P-E3: New Approaches to Immunostimulation: Wednesday, 2/25/2015
P-E4: Cellular Immune Response to HIV: Thursday, 2/26/2015

F: HIV Persistence, Reservoirs, Latency, Eradication, including Gene Therapy
P-F1: Immune-Based Strategies in Latency: Tuesday, 2/24/2015
P-F2: Viral Reservoir Dynamics During ART: Thursday, 2/26/2015
P-F3: Cellular Factors of Latency: Thursday, 2/26/2015
P-F4: Dynamics of Latency and Reactivation: Wednesday, 2/25/2015
P-F5: Gene Editing: Wednesday, 2/25/2015
P-F6: HDAC Inhibitors: Tuesday, 2/24/2015
P-F7: Pharmacologic Latency-Reactivation Agents: Tuesday, 2/24/2015
P-F8: Latency Models and Assays: Wednesday, 2/25/2015
P-F9: Stem Cell Transplantation: Wednesday, 2/25/2015

G: Neuropathogenesis
P-G1: CNS Reservoirs: Tuesday, 2/24/2015
P-G2: Optimizing ART for HAND Treatment and Prevention: Tuesday, 2/24/2015
P-G3: Neurologic Disorders in Resource-Limited Settings: Wednesday, 2/25/2015
P-G4: HAND Genetics: Thursday, 2/26/2015
P-G5: HAND Diagnosis and Predictors: Tuesday, 2/24/2015
P-G6: Inflammation and Markers of Brain Injury in HAND: Thursday, 2/26/2015
P-G7: Aging and Cognitive Decline: Wednesday, 2/25/2015
P-G8: Mitochondrial Dysfunction in HAND and Depression: Thursday, 2/26/2015
P-G9: Neuropathogenesis Mechanisms: Thursday, 2/26/2015

H: Clinical Pharmacology
P-H1: Pharmacokinetics, Pharmacodynamics, and Adherence: Tuesday, 2/24/2015
P-H2: Pharmacogenomics: Tuesday, 2/24/2015
P-H3: Drug-Drug Interactions: Tuesday, 2/24/2015
P-H4: Pharmacokinetics in Compartments and Reservoirs and of Novel Formulations: Thursday, 2/26/2015

I: Antiretroviral Therapy: Preclinical Studies
P-I1: Drug Development: Wednesday, 2/25/2015

J: Antiretroviral Therapy: Randomized Clinical Trials
P-J1: ART: Recent Perspectives: Tuesday, 2/24/2015

K: Antiretroviral Therapy: Observational Studies
P-K1: ART: Adherence, Adherence, Adherence: Tuesday, 2/24/2015
P-K2: ART: Monitoring and Biomarkers: Tuesday, 2/24/2015
P-K4: ART: Mortality: Wednesday, 2/25/2015
L: HIV Drug Resistance
P-L1: HIV Drug Resistance: Mechanisms and Mutations: Thursday, 2/26/2015
P-L2: HIV Subtypes and Resistance: Thursday, 2/26/2015
P-L4: HIV Drug Resistance: Global Perspective and Clinical Implications: Thursday, 2/26/2015

M: HIV Diagnostics
P-M1: Nucleic-Acid–Based Detection of HIV: Tuesday, 2/24/2015
P-M2: Comparison of HIV Incidence Assays: Wednesday, 2/25/2015

N: Hepatitis Viruses
P-N1: Natural History and Prognosis of HCV Infection: Tuesday, 2/24/2015
P-N2: HCV Therapy: Observations From Cohort Studies: Tuesday, 2/24/2015
P-N3: Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits: Tuesday, 2/24/2015
P-N4: HCV: Getting the Drugs to Those Who Need Them: Tuesday, 2/24/2015
P-N5: HCV: Epidemiology and Case Detection: Wednesday, 2/25/2015
P-N6: Acute HCV Infection: Wednesday, 2/25/2015
P-N7: Immunopathogenesis of HCV Infection: Wednesday, 2/25/2015
P-N8: HCV Therapeutics: Preclinical Observations and Clinical Trials of DAAs: Thursday, 2/26/2015
P-N9: Mental Health and Treatment Adherence with Direct-Acting Antivirals: Thursday, 2/26/2015
P-N10: HCV: Resistance to Antiviral Agents: Thursday, 2/26/2015
P-N11: Other Hepatitis Viruses: HBV, HDV, HEV: Thursday, 2/26/2015

O: HIV-Related and Non–HIV-Related Malignancies
P-O1: HPV Infections and Cancers: Tuesday, 2/24/2015
P-O2: AIDS-Related Cancers: Lymphoma and KS: Wednesday, 2/25/2015
P-O3: Cancer and Cancer Risk in HIV Subpopulations and Lung Cancer: Thursday, 2/26/2015

Q: Other Complications of HIV Infection and Antiretroviral Therapy
P-Q1: Inflammation: Biomarkers and Relationship to Outcomes: Tuesday, 2/24/2015
P-Q2: Bone Metabolism and ART: Mechanisms and Outcomes: Tuesday, 2/24/2015
P-Q3: Bone Disease: Mechanisms of Bone Loss and Fracture Risk: Tuesday, 2/24/2015
P-Q4: Measuring Bone Density: Tuesday, 2/24/2015
P-Q6: Aging: Frailty, Telomeres, and mtDNA: Tuesday, 2/24/2015
P-Q7: Diabetes and Other Endocrine Disorders: Tuesday, 2/24/2015
P-Q8: Renal Dysfunction: ART and Biomarkers: Thursday, 2/26/2015
P-Q9: Renal Transplantation: Long-Term Outcomes: Thursday, 2/26/2015
P-Q10: Pulmonary Disease: Thursday, 2/26/2015
P-Q11: Body Composition and Risk Factors for Abnormalities: Thursday, 2/26/2015
P-Q12: Complications: Liver Disease Without Viral Hepatitis: Thursday, 2/26/2015
P-Q13: Depression and Alcohol Use Disorders: Thursday, 2/26/2015

R: Tuberculosis and Other Opportunistic Infections
P-R1: Immune Reconstitution Inflammatory Syndrome in Opportunistic Infections: Tuesday, 2/24/2015
P-R2: T-Cell Responses to Tuberculosis Infection: Tuesday, 2/24/2015
P-R3: TB Diagnostic Challenges: Tuesday, 2/24/2015
P-R4: TB Adverse Events, Recurrence, and Mortality: Tuesday, 2/24/2015
P-R5: Cryptococcal Meningitis: Host Response, Treatment, and Outcomes: Thursday, 2/26/2015
P-R6: Syphilis and HIV Coinfection: Tuesday, 2/24/2015
P-R7: Opportunistic Infections: Odds and End Organs: Tuesday, 2/24/2015

S: HIV in Women and Women’s Health
P-S1: Access and Engagement: Thursday, 2/26/2015
P-S2: Cervical Sampling, Shedding, and Outcomes: Tuesday, 2/24/2015
P-S3: Hormonal Contraception: Thursday, 2/26/2015

T: Maternal/Fetal HIV
P-T2: Rates and Risks of MTCT and HIV-Free Survival: Tuesday, 2/24/2015
P-T3: Option B+: Retention and Transmission: Tuesday, 2/24/2015
P-T4: Health Outcomes of HIV- and ARV-Exposed Infants, Children, and Youth: Thursday, 2/26/2015
P-T5: Coinfections Among HIV-Exposed Infants and Children: Thursday, 2/26/2015
P-T6: ART Adherence, Adverse Effects, and Retention Among Pregnant Women and Infants: Tuesday, 2/24/2015
P-T7: Pharmacokinetics and Safety of ART During Pregnancy: Tuesday, 2/24/2015
P-T8: Planning and Preventing Pregnancy: Tuesday, 2/24/2015
P-T9: Mechanisms of MTCT and Maternal/Infant Health: Thursday, 2/26/2015
P-T10: Immune Mechanisms in MTCT: Tuesday, 2/24/2015
P-T11: PMTCT-Associated Drug Resistance in Women and Infants: Tuesday, 2/24/2015

U: Pediatrics and Adolescents
P-U1: HIV Diagnosis in Infants and Children: Tuesday, 2/24/2015
P-U2: Early ART and HIV Persistence: Tuesday, 2/24/2015
P-U3: Treatment Outcomes Among Children and Youth With HIV: Wednesday, 2/25/2015
P-U4: Treatment and Monitoring Strategies in Children: Wednesday, 2/25/2015
P-U5: Determinants of Disease Progression in Children: Tuesday, 2/24/2015
P-U6: Complications of HIV and ART: Pulmonary and Cardiovascular Outcomes: Thursday, 2/26/2015
P-U7: Complications of HIV and ART: Bones, Brains, and Kidneys: Thursday, 2/26/2015
P-U8: Tuberculosis and Other Coinfections in Children With HIV: Wednesday, 2/25/2015
P-U9: Responses to Vaccines in Children: Tuesday, 2/24/2015
P-U10: Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth: Tuesday, 2/24/2015

V: Prevention and Intervention Studies
P-V1: Postexposure Prophylaxis (PEP): Wednesday, 2/25/2015
P-V2: PrEP and Microbicide Challenge: Thursday, 2/26/2015
P-V3: PrEP: Uptake: Tuesday, 2/24/2015
P-V4: PrEP: Measures and Correlates of Adherence: Tuesday, 2/24/2015
P-V6: HIV Prevention, Miscellaneous: Thursday, 2/26/2015

W: Epidemiology
P-W1: HIV Testing and the Continuum of Care in the Industrialized World: Tuesday, 2/24/2015
P-W2: HIV Testing and the Continuum of Care in the Developing World: Tuesday, 2/24/2015
P-W3: Risk Factors for Transmission in MSM: Wednesday, 2/25/2015
P-W4: Transmission Through Needles and Heterosexual Contact: Wednesday, 2/25/2015
P-W5: Incidence and Prevalence of HIV Infection, Including Acute HIV: Thursday, 2/26/2015
P-W6: Disease Progression, Morbidity, and Mortality: Thursday, 2/26/2015
P-W7: HIV Stigma: Thursday, 2/26/2015

X: Health Care Delivery and Health Systems
P-X1: Paying for Care: Tuesday, 2/24/2015
P-X2: Linkage to and Retention in Care: Wednesday, 2/25/2015
P-X3: Guidelines and Their Implementation: Thursday, 2/26/2015

Y: Implementation Science
P-Y1: Male Circumcision: Risk, Innovation, and Scale-Up: Thursday, 2/26/2015
P-Y2: Linkage to Care and ART Initiation: Wednesday, 2/25/2015

Z: Population and Economic Modeling
P-Z1: Costs and Cost Effectiveness: Tuesday, 2/24/2015
P-Z2: Modeling HIV Epidemiology: Wednesday, 2/25/2015
P-Z3: Modeling the Impact of HIV Interventions: Thursday, 2/26/2015
POSTER LISTINGS, BY CATEGORY

TUESDAY, FEBRUARY 24, 2015

Session P-A1 Poster Session
2:30 pm – 4:00 pm
Cellular Innate Immunity

183 STAT5 Inhibition Reduces HIV-1 Infection and TLR7/8 Responses in Human Macrophages
   Sofia Appelberg1; Carla N. Mavian1; Julie C. Williams1; Philip Lichlyter1; John Sleasman1; Maureen M. Goodenow2
   1University of Florida, Gainesville, FL, US; 2Duke University, Durham, NC, US

184 Regulation of the Innate Immune Sensing of HIV by the Viral Capsid and the Cytosolic DNA Sensor cGAS
   Nicolas Manel
   Institut Curie, Paris, France

185 cGAS Induced Type I IFN Responses in Dendritic Cells From HIV Elite Controllers
   Enrique Martin-Gayo1; Jacqueline Cronin1; Zhengyu Ouyang1; Taylor Hickman1; John Trombetta1; Cara C. Wilson1; Mario Santiago1
   1University of Colorado Anschutz Medical Campus, Aurora, CO, US

186 Characterization of Interferon-α Subtypes in the LPAC Model
   Michael Harper1; Kathrin Gibbert1; Eric Lee1; Kejun Guo1; Stephanie Dillon1; Martin McCarter1; Ulf Dittmer1; Cara C. Wilson1; Mario Santiago1
   1University of Colorado Anschutz Medical Campus, Denver, CO, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

187 HIV Vpu Inhibits NF-kB Activity but Does Not Interfere With Interferon Regulatory Factor 3
   Lara Manganaro; Elisa de Castro; Ana Maestre; Adolfo Garcia-Sastre; Ana Fernandez-Sesma; Viviana A. Simon
   Icahn School of Medicine at Mount Sinai, New York, NY, US

188 HIV-1 Exploits CD169 to Evade IFNα-Induced Antiviral State in Myeloid Cells
   Hisashi Akiyama1; Nora Ramirez1; Gregory Gibson2; Simon Watkins2; Zandrea Ambrose2; Rahm Gummeluru2
   1Boston University School of Medicine, Boston, MA, US; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, US

189 Interferon-Induced Transmembrane Proteins (IFITMs) Antagonize Postintegration Replication of HIV but Are Overcome by Viral Membrane Accessory Proteins
   Wingyi Lee; Ifrah Omar; Richard D. Sloan
   Queen Mary University of London, London, United Kingdom

190 HSV-1-Induced Enhancement of HIV-1 Replication Is Dependent on Decrease in IFITM3 Levels
   Viviane Andrade1; Milene Miranda1; Mario Stevenson1; Thiago M. Souza1
   1University of Miami, Miami, FL, US; 2Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

191 Characterization of the Activity of an Innate Immunity Protein, the Apolipoprotein L6
   Nitisha Pyndiah1; Angela Ciuffi1; Amalia Telenti1
   1Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 2J Craig Venter Institute, San Diego, CA, US

192 HIV and SIV Inhibition by RNA-Associated Early Stage Antiviral Factor (REAF)
   Aine McKnight
   Queen Mary University of London, London, United Kingdom

193 Translational Control of APOBEC3G/F Restriction Factors by the HIV-1 Vif Protein
   Camille Libre1; Santiago X. Guererro1; Julien Batisse1; Roland Marquet1; Jean-Christophe Paillart1
   1IBMC CNRS, Strasbourg, France; 2Centre for Genomic Regulation, Barcelona, Spain

194 Evidence for Lentivirus-Driven Evolution of APOBEC3C
   Cristina Wittkopp; Michael Emerman
   Fred Hutchinson Cancer Research Center, Seattle, WA, US

195 Reevaluation of the Role of the Small Host Cell GTPase Rab6 in the HIV-1 Replication Cycle
   Isaac Zentner; Simon Cocklin
   Drexel University College of Medicine, Philadelphia, PA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-A2 Poster Session
2:30 pm – 4:00 pm
Nucleus Entry, Integration, and Export

196 The Mutated Form of Transportin 3 From Patients With Limb-Girdle Muscular Dystrophy 1F Hijacks Wild-Type Transportin 3 and Interferes With CPSF6 Subcellular Localization, Impairing HIV-1 Nuclear Entry
   Sara Rodriguez-Mora1; Mayte Coiras1; Mercedes Bermejo1; Elena Mateos1; Ramon Marti2; Juan Jesus Vilchez1; Antonio Luis Andreu3; Jose Alcami1
   1Instituto de Salud Carlos III, Madrid, Spain; 2Vall d’Hebron Institut de Recerca, Barcelona, Spain; 3Hospital Universitari i Politècnic La Fe, Valencia, Spain
197 | Longitudinal Epigenome-Wide Association Study of Pre- and Post-HIV-Infected Subjects
Sophie Limou; George W. Nelson; Elizabeth Binns-Roemer; Jia Li; Fathi Elloumi; James J. Goedert; Cheryl A. Winkler
1Frederick National Laboratory Operated by Leidos Biomedical Research, Inc, for the National Cancer Institute, Frederick, MD, US; 2Frederick National Laboratory Operated by Leidos Biomedical Research, Inc, for the National Cancer Institute, Frederick, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US

198 | IN Variants Retarget HIV-1 Integration and Are Associated With Disease Progression
Frauke Christ; Jonas Demeulemeester; Zeger Debyser; Rik Gijsbers; Jan De Rijck; Thumbi Ndung’u; Paradise Madalal
1KU Leuven, Leuven, Belgium; 2University of KwaZulu-Natal, Durban, South Africa

199 | HIV-1 Integration Sites in Macrophages and CD4+ T Cells Are Distinct
Yik Lim Kok; Valentina Vongrad; Mohamed Shilaih; Herbert Kuster; Roger Koyou; Huldrych F. Günthard; Karin J. Metzner
University Hospital Zurich, Zurich, Switzerland

200 | A Screening for DNA Repair Enzymes That Affect HIV-1 Infection
Noriyoshi Yashinaga; Yusuke Matsui; Kesiuke Shindo; shunichi Takeda; Akifumi Takaori-Kondo
1Kyoto University, Kyoto, Japan; 2Kyoto University, Kyoto, Japan

201 | The Activity of HIV-1 Rev/RRE Varies Greatly Between Isolates
Patrick E. Jackson; Denis Tebit; David Rekosh; Marie-Louise Hammerskild
1University of Virginia, Charlottesville, VA, US; 2University of Virginia, Charlottesville, VA, US

202 | A Surprising New Function of SAMHD1 as a Pro-Pathogenic Factor in HIV Infection
Gilad Doitsh; Nicole Galloway; Xin Geng; Isa Monus Arias; Zhiyuan Yang; Warner C. Greene
The J. David Gladstone Institute, University of California San Francisco, San Francisco, CA, US

203 | Mapping Vpx and Vpr Specificity in Antagonism of SAMHD1
Chelsea Spragg; Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, US

204 | Differentiation Stimuli Strongly Impact the Ability of Macrophages to Support HIV-1 Replication Due to SAMHD1 Restriction
Ester Ballana; Roger Badia; Eva Riveira-Muñoz; Alba Ruiz; Javier Torres-Torrenteras; Bonaventura Clotet; Eduardo Pauls; Ramon Martí; José Esté
HIV Pathogenesis Research Group
1IrsiCaixa Institute for AIDS Research, Badalona, Spain; 2Institut de Recerca Hospital Universitari Vall d’Hebron, Barcelona, Spain

205 | Essential Role of Cyclin D3 in dNTP Pool Control and HIV-1 Replication in Macrophages
Ester Ballana; Alba Ruiz; Eduardo Pauls; Javier Torres-Torrenteras; Roger Badia; Eva Riveira-Muñoz; Bonaventura Clotet; Ramon Martí; José Esté
HIV Pathogenesis Research Group
1IrsiCaixa Institute for AIDS Research, Badalona, Spain; 2Institut de Recerca Hospital Universitari Vall d’Hebron, Badalona, Spain

206 | Low SAMHD1 Expression Renders Activated and Proliferated CD4+ T Cells Susceptible to HIV-1
Nabila Seddiki; Nicolas Ruffin; Vedran Brezar; Diana Ayinde; Julian Schulze zur Wiesch; Jan van Lunzen; Olivier Schwartz; Jean-Daniel Lelièvre; Jacques Banchereau; Yves Lévy
1Inserm U955 Eq16/UPEC, Créteil, France; 2Institut Pasteur, Paris, France; 3University Medical Center, Hamburg-Eppendorf and Heinrich-Pette-Institute, Hamburg, Germany

207 | SAMHD1 Partially Blocks Lentiviral Gene Transfer Into Hematopoietic Stem Cells
Duo Li; Erika Schlaepfer; Annette Audige; Baek Kim; Roberto Speck
1University Hospital Zurich, Zurich, Switzerland; 2Department of Pediatrics Emory School of Medicine, Atlanta, GA, US

THURSDAY, FEBRUARY 26, 2015

208 | Fresh Semen Harbors HIV-Enhancing Amyloids and Decreases the Efficacy of Microbicides
Jan Munch; Onofrio Zirafi; Shariq Usmani; Kyeong-Ae Kim; Frank Kirchhoff; Christopher D. Pilcher; Haihuan Liu; H. Ewa Witkowska; Warner C. Greene; Nadia R. Roan
1University of California San Francisco, San Francisco, CA, US; 2The J. David Gladstone Institutes, San Francisco, CA, US; 3Ulm University Medical Center, Ulm, Germany

209 | Semen’s HIV Enhancing Activity Is an Individual Characteristic Independent of VL
Christopher D. Pilcher; Teri Liegel; Jason Neidleman; H. Ewa Witkowska; Wendy Hartogensis; Karin Marzen; Peter Bacchetti; Frederick M. Hecht; Warner C. Greene; Nadia R. Roan
University of California San Francisco, San Francisco, CA, US
210 Hyaluronan Reduces HIV Infection of CD4+ T Cells and Greatly Enhances HIV Inhibition by Tenofenvir
Peilin Li; Katsuya Fujimoto; Lilly Bourguignon; Steven Yuki; Steven Deeks; Philipp Kaiser; Peggy Kim; Diane Havlir; Harry Lampiris; Joseph K. Wong
University of California San Francisco, San Francisco, CA, US

211 Alpha-defensins increase HIV transcytosis: role in STI-mediated enhanced HIV transmission
Kimyata B. Valere1; Aprille Rapita1; Alison Quayle2; Wuyan Lu1; Eliseo Eugenie1; Theresa Chang2
1Rutgers University-New Jersey Medical School, Willingboro, NJ, US; 2University Health Science Center, New Orleans, LA, US; 3University of Maryland School of Medicine, Baltimore, MD, US

212 The Design and Investigation of Mechanism of Novel Potent HIV-1 Entry Inhibitor SC12
Marina Tuyshime; Simon Cocklin
Drexel University College of Medicine, Philadelphia, PA, US

213 Optimization of vCLL2-Based CXCR4 Inhibitors by Phage Display and Rational Design
Virginie Fierez1; Martyna Szpakowska1; Kari Thibault1; Amor Mosbah1; Sabrina Dere2; Xavier Dervil2; Pierre-Arnaud Gauthier1; Michele Baudy-Floc’h1; Carole Devaux1; Andy Chevigné1
1CRP-sante, Laboratory of Retrovirology, 84 Rue Val Fleuri, 1526 Luxembourg, Luxembourg; 2University of Rennes 1, UMR CNRS 6226, Avenue du Général Leclerc, 35042 Rennes, France

214 HIV-1 Infection of Female Primary Genital Epithelial Cells After Pseudotyping With HTLV-1: Potential Driver of Sexual Transmission of HIV-1
Yuyang Tang1; Alvin George1; Oksana Petrecchio1; Brian Imbiakha1; Stephanie Sweet1; Yuet Sum Tanaka1; Franklin Nouvet1; James E. Hildreth1
1University of California Davis, Davis, CA, US; 2University of the Ryukyus, Nishihara-cho, Japan

WednesDay, FebruaRy 25, 2015

Session P-A5 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Envelopes, Receptors, and Tropism

215 Evaluation of HIV-1 Clones for Unique Properties Associated With Transmission
Katja Klein1; Annette Ratcliffe2; Gabrielle Nickell2; Immaculate Nankya3; Mike Lobritz1; Yong Gao1; Robin Shattock1; Eric J. Arts1
1University of Western Ontario, London, Canada; 2Case Western Reserve University, Cleveland, OH, US; 3Imperial College London, London, United Kingdom

216 Selection of HIV Env Mutants With Altered Trimmers by EMPIRIC Saturation Mutagenesis
Maria Dueñas-Decamp1; Li Jiang; Dan Bolon; Paul R. Clapham
University of Massachusetts Medical School, Worcester, MA, US

217 Characterization of HIV-1 Envelopes in Acutely and Chronically Infected Injection Drug Users
Behzad Etemad1; Oscar A. Gonzalez2; Laura F. White1; Oliver B. Laeyendecker3; Greg D. Kirk4; Shrut Mehta5; Manish Sagar1
1Boston University School of Medicine, Boston, MA, US; 2Boston University, MA, US; 3Johns Hopkins University, Baltimore, MD, US

218 Phenotypic Characterization of Transformed/Founder Virus in HIV-1 Transmission Pairs
Corinna S. Oberle1; Beda Joos1; Nottania K. Campbell1; David Beauparlant2; Herbert Kuster1; Corinne Schenkel1; Peter Ruerst1; Alexandra Trkola1; Karin J. Metzner1; Huldrych F. Günthard1
1University Hospital Zürich, Zürich, Switzerland; 2Institute of Medical Virology, Zurich, Switzerland

219 HIV Coreceptor Tropism Switching Is Correlated With Binding Affinity to CXCR4
Homero Vazquez1; Antoine Chaillon1; Douglas D. Richman1; Sara Gianella Weibel1; Gabriel Wagner2; David M. Smith3
1University of California San Diego, San Diego, CA, US; 2Inserm UMR US966, Tours, France; 3Veterans Affairs Medical Center, San Diego, CA, US

220 Selective Cell-Free or Cell-to-Cell HIV-1 Infection by gp41 Cytoplasmic Tail Mutants
Natasha D. Durham1; Benjamin K. Chen1
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2Icahn School of Medicine at Mount Sinai, New York, NY, US

221 Analysis of Viral Evolution in the Blood Reveals Potential Insight Into the Evolution of Macrophage Tropism
Maria M. Bednar1; LiHua Ping1; Kathryn Arrildt1; Christa Sturdevant2; Sarah B. Joseph1; Laura Kincer1; Celia LaBranche1; David Montefiori1; Myron Cohen1; Ronald Swanstrom1
1University of North Carolina, Chapel Hill, NC, US; 2Duke University, Durham, NC, US; 3University of North Carolina, Chapel Hill, NC, US

222 Mechanistic Differences in Interactions of HIV-1 and HIV-2 With Dendritic Cells
Suzanne D. Kijewski; Hisashi Akiyama; Caitlin Miller; Nora P. Ramirez; Rahm Gummuru
Boston University School of Medicine, Boston, MA, US

223 Identification of the First Nonhuman Primate CD4 Receptor for 1/F HIV-1 Isolates
Nicholas Meyerson1; Amit Sharma1; Gregory Wilkerson1; Julie M. Overbaugh1; Sara Sawyer2
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2The University of Texas at Austin, Austin, TX, US; 3University of Texas, MD Anderson Cancer Center, Bastrop, TX, US

224LB Vpr Increases Env Spikes on Virions to Enhance HIV-1 Replication in Nondividing Myeloid Cells
Tao Zhou1; Xianfeng Zhang1; Yonghui Zheng1
1Michigan State University, East Lansing, MI, US; 2Harbin Veterinary Research Institute, Harbin, China
THURSDAY, FEBRUARY 26, 2015

Session P-A6 Poster Session  
Poster Hall  
2:30 pm – 4:00 pm  
Nef Functions

225  
Env and Nef Cooperatively Contribute to HIV-1—  
Induced pDC Activation via CD4-Dependent  
Mechanisms
Natalia J. Reszka-Blanco1; Vijay Sivaraman1; Liguo Zhang1; Lishan Su1  
1University of North Carolina, Chapel Hill, NC, US; 2Key Lab of Infection and Immunity, Institute of Biophysics, Chinese Academy of Science, Beijing, China

226  
Naturally Occurring Polymorphisms in HIV-1 Nef  
Impair Its Functions and Decrease Viral Replication  
Capacity
Thomas Vollbrecht2; Lorelei Bornfleth1; Patricia Frohnen1; Martha J. Lewis1  
1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 2University of California San Diego (UCSD), La Jolla, CA, US

227  
Dynamic Range of Down-Regulation of HIV-1 Entry  
Receptors by Primary Nef Isolates
Mako Toyoda1; Yoko Ogata1; Macdonald Mahiti1; Florencia Pereyra1; Toshiyuki Miura1; Bruce Walker1; zabrina L. Brumme1; Mark A. Brockman1; Takamasa Uno1  
1Kumamoto University, Kumamoto, Japan; 2University of Tokyo, Tokyo, Japan; 3Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, US; 4Simon Fraser University, Burnaby, Canada

228  
Differential Down-Regulation of HLA Class I Allotypes  
by HIV-1 Nef Primary Isolates
Macdonald Mahiti1; XiaoFei Jia1; Mako Toyoda1; Francis Mwimanz1; Bruce Walker1; zabrina L. Brumme1; Mark Brockman1; Yong Xiong1; Takamasa Uno1  
1Kumamoto University, Kumamoto, Japan; 2Yale University, New Haven, CT, US; 3Ragon Institute of MGH, MIT and Harvard University, Boston, MA, US; 4Simon Fraser University, Burnaby, Canada

Session P-B1 Poster Session  
Poster Hall  
2:30 pm – 4:00 pm  
Viral Origins and Recombinant Forms

229  
Geopolitical Effects in the Epidemiology of HIV-1  
Subtype
Gikas Magiorkinis1; Kostantinos Angelis1; Ioannis Mamais1; Angelos Hatzakis1; Jan Albert1; Glenn Lawyer1; Annemarie Wensing1; Charles Bouchet1; Anne-Miekqe Vandamme1; Dimitrios Paraskevis1  
1University of Athens, Athens, Greece; 2University of Oxford, Oxford, United Kingdom; 3Karolinska Institutet, Stockholm, Sweden; 4Max Planck Institute for Informatics, Saarbrücken, Germany; 5University Medical Center Utrecht, Utrecht, Netherlands; 6Erasmus University Medical Center, Rotterdam, Netherlands; 7KU Leuven, Leuven, Belgium

230  
The 2 Phases of HIV-1 Group O Diversification
Marie Leoz1; Felix Feyertag1; Anfumbomb Kfutwah1; Philippe Maucleure1; Guillaume Lachenal1; Florence Damond1; Veronique Lemee1; Francois Simon1; David Robertson1; Jean-Christophe Plantier1  
1University Hospital Rouen, Rouen, France; 2Manchester University, Manchester, United Kingdom; 3Centre Pasteur du Cameroun, Yaounde, Cameroon; 4Direction Interarmées du Service de Santé, Noumea, New Caledonia; 5Université Paris Diderot, Paris, France; 6APHP CHU Bichat Claude Bernard, Paris, France; 7APHP CHU Saint Louis, Paris, France

231  
Evidence for More Major HIV-1M Lineages From the  
Early Stages of the HIV-1 Epidemic
Marcel Tonga Passo1; Wendy A. Burgers; Etel Mpoudi-Ngole; Jeffrey Dorfman1; Darren P. Martin1  
1International Center for Genetic Engineering and Biotechnology, Cape Town, Cape Town, South Africa; 2Division of Medical Virology, University of Cape Town, Cape Town, South Africa; 3Institute of Medical Research and Study of Medicinal Plants (IMMP), Yaounde, Cameroon, Yaounde, Cameroon; 4Computational Biology Group, University of Cape Town, Cape Town, South Africa

232  
HIV-1/M+O Dual Infections and HIV-MO Recombinants  
in France From 2004 to 2014
Pierre Cappy1; Fabienne De Oliveira1; Veronique Lemee1; Jean-Louis Gaillard1; Laurence Bouquet1; Jean-Dominique Poveda1; Magali Bouvier1; Anne Maillard1; Thomas Mourez; Jean-Christophe Plantier1  
1Rouen University Hospital, Rouen, France; 2Ambroise Paré Hospital, Paris, France; 3Lille University Hospital, Lille, France; 4CERBA Laboratory, Saint-Ouen L’Hamon, France; 5Henri Mondor Hospital, Créteil, France; 6Pontchaillou Hospital, Rennes, France

233  
Evidence of Intra-Familial Transmission of an HIV-1  
M/O Intergroup Recombinant Virus
Paul Alain T. Ngoupo1; Serge Alain Sadeh-Mba1; Fabienne De Oliveira1; Valérie Ngo1; Laure Ngo1; Patrice Ichendjou1; Veronique Penlap Mbeng1; Richard Njouom1; Anfumbomb Kfutwah1; Jean-Christophe Plantier1  
1Centre Pasteur of Cameroon, Yaounde, Cameroon; 2Virology, CHU Rouen, Rouen, France; 3University of Yaounde I, Yaounde, Cameroon; 4Epidemiology, Centre Pasteur of Cameroon, Yaounde, Cameroon

234  
Searching for Rare HIV Strains in Rural Democratic  
Ana S. Vallari1; Carole McArthur2; Larry Streshley3; Catherine Brennan4  
1Abbott Laboratories, Chicago, IL, US; 2University of Missouri–Kansas City, Kansas City, MO, US; 3IMA World Health, Kinshasa, Congo (the Democratic Republic of the)

235  
Clinical and Virological Characterization of CRF07_BC  
infection
Szu-Wei Huang1; Sheng-Fan Wang1; Chih-Hao Lee1; Wing-Wai Wong2; Hung-Chin Tsai; Chia-Jui Yang; Chin-Tien Wang; Jaang-Jiun Wang; Daniel Kuritzkes1; Yi-Ming A. Chen1  
1International Center for Genetic Engineering and Biotechnology, Cape Town, Cape Town, South Africa; 2Division of Medical Virology, University of Cape Town, Cape Town, South Africa; 3Institute of Medical Research and Study of Medicinal Plants (IMMP), Yaounde, Cameroon, Yaounde, Cameroon; 4Children’s Healthcare of Atlanta and Emory University School of Medicine, Atlanta, GA, US; 5University of Athens, Athens, Greece; 6University of Oxford, Oxford, United Kingdom; 7Karolinska Institutet, Stockholm, Sweden; 8Max Planck Institute for Informatics, Saarbrücken, Germany; 9University Medical Center Utrecht, Utrecht, Netherlands; 10Erasmus University Medical Center, Rotterdam, Netherlands; 11KU Leuven, Leuven, Belgium
236 Reconstructing the HIV-1 Epidemics in Burkina Faso Using Early Samples
Gonzalo Yebra; Marcia L. Kalish; Andrew J. Leigh Brown
1 University of Edinburgh, Edinburgh, United Kingdom; 2Vanderbilt University, Nashville, TN, US

237 Neutralizing Antibodies in Humans Infected With Zoonotic Simian Foamy Viruses
Caroline Lambert; Julie Gouzi; Régane Rua; Edouard Betsem; Antoine Gessain
1 Institut Pasteur, Paris, France; 2Ecole Vétérinaire, Maison-Alfort, France; 3University of Yaounde, Yaounde, Cameroon

TUESDAY, FEBRUARY 24, 2015

Session P-B2 Poster Session

238 Large Phylogenetically Linked HIV Cluster in King County, Washington, 2008 to 2014
Susan E. Buskin; Joshua T. Herbeck; Katelynne M. Gardner Toren; Michelle R. Perry; Amy Bennett; Matthew R. Golden
1 Public Health—Seattle & King County, Seattle, WA, US; 2University of Washington, Seattle, WA, US

239 Reconciling Named Partner and Genetic Partner HIV-1 Transmission Networks in New York City
Joel O. Wertheim; Sergei L. Kosakovsky Pond; Konrad Scheffler; Davey M. Smith; Sanjay Mehta; Sharmila Shah; Lisa Forgione; Lucia V. Torian
1 University of California San Diego, San Diego, CA, US; 2New York City Department of Health and Mental Hygiene, New York, NY, US

240 Efforts to Characterize Community HIV Transmission Dynamics May Be Critically Dependent on Provision of Both Partner Services and Genetic Sequence Analysis
Nella L. Green; Christy Anderson; Sergei L. Kosakovsky Pond; Martin Hoenigl; David M. Smith; Sanjay Mehta; Susan Little
1 University of California San Diego, San Diego, CA, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-B3 Poster Session

241 Growth and Geographic Spread of HIV Transmission Clusters, United States, 2007-2012
Alexandra M. Oster; Joel Wertheim; Ellsworth Campbell; Angela L. Hernandez; Neeraja Saduwala; William M. Switzer; M. Cheryl Ocfemia; Anupama Shankar; H. Irene Hall

242 HIV Transmission Networks Among the USA, Mexico, and Central America
Santiago Avila-Rios; Joel O. Wertheim; Ann M. Dennis; Gustavo Reyes-Terán; Carlos Mejia-Villatoro; Elsa Y. Palou; Guillermo Porras-Cortes; Juan M Pascale; Marvin Manzanero; Sanjay Mehta
1 National Institute of Respiratory Diseases, Mexico City, Mexico; 2University of California San Diego (UCSD), San Diego, CA, US; 3Roosevelt Hospital, Guatemala City, Guatemala; 4Hospital Escuela Universitaria, Tegucigalpa, Honduras; 5Gorgas Memorial Institute for Health Studies, Panama, Panama; 6Vivian Pellas Metropolitan Hospital, Managua, Nicaragua; 7Ministry of Health, Belmopan, Belize; 8University of North Carolina, Chapel Hill, NC, US

243 Sexual Networks Across Risk Groups Persistently Contribute to Local Spread of HIV
Marije Hofstra; Tania Mudrikova; Marieke Pingen; Kristine Koekkoek; Arjan Van Laarhoven; Rob Schuurman; Andy L. Hoepelman; Annemarie M. Wensing
1 University Medical Center Utrecht, Utrecht, Netherlands; 2University Medical Center Utrecht, Utrecht, Netherlands

244 Estimation of HIV-1 Transmission During Recent Infection in Switzerland
Alex Marzel; Mohamed Shilaih; Wan-Lin Yang; Jürg Böni; Sabine Verly; Thomas Klimkait; Vincent Aubert; Huldrych F. Günthard; Roger Koyou
1 On behalf of the Swiss HIV Cohort Study (SHCS) 2Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; 3Swiss National Center for Retroviruses, Zurich, Switzerland; 4Laboratory of Virology, Geneva, Switzerland; 5Department of Biomedicine–Petersplatz, Basel, Switzerland; 6Division of Immunology and Allergy, Lausanne, Switzerland; 7The Swiss HIV Cohort Study, Zurich, Switzerland

245 Clustering of Swiss HIV Patients Not Enrolled in the Swiss HIV Cohort Study (SHCS)
Mohamed Shilaih; Alex Marzel; Jürg Schüpbach; Jürg Böni; Sabine Verly; Thomas Klimkait; Vincent Aubert; Huldrych F. Günthard; Roger Koyou
1 The Swiss HIV Cohort Study (SHCS) 2University Hospital Zurich, Zurich, Switzerland; 3Geneva University Hospital, Geneva, Switzerland; 4University Hospital Lausanne, Lausanne, Switzerland; 5University of Basel, Basel, Switzerland; 6University of Zurich, Zurich, Switzerland

246 HIV Transmission Network Structure Reveals Characteristics of Bridging Individuals
Sanjay Mehta; Joel O. Wertheim; Konrad Scheffler; Susan Little; Richard R. Garfein; Sergei L. Kosakovsky Pond; David M. Smith
1 University of California San Diego, San Diego, CA, US; 2ICF International, Atlanta, GA, US

247 Phylodynamic Analysis of HIV Sub-Epidemics in Mochudi, Botswana
Vladimir Novitsky; Denise Kuehnert; Sikkhulile Moyo; Erik van Widenfeld; Lilian Okui; Max Essex
1 Harvard School of Public Health, Boston, MA, US; 2ETH Zürich, Zürich, Switzerland; 3Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
248 Exploring Transmission Dynamics of HIV in Rural Kwazulu-Natal, Using Phylogenetics
Eduan Wilkinson1; Siva Danaviah1; Justen Manasa1; Frank Tanser1; Kobus Hersb1; Deenan Pillay1; Tuilio de Oliveira1
On behalf of the PANGEA_HIV Consortium
1University of Kwazulu-Natal, Durban, South Africa; 2University College London, London, United Kingdom

249 Detecting Changes in Incidence Using Phylogenetic Tools: Simulation-Based Studies Within the PANGEA_HIV Initiative
Emma B. Hodcroft1; Oliver Ratmann1; Anne Cori2; Mike Pickles2; Samantha Lycett1; Manon L. Ragonnet-Cronin2; Matthew Hall1; Andrew J. Leigh Brown1; Christophe Fraser1
On behalf of the Pangea_HIV Consortium
1University of Edinburgh, Edinburgh, United Kingdom; 2Imperial College London, London, United Kingdom; 3University of Glasgow, Glasgow, United Kingdom

TUESDAY, FEBRUARY 24, 2015

Session P-B4 Poster Session
2:30 pm – 4:00 pm
Transmission Networks: MSM

250 HIV Transmission Among Seattle Adolescents
Joshua Herbeck1; Elizabeth Wolf1; Stephen van Rompvaey2; Mari M. Kitahata3; Lisa Frenkel4
1University of Washington, Seattle, WA, US; 2Center for AIDS Research, Seattle, WA, US

251 Characterization of Large Cluster Viral Networks Sustaining the Montreal MSM Epidemic
Bluma Brenner1; Ruxandra-Ilinca Ibanescu2; Daniela Moisi2; Isabelle Hardy1; Jean-Pierre Routy1; Joanne Otis1; Mark Wainberg1; Michel Roger1
1McGill University, Montreal, Canada; 2Lady Davis Institute, Montreal, Canada; 3Université de Montréal, Montreal, Canada; 4UQAM, Montreal, Canada

252 Sources of HIV-1 Transmission in the Ongoing, Concentrated HIV Epidemic Among Men Having Sex With Men in the Netherlands Between July 1996 and December 2010
Oliver Ratmann1; Ard van Sighem2; Daniela Bezemer2; Alexandra Gavrushkina2; Peter Reiss3; Frank de Wolf1; Christophe Fraser1
1Imperial College London, London, United Kingdom; 2Stichting HIV Monitoring Foundation, Amsterdam, Netherlands; 3University of Amsterdam, Amsterdam, Netherlands; 4University of Auckland, Auckland, New Zealand

THURSDAY, FEBRUARY 26, 2015

Session P-B5 Poster Session
2:30 pm – 4:00 pm
Next Generation of Next-Generation Sequencing

254 Present Applications of a High-Throughput, Single Measure HIV Genomic Incidence Assay
Sung Yong Park1; Tanzy Love2; Nolan Goeken1; Robert Bolan1; Alan S Perelson3; Michael Dube1; Ha Youn Lee1
1Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 2University of Rochester School of Medicine and Dentistry, Rochester, CA, US; 3Los Angeles Gay and Lesbian Center, Los Angeles, CA, US; 4Los Alamos National Laboratory, Los Alamos, CA, US

255 A Comprehensive Analysis of Primer IDs to Study Heterogenous HIV-1 Populations
David Seifert1; Armin Töpfer1; Francesca Di Giallonardo2; Stefan Schmutz1; Huldrych F. Günthard3; Volker Roth1; Niko Beerwinkel1; Karin J. Metzner1
1ETH Zurich, Basel, Switzerland; 2University Hospital Zurich, Zurich, Switzerland; 3University of Basel, Basel, Switzerland

256 Near Full Length HIV-1 Sequencing to Understand HIV Phylogenetics in Africa in Real Time
Siva Danaviah; Justen Manasa; Eduan Wilkinson; Sureshnee Pillay; Zandile Sibisi; Sthembiso Mswebi; Deenan Pillay; Tuilio de Oliveira
University of Kwazulu-Natal, Durban, South Africa

257 Pan-HIV Next-Gen Sequencing Strategy for Viral Surveillance
Michael G. Berg1; Julie Yamaguchi1; Elodie Alessandri-Gradt1; Jean-Christophe Plantier1; Catherine Brennan1
1Abbott Laboratories, Abbott Park, IL, US; 2Virology Unit, National Reference for HIV, Rouen, France

258 PCR-Free Full Genome Characterization of Diverse HIV-1 Strains by Nextgen Sequencing
Viswanath Ragapathy1; Feng Gao2; Ana Sanchez2; Marco Schito3; Thomas Denny1; Michael Busch1; Jianguin Zhao2; Christelle Mbondji2; SaiVikram Venmula3; Indira Hewlett4
1US Food and Drug Administration, Silver Spring, MD, US; 2Duke Human Vaccine Institute and Departments of Medicine, Duke University Medical Center, Durham, NC, US; 3Henry Jackson Foundation, DAIDS, NIAID, Bethesda, MD, US; 4Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US

259 Full-Length Env Deep Sequencing in a Donor With Broadly Neutralizing V1/V2 Antibodies
Ben Murrell1; Melissa Laird1; Elise Landais2; Caroline Ignacio2; Ellen Paxinos2; Pham Phung3; Sergei L. Kosakovsky Pond1; Douglas D. Richman1; Pascal Poignies1; Dawey M. Smith1
1University of California San Diego, La Jolla, CA, US; 2Pacific Biosciences, Menlo Park, CA, US; 3The International AIDS Vaccine Initiative, Neutralizing Antibody Center, La Jolla, CA, US; 4LabCorp, South San Francisco, CA, US
TUESDAY, FEBRUARY 24, 2015

Session P-C1 Poster Session
2:30 pm – 4:00 pm
The Gut Microbiome

260 Functional Profiling of the Gut Microbiome in HIV Infection
Yolanda Guíllén; Marc Noguera-Julian; Muntsa Rocafort; Mariona Parera; Maria Casadellà; Isabel Bravo; Josep Coll; Julià Blanco; Bonaventura Clotet; Roger Paredes
MetaHIV Study Group
IrsiCaixa AIDS Res Inst, Hosp Univ Germans Trias i Pujol, Univ Autònoma de Barcelona, Badalona, Spain

261 Gut Microbiota Correlates with HIV-1 Control and Immune Status
Muntsa Rocafort; Marc Noguera-Julian; Yolanda Guíllén; Mariona Parera; Maria Casadellà; Isabel Bravo; Josep Coll; Julià Blanco; Bonaventura Clotet; Roger Paredes
MetaHIV-Pheno Study Group
IrsiCaixa AIDS Res Inst, Hosp Univ Germans Trias i Pujol, Univ Autònoma de Barcelona, Badalona, Spain

262 Butyrate Reduces Pathobiont-Associated HIV-1 Infection and Activation of Gut T Cell
Jon Kibbie; Stephanie Dillon; Eric Lee; Charles Robertson; Daniel N. Frank; Martin McCarter; Cara C. Wilson
University of Colorado Anschutz Medical Campus, Aurora, CO, US

263 Maraviroc Does Not Induce Changes in the Gut Microbiome of HIV-Infected Individuals
Andrey Vitimirov; David M. Smith; Susanna R. Var; Maile Karris; Parrii Jordan; Douglas D. Richman; Susan Little; Josué Pérez-Santiago
University of California San Diego, La Jolla, CA, US

264 Fecal Microbiota of HIV Controllers Is Similar to That of Non–HIV-Infected Individuals
Selma N. Alva Hernández; Sandra M. Pinto Cardoso; Norma Téllez; Akio Murakami-Ogasawa; Gustavo Reyes-Terán
National Institute of Respiratory Diseases, Research Center in Infectious Diseases, Mexico City, Mexico

265 Impact of 2 Antiretroviral Regimens on Fecal Microbial Diversity and Composition
Sandra M. Pinto Cardoso; Selma N. Alva Hernández; Norma Téllez; Akio Murakami-Ogasawa; Gustavo Reyes-Terán
National Institute of Respiratory Diseases, Mexico City, Mexico

266 Targeting Gut Dysbiosis With Prebiotics and Glutamine in HIV-Infected Subjects
Sergio Serrano-Villar; Jorge Vázquez-Castellanos; Alejandro Vallesjo; Sara Ferrando-Martínez; Talia Sainz; Mar Vera; Santiago Moreno; Andrés Moya; Maria José Gosalbes; Vicente Estrada
University Hospital Ramón y Cajal, Madrid, Spain; FISABIO-Salud Pública, Valencia, Spain; University Hospital La Paz, Madrid, Spain; University Hospital Virgen del Rocío, Sevilla, Spain; Centro Sandoval, Madrid, Spain; University Hospital Clínico San Carlos, Madrid, Spain

Session P-C2 Poster Session
2:30 pm – 4:00 pm
The Mucosa in HIV/SIV Pathogenesis

267 Impact of Mucosal Immunity and HIV Persistence on CD4/CD8 Ratio After ART Initiation
Sergio Serrano-Villar; Talia Sainz; Tae Wook-Chun; Netanya S. Utyay; Zhong-Min Ma; Basile Siewe; Steven Deeks; Richard Pollard; Christopher Miller; David Asmuth
University Hospital Ramón y Cajal, Madrid, Spain; University Hospital La Paz, Madrid, Spain; National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; University of California Davis, Davis, CA, US; University of Texas, Galveston, TX, US; Rush University Medical Center, Chicago, IL, US; University of California San Francisco, San Francisco, CA, US

268 Monocyte/Macrophage Activation and Recruitment to Mucosal Sites in SIV Pathogenesis
Jan Kristoff; Jenny Stock; Tianyu He; Bruno Andrade; Benjamin Policicchio; Alan Landay; Ivo Francischetti; Cristian Apetrei; Irini Sereti; Iona Pandrea
University of Pittsburgh, Pittsburgh, PA, US; National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; Rush University, Chicago, IL, US

269 Rectal Tenofovir Gel Usage Is Associated With Changes in the Mucosal Proteome
Adam Burgener; Laura Romas; Kenzie Bise; Kenneth H. Mayer; Irma Febo; Ross Cranston; Alex Garbarallo-Díezeg; Ian McGowan
University of Manitoba, Winnipeg, Canada; University of Pittsburgh, Pittsburgh, PA, US; Harvard Medical School, Boston, MA, US; Columbia University, New York, NY, US; University of Puerto Rico, San Juan, US

270 Links Between Systemic and Mucosal Immunity in Treated HIV Infection
Talia Sainz; Sergio Serrano-Villar; Gregory Melcher; Zhong-Min Ma; Christopher Miller; Netanya S. Utyay; Basile Siewe; Paolo Troia-Cancio; Elizabeth Sinclair; David Asmuth
Hospital Universitario Gregorio Marañón, Madrid, Spain; Hospital Ramon y Cajal, Madrid, Spain; University of California Davis, Davis, CA, US; University of Texas Medical Branch, Galveston, TX, US; Rush University Medical Center, Chicago, IL, US; University of California San Francisco (UCSF), San Francisco, CA, US

271 No Impact of Early Intensified Antiretroviral Therapy on Gut Immune Reconstitution
Connie J. Kim; Rodney Rousseau; Colin Kovacs; Sanja Huibner; Gabor Kandel; Erika Benko; Cristian Apetrei; Irini Sereti; Kamnoosh Shahabi; Tae Wook Chun; Mario Ostrouski; Rupert Kaul
Toronto General Hospital, Toronto, Canada; University of Toronto, Toronto, Canada; Maple Leaf Medical Clinic, Toronto, Canada; St. Michael’s Hospital, Toronto, Canada; National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
272 Altered Properties of Mucosal NK Cell Subsets During Acute HIV-1 Infection
Alexandra Schuetz; Yuwadee Phuang-Ngern; Eugene Kroon; Rungsun Rerknimitr; Nitya Chomchey; Nityata Phanuphak; Merlin L. Robb; Jerome H. Kim; Mark de Souza; Jintanat Ananworanich
RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups
1Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; 2Thai Red Cross AIDS Research Center, Bangkok, Thailand; 3Chulalongkorn University, Bangkok, Thailand; 4US Military HIV Research Program, Silver Spring, MD, US

273 Loss of Cervical Gamma Delta T Cells in HIV-Infected Women
Natasa Strbo; Maria L. Alcaide; Laura Romero; Hector Bolivar; Deborah L. Jones; Eckhard R. Podack; Margaret A. Fischl
1University of Miami, Miami, FL, US; 2University of Miami, Miami, FL, US

274 T Regulatory Cells Disrupt the CCL20-CCR6 Axis Driving Th17 Homing to the Gut
Claire Loiseau; Mary Requena; Michelle Cazabat; Nicolas Carrere; Bertrand Suc; Bruno Marchou; Jacques Izopet; Pierre Delobel
1Inserm, Toulouse, France; 2Centre Hospitalier Universitaire de Toulouse, Toulouse, France

WEDNESDAY, FEBRUARY 25, 2015

Session P-C3 Poster Session Poster Hall
2:30 pm – 4:00 pm
Innate and Unconventional T-Cell Responses

275 Effect of KIR2D-Mediated Immunity on Clinical Outcome Among CRF01_AE-Infected Thais
Masahiko Mori; Nuanjun Wichukchinda; Reiko Miyahara; Archawin Rojanawiwat; Panita Pathivivanich; Toshiyuki Miura; Michio Yasunami; Koya Aiyoshi; Pathom Sawanpanyalert
1Institute of Tropical Medicine, Nagasaki University, Nagasaki City, Japan; 2Ministry of Public Health, Nonthaburi, Thailand; 3Day Care Centre, Lampang Hospital, Lampang, Thailand

276 HLA-KIR-Associated Sites in Gag and Their Effects on Clinical Outcome in Thailand
Masahiko Mori; Nuanjun Wichukchinda; Reiko Miyahara; Archawin Rojanawiwat; Panita Pathivivanich; Toshiyuki Miura; Michio Yasunami; Koya Aiyoshi; Pathom Sawanpanyalert
1Institute of Tropical Medicine, Nagasaki University, Nagasaki City, Japan; 2Ministry of Public Health, Nonthaburi, Thailand; 3Day Care Centre, Lampang Hospital, Lampang, Thailand

277 In KIR3DL1/S1 Heterozygotes Are KIR3DL1 and KIR3DS1 Co-DominantlyExpressed?
Zahra Kiani; Nicole F. Bernard; Julie Bruneau
1McGill University, Montreal, Canada; 2Centre de Recherche du Centre Hospitalier de l’Universite de Montreal, Montreal, Canada

Session P-C4 Poster Session Poster Hall
2:30 pm – 4:00 pm
Monocytes, Dendritic Cells, and Neutrophils

283 Siglec-1 on Monocytes From Untreated HIV-1–Infected Patients Enhances HIV-1 Transfer
Maria Pino; Susana Benet; Itziar Erkizia; Judith Dalmau; Dan Ouchi; Bonaventura Clop; Javier Martinez-Picado; Nuria Izquierdo-Usenos
Icahn School of Medicine at Mount Sinai, New York, NY, US

284 Soluble CD40 Ligand Contributes to Dendritic Cell Mediated T-Cell Dysfunction
Elizabeth A. Miller; Ramya Gopal; Vanessa Valdes; Jeffrey S. Berger; Nina Bhardwaj; Meagan O’Brien
Icahn School of Medicine at Mount Sinai, New York, NY, US

285 The Alarmin HMGB1 Is Crucial for the Acquisition of Antiviral pDC Effector Functions
Hela Saidi; Marlene Bras; Pauline Formaglio; Bruno Charbit; Marie-Thérèse Melki; Marie-Lise Gougeon
On behalf of the Antiviral Immunity, Biotherapy and Vaccine Unit
1Institut Pasteur, Paris, France; 2Sebia, Evry, France

278 Disruption of Innate-Like Unconventional T-Cell Subsets in HIV-Infected Children
Alka Khaitan; Adam Kravietz; Ilmet Tiina; Mussa Mwamzuka; Fatma Marshed; Cihan Tastan; Abid Ahmed; Bill Borkowsky; Derya Unutmaz
1New York University School of Medicine, New York, NY, US; 2Bomu Hospital, Mombasa, Kenya; 3New York University School of Medicine, New York, NY, US

279 HIV-1 Alters Innate Immune Response to BCG, Which Differs From SIV Infected Mangabeys
Melanie Gasper; David Sherman; Donald Sodora
Seattle Biomed, Seattle, WA, US

280 High-Level Replication Allows SHIVs to Overcome the Macaque Interferon Response
David F. Boyd; Amit Sharma; Julie M. Overbaugh
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

281 Elevated IFN-γ in HIV Patients Using a Novel Assay for Adaptive and Innate Immunity
Michelle K. Yong; Paul Cameron; Tim Spelman; Julian Elliott; Christopher Fairley; Jeffrey Boyle; Misato Miyamasu; Sharon R. Lewin
1Monash University/Alfred Hospital, Melbourne, Australia; 2Burnet Institute, Melbourne, Australia; 3Qiagen, Melbourne, Australia; 4Melbourne Sexual Health Centre, Melbourne, Australia

282 TLR8 Regulation of LILRA3 Is Abrogated in HIV Infection and Correlates to CD4 Counts and Virus Loads
Hui Zhi Low; Gerrit Ahrenstorff; Torsten Witte
Hannover Medical School, Hannover, Germany

Poster Listings
TUESDAY, FEBRUARY 24, 2015

Session P-C5 Poster Session
2:30 pm – 4:00 pm
Studies of HIV-Exposed Uninfected Individuals

287  HIV-Exposed Seronegative MSM Have Increased Novel Antiviral Factors in Rectal Mucosa
Laura Romas 1; Klara Hasselrot 2; Kristina Brüilden 3; Carolina Herrera 4; Garrett Westmacott 5; Francis Plummer 6; Terry B. Ball 7; Adam Burgener 1; 1University of Manitoba, Winnipeg, Canada; 2Karolinska Institutet, Stockholm, Sweden; 3Imperial College London, London, United Kingdom; 4Public Health Agency of Canada, Winnipeg, Canada

288  PBMC From Highly Exposed Seronegative Individuals Inhibit Transmitted Founder HIV
Kevin C. Olivieri 1; Eunyoung Kim 2; Susan Little 3; Michael Turchin 3; Vanessa Serrano 1; Anma Rasheed 1; Quy Nguyen 2; Paul Dejeseus 1; Steven Wolinsky 1; Sumit Chanda 1; 1Sanford-Burnham Medical Research Institute, San Diego, CA, US; 2University of California San Diego, La Jolla, CA, US; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US

289  HIV-1-Exposed Seronegative Persons Have Lower Mucosal Innate Immune Reactivity
Jennifer A. Fulcher 1; Jennifer C. Hoffman 1; Laura M. Romas 1; Karen Tanner 1; Terry Saunders 1; Julie Elliott 1; Adam D. Burgener 2; Peter A. Anton 2; Otto O. Yang 2; 1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 2University of California San Diego (UCSD), San Diego, CA, US

290  Increased Levels of Regulatory T-cells Correlate With Protection From HIV Infection
Laura Pattacini 1; Jared Baeten 2; Katherine Thomas 3; Taylor Fluharty 4; Pamela Murmane 5; Deborah Donnell 5; Nelly Mugo 5; Jairam R. Lingappa 6; Connie Celum 1; Jennifer Lund 1; 1Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US; 3Georgetown University, Washington, DC, US; 4University of California San Francisco, San Francisco, CA, US; 5University of Washington, Seattle, WA, US

Session P-C6 Poster Session
2:30 pm – 4:00 pm
Host Factors in HIV Pathogenesis

291  Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control
István Bartha 1; Paul J. McLaren 2; Chanson J. Brumme 3; Richard Harrigan 4; Amalio Telenti 5; Jacques Fellay 6; 1École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; 2Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3J. Craig Venter Institute, La Jolla, CA, US

292  Host Gene Expression Profiles and HIV-1 Infection Outcomes
Romeo D. Maceykprang 1; Ali Filali 2; Mark Cameron 3; Rafick P. Sekaly 2; Elly Kabatari 4; Allan Ronald 1; Glenda Gray 1; Connie Celum 1; M Juliana McElrath 1; Jairam R. Lingappa 1; 1University of Washington, Seattle, WA, US; 2Case Western Reserve University, Cleveland, OH, US; 3Makerere University College of Health Sciences, Kampala, Uganda; 4University of Minnesota, Minneapolis, MN, USA; 5Fred Hutchinson Cancer Research Center, Seattle, WA, US

293  Refinement of Association Signals Assessment of Residual Heritability in Host Control of HIV Viral Load
Paul J. McLaren 1; Istvan Bartha 1; Jacques Fellay 2; École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

294  Genetic and Clinical Predictors of CD4 Recovery DuringSuppressive cART: WHS
Ruth M. Greenblatt 1; Kord Kober 1; Peter Bacchetti 1; Ross Boylan 1; Kathryn Anastos 1; Mardge Cohen 1; Mary A. Young 1; Deborah Gustafson 2; Bradley Auouzerat 1; 1University of California San Francisco, San Francisco, CA, US; 2Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, New York, NY, US; 3Georgetown University, Washington, DC, US; 4State University of New York, Downstate, Brooklyn, NY, US; 5CORE Center, Chicago, IL, US; 6National Institutes of Health (NIH), Bethesda, MD, US

295  Host Genetic Predictors of Plasma Kynurenine/Tryptophan Among Treated HIV+ Ugandans
Sulgi A. Lee 1; Joel Mefford 1; Yong Huang 1; John S. Witte 1; Jeffrey Martin 1; David R. Bangsberg 1; Taisei Mushiroda 1; Michiaki Kubo 1; Deanna Kroetz 1; Peter W. Hunt 1; 1University of California San Francisco, San Francisco, CA, US; 2Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, New York, NY, US; 3Massachusetts General Hospital and Harvard University, Boston, MA, US; 4RIKEN Center for Genomic Medicine, Wako, Japan

296  Regulation of IL-32 Expression by a Promoter Polymorphism and MicroRNA29b in HIV-1 Patients
Carolina Scagnolari 1; Giulia Cacciotti 1; Carlo Selvaggi 1; Noemi Giustini 1; Ivano Mezzaroma 1; Massimo Gentile 1; Gabriella D’Ettorre 1; Ombretta Turziani 1; Vincenzo Vullo 1; Guido Antonelli 2; Sapienza University of Rome, Rome, Italy

297  LILRA3 Deletion Is a Genetic Risk Factor of HIV Infection
Gerrit Ahrenstorff 1; Hui Zhi Low 1; Katja kniesch 1; Matthias Stoll 2; Dirk Meyer-Olson 2; Torsten Matthias 2; Reinhold E. Schmidt 1; Torsten Witte 1; 1Hannover Medical School, Hannover, Germany; 2AESC Diagnostics, Wedelshaus, Germany
298LB  SIV Infection Triggers Endothelial Dysfunction and Diminished Expression of Krüppel-Like Factor 2 (KLF2) in Nonhuman Primates  
Soumya Panigrahi1; Michael L. Freeman1; Joseph C. mudd1; Nicholas Funderburg2; Scott Sieg1; David A. Zidar1; Mirko Piairdini3; Francois Villinger1; Mukes K. Jain1; michael lederman1  
1Case Western Reserve University/University Hospitals Medical Center, Cleveland, OH, US; 2Ohio State University School of Health and Rehabilitation Sciences, Columbus, OH, US; 3Emory University, Atlanta, GA, US; 4Lab of Molecular Microbiology, Bethesda, MD, US

299LB  A Novel Method Using H2O2 to Measure Collagen Turnover in HIV-Infected Individuals  
Leslie R. Cockerham1; Claire Emerson2; Ma Somsock1; Kara Harvill1; Kevin Li1; Scott M. Turner2; Martin L. Decaris3; Marc K. Hellerstein3; Steven G. Deeks1; Hiroyu Hatano1  

THURSDAY, FEBRUARY 26, 2015

Session P-C7 Poster Session  
2:30 pm – 4:00 pm  
HIV/CMV Interactions in Transmission and Pathogenesis

300  Effect of CMV and HIV Replication on T-Cell Exhaustion and Senescence During ART  
Jennifer M. Dan1; Marta Massanella1; David M. Smith1; Eric S. Daar1; Michael P. Dube1; Richard Haubrich1; Sheldon Morris1; Sara Gianella Weibel1  
1University of California San Diego, La Jolla, CA, US; 2Harbor–University of California Los Angeles Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US

301  HIV Myeloid Derived Suppressor Cells Control Cytomegalovirus Inflammation by IL-27  
Ankita Garg; Stephen Spector  
University of California San Diego, La Jolla, CA, US

302  Persistent Elevation of Inflammation Markers in HIV+ Persons With CMV Disease  
Melissa Schechter1; Bruno Andrade2; Eleanor M. Wilson1; Virginia Sheikh1; Sonya Krishnan1; Margaret Caplan1; Gregg Roby1; Adam Rupert1; Peter Burbelo1; Irini Sereti1  
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2National Institute of Allergy and Infectious Diseases, Bethesda, MD, US

303  sCD163 Increase in HIV/CMV-Coinfected Subjects Included in ICONA Cohort  
Serena Vita1; Miriam Lichtner1; Giulia Marchetti2; Claudia Mascia1; Esther Merlini1; Paola Cicconi1; Vincenzo Vollaro1; Pier Luigi Viale1; Alberto Costantini1; Antonella d’Arminio Monforte1  
For the ICONA Foundation Study

304  Genital CMV Shedding Predicts Syphilis Acquisition in HIV-infected MSM on ART  
Sara Gianella Weibel1; David M. Smith1; Eric Daar1; Michael Dube2; Andrea Lisco2; Christophe Vannoupillie2; Richard Haubrich1; Sheldon Morris1  
1University of California San Diego, La Jolla, CA, US; 2Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US; 4National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 5National Institute of Child Health and Human Development, Bethesda, MD, US

Session P-C8 Poster Session  
2:30 pm – 4:00 pm  
Aging and Immune Senescence

305  Early Start of ART Affects Late Markers of Immune Senescence  
Sharon L. Karmon; Teresa H. Evering; Melissa La Mar; Martin Markowitz  
Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY, US

306  Chronic HIV Infection Exacerbates Cellular Aging Markers in Isolated T-Cell Subsets  
Anthony Hsieh; Beherose Sattha; Hélène Côté  
CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA cohort)  
University of British Columbia, Vancouver, Canada

307  Age Associated Increases in Markers of Microbial Translocation and Inflammation in HIV-1 Infection  
Eileen Scully1; Ainsley Lockhart1; Lisa Huang1; Marisol Romero-Tejeda1; Mary Albrecht1; Christine D. Palmer1; Ronald Boschi1; Marcus Alfelt2; Daniel Kurtzkes2; Nina Lin2  
1Ragon Institute of MGH, MIT and Harvard, Jamaica Plain, MA, US; 2Brigham and Women’s Hospital, Boston, MA, Boston, MA, US; 3Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 4Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 5Boston University School of Medicine, Boston, MA, US

Session P-C9 Poster Session  
2:30 pm – 4:00 pm  
Immune Pathogenesis of IRIS

308  Vitamin D, D-Dimer, IFNγ and sCD14 Predict IRIS in a Prospective Multicenter Study  
Laura W. Musselwhite1; Ann Tierney2; Susan Ellenberg3; Pablo F. Belanzarán-Zamudio4; Adam Rupert1; Ian Sanne4; Michael M Lederman1; Juan Sierra-Madero5; Irini Sereti5  
1Duke University, Durham, NC, US; 2University of Pennsylvania, Philadelphia, PA, US; 3Leidos Biomedical Inc., Reston, VA, US; 4University of the Witwatersrand, Johannesburg, South Africa; 5Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico; 6Case Western Reserve University, Cleveland, OH, US; 7National Institutes of Health (NIH), Bethesda, MD, US
309 LC-MS Analysis of Metabolites Differentiating IRIS From Non-IRIS in ACTG Study A5221
Mary A. De Groot1; Laura Ashton; Marisa Harton; Sam Bokatzien; Kristofor Webb; Carlos Adriano Matos de Silva; Reem Al-Mubarak; Seabratra Mahapatra; Diane Havlir; John Belisle

310 Associations Between Plasma Cytokine and Microbial Translocation Biomarkers and IRIS
Margaret A. Fischer1; Linda J. Harrison; Varghese George; Margaret Roach; Xiao-Dong Li; David Asmuth; Pablo Tebas; Camlin Tierney; Catherine Godfrey; Savita Pahwa
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 2University of Miami Miller School of Medicine, Miami, FL, US; 3University of California Davis, Sacramento, CA, US; 4University of Pennsylvania, Philadelphia, PA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

311 Potential Role of IL-1 and IL-10 Pathways in IRIS Pathogenesis
Ainhoa Perez-Diez; Elizabeth Richards; Stig Jensen; Eleanor M. Wilson; Virginia Sheikh; Maura M. Manion; Bruno Andrade; Timothy Myers; Irini Sereti
National Institute of Allergy and Infectious Diseases (NIAID), Rockville, MD, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-C10 Poster Session
2:30 pm – 4:00 pm
Poster Hall

Immune Activation and HIV Pathogenesis

312 Inflammatory Biomarkers Decline but Do Not Normalize After 10 Years of cART
Kenneth A. Lichtenstein1; Carl Armon; Vijaya Knight; Rafeul Alam
1National Jewish Health, Denver, CO, US; 2Children’s Hospital Colorado, Aurora, CO, US

313 Persistently High IL-18 and sCD14 Are Independently Associated With Clinical Failure
Ashwin Balagopal1; Nikhil Guptha2; James Hakimi2; Mina C. Hosseinipour; Nagalingeswaran Kumarsamy; Andrea Cox; Ian Sanne2; David Asmuth; Thomas Campbell; Amita Gupta
On behalf of the ACTG
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3University of North Carolina, Chapel Hill, NC, US; 4K.G. Care, Chennai, India; 5University of California San Diego, San Diego, CA, US; 6University of Colorado, Denver, CO, US; 7ACTG, Washington, DC, US

314 Impact of Partner HIV Status on Immune Activation and Inflammation During Chronic HIV
Shaneen Z. Jaumdally1; Pamela Gumbi; Hoyam Gamieldien; Anabela Picton; Caroline Tiemessen; Linda Masson; Lenine Liebenberg; David Coetzee; Anna-Lise Williamson; Jo-Ann Passmore
1University of Cape Town, Cape Town, South Africa; 2National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; 3Centre for AIDS Programme Research in South Africa, Durban, South Africa; 4University of Cape Town, Cape Town, South Africa

315 Pretherapy Inflammation and Long-Term CD4 Response to Antiretroviral Therapy
Amit C. Achhra1; Andrew N. Phillips2; Sean Emery3; Rodger D. MacArthur; Hansjakob Furrer; Stéphane De Wit; Marcelo H. Losso4; Matthew G. Law
On behalf of the INSIGHT SMART and FIRST Study groups
1Kirby Institute, University of New South Wales, Sydney, Australia; 2University College London, London, United Kingdom; 3Wayne State University, Detroit, MI, US; 4University Hospital Bern, Bern, Switzerland; 5Saint-Pierre University Hospital, Brussels, Belgium; 6Hospital J.M. Mejia, Buenos Aires, Argentina

316 Plasma Levels of sCD163 Predict All-Cause Mortality From HIV Infection
Troels Bygum Knudsen1; Janne Petersen; Holger Jon Møller; Saren Moestrup; Jesper Eugen-Olsen; Gitte Kronborg; Thomas Benfield1
1Copenhagen University Hospitals, Hvidovre, Copenhagen, Denmark; 2Copenhagen University Hospitals, Hvidovre, Copenhagen, Denmark; 3Aarhus University Hospital, Aarhus, Denmark; 4Aarhus University, Aarhus, Denmark

317 Immunologic Pathways That Predict Mortality in HIV+ Ugandans Initiating ART
Sulggi A. Lee; Helen Byakwaga; Yap Boum; Tricia Burdo; Yong Huang; Jessica Haberer; Annet Kembabazi; David R. Bangsberg; Jeffrey Martin; Peter W. Hunt
1University of California San Francisco, San Francisco, CA, US; 2Mbarara University of Science and Technology, Mbarara, Uganda; 3Boston College, Boston, MA, US; 4University of California San Francisco, San Francisco, CA, US; 5Massachusetts General Hospital and Harvard University, Boston, MA, US

318 Immune Activation Impairs Yellow Fever Vaccine Efficacy in HIV-Infected Patients
Vivian I. Avelino-Silva; Karina T. Miyaji; Marisol Simoes; Marcos Freire; Ana Sartori; Peter W. Hunt; Karine Milani; Augusto Mathias; Ana Paula Batista; Esper G. Kallas
1University of Sao Paulo Medical School, Sao Paulo, Brazil; 2Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 3University of California San Francisco, San Francisco, CA, US; 4University of Sao Paulo Medical School, Sao Paulo, Brazil

319 Association Between sCD163 and CMV IgG in Virologically Suppressed HIV+ Patients
Aimee Hodowanec1; Brett Williams; Barbara Hanson; Britt Livak; Sheila Keating; Nell Lurain; Oluwatoyin M. Adeyemi
1Rush University Medical Center, Chicago, IL, US; 2University of Chicago, Chicago, IL, US; 3Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US; 4Ruth M Rothstein CORE Center, Chicago, IL, US
Session P-C11 Poster Session
2:30 pm – 4:00 pm
Manipulating Immune Activation

320 The mTORC1 Inhibitors, Temsirolimus and Everolimus, Suppress HIV Patient-Derived CD4+ T-Cell Death and Activation In Vitro
Clovis S. Palmer1; Matias Ostrowski1; Jingling Zhou1; Linda Lam1; Alan Landay2; Anthony Jaworowski3; Joseph M. McCune2; Suzanne M. Crowe4
1Burnet Institute, Melbourne, Australia; 2Rush University Medical Center, Chicago, IL, US; 3University of California San Francisco, San Francisco, CA, US; 4Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina

321 Decreased Monocyte Activation With Daily Acyclovir Use in HIV-1/HSV-2 Coinfected Women
Andrew D. Redd1; Kevin Newell2; Eshan U. Patel3; Fred Nalugoda4; Paschal Ssebbowa5; Sarah Kaliballa6; Ronald H. Gray7; Thomas C. Quinn8; David Serv Sadd2; Stephen J. Reynolds9
1National Institute of Allergy and Infectious Diseases (NIAID), Washington, DC, US; 2Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, US; 3Rakai Health Sciences Program, Kalisizo, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5Makerere University College of Health Sciences, Kampala, Uganda

322 Atorvastatin Reduced T-Cell Activation and Exhaustion Among Suboptimal Immune Responders: A Randomized Crossover Placebo Controlled Trial
Damalie Nakanjako
Makerere University Infectious Diseases Institute, Kampala, Uganda

323 P2X Type Purinergic Antagonists Can Block HIV-1 Infection and Associated Inflammation
Talia Swartz1; Meagan O’Brien1; Anthony Esposito1; Nina Bhardwaj1; Benjamin Chen1
1Icahn School of Medicine at Mount Sinai, New York, NY, US

THURSDAY, FEBRUARY 26, 2015

Session P-CT2 Poster Session
2:30 pm – 4:00 pm
Pathogenesis in Lymph Nodes

324 CD4+ T cell death mediated by pyroptosis in early SIV infected lymphatic tissues
Wuxun Lu1; Guobin Kang1; Fangnui Ma1; Yamin Wan2; Yue Li3; Mark Lewis4; Qingsheng Li5
1University of Nebraska-Lincoln, Lincoln, NE, US; 2Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; 3BIOQUAL, Inc., Rockville, MD, US

325 Fibrosis in Lymphoid Tissue Is Associated With Peripheral Blood Regulatory T Cells
Julie C. Gaardbo1; Patricia S. Nielsen2; Lise Mette R. Gjerdrum3; Karoline Springborg4; Elisabeth Ralfkiaer1; Henrik Ullum1; Åse Andersen1; Susanne D. Poulsen1
1University of Copenhagen, Rigshospitalet, Copenhagen, Denmark; 2Aarhus University Hospital, Aarhus, Denmark; 3Bispebjerg Hospital, University Hospital of Copenhagen, Denmark, Copenhagen, Denmark; 4Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

326 Decreased Tfh/Tn Ratio in SIV-Infected Rhesus Macaques
Ankita Chowdhury1; Perla Del Río-Estrada2; Steven Bosingwer3; Guido Silvestri1
Emory University, Atlanta, GA, US

Session P-C13 Poster Session
2:30 pm – 4:00 pm
Dissecting Pathogenesis Through In Vitro Studies

327 A Dual-Tropic HIV-1 Env Interacts With CCR5 to Deplete Bystander CD4 T Cells In Vitro and In Vivo
Li-Chung Tsao1; Haitao Guo2; Jerry Jeffrey3; James A. Hoxie4; Lishan Su5

328 Investigation of the Association of Gag-Protease Dependent Replication Capacities With Clinical Outcomes of HIV-1 Infection
Keiko Sakai1; Takayuki Chikata1; Hiroyuki Gatanaga2; Shinichi Oka3; Masafumi Takiguchi1
1Kumamoto University, Kumamoto-shi, Japan; 2National Center for Global Health and Medicine, Tokyo, Japan

329 Association of Bacteria-Induced IL-23 and Th17 Frequencies in HIV-1+ Individuals
Jennifer Manuzak1; Sonia Amraoui1; Nipa Decroix2; Pierre Loulergue2; Odile Launay3; Marco Iannetta2; Jean-Baptiste Guillerme2; Lene Vimeux1; Anne Hosmalin1
1Inserm U1016, Institut Cochin, Paris, France; 2Centre d’Investigation Clinique CIC 1417, Inserm-AP-HP, Hôpital Cochin, Paris, France

330 Effect of Methamphetamine Use on T-Cell Proliferation In Vivo and Ex Vivo
Marta Massanella1; Sara Gianella2; Jennifer M. Dan3; Eric Daar4; Michael P. Dube5; Richard H. Haubrich2; Douglas D. Richman4; Davey M. Smith3; Sheldon Morris2; Rachel D. Schrier1
1La Jolla Institute of Allergy and Immunology, La Jolla, CA, US; 2Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance, CA, US; 3University of Southern California Keck School of Medicine, Los Angeles, CA, US; 4University of California San Diego, La Jolla, CA, US
**Program and Agenda**

**Session P-C14 Poster Session**

**Poster Hall**

2:30 pm – 4:00 pm

**Dissecting Pathogenesis Through In Vivo Studies**

331  **A Random Forest Approach to Define Immunological Thresholds for CD4 Recovery in HIV-Treated Individuals**

Josué Pérez-Santiago¹, Marta Massanella¹, Dan Ouchi¹, Elisabet Gómez², Cecilia Cabrera¹, Bonaventura Clotet³, Eugenia Negredo⁴, Julíà Blanco⁵

¹University of California San Diego, La Jolla, CA, US; ²IRScAix Institute for AIDS Research, Badalona, Spain; ³Uluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain

332  **Disease Progression in HIV Controllers; Uptake and Outcome of Antiretroviral Therapy**

Jane R. Deayton¹, Katherine C. Groves¹, David F. Bibby¹, Duncan A. Clark¹, Iain Reeves¹, Jane Anderson¹, Chloe M. Orkin¹, Eithne O’Sullivan¹, Áine McNicht¹

¹Barts and the London, Queen, London, United Kingdom; ²Barts Health NHS Trust, London, United Kingdom; ³Homerun University Hospital NHS Foundation Trust, London, United Kingdom; ⁴Barts Health NHS Trust, London, United Kingdom

333  **Immunological and Virological Progression in HIV Controllers**

Nicolas Noel¹, Nathalie Lerolle¹, Camille Leccuroix², Cécile Goujard¹, Alain Venet¹, Asier Sáez-Cirión³, Bonaventura Clotet³, Eugenia Negredo⁴, Laurence Meyer³, Faroudy Boufassa³, Olivier Labbe⁴

¹University of Basel, Basel, Switzerland; ²Institute for Immunogenetics, The Swiss HIV Cohort Study; ³Institut Pasteur, Paris, France; ⁴Swiss National Center for Retroviruses, Zürich, Switzerland

334  **HIV Replication History Is Associated With Plasma IL-7 Levels in Aviremic Youths**

Daniel Scott-Algara¹, Jerome Lechenadec¹, Josiane Warszawski¹, Thomas Montange¹, Jean-Paul Viard¹, Catherine Dollfus¹, Véronique Avetand-Fenoel¹, Laurence Meyer³, Faroudy Boufassa³, Olivier Labbe⁴

¹University of California San Diego, La Jolla, CA, US; ²Inserm U1012, Régulation de la Réponse Immune, Infection VIH-1 et Autoimmunité, Le Kremlin Bicêtre, France; ³Institut Pasteur, Unité de Régulations des Infections Rétrovirales, Paris, France; ⁴APHP, Service de Virologie, Hôpital Necker – Enfants Malades, Paris, France

335  **Enhanced Immunologic Reconstitution With Initiation of ART at HIV-1 Seroconversion (PHI)**

Sabine I. Kinloch¹, Colette Smith¹, Kwong Tsz-Shan¹, Jayne Ellis¹, Margaret Johnson²

¹University College London, London, United Kingdom; ²Royal Free London NHS Foundation Trust, London, United Kingdom

336  **cART-Driven Recovery of Immune Function Preferentially Targeting CXCR4-Tropic HIV-1**

Joëlle Bader¹, Martin Däumer¹, Jürg Böni¹, Meri Gorgievski¹, Thomas Klimkait¹

¹The Swiss HIV Cohort Study; ²University of Basel, Basel, Switzerland; ³Institute for Immunogenetics, Kaiserslautern, Germany; ⁴University of Berne, Berne, Switzerland; ⁵Swiss National Center for Retroviruses, Zürich, Switzerland

337  **Repeated injections of r-hIL-7 in HIV Patients receiving ART in INSPIRE 2 & 3 trials**

Rodolphe Thiebaut¹, Ana Jamé¹, Jean-Pierre Routy¹, Irini Sereti¹, Margaret A. Fischl¹, Prudence Ives¹, Roberto Speck², Giuseppe Tambussi², Yves Lévy³, Michael M Lederman⁴ on behalf of Inspire 2 and Inspire 3 study groups

¹Bordeaux University, Bordeaux, France; ²McGill University, Montreal, Canada; ³National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; ⁴University of Miami, Miami, FL, US; ⁵Wits Health consortium, Johannesburg, South Africa; ⁶University Hospital Zurich, Zurich, Switzerland; ⁷San Raffaele Scientific Institute, Milano, Italy; ⁸INSERM, Paris, France; ⁹Case Western Reserve University, Cleveland, OH, US

**TUESDAY, FEBRUARY 24, 2015**

**Session P-E1 Poster Session**

**Poster Hall**

2:30 pm – 4:00 pm

**The Effect of HIV Infection on B Cells**

339  **Acute HIV-1 Infection Is Associated With Rapid Changes in B-Cell Subsets and Levels of CXCL13**

Jennifer K. Maroa¹, Anne-Sophie Dugust², Zelia Euler¹, Yathisha Ramlakhan¹, Krista Dong¹, Bruce Walker¹, Thumbi Ndung’u³, Katherine R. Calvo³, Susan Moir¹, Anthony S. Fauci¹

¹University of Kwazulu-Natal, Durban, South Africa; ²Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; ⁴HIV Pathogenesis Programme, Durban, South Africa

340  **Bone Marrow Plasma Cells Dictate Serum HIV-Specific Antibodies in Chronic Viremia**

Jairo Mauricio Montezuma-Rusca¹, Olivia R. Fankuchen¹, Lela Kardava¹, Clarisa M. Pineda-Peña¹, Jorge Pérez³, Lissette Pérez³, Kristel Van Laethem⁴, Anne-Mieke Vandamme⁴

¹Bordeaux University, Bordeaux, France; ²McGill University, Montreal, Canada; ³National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; ⁴University of Maryland, Rockville, MD, US; ⁵NIH Clinical Center, Bethesda, MD, US

341  **Reduced Expression of Blimp-1 on Memory B Cells in Patients with HIV-1 Infection**

Claudia Beisel¹, Ilona Toth¹, Jan van Lunzen¹, Julian Schulze zur Wiesch², Claudia Beisel²

¹University Hospital Hamburg-Eppendorf, Hamburg, Germany

342  **Similar or Higher Memory Responses to Influenza Vaccination in Aviremic HIV-infected Patients on Antiretroviral Therapy**

Zhenwu Luo; Lisa Martin; J. Michael Kilby; Wei Jiang

Medical University of South Carolina, Charleston, SC, US
Estimating and Visualizing HIV-1 Susceptibility to Broadly Neutralizing Antibodies
Anna Feldmann; Nico Pfeifer
Max Planck Institute for Informatics, Saarbrücken, Germany

Sequential SHIV-Env Clones With Neutralization Sensitivity for Breadth Development
Manzue Jia; Cecilia Cheng-Mayer; Xueling Wu
Aaron Diamond AIDS Research Center, New York, NY, US

V1V2 Neutralizing Epitopes Are Conserved Within Divergent Groups of HIV-1
Marion Morgand; Mélanie Bouvin-Pley; Craig S Pace; David Ho; Pascal Poignard; Marie Pancera; Jean-Christophe Plantier; François Simon; Martine Brabant; François Barin
Université de Tours, Inserm U966, Tours, France; Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, US; Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, US; Vaccine Research Center, NIAID, NIH, Bethesda, WA, US; Université de Rouen, CHU Charles Nicolle, Rouen, France; Laboratoire de Virologie, Hôpital St Louis, Paris, France; Université de Tours, Inserm U966, Laboratoire de Bactériologie-Virologie, CNR du VIH, CHU Bretonneau, Tours, France

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes
Rui Kong; Mark Louder; Kshitij Wagh; Robert Bailer; Kelli Greene; Hongmei Gao; Michel Nussenzweig; Bette Korber; David Montefiori; John Mascola
1Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 2Los Alamos National Laboratory, Los Alamos, NM, US; 3Duke University Medical Center, Durham, NC, US; 4The Rockefeller University, New York, NY, US

Improved Antibody Cross-Neutralizing Activity in HIV-1 Dual-Infected LTNP Patients
Maria Pernas; Concepción Casado; Víctor Sanchez-Merino; Alberto Sanchez-Merino; Isabel Olivares; eloisa Yuste; Cecilio Lopez-Galindez
Instituto de Salud Carlos III, Majadahonda, Spain; Instituto d'Investigacions Biomèdiques, Barcelona, Spain

Characterization of CD4 Independent HIV-1 Envelope as Potential Immunogens
LiFei Yang; Bradley Cleveland; Andrea P. Jordan; Patricia Polacino; James A. Hoxie; Shiu-Lok Hu
1University of Washington, Seattle, WA, US; 2University of Pennsylvania, Philadelphia, PA, US

Phenotypic Neutralization Sieve Analysis of an SIV Nonhuman Primate Vaccine Challenge Study
Fang-Hua Lee; Brandon F. Keele; Robert Doms; George M. Shaw; Mario Roederer; Katharine J. Bar
1University of Pennsylvania, Philadelphia, PA, US; 2Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 3National Cancer Institute, Frederick, MD, US

AvFc, a Novel Fc Fusion Protein Targeting Env High-Mannose Glycans
Nobuyuki Matoba; Adam Husk; J. Calvin Koukouam; Krystal Hamorsky; Tiffany Grooms-Williams; Garima Mahajan
University of Louisville James Graham Brown Cancer Center, Owensboro, KY, US

DARPins as Entry Inhibitor Alternative to HIV-1 Broadly Neutralizing Antibodies
Emanuel Stiegeler; Nicolas Friedrich; Thomas Reinerb; Mylene Morin; Yufan Wu; Jonas V. Schaefer; Peter Ruset; John Robinson; Andreas Plückthun; Alexandra Tkola
University of Zurich, Zurich, Switzerland

Use of Pre-ART-Adjusted Endpoints in the Analysis of an HIV Therapeutic Vaccine Trial
Yunda Huang; Lily Zhang; Darren Jolliffe; Amt-Ove Hovden; Mats Okvist; Pantaleo Giuseppe; Maja A. Sommerfelt
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2Lausanne University Hospital, Lausanne, Switzerland; 3S-cubed Biometrics Ltd, Oxfordshire, United Kingdom; 4Bionor Pharma ASA, Oslo, Norway

Decreased HIV-Specific T-Regulatory Responses Mark Effective Vaccine-Induced Immunity
Vedran Brezara; Nicolas Ruffin; Laura Richert; Mathieu Sureaua; Christine Lacabaratz; Karolina Palucka; Rodolphe Thiebaut; Jacques Bandchereau; Yves Lévy; Nabilah Seddikia
1Inserm U955 (Eq16)-UPEC-VRI, Créteil, France; 2Univ Bordeaux-ISPED-Inserm U967-VRI, Bordeaux, France; 3Ralph M. Steinman Center for Cancer Vaccines—Baylor Institute for Immunology Research, Dallas, TX, US

Viral Reservoir Dynamics After Therapeutic Vaccination and cART Interruption
Cristina Andres; Carmen Alvarez-Fernandez; Nuria Climent; Teresa Gallart; Montserrat Plana; Agathe Leon; Nicolas Chomont; Jose M. Gatell; Felipe Garcia; Sonsoles Sanchez-Palomino
1Hospital Clinic, Barcelona, Spain; 2Vaccine and Gene Therapy Institute, Port St Lucie, FL, US

HIV-1 Envelope Epitope Recognition Is Influenced by Immunoglobulin D, Gene Segment Repertoire
Yuge Wang; Aaron Sanchez-Silva; Barton Haynes; Harry Schroeder
1Duke University, Durham, NC, US; 2University of Alabama at Birmingham, Birmingham, AL, US; 3University of Alabama at Birmingham, Birmingham, AL, US

Human Rhinovirus Displaying HIV-1 4E10 Epitope Elicits Broad Neutralization in HcCAM-1 Tg Mice
Guohua Yi; Xiongying Tu; Preeti Bharaj; Premila Shankar; Manjunath Swamy
1Texas Tech University Health Sciences Center, El Paso, TX, US; 2University of Minnesota, St Paul, MN, US
357  A New Mucosal Vaccine With Inactivated Bacteria Linked to Adjuvanted Nanoparticles
Georg Stary1; Andrew Olive1; Aleksandar F. Radovic-Moreno2; David Alvarez2; Mario Pero2; Vladimir Urbanac; Omid Farokhzad3; Robert Langer4; Stambach Michael1; Ulrich H. von Andrian1
1Harvard Medical School, Boston, MA, US; 2Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, US; 3Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Boston, MA, US; 4The Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

358  A Superagonist Antibody to Human Interleukin-21 Increases HIV-Specific T-Cell Function
Yew Ann Leong1; Yanfang Cui1; Zhiwan Chen1; Fiona Wightman1; Pellegrini Marc1; Jamie Rossjohn1; Sharon R. Lewin1; Alan Landay4; Charles Mackay3; Di Yu1
1Monash University/Alfred Hospital, Melbourne, Australia; 2Department of Chemical Anesthesiology, Boston, MA, US; 4The Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Cambridge, MA, US

THURSDAY, FEBRUARY 26, 2015

Session P-E4 Poster Session
2:30 pm – 4:00 pm
Cellular Immune Response to HIV

359  Evolution of HIV-Specific CD8+ T-Cell Responses in Hyperacute HIV Infection
Zaza M. Ndhlovu1; Nikoshia Mewala1; Philomena Kamya1; Thandeka Nkosi1; Karyn Pretorius1; Nasreen Imsail1; Amber Moodley1; Krista Dong1; Thumbi Ndungu1; Bruce Walker2
1University of KwaZulu-Natal, Durban, South Africa; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

360  Nonclassical Regulatory HIV-1–Specific CD8 T Cells in HIV-1 Disease Progression
Selena Viganzo1; Chun L1; Jordi J. Negron1; Bruce D. Walker1; Mathias Lichterfeld1; Xu G. Yu2
1Massachusetts General Hospital, Boston, MA, US; 2The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

361  Nef Plays a Role in the Resistance of SIV-Infected Macrophages to CD8+ T-Cell Suppression
Jennifer N. Rainbo; Mauricio A. Martins; Francesc Cunyat; David I. Watkins; Mario Stevenson
University of Miami, Miami, FL, US

362  Defining Efficacious HIV-Specific CTL Responses Using Saporin-Conjugated Tetramers
Ellen M. Leitman1; Stuart Sims1; Rebecca P. Payne1; Fabian Chen1; Lynn Riddell2; Soren Buus1; Steven Deeks1; Bruce Walker2; Philippa C. Matthews2; Philip J. Goulder1
1University of Oxford, Oxford, United Kingdom; 2ETH Zurich, Basel, Switzerland; 3Royal Berkshire Hospital, Reading, United Kingdom; 4Northamptonshire Healthcare NHS Trust, Northampton, United Kingdom; 5University of Copenhagen, Copenhagen, Denmark; 6University of California San Francisco, San Francisco, CA, US; 7Ragon Institute of MGH, MIT and Harvard, Charlestown, MA, US

363  Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in SIV Infection
Shayarana Gooneratne1; Hamid Alinejad-Rokny2; Diako Ebrahim Mohammadi1; Patrick Bohn1; Roger Wiseman3; David O’Connor3; Miles Davenport4; Stephen Kent1
1University of Melbourne, Melbourne, Australia; 2University of New South Wales, Kensington, Australia; 3University of Wisconsin Madison, Madison, WI, US

364  HLA Class-II–Associated HIV Polymorphisms Predict Escape From CD4 T-Cell Responses
Nathaniel B. Erdmann1; Victor Du1; Jonathan M. Carlsson2; John Sidney3; Ling Yue4; Susan Allen4; Eric Hunter5; Sonya L. Heath1; Anju Bansal1; Paul A. Goepfert1
1University of Alabama at Birmingham, Birmingham, AL, US; 2Microsoft Research, Los Angeles, CA, US; 3La Jolla Institute of Allergy and Immunology, La Jolla, CA, US; 4Emory University, Atlanta, GA, US

365  Rapid Construction of HIV-1-Specific T Cell Receptor Gene Therapy Lentiviral Vectors
Christian Hofmann; Christian-Raul Aguiera-Sandoval; Arumugam Balamurugan; Priya Patel; Brian Diep; Edward Martin; Sangeun Park; Diana Y. Chen; Hwee Ng; Otto O. Yang
University of California Los Angeles, Los Angeles, CA, US

366  The Role of Exosomes in Semen in Suppressing Natural and Vaccine-Induced Immunity
Lucia Vojtech; Sean Hughes; Claire Levy; Florian Hladik
University of Washington, Seattle, WA, US

367  IFN-alpha Stimulated NK Lysis of HIV-Infected CD4+ T Cells Requires NKP46 and NKG2D
Costin Tomescu1; Domenico Mavilio; Luis J. Montaner1
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, US

TUESDAY, FEBRUARY 24, 2015

Session P-F1 Poster Session
2:30 pm – 4:00 pm
Immune-Based Strategies in Latency

368  Stimulation of Broad CTL Response Is Required to Clear Latent HIV-1 in Humanized Mice
Liang Shan1; Kai Deng2; Richard Flavell1; Robert F. Siliciano2
1Yale University, New Haven, CT, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US

369  In vivo effects of Panobinostat and Romidepsin on HIV-1-specific CD8 T Cell Immunity
Rikke Olesen1; Thomas A. Rasmussen1; Mathias Lichterfeld1; Mette E. Graversen1; Steffen Leth1; Lars Østergaard1; Ole S. Søgaard1; Martin Tolstrup1
1Aarhus University Hospital, Aarhus, Denmark; 2Ragon Institute of MGH, MIT and Harvard, Boston, MA, US
370  Vaccine Induced Follicular CD8 T Cells Enhance Control of Pathogenic SIV Infection
Geetha H. Mylvaganam; Daniel Rios; Gregory Tharp; Steven Bosinger; Vijayakumar Veliu; Rama R. Amara
Emory University, Atlanta, GA, US

371  Blockade of PD-L1 Does Not Reverse HIV Latency in CD4+ T Cells Ex Vivo
Elizabeth Fyne1; Shalyn Campellone2; Huilin Qi3; Amy Sheaffer4; Stephen Mason5; John W. Mollins1
1University of Pittsburgh, Pittsburgh, PA, US; 2Bristol-Myers Squibb Co., Wallingford, CT, US

372  Impact of HIV Latency Reversing Agents on Natural Killer Cells
Carolina Garrido; Julia Sung; Swati Gupta; Katherine Sholtis; Nancie Archin; David Margolis
Medicine, University of North Carolina
University of North Carolina, Chapel Hill, NC, US

THURSDAY, FEBRUARY 26, 2015

Session P-F2 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Viral Reservoir Dynamics During ART

373  The Earlier cART Is Initiated During PHI, the More Intracellular HIV-DNA Decreases
Moussa Laanani1; Jade Ghosn2; Asma Essat2; Adeline Melard2; Rémonie Seng2; Emmanuel Mortier4; Cécile Goujard2; Laurence Meyer2; Christine Rouzioux1
On behalf of the ANRS PRIMO Cohort Study Group
1APHP, Hôpital Dieu University Hospital, Paris, France; 2APHP, Bicêtre Hospital, Le Kremlin-Bicêtre, France; 3APHP, Necker Hospital, Paris, France; 4APHP, Louis Mourier Hospital, Colombes, France

374  Decay Rate and HIV-1 DNA Reservoir Size Following Early Infant Antiretroviral Therapy
Priyanka Uprey1; Kaitlin Rainwater-Lovett1; Ellen G. Chadwick1; Edmund Gapparelli1; Carrie Ziemniak2; Katherine Luzuriaga1; Larry Moulton1; Deborah Persaud1
International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1030 trial group
1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 4University of California San Diego, San Diego, CA, US; 5University of Massachusetts Medical School, Boston, MA, US

375  Detectable CMV in PBMC Is Associated With Slower HIV DNA Decay During Suppressive ART
Sara Gianella Weibel1; Christy Anderson1; Susanna R. Var2; Michelli Faria de Oliveira1; Marta Massanella1; Susan J. Little1; Douglas D. Richman1; Matt Strain1; Josue Pérez-Santiago1; David M. Smith1
University of California San Diego, La Jolla, CA, US

376  Stable Total HIV-1 DNA Levels Prior and Post ART Interruption in Chronic HIV
Emmanouil Papasavvas1; Matthew Strain1; Steven Lada1; Jocelin Joseph1; Livio Azzone1; Karam Mouzner1; Jay R. Kostman1; Douglas D. Richman1; Luis J. Montaner1

377  Aviremia 10-Year Post-ART Discontinuation Initiated at Seroconversion
Sabine I. Kinloch1; Lucy Dorrell1; Hongbing Yang1; Linos Vandekerckhove1; Ward de Spiegelaere1; Eva Malatinkova1; Sabine Yerly1; Daniel Webster1; Margaret Johnson1
1University College London, London, United Kingdom; 2University of Oxford, Oxford, United Kingdom; 3Universitair Ziekenhuis Gent, Gent, Belgium; 4Geneva University Hospital, Geneva, Switzerland; 5Royal Free London NHS Foundation Trust, London, United Kingdom

378  Identifying HIV Variants that Rebound after Treatment Interruption
Mary F. Kearney1; Wei Shao1; Rajesh T. Gandhi1; Brandon F. Keele1; Jonathan Z. Li1
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2National Cancer Institute (NCI), Frederick, MD, US; 3Frederick National Laboratories for Cancer Research, Frederick, MD, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

379  Characterizing the Active HIV Reservoir on ART: Cell-Associated HIV RNA and Viremia
Feiyu Hong1; Elizabeth Fyne1; Anthony R. Cillo2; Margaret A. Bedison2; Dianna Koontz1; John W. Mellors1
University of Pittsburgh, Pittsburgh, PA, US

380  Liver Macrophages and HIV-1 Persistence
Abraham J. Kandathil1; Christine M. Durand1; Jeffrey Quinn1; Andrew Cameron1; David L. Thomas1; Ashwin Balagopal1
1Johns Hopkins School of Medicine, Baltimore, MD, US

381  Large-Scale Analysis of HIV-1 Integration Sites in Untreated and Treated Patients
Stephanie Lau1; Diana Schenkwein1; Neeltje Kootstra2; Frank A. Giordano2; Christoph Stephan3; Hans-Georg Krausslich4; Winfried Kern1; Susanne Usadel1; Manfred Schmidt1; Christoph von Kalle1
1National Center for Tumor Diseases; German Cancer Research Center, Heidelberg, Germany; 2Sanquin Research, Landsteiner Laboratory, and Center for Infectious Diseases and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 3University Hospital Frankfurt, Frankfurt, Germany; 4Department of Infectious Diseases, Wroclaw, University Hospital Heidelberg, Heidelberg, Germany; 5Heidelberg University, Heidelberg, Germany; 6Division of Infectious Diseases, Department of Medicine, Albert-Ludwigs-University Center for Infectious Diseases & Travel Medicine, and IFB-Center for Chronic Immunodeficiency, University Hospital, Freiburg, Germany
### Program and Agenda

#### Poster Listings

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-F4 Poster Session</th>
<th>Poster Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>382</td>
<td>Identical Sequence Expansions Are Predominantly Found in Effector Memory T Cells</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>382</strong></td>
<td><strong>Identical Sequence Expansions Are Predominantly Found in Effector Memory T Cells</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Susanne von Stockenstrom</strong></td>
<td><strong>Eunok Lee</strong>; Lina Odevall; Elizabeth Sinclair; Hiroyu Hatano; Peter Bacchetti; Peter W. Hunt; Steven G. Deeks; Frederick M. Hecht; Sarah E. Palmer</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>383</td>
<td>Long-Term Effect of Primary ART During Primary HIV Infection on the Viral Reservoir</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>383</strong></td>
<td><strong>Long-Term Effect of Primary ART During Primary HIV Infection on the Viral Reservoir</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Alexander Pasternak</strong>; Jan Prins; Ben Berkhour</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>384</td>
<td>Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>384</strong></td>
<td><strong>Minor Contribution of Host-HIV Readthrough Transcripts to the Level of HIV-1 gag RNA</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Alexander Pasternak</strong>; Una O'Doherty; Ben Berkhour</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>385</td>
<td>MicroRNA-155 Reinforces HIV Latency by Downregulating the TRIM32 Viral Activator</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>385</strong></td>
<td><strong>MicroRNA-155 Reinforces HIV Latency by Downregulating the TRIM32 Viral Activator</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Debbie S. Ruelas</strong>; Jonathan Chan; Eugene Oh; Amy Heidersbach; Andrew Hebbeler; Eric Verdin; Warner C. Greene</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>386</td>
<td>Select Host Restriction Factors Are Associated With HIV Persistence During Therapy</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>386</strong></td>
<td><strong>Select Host Restriction Factors Are Associated With HIV Persistence During Therapy</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Mohamed Abdel-Mohsen</strong>; Leonard Chavez; Charlene Wang; Matt Strain; Xutao Deng; Christopher D. Pilcher; Teri Liegler; Douglas D. Richman; Steven Deeks; Satish Pillai</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>387</td>
<td>Selectively Eliminating HIV Latently Infected Cells Without Viral Reactivation</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>387</strong></td>
<td><strong>Selectively Eliminating HIV Latently Infected Cells Without Viral Reactivation</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Grant R. Campbell</strong>; Rachel S. Bruckman; Yen-Lin Chu; Stephen A. Spector</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>388</td>
<td>PD1 Identifies Latently HIV-Infected Nonproliferating and Proliferating CD4+ T Cells</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>388</strong></td>
<td><strong>PD1 Identifies Latently HIV-Infected Nonproliferating and Proliferating CD4+ T Cells</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Renee M. van der Sluis</strong>; Nitasha A. Kumar; Vanessa A. Evans; Rafick P. Sekaly; Remi Fromentin; Nicolas Chomont; Paul U. Cameron; Sharon R. Lewin</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>389</td>
<td>Nascent LTR-Driven Transcription Can Lead to Translation of HIV Proteins in Resting CD4+ T Cells</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>389</strong></td>
<td><strong>Nascent LTR-Driven Transcription Can Lead to Translation of HIV Proteins in Resting CD4+ T Cells</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Laura DeMaster</strong>; Alexander Pasternak; Una O’Doherty</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>389LB</td>
<td>2B4+PD1+ Naïve and Memory CD4+ T Cells Are Associated With Residual Viremia on ART</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>389LB</strong></td>
<td><strong>2B4+PD1+ Naïve and Memory CD4+ T Cells Are Associated With Residual Viremia on ART</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>Cynthia Klarman; Feiyu Hong; John Bui; Anthony R. Cillo; Arcadio Agudelo-Hernandez; Deborah A. McMahon; Charles R. Rinaldo; John W. Mellors; Bernard J. Macenagay</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>390</td>
<td>Long-Term Effect of Primary ART During Primary HIV Infection on the Viral Reservoir</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>390</strong></td>
<td><strong>Long-Term Effect of Primary ART During Primary HIV Infection on the Viral Reservoir</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Laura DeMaster</strong>; Alexander Pasternak; Una O’Doherty</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>391</td>
<td>WEDNESDAY, FEBRUARY 25, 2015</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>391</strong></td>
<td><strong>WEDNESDAY, FEBRUARY 25, 2015</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Influenza Vaccination Increases HIV-1 Transcription During Antiretroviral Therapy</strong></td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td><strong>Christina C. Yek</strong>; Sara Gianella; Montserrat Planas; Pedro Castro</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>392</td>
<td>Defective HIV-1 Proviruses Can Be Transcribed Upon Activation</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>392</strong></td>
<td><strong>Defective HIV-1 Proviruses Can Be Transcribed Upon Activation</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>Ya-Chi Ho</strong>; Ross Pollack; Patrick Yong; Robert F. Siliciano</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>393</td>
<td>Kinetics of HIV-1 Gene Expression Following Reactivation in a Primary Cell Model of Latency</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>393</strong></td>
<td><strong>Kinetics of HIV-1 Gene Expression Following Reactivation in a Primary Cell Model of Latency</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>Victoria Walker-Sperling; Joel Blankson</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>394</td>
<td>Variable HIV Replication Competency Following Latency Disruption in CD4+ T Cells</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>394</strong></td>
<td><strong>Variable HIV Replication Competency Following Latency Disruption in CD4+ T Cells</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>Jason M. Hataye; Joseph Casazza; David Ambrozak; Eli Boritz; Takuya Yamamoto; Daniel Douek; Richard A. Koup</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>395</td>
<td>Latent HIV-1 Reactivation and Lysosomal Destabilization Synergize to Host Cell Death</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>395</strong></td>
<td><strong>Latent HIV-1 Reactivation and Lysosomal Destabilization Synergize to Host Cell Death</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>Metodi Stankov; Christina Suhr; Hazel Lin; Diana Panayotova-Dimitrova; Christine Goffinet; Georg Behrens</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
<tr>
<td>396</td>
<td>Noninduced Proviral Genome Characterization in Perinatal HIV Infection</td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td><strong>396</strong></td>
<td><strong>Noninduced Proviral Genome Characterization in Perinatal HIV Infection</strong></td>
<td>2:30 pm – 4:00 pm</td>
</tr>
<tr>
<td>Kaitlin Rainwater-Lovett; Carrie Ziemniak; Douglas Watson; Katherine Luzzuari; Priyanka Uperty; Yuhui Chen; Ya-Chi Ho; Deborah Persaud</td>
<td>2:30 pm – 4:00 pm</td>
<td></td>
</tr>
</tbody>
</table>
397 Multiple Rounds of T-Cell Activation Induce Additional HIV-1 From the Latent Reservoir
Nina N. Hosmane; Adam A. Capoferri; Robert F. Siliciano
Johns Hopkins University School of Medicine, Baltimore, MD, US

398 The Inducible HIV-1 Reservoir Predicted by Combinations of pre- and on-ART Parameters
Anthony R. Cillo; Michele Sobolowsk; Elizabeth Fyne; Dianna Koontz; Feiyu Hong; John W. Mellors
University of Pittsburgh, Pittsburgh, PA, US

399 Effects of Antineoplastic Chemotherapy on Dynamics of HIV Population Genetics In Vivo
Sarah A. Watters; Wei Shao; Kieron Dunleavy; Margaret Sholvin; Mark N. Polizzotto; Thomas S. Uldrick; Robert Yarchooan; Wyndham Wilson; Frank Maldarelli
1National Cancer Institute (NCI), Frederick, MD, US; 2National Cancer Institute (NCI), Frederick, MD, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4National Cancer Institute (NCI), Bethesda, MD, US; 5National Cancer Institute (NCI), Bethesda, MD, US; 6National Cancer Institute (NCI), Bethesda, MD, US

Session P-F5 Poster Session
2:30 pm – 4:00 pm
Gene Editing

400 Targeted Disruption of Essential HIV-1 Proviral Genes by Rare-Cutting Endonucleases
Harshana S. De Silva Feelixe; Nixon Niyonzima; Harlan L. Pietz; Martine Aubert; Dan Stone; Keith R. Jerome
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US

401 Enhancing Anti-HIV Gene Therapy: Combining MegaTAL Nuclease Gene Editing With Selection Cassettes
Biswajit Paul; Alexander Astrakhan; Patrick Younan; Blythe D. Sather; Jordan Jarjour; Guillermo Romano; John P. Kowalski; Iram Khan; David J. Rawlings; Hans-Peter Kim

402 A Phase I Clinical Trial of Autologous CD4+ T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease in Patients With HIV-1
Jeffrey M. Jacobson; Hideto Chono; Meghan Metz; Gabriela Plesa; Julie Jadlowks; Simon Lacey; Bruce Levine; Hirofumi Yoshioka; Junichi Minemo; Carl H. June
1Drexel University College of Medicine, Philadelphia, PA, US; 2Takara Bio Inc., Shiga, Japan; 3University of Pennsylvania, Philadelphia, PA, US

403 CRISPRs Are Able to Efficiently Target Latent HIV and Halt New Infections
Robert Jan Lebbink; Dorien de Jong; Femke Wolters; Emmanuel J. Wiertz; Monique Nijhuis
University Medical Center Utrecht, Utrecht, Netherlands

TUESDAY, FEBRUARY 24, 2015
Session P-F6 Poster Session
2:30 pm – 4:00 pm
Poster Hall

HDAC Inhibitors

404 Histone Deacetylase (HDAC) and Histone Acetyltransferase (HAT) Inhibitors Have Opposing Effects on Cellular Susceptibility to HIV Infection
Mark B. Lucera; Curtis Dobrowolski; Jonathan Karn; John C. Tilton
1Case Western Reserve University, Cleveland Heights, OH, US; 2Case Western Reserve University, Cleveland, OH, US

405 Panobinostat Dosing Has Broad but Transient Immunomodulatory Effects in HIV Patients
Martin Tolstrup; Christel R. Brinkmann; Thomas A. Rasmussen; Rikke Olesen; Anne Sofie Kjær; Mathias Lichterfeld; Charles Dinnarello; Lars Østergaard; Ole S. Sagaard
1Aarhus University Hospital, Aarhus, Denmark; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3University of Colorado, Denver, CO, US

406 Multi-Dose Romidepsin in SIV-Infected RMs Reactivates Latent Virus in Absence of ART
Benjamin Policicchio; Egidio Brocca-Cofano; Guiling Xu; Dongzhu Ma; Hui Li; George Richter-Hare; Tammy Dunsmore; George M. Shaw; Ivona Pandrea; Cristian Apetrei
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Pennsylvania, Philadelphia, PA, US

407 Suberanilohydroxamic Acid (SAHA)-Induced Histone Modifications in the HIV Promoter in a Human, Primary CD4 T Cell Model of Latency
Brian Reardon; Amey Mukim; Savitha Deshmukh; Christopher H. Woelk; Douglas D. Richman; Celsa A. Spina
1University of California San Diego, La Jolla, CA, US; 2VA San Diego Healthcare System, La Jolla, CA, US; 3University of Pennsylvania, Philadelphia, PA, US

408 Donor-to-Donor Variation in the Host Gene Expression Response to SAHA
Bastiaan Moesker; Brian Reardon; Nadejda Beliakova-Bethell; Akul Singhania; Michael S. Breen; Christopher H. Woelk
1University of California San Diego, La Jolla, CA, US; 2University of California San Diego, La Jolla, CA, US

409 Off-Target Effects of SAHA May Inhibit HIV Activation
Cory H. White; Harvey E. Johnston; Antigoni Manousopoulou; Celsa A. Spina; Douglas D. Richman; Spiros D. Garbis; Christopher H. Woelk
1University of California San Diego, La Jolla, CA, US; 2University of California San Diego, La Jolla, CA, US

410 Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection
Grant R. Campbell; Rachel S. Bruckman; Yen-Lin Chu; Stephen A. Spector
University of California San Diego, La Jolla, CA, US
**Program and Agenda**

**Poster Listings**

**Session P-F7 Poster Session**
**Poster Hall**

2:30 pm – 4:00 pm

**Pharmacologic Latency-Reactivation Agents**

**411 HIV-1 Reactivation Increases Mitochondrial Priming of the Latent Reservoir**
Jeremy A. Ryan; Allison L. Schure; Zella Euler; Anthony Letai; Athie Tsibris

1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Dana-Farber Cancer Institute, Boston, MA, US; 3Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US

**419 Ex Vivo Identification of Highly Effective Latency-Reversing Drug Combinations**
Gregory M. Laird; C. Corin Bullen; Daniel I. Rosenbloom; Alyssa R. Martin; Alison L. Hill; Christine M. Durand; Janet D. Siliciano; Robert F. Siliciano

1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Columbia University, New York, NY, US; 3Harvard University, Boston, MA, US

**Session P-F8 Poster Session**
**Poster Hall**

2:30 pm – 4:00 pm

**Latency Models and Assays**

**420 Investigating Mechanisms of HIV Persistence Using Droplet Digital PCR Approaches**
Elizabeth M. Anderson; Robert Gorelick; Shawn Hill; Catherine A. Rhem; Mary Kearney; John W. Mellors; John M. Coffin; Mike Piatak; Frank Maldarelli

1National Cancer Institute at Frederick, Frederick, MD, US; 2Leidos Biomedical Research, Inc, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

**421LB High-Throughput Single-Cell Quantification of HDACi-Based HIV Reservoir Reactivation**
Robert W. Yucha; Emily Hanhauser; Kristen S. Hobbs; Hellen Bae; Fatih Inci; Hadi Shafiee; Shuqi Wang; Daniel Kuritzkes; Utkan Demirci; Timothy J. Henrich

1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Brigham and Women's Hospital, Cambridge, MA, US; 3Fundació Lluita contra la SIDA, Barcelona, Spain; 4Stanford University, Palo Alto, CA, US

**422 Evaluation of HIV-1 Latency-Reversing Agents by a Modified Virus Growth Assay (VOA)**
Riddhima Banga; Francesco Procopio; Matthias Cavassini; Alessandra Noto; Song Ding; Giuseppe Pantaleo; Matthieu Perreau

Lausanne University Hospital, Epalinges, Switzerland

**423 “Kick and Kill” of Latent HIV-1 Infection in Naïve and Central Memory CD4+ T cells**
Jennifer M. Zerbato; Nicolas Sluis-Cremer

University of Pittsburgh, Pittsburgh, PA, US

**424 HIV Reactivation in the In Vitro TCM Latency Model – Reasons and Solutions**
Paweł Bonczkowski; Laura J. Martins; Ward de Spiegeleire; Alberto Bosque; Eva Malatinova; Christopher H. Woelk; Cory H. White; Adam M. Spivak; Vicente Planelles; Linos Vandekerckhove

1University Of Utah School of Medicine, Salt Lake City, UT, US; 2University of California San Diego (UCSD), La Jolla, CA, US; 3University Hospital, Ghent, Belgium; 4University of Southampton, Southampton, United Kingdom; 5University of California San Diego (UCSD), La Jolla, CA, US; 6Harvard University Hospital, Salt Lake City, UT, US

**425 CD4+ Tissue-Resident Memory T Cells Are an Important Reservoir for HIV Persistence**
Angela R. Wahl; J. Victor Garcia

University of North Carolina, Chapel Hill, NC, US

**Wednesday, February 25, 2015**

**Program and Agenda**

**Poster Listings**

**Session P-F7 Poster Session**
**Poster Hall**

2:30 pm – 4:00 pm

**Pharmacologic Latency-Reactivation Agents**

**411 HIV-1 Reactivation Increases Mitochondrial Priming of the Latent Reservoir**
Jeremy A. Ryan; Allison L. Schure; Zella Euler; Anthony Letai; Athie Tsibris

1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Dana-Farber Cancer Institute, Boston, MA, US; 3Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US

**419 Ex Vivo Identification of Highly Effective Latency-Reversing Drug Combinations**
Gregory M. Laird; C. Corin Bullen; Daniel I. Rosenbloom; Alyssa R. Martin; Alison L. Hill; Christine M. Durand; Janet D. Siliciano; Robert F. Siliciano

1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Columbia University, New York, NY, US; 3Harvard University, Boston, MA, US

**Session P-F8 Poster Session**
**Poster Hall**

2:30 pm – 4:00 pm

**Latency Models and Assays**

**420 Investigating Mechanisms of HIV Persistence Using Droplet Digital PCR Approaches**
Elizabeth M. Anderson; Robert Gorelick; Shawn Hill; Catherine A. Rhem; Mary Kearney; John W. Mellors; John M. Coffin; Mike Piatak; Frank Maldarelli

1National Cancer Institute at Frederick, Frederick, MD, US; 2Leidos Biomedical Research, Inc, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

**421LB High-Throughput Single-Cell Quantification of HDACi-Based HIV Reservoir Reactivation**
Robert W. Yucha; Emily Hanhauser; Kristen S. Hobbs; Hellen Bae; Fatih Inci; Hadi Shafiee; Shuqi Wang; Daniel Kuritzkes; Utkan Demirci; Timothy J. Henrich

1Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, US; 2Brigham and Women's Hospital, Cambridge, MA, US; 3Fundació Lluita contra la SIDA, Barcelona, Spain; 4Stanford University, Palo Alto, CA, US

**422 Evaluation of HIV-1 Latency-Reversing Agents by a Modified Virus Growth Assay (VOA)**
Riddhima Banga; Francesco Procopio; Matthias Cavassini; Alessandra Noto; Song Ding; Giuseppe Pantaleo; Matthieu Perreau

Lausanne University Hospital, Epalinges, Switzerland

**423 “Kick and Kill” of Latent HIV-1 Infection in Naïve and Central Memory CD4+ T cells**
Jennifer M. Zerbato; Nicolas Sluis-Cremer

University of Pittsburgh, Pittsburgh, PA, US

**424 HIV Reactivation in the In Vitro TCM Latency Model – Reasons and Solutions**
Paweł Bonczkowski; Laura J. Martins; Ward de Spiegeleire; Alberto Bosque; Eva Malatinova; Christopher H. Woelk; Cory H. White; Adam M. Spivak; Vicente Planelles; Linos Vandekerckhove

1University Of Utah School of Medicine, Salt Lake City, UT, US; 2University of California San Diego (UCSD), La Jolla, CA, US; 3University Hospital, Ghent, Belgium; 4University of Southampton, Southampton, United Kingdom; 5University of California San Diego (UCSD), La Jolla, CA, US; 6Harvard University Hospital, Salt Lake City, UT, US

**425 CD4+ Tissue-Resident Memory T Cells Are an Important Reservoir for HIV Persistence**
Angela R. Wahl; J. Victor Garcia

University of North Carolina, Chapel Hill, NC, US
426 HIV-1 Reprograms Resting CD4 T Cells via Foxo1 and L-Selectin Suppression
Benjamin Triniti1; Chi N. Chan1; Caroline S. Lee1; Joy Folkvord2; Elizabeth Connick2; David N Levy1
1New York University, New York, NY, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

427 Measurements of Viral Transcription in Elite Suppressor CD4+ T Cells
Christopher W. Pohlmeier1; C. Korin Bullen; Greg Laird; Alyssa R. Martin; Victoria Walker-Sperling; Stanley U. Chioma; Robert F. Siliciano; Joel Blankson
Johns Hopkins University School of Medicine, Baltimore, MD, US

428LB Short-Term Disulfiram to Reverse Latent HIV Infection: A Dose Escalation Study
Julian H. Elliott1; James H. McMahon1; Wendy Hartogensis2; Namandje Bumpus1; Christina Chang1; Sulggi A. Lee2; Jeff Lifson1; Peter Bacchetti1; Steven Deeks1; Sharon R. Lewin1
on behalf of the Disulfiram Study investigators
1University of California San Diego, La Jolla, CA, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

430 HIV-1 Reservoirs and Humoral Immunity in Allogeneic Stem Cell Transplantation Patients
Kathryn E. Stephenson1; George H. Neubauer1; Emily Hanhauser1; Marcelo J. Wolff2; Cristian Carvallo3; Francisco M. Marty4; Steven G. Deeks1; Daniel R. Kuritzkes1; Dan H. Barouch1; Timothy J. Henrich4
1Monash University/Alfred Hospital, Melbourne, Australia; 2University of California San Francisco, San Francisco, CA, US; 3Johns Hopkins University, Baltimore, MD, US; 4University of Melbourne, Melbourne, Australia; 5National Cancer Institute, Frederick, MD, US

432 Allogeneic Transplantation With CCR5 Δ32/Δ32 Cord Blood Hematopoietic Cells in an HIV-Infected Patient
Rafael Duarte1; Maria Salgado2; Isabel Sanchez-Ortega3; Sara Morón-López2; Maria C. Puertas3; Lawrence D. Petz3; Sergei Querol3; Bonaventura Clotet1; Javier Martínez-Picado2
1Institut Català d’Oncologia, L’Hospitalet del Llobregat, Spain; 2IRSI Caixa Institute for AIDS Research, Badalona, Spain; 3Barcelona Cord Blood Bank, Barcelona, Spain; 4StemCyte International Cord Blood Center, Covina, CA, US

433 CCR5 Editing in Hematopoietic Stem Cells in a Nonhuman Primate Model of HIV/AIDS
Christopher W. Peterson1; Jianbin Wang2; Patricia Polacino3; Michael C. Holmes3; Shiu-Lok Hu4; Philip D. Gregory5; Hans-Peter Kiem1

434 Cytoxan Enhancement of SB-728-T Engraftment: A Strategy to Improve Anti-HIV Response
Gary Blick1; Jay Lalezari2; Ricky Hu3; Erinn DeJesus3; Trevor Hawkins3; Ronald T. Mitsuyasu4; Shelley Wang5; Gary Lee5; Winnson Tang1; Dale Ando1; Sangamo BioSciences, Inc., Richmond, CA, US; 2CIRCLE CARE Center, Norwalk, CT, US; 3Quest Clinical Research, San Francisco, CA, US; 4New York University School of Medicine, New York, NY, US; 5Orlando Immunology Center, Orlando, FL, US; 6Southwest Care Center, Santa Fe, NM, US; 7University of California Los Angeles CARE Center, Los Angeles, CA, US

TUESDAY, FEBRUARY 24, 2015

435 Highly Precise Measurements of HIV DNA in CSF and Blood by Droplet Digital PCR
Michelli Faria de Oliveira1; Sara Gianella1; Scott Letendre2; Konrad Scheffler1; Sergei L. Kosakovsky Pond1; Davey M. Smith1; Matt Strain1; Ronald J. Ellis1
1University of California San Diego, La Jolla, CA, US; 2HIV Neurobehavioral Research Center, San Diego, CA, US

436 Antiretroviral Concentrations in Brain Tissue Are Similar to or Exceed Those in CSF.
Namandje Bumpus1; Qing Ma2; David J. Moore1; Brooke M. Best2; Ronald J. Ellis1; Cristian L. Achim2; Melanie Crescini2; Courtney Fletcher1; Igor Grant1; Scott Letendre1
The CNTR Group1; 2University of California San Diego, La Jolla, CA, US

1University of California San Diego, San Diego, CA, US; 2University of Nebraska Medical Center, Omaha, NE, US; 3University of Nebraska Medical Center, Omaha, NE, US; 4University at Buffalo, Buffalo, NY, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Johns Hopkins Medical Institutions, Baltimore, MD, US; 7Institut Català d’Oncologia, L’Hospitalet del Llobregat, Spain; 8University of Colorado School of Medicine, Aurora, CO, US; 9Johns Hopkins Hospital, Baltimore, MD, US; 10University at Buffalo, Buffalo, NY, US; 11University of California San Francisco, San Francisco, CA, US; 12University of Washington, Seattle, WA, US; 13Fred Hutchinson Cancer Research Center, Seattle, WA, US; 14University of California Los Angeles CARE Center, Los Angeles, CA, US

456 CNS Reservoirs

431 Breakthrough of Preexisting X4-Capable HIV After Allogeneic Stem-Cell Transplantation
Jens Verheyen1; Alexander Thielem1; Miriam Dirks1; Nadine Lübke1; Marek Widera1; Lambros Kordelas1; Martin Däumer1; Stefan Esser1
1University Hospital Essen, University Duisburg-Essen, Essen, Germany; 2Institute of Immunology and Genetics, Kaiserslautern, Germany; 3University of Cologne, Cologne, Germany; 4University Hospital Essen, University Duisburg-Essen, Essen, Germany; 5University Hospital Essen, University Duisburg-Essen, Essen, Germany
437 HIV DNA Peripheral Reservoirs Have a Nonlinear Impact on Brain Pathology
William Hey-Cunningham; Nadene Dermody; Phillip Chan; Bruce Brew; Kersten Koelsch; Lucette A. Cysique
1NeuRA, University of New South Wales, Randwick, Australia; 2Kirby Institute, University of New South Wales, Sydney, Australia; 3Macquarie University, Sydney, Australia; 4Queen Elizabeth Hospital, HKSH, Hong Kong, China; 5St. Vincent's Hospital, University of New South Wales, Sydney, Australia

438 Acute HIV CSF/Plasma RNA Ratios Are Variable and Greater Than in Chronic HIV
Joanna Hellmuth; Serena Spudich; Eugene Kroon; Napponon Saisatsa; Somprarthana Rattanamanee; Sukalaya Lerdbum; Linda L. Jagodzinski; Shelly J. Krebs; Jintanat Ananworanich; Victor G. Valcour
The RV254/SEARCH010 Study Group
1University of California San Francisco, San Francisco, CA, US; 2Yale University School of Medicine, New Haven, CT, US; 3Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4University of Hawaii, Honolulu, HI, US; 5Chulalongkorn University, Bangkok, Thailand; 6Walter Reed Army Institute of Research, Silver Spring, MD, US; 7Henry M. Jackson Foundation for the Advancement of Military Medicine, Silver Spring, MD, US; 8US Military HIV Research Program, Bethesda, MD, US

439 Greater CSF HIV Reduction and CSF Rapid Decay Associated with Improved Neurocognition
Kevin R. Robertson; Natalie M. Bowman; Sarah B. Joseph; Prema Menezes; Nisha Bhatia; Christopher Lippincott; Michael Vinikoor; Joseph Eron; Richard Price
THINC UNC
1University of North Carolina, Chapel Hill, Chapel Hill, NC, US; 2University of California San Francisco, San Francisco, CA, US

440 HIV-1 Replication in the CNS Is Associated With Increased Neurocognitive Impairment
Sarah B. Joseph; Laura Kincer; Natalie M. Bowman; Prema Menezes; Kevin Robertson; Albert M. Anderson; David W. Loring; Joseph Eron; Richard W. Price; Ronald Swanstrom
1University of North Carolina, Chapel Hill, Chapel Hill, NC, US; 2Emory University, Atlanta, GA, US; 3Emory University, Atlanta, GA, US; 4University of California San Francisco, San Francisco, CA, US; 5University of North Carolina, Chapel Hill, Chapel Hill, NC, US

Poster listings for CROI 2015.

441 Maraviroc-Enhanced CART Improves Cognition in Virally Suppressed HAND: A Pilot Study
Thomas M. Gates; Lucette A. Cysique; Joga Chaganti; Krista J. Siefried; Bruce J. Brew
1St Vincent's Hospital, Sydney, Sydney, Australia; 2Neuroscience Research Australia (NeuRA), Sydney, Australia

442 Similar Neurocognitive Performance in Patients on ATV/r Monotherapy vs Triple Therapy
Giada Caramatti; Francesca Ferretti; Antonio Di Biagio; Amedeo Capetti; Andrea Antinori; Fiorella Di Sora; Roberta Gagliardini; Concetta Vinci; Adriano Lazzarin; Laura Galli
1San Raffaele Scientific Institute, Milan, Italy; 2Azienda Ospedaliera San Martino, Genoa, Italy; 3L. Sacco University Hospital, Milan, Italy; 4National Institute for Infectious Diseases IRCCS Lazzaro Spallanzani, Rome, Italy; 5Ospedale San Giovanni, Rome, Italy; 6Catholic University of the Sacred Heart, Rome, Italy

443 Cerebrospinal Fluid Markers in Long-Term Atazanavir/Ritonavir Monotherapy
Francesca Feretti; Alba Bigoloni; Valeria Longo; Laura Galli; Laura Passeri; Simonetta Gerevini; Vincenzo Spagnuolo; Adriano Lazzarin; Paola Cinque; Antonella Castagna
San Raffaele Scientific Institute, Milan, Italy

444 Neurocognitive Decline Is Associated With Antiretroviral Concentrations in Plasma and Cerebrospinal Fluid (CSF)
Qing Ma; Xiao Liu; Robert Heaton; Fujie Zhang; Hua Jin; Hao Wu; Melanie Crescini; Hongxiong Zhao; Hui Zeng; Scott Letendre
1University of California San Diego, San Diego, CA, US; 2Chinese Center for Disease Control and Prevention, Beijing, China

445 Viral Decay Rate in the Cerebrospinal Fluid After Initiating Antiretroviral Therapy
Natalie M. Bowman; Sarah B. Joseph; Prema Menezes; Jessica Margolis; Christopher Lippincott; Michael J. Vinikoor; Kevin R. Robertson; Richard Price; Ronald Swanstrom; Joseph Eron
1University of North Carolina, Chapel Hill, NC, US; 2University of California San Francisco (UCSF), San Francisco, CA, US

446 Rates of Nonconfounded HIV-Associated Neurocognitive Disorder After Early cART
Teresa H. Evering; Allison Applebaum; Melissa LaMar; Donald Garmon; David Dorfman; Martin Markowitz
1Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY, US; 2Memorial Sloan-Kettering Cancer Center, New York, NY, US; 3Mount Sinai School of Medicine, New York, NY, US

447 The Impact of HAART CNS Penetration Effectiveness on Brain Integrity in HIV+ Adults
Laurie Baker; Robert H. Paul; Jodi M. Heaps; Mario Ortega; Christin Usher; Jeewon Chang; Beau Ances
1University of Missouri St Louis, St Louis, MO, US; 2Washington University School of Medicine, St Louis, MO, US

448 Efavirenz Use Is Not Associated with Increased Risk of Neuropsychological Impairment
Sean B. Rourke; John Gill; Anita Rachlis; Colin Kovacs; Gordon Arbes; Jason Brunetta; Adriana Carvalhal; Chris Power; Ann N. Burchell; Tesgeay Bekele
1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3The Ontario HIV Treatment Network, Toronto, Canada; 4Maple Leaf Medical Clinic, Toronto, Canada; 5St. Michael’s Hospital, Toronto, Canada
Cerebrospinal Fluid Cytokines and HIV-Associated Neurocognitive Disorders in Uganda

Mahsa Abassi1; Gertrude Nakigozi2; Noeline Nakasujja2; Xiangrong Kong3; David B. Meya4; Kevin Robertson5; Ronald H. Gray6; Maria J. Wawer2; Ned Sacktor2; David R. Boulware1

1University of Minnesota, Minneapolis, MN, US; 2Infectious Disease Institute, Kampala, Uganda; 3Rakai Health Sciences Program, Entebbe, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US

A Comparison of 5 Brief Screening Tools for HAND in the USA and South Africa

John A. Joska1; Jade Witten3; Kevin Thomas3; Come Robertson3; Martine Casson-Crook1; Heidi Roosa2; Jason Creighton2; Jennifer Lyons1; Justin McArthur2; Ned Sacktor2

1University of Cape Town, Cape Town, South Africa; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US

Subtype Associations With HIV-Associated Neurocognitive Dysfunction

Tyler R. Day; Davey M. Smith; Robert Heaton; Donald Franklin; Myres W. Tilghman; Josué Pérez-Santiago

University of California San Diego, San Diego, CA, US

Peripheral Neuropathy at First-Line Failure and on Second Line in Sub-Saharan Africa

Alejandro Arenas-Pinto1; Jennifer Thompson2; Godfrey Musoro3; Helen Mussana3; Abbas Lugewma3; Andrew D. Kambugu3; Aggrey Mweemba3; Sarah Walker3; Paton Nicholas3

On behalf of the EARNEST Trial Team

1University College London, London, United Kingdom; 2Makerere University, Kampala, Uganda; 3Joint Clinical Research Centre, Mbarara, Uganda; 4University of Zimbabwe, Harare, Zimbabwe; 5Joint Clinical Research Centre, Kampala, Uganda; 6University Teaching Hospital, Lusaka, Zambia

Prevalence of and Risk Factors for Peripheral Neuropathy in Rakai, Uganda

Deanna R. Saylor1; Gertrude Nakigozi2; Noeline Nakasujja2; Xiangrong Kong3; Kevin Robertson4; Ronald H. Gray4; Maria J. Wawer4; Ned Sacktor2

1Johns Hopkins School of Medicine, Baltimore, MD, US; 2Rakai Health Sciences Program, Entebbe, Uganda; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 5University of North Carolina, Chapel Hill, NC, US

Predictors of Cognitive Performance Among HIV-Infected Patients in East Africa

Victor G. Valcour1; Francis Kiweewa2; Rosemary Namagembe2; Rither Langat2; Samoel Khamadi1; Kyra Hansson1; Christina S. Polyak1; Julie Ake1

On behalf of the RV329 AFFRICOS Study Team

1University of California San Francisco, San Francisco, CA, US; 2Walter Reed Project, Kampala, Uganda; 3Walter Reed Project, Kericho, Kenya; 4Walter Reed Project – Tanzania, Mbeja, United Republic of Tanzania; 5Walter Reed Army Institute of Research, Silver Spring, MD, US
**THURSDAY, FEBRUARY 26, 2015**

**Session P-G4 Poster Session**
2:30 pm – 4:00 pm

**HAND Genetics**

460 Mitochondrial DNA Haplogroups and CSF Neuroinflammation in the CHARTER Cohort

Todd Hulgan1; David Samuels1; Ronald J. Ellis1; William Bush1; Scott Letendre1; Donald Franklin1; Igor Grant1; Asha R. Kallianpur1

CHARTER Group

1University of California San Diego, San Diego, CA, US; 2Case Western Reserve University, Cleveland, OH, US; 3Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH, US; 4Vanderbilt University, Nashville, TN, US

461 Iron-Regulatory Genes Are Associated With Neuroimaging Traits in HIV Infection

Tricia A. Thornton-Wellsi; Christine Fennema-Notestine1; Todd Hulgan1; Scott Letendre1; Ronald J. Ellis1; Asha R. Kallianpur1; for the CHARTER Group

1Cleveland Clinic/Lerner Research Institute, Cleveland, OH, US; 2Vanderbilt University School of Medicine, Nashville, TN, US; 3University of California San Diego, San Diego, CA, US; 4Vanderbilt University School of Medicine, Nashville, TN, US; 5University of California San Diego, San Diego, CA, US; 6University of California San Diego, San Diego, CA, US; 7University of California Los Angeles, Long Beach, CA, US; 1University of California San Diego, San Diego, CA, US; 2University of California San Diego, San Diego, CA, US; 3University of California Los Angeles, Los Angeles, CA, US

462 Synergistic Effects of MBL2/APP Polymorphisms on Neuroimaging in CHARTER

Kumud Singh1; Qianqian Deng1; Christine Fennema-Notestine1; Florin Vaida1; Ronald Ellis1; Scott Letendre1; Donald Franklin1; Debralee Rosario1; Robert Heaton1; Igor Grant1

CHARTER

University of California San Diego, La Jolla, CA, US

**TUESDAY, FEBRUARY 24, 2015**

**Session P-G5 Poster Session**
2:30 pm – 4:00 pm

**HAND Diagnosis and Predictors**

465 Relative Risk and Factors Associated With Progression to Symptomatic HAND

Sean B. Rourke1; John Gill1; Anita Rachlis1; Colin Kovacs1; Gordon Arbess1; Jason Brunetta1; Adriana Carvalhal1; Chris Power1; Ann N. Burchell1; Tegeay Bekele1

1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3Maple Leaf Medical Clinic, Toronto, Canada; 4The Ontario HIV Treatment Network, Toronto, Canada; 5St. Michael's Hospital, Toronto, Canada

466 Monocyes Activation Characterizes Immune Failure but Not Cognitive Impairment on ART

Antonio Muscatello1; Davide Mangioni1; Paolo Perseghin1; Arianna Incontri1; Alessandro Soria1; Nicola Squillace1; Giuseppe Lapadula1; Sebastiano Leone1; Andrea Gori1; Alessandra Bandera1

1S. Gerardo Hospital, Monza, Italy; 2San Gerardo Hospital–UOS Aferesi e Nuove Tecnologie Trasfusionali–SIMT, Monza, Italy

467 The VACS Index Predicts Change in Neurocognitive Functions in People With HIV

Sean B. Rourke1; John Gill1; Anita Rachlis1; Amy Justice1; Colin Kovacs1; Gordon Arbess1; Jason Brunetta1; Adriana Carvalhal1; Chris Power1; Ann N. Burchell1

1University of Toronto, Toronto, Canada; 2University of Alberta, Calgary, Canada; 3Maple Leaf Medical Clinic, Toronto, Canada; 4The Ontario HIV Treatment Network, Toronto, Canada; 5St. Michael’s Hospital, Toronto, Canada; 6University of Alberta, Edmonton, Canada; 7Yale University School of Medicine, New Haven, CT, US

468 When Diagnosing HAND, Should Visuospatial Functioning be Evaluated?

Talia Shirazi1; Angela Summers1; Sally Steinbach1; Suad Kapetanovic1; Avindra Nath1; Bryan Smith1; Joseph Snow1

1National Institute of Mental Health (NIMH), Bethesda, MD, US; 2National Institute of Neurological Disorders and Stroke, Bethesda, MD, US

469 Predictors of Neurocognitive Decline Among Aviremic Individuals in the CHARTER Cohort

Marie-Josée Brouillette1; Tracy Yuen1; Susan C. Scott1; Lesley K. Fellows1; Robert Heaton1; Scott Letendre1; Ronald J. Ellis1; Nancy Mayo1

the CHARTER group

1McGill University Health Centre, Montreal, Canada; 2McGill University Health Centre, Montreal, Canada; 3Montreal Neurological Hospital, Montreal, Canada; 4University of California San Diego, San Diego, CA, US

470 Association Between Plasma Homocysteine Levels and Neurological Injury in Untreated HIV

Erika Ahlgren1; Lars Hagberg1; Lars-Magnus Andersson1; Staffan Nilsson1; Dietmar Fuchs1; Henrik Zetterberg1; Magnus Gisslen1

1University of Gothenburg, Gothenburg, Sweden; 2Chalmers University of Technology, Gothenburg, Sweden; 3Innsbruck Medical University, Innsbruck, Austria
**471** Plasma MicroRNA Profiling Predicts HIV-Associated Neurocognitive Disorder
Eugene L. Ashashop
William G. Branton
Segun M. Akinwumi
Noshin Koenig
Esther Fujinawa
John Gill
Christopher Power
1 University of Alberta, Edmonton, Canada; 2University of Alberta, Edmonton, Canada; 3Southern Alberta Clinic, Calgary, Canada

**472** Performance of 4 Tools to Screen for HIV-Associated Cognitive Impairment
Judith Schouten
Tanja Su
Rosan A. van Zoest
Ferdinand W. Wit
Ineke G. Stolte
Alan Winston
Peter Portegies
Gert J. Geurtse
Ben A. Schmand
1 Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3Imperial College London, London, Netherlands; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 5Public Health Service of Amsterdam, Amsterdam, Netherlands

**THURSDAY, FEBRUARY 26, 2015**

**2:30 pm – 4:00 pm**

**Session P-G6 Poster Session**

**Inflammation and Markers of Brain Injury in HAND**

**473** Astrocyte and Microglial Activation in Acute and Chronic HIV Pre- and Post-cART
Michael Peluso
Victor G. Valcour
Jintanat Ananworanich
James L. Fletcher
Somporn Tipsuk
Bonnie Slika
Nittaya Panuphak
Magnus Gisslen
Henrik Zetterberg
Seren A Spudich
RYS245/SEARCH 010 & SEARCH 011 Study Teams
1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US; 2University of California San Francisco, San Francisco, CA, US; 3Walter Reed Army Institute of Research, Bethesda, MD, US; 4That Red Cross AIDS Research Centre, Bangkok, Thailand; 5University of Gothenburg, Gothenburg, Sweden; 6Yale University, New Haven, CT, US

**474** CNS Immunoactivation and Neuronal Damage in Patients With Progressive Neurocognitive Impairment
Arvid Edén
Donald Franklin
Henrik Zetterberg
Dietmar Fuchs
Robert Heaton
Scott Letendre
Thomas Marcotte
Richard Price
Igor Grant
Magnus Gisslen
1University of Gothenburg, Gothenburg, Sweden; 2University of California San Diego, San Diego, CA, US; 3Innsbruck Medical University, Innsbruck, Austria; 4University of California San Francisco, San Francisco, CA, US

**475** Endothelial Function and CNS Measures in Primary HIV Infection Pre and Post Early ART
Sebastian Urday
Zaina Zayyad
Julia Peterson
Felicia C. Chow
Kevin R. Robertson
Richard Price
Priscilla Hsu
Seren A Spudich
1Yale University, New Haven, CT, US; 2University of California San Francisco, San Francisco, CA, US; 3University of North Carolina, Chapel Hill, NC, US

**476** Platelet-Endothelial Interactions in SIV-Associated CNS Disease
Claire E. Lyons
Hannah Schneider
Liz Engle
Suzanne E. Queen
Craig N. Morrell
Joseph L. Mankowski
Kelly A. Pate
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Tufts University, North Grafton, MA, US; 3Colorado State University, Fort Collins, CO, US; 4University of Rochester, Rochester, NY, US

**477** Microbial Translocation Is Associated With Neuroinflammation in HIV Subjects on ART
Jaime H. Vera
Qi Guo
Adriano Boasso
Louise Greathhead
James Cole
Courtney Bishop
Rabiner Iain
Roger Gunn
Paul Matthews
Alan Winston
1Imperial College London, London, United Kingdom; 2Imanova Centre for Imaging Sciences, London, United Kingdom

**478** DKK1 Is Associated With HIV-Associated Neurocognitive Impairment
Chunjian Yu
Melanie Seaton
Scott Letendre
Robert Heaton
Lena Al-Harthi
1Rush University Medical Center, Chicago, IL, US; 2University of California at San Diego, San Diego, CA, US

**479** Markers of HIV-Associated Cognitive Impairment Are Elevated in HIV-Infected Patients With Neurosyphilis
Emily Ho
Lauren Tantalo
Sharon Sahi
Trudy Jones
Shelia Dunaway
Christina Marra
University of Washington, Seattle, WA, US

**CROI 2015**

**480** CD14+ PBMC Secrete Cytokines Linked to HIV-Associated Neurocognitive Disorders
Melissa A. Agsalda-Garcia
Victor G. Valcour
Pasiri Sithinamsuwan
Guangxiang G. Zhang
Cecilia M. Shikuma
James L. Fletcher
Nicholas Hutchings
Alexandra Schuetz
Jintanat Ananworanich
Bruce Shiramizu
1University of California San Francisco, San Francisco, CA, US; 2Phramongkutklao Hospital, Bangkok, Thailand; 3The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, US; 5Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

**481** MBL-HIV1gp120 Immunoreactivity Is Associated With Markers of Neuronal Injury
Carmen Teedorf
Damhni Nguyen
Nishi Kadakia
Rick Maung
Benchawanna Soontornniyomkij
Cristian Achim
David Moore
Eliezer Masliah
Marcus Kaul
Kumud Singh
1University of California San Diego, San Diego, CA, US; 2The Sanford Burnham Medical Research Institute, La Jolla, CA, US

**WEDNESDAY, FEBRUARY 25, 2015**

**2:30 pm – 4:00 pm**

**Session P-G7 Poster Session**

**Aging and Cognitive Decline**

**482** Amyloid Uptake by PET Imaging in Older HIV+ Individuals With Cognitive Impairment
Ned Sacktor
Richard Skolasky
Heidi Roosa
Yun Zhou
Weiguo Ye
Noble George
Dean Wong
Mona Mohamed
Johns Hopkins University School of Medicine, Baltimore, MD, US

**CROI 2015**
483 Lower CSF Amyloid-β Levels Are Associated With Worse Neurocognitive Functioning in HIV-Infected Adults With a Family History of Dementia
Parinya L. Fazelii; David J. Moore1; Donald Franklin1; Robert Heaton1; Christina Marra2; Benjamin B. Gelman3; Allen McCutchan1; Igor Grant1; Scott Letendre1
1University of California San Diego, San Diego, CA, US; 2University of Washington Seattle, Seattle, WA, US; 3University of Texas Medical Branch, Galveston, TX, US

484 Cystatin C Is Associated With Neurocognitive Impairment in Older HIV+ Adults
Marissa Sakoda1; Parinya L. Fazelii; Scott Letendre3; Dilip Jeste3; Igor Grant1; David J. Moore1
1John A. Burns School of Medicine at the University of Hawaii, Honolulu, HI, US; 2University of California San Diego, San Diego, CA, US

485 Leptomeningeal Enhancement on MRI in the Aging HIV-Positive Population
Bryan R. Smith1; Sally Steinbach1; Govind Nair2; Caryn Morse3; Joseph Snow1; Suad Kapetanovich1; Henry Masur1; Avindra Nath1; Daniel S. Reich1
1National Institutes of Health, Bethesda, MD, US; 2National Institute of Mental Health, Bethesda, MD, US; 3National Institutes of Health, Clinical Center, Bethesda, MD, US

486 Hepatitis C Infection and Cognition in Older HIV+ Adults: Data From the Center of Excellence on Disparities in HIV and Aging (CEDHA)
Oluwatoyin M. Adeyemi1; Sue Leurgans2; Alan Landay3; David Bennett4; Lisa Barnes2
1Ruth M Rothstein CORE Center, Cook County Health and Hospitals System, Chicago, IL, US; 2Rush University Medical Center, Chicago, IL, US

487 Neurocognitive Screening Tests Are Associated With Cardiovascular Risk and VACS Scores
Andrea Calcagno1; Marielisabetta Scarvaglieri1; Daniela Vai2; Alessandro Livelli1; Letizia Marinario1; Giancarlo Orofino1; Nicolo Pagani1; Daniele Imperiale2; Giovanni Di Perri1; Stefano Bonora1
1University of Torino, Torino, Italy; 2ASLTO2, Torino, Italy; 3ASLTO2, Torino, Italy

488 Aerobic Exercise Attenuates Cognitive Decline and Brain Volume Loss Associated With HIV
Brian Basco1; Mario Ortega1; Jodi M. Heaps5; Laurie Baker1; Florin Vaida1; Beau Ances1
1Washington University School of Medicine, St. Louis, MO, US; 2University of Missouri St. Louis, St. Louis, MO, US; 3Missouri Institute of Mental Health, St. Louis, MO, US; 4University of California San Diego, San Diego, CA, US

489 The Impact of Physical Activity on Cognition in Men With and Without HIV
Anne Monroe1; Long Zhang2; Lisa P. Jacobson3; Todd T. Brown4; Michael Plankey5; Eric Miller6; James T. Becker7; Eileen Martin6; Ned Sacktor6
On behalf of the Multicenter AIDS Cohort Study
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of California Los Angeles, Los Angeles, CA, US; 4Georgetown University, Washington, DC, US; 5University of Pittsburgh, Pittsburgh, PA, US; 6Rush University Medical Center, Chicago, IL, US; 7Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

490 Abnormal Lung Function Associated With Abnormal Brain Structure and Function in HIV
Alison Morris1; Lawrence Kingsley2; Matthew Gingo3; Meghan Fitzpatrick4; Roger Detels5; Oto Martinez4; Eric Miller5; Jeffrey Alger6; Eric Kleeberg7; James T. Becker1
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Pittsburgh, Pittsburgh, PA, US; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

491 HIV DNA and Neurocognitive Impairment in Older Subjects onSuppressive ART
Michelli Faria de Oliveira1; Ben Murrell1; Josué Pérez-Santiago1; Milenka Vargas1; Ronald J. Ellis5; Scott Letendre1; Igor Grant2; Davey M. Smith1; Steven P. Woods3; Sara Gianella6
1University of California San Diego, La Jolla, CA, US; 2HIV Neurobehavioral Research Center, San Diego, CA, US

492 Suppressive ART Is Key to Reduce Neurocognitive Impairment in Aging HIV+ Individuals
Christina C. Yek1; David M. Smith5; Gabriel Wagner1; Susan Morgello4; Scott Letendre1; Igor Grant1; Sergei L. Kosakovsky Pond3; Sara Gianella6
On behalf of the CHARTER group
1University of California San Diego, San Diego, CA, US; 2Icahn School of Medicine at Mount Sinai, New York, NY, US

493 Mixed Membership Trajectory Model of Cognitive Impairment in the MACS
Samantha A. Molsberry1; Fabrizio Lecci2; Brian Junker3; Sandra Reynolds4; Andrew Levine5; Eileen Martin3; Cynthia A. Munro6; Ned Sacktor7; James T. Becker8; Neuropsychology Working Group O. Multicenter AIDS Cohort Study9
1University of Pittsburgh, Boston, MA, US; 2Carnegie Mellon University, Pittsburgh, PA, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4University of California Los Angeles, Los Angeles, CA, US; 5Johns Hopkins Bloomberg School of Public Health, Chicago, IL, US; 6Rush University Medical Center, Chicago, IL, US; 7Johns Hopkins University School of Medicine, Baltimore, MD, US; 8National Institutes of Health (NIH), Bethesda, MD, US

494 Brain Structural Correlates of Trajectories to Cognitive Impairment in HIV Disease
James T. Becker1; Mikhail Popov2; Samantha A. Molsberry1; Fabrizio Lecci2; Brian Junker3; Sandra Reynolds4; Eric Miller5; Cynthia A. Munro6; Ann Ragin7; Ned Sacktor7
1University of Pittsburgh, Pittsburgh, PA, US; 2Carnegie Mellon University, Pittsburgh, PA, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Northwestern University, Feinberg School of Medicine, Chicago, IL, US
THURSDAY, FEBRUARY 26, 2015

Session P-G9 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Neuropathogenesis Mechanisms

501 Role of HIV Strain, Accessory Proteins, and Cytokines in Macrophage HO-1 Deficiency
Alexander J. Gill; Patricia J. Vance; Ronald G. Collman; Dennis L. Kolson
University of Pennsylvania, Philadelphia, PA, US

502 Atorvastatin Reverses the HIV-induced HO-1 Defect in Primary Human Macrophages
Melanie R. Duncan; Alexander J. Gill; Anjana Yadav; Dennis L. Kolson; Ronald G. Collman
University of Pennsylvania, Philadelphia, PA, US

503 Enhanced Antagonism of BST-2 by Neurovirulent SIV Envelope
Kenta Matsuda; Chia-Yen Chen; Fan Wu; Ronald Plishka; Alicia Buckler-White; Klaus Strebel; Vanessa M. Hirsch
National Institutes of Health (NIH), Bethesda, MD, US

504 MEMRI Reflects HIV-1-Associated Human Pathobiology in a Rodent NeuroAIDS Model
Aditya N. Bade; Santhi Gorantla; Prasanta K. Dash; Edward Makarov; Balasrinivasa R. Sajja; Larisa Poluektova; Howard Gendelman; Michael Boska; Yutong Liu
University of Nebraska Medical Center, Omaha, NE, US

505 Detectable CSF Tat Despite Dual Compartment HIV Viral Suppression With cART
Bruce Brew1; Lucette A. Cysique2; Simon Jones4; Tory Johnson3; Avindra Nath4
1St Vincent’s Hospital, Sydney, Sydney, Australia; 2Neuroscience Research Australia, Sydney, Australia; 3National Institute of Neurological Disorders and Stroke, Bethesda, MD, US; 4St Vincent’s Centre for Applied Medical Research, Sydney, Australia

506 DNA Methylation Changes in HIV-Positive Men With Cognitive Decline
Jeremy Martinson; Gregory Joseph; Lawrence Kingsley; James T. Becker
Pitt Mens Study
University of Pittsburgh, Pittsburgh, PA, US

507 HIV Induces Astrocyte Senescence and Is Reversed by Beta-Catenin Induction
Chunjiang Yu; Victoria Latgen; Lena Al-Harthi
Rush University Medical Center, Chicago, IL, US

508 Wnts-Mediated Astrocyte/CD8+ T-Cell Interactions Impacting HIV Neuropathogenesis
Maureen H. Richards1; Melanie S. Seaton1; Stephanie Kim2; Srinivasa Narasipura1; Lena Al-Harthi1
1Rush University Medical Center, Chicago, IL, US; 2Brown University, Boston, MA, US
TUESDAY, FEBRUARY 24, 2015

Program and Agenda
Poster Listings

510 Pharmacokinetic and Pharmacodynamic Evaluation of NNRTI IQP-0528 Duogel™ in Macaques
Lara E. Pereira1; Pedro Mesquita2; Anthony Ham3; Tyana Singletary4; Janet McNicholl1; Karen W. Buckheit1; Robert Buckheit1; James M. Smith1
1LifeSource Biomedical LLC, Moffett Field, CA, US; 2Albert Einstein College of Medicine, Bronx, NY, US; 3ImQuest Biosciences, Frederick, MD, US; 4Anyar Inc., Fort Walton Beach, FL, US; 5US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

511 Tenofovir PK in Adults With Renal Dysfunction on LPV/r and NNRTI-Based ART
Tim R. Cressy1; Anchalee Avihingsanon2; Guttiga Halve3; Prattana Leenarunmakul4; Pra-ornsuda Sukrakanchana5; Anthony T. Podany6; Courtney Fletcher1; Gonzague Jourdain1; Virat Kimbuayatem6; Chureeratana Bowonwatanuwong2
1PHPT-IRD UMI 174 Chiang Mai University/Harvard School of Public Health, Chiang Mai, Thailand; 2HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 3Phayao Hospital, Phayao, Thailand; 4Nakomping Hospital, Chiang Mai, Thailand; 5Chiang Mai University, Chiang Mai, Thailand; 6University of Nebraska Medical Center, Omaha, NE, US; 7Sanpatong Hospital, Sanpatong, Thailand; 8Chonburi Hospital, Chonburi, Thailand

512 Population Pharmacokinetics of Cotrimoxazole West African HIV-Infected Children
Claire Pressiat1; Sihem Benaboud2; Jean-Marc Treluyer2; Véronique Méa-Assande2; Caroline Tonaba1; Sophie Dattez1; Diame Ye1; Yi ZHENG3; Valerie Leroy3; Deborah HIRT1
MONOD ANRS 12206
1Paris Descartes University, EA 08, Paris, France; 2Clinical Pharmacology Department, AP-HP, Paris Centre Hospital Group, Paris, France; 3Avocatier Department of Paediatrics, CHU Bordeaux, Dax, France; 4Department of Paediatrics, CHU Bordeaux, Bordeaux, France; 5Department of Paediatrics, CHU Charles de Gaulle, Universite de Dax-Occitanie, Dax, France; 6Department of Paediatrics, CHU Bordeaux, Bordeaux, France; 7Department of Paediatrics, CHU Charles de Gaulle, Universite de Dax-Occitanie, Dax, France; 8Department of Paediatrics, CHU Bordeaux, Bordeaux, France; 9Department of Paediatrics, CHU Bordeaux, Bordeaux, France

513 ART Choice Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Sumil Parikh1; Norah Mwebeza1; Richard Kajubi1; Joshua Ssebuliba1; Sylvia Kiconco1; Liusheng Huang2; Qin Gao1; Abel Kakura1; Jane Achau1; Francesca T. Awekeya1
1University of California, San Francisco, San Francisco, CA, US; 2Yale University, New Haven, CT, US; 3Makerere University College of Health Sciences, Kampala, Uganda

514 Exploring Long-Term Adherence Markers Using Hair and Dried Blood Spots in iPrEx OLE
Monica Gandhi1; David V. Gleidden1; Albert Liu2; Peter L. Anderson3; Howard Homg4; Juan Guanaria1; Beatrix Grinsztejn4; Suwat Charriyalertsak1; Linda-Gail Bekker4; Robert M. Grant1
1University of California San Francisco, San Francisco, CA, US; 2San Francisco Department of Public Health, San Francisco, CA, US; 3Investigaciones Medicas en Salud, Lima, Peru; 4Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 5Chiang Mai University, Chiang Mai, Thailand; 6University of Cape Town, Cape Town, South Africa; 7University of Colorado, Denver, CO, US

515 UGT1A1 Genotype Predicts Bilirubin-Related Discontinuation of Atazanavir/Ritonavir
Saran Vardhanabhat1; Heather J. Ribaudo2; Raphael J. Landovitz2; Igbo Ofotokun1; Jeffrey L. Lennox2; Judith S. Currier1; Lana M. Olson1; David W. Haas4
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 2UCLA Center for Clinical AIDS Research & Education, Los Angeles, CA, US; 3Emory University School of Medicine, Atlanta, GA, US; 4Vanderbilt University School of Medicine, Nashville, TN, US

516 ABCB1 Polymorphism Affects Tenofovir Exposure as Determined by Areas-Under-the-Time-Concentration-Curve With 24-hour Intensive Pharmacokinetic Monitoring
Sanjiv M. Baxi1; Peter Bacchetti2; Mardge Cohen2; Jack A. Dehovitz2; Kathryn Anastos2; Stephen J. Gange5; Mary A. Young6; Monica Gandhi1; Bradley Aouizerat1
1University of California San Francisco, San Francisco, CA, US; 2John Stroger (formerly Cook County) Hospital, Chicago, IL, US; 3State University of New York Downstate Medical Center, Brooklyn, NY, US; 4Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US; 5Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 6Georgetown University, Washington, DC, US

517 Pharmacogenomics of Plasma Tenofovir Clearance and Change in Creatinine Clearance
Valentine Wanga1; Charles Venuto2; Gene D. Morse3; Edward A. Acosta1; Eric Daar4; David W. Haas1; Chui Li1; Bryan E. Shepherd1
1Vanderbilt University School of Medicine, Nashville, TN, US; 2University of Rochester Medical Center, Rochester, NY, US; 3State University of New York at Buffalo, Buffalo, NY, US; 4Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, CA, US; 5University of Alabama at Birmingham, Birmingham, AL, US

518 Variant ITPA Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels
Leah C. Jimmerson1; Thomas J. Urban2; Eric Meissner3; Ariel Hodara4; Jacob A. Langness5; Christina Aquilante1; Aimee Truesdale5; Fafa Baouchi-Mokrane1; Michelle Ray1; Jennifer J. Kiser1
1University of Colorado, Aurora, CO, US; 2University of North Carolina, Chapel Hill, NC, US; 3NIH, Bethesda, MD, US; 4University of Colorado Health, Aurora, CO, US; 5Denver Health and Hospital Authority, Denver, CO, US
Session P-H3 Poster Session
2:30 pm – 4:00 pm

Drug-Drug Interactions

519 Interactions of Antiretroviral Drugs With the SLC22A1 (OCT1) Drug Transporter
Darren M. Moss; Neill Liptrott; Marco Siccardi; Andrew Owen
University of Liverpool, Liverpool, United Kingdom

520 EFV but Not ATV/r Significantly Reduces Atovalouquone Concentrations in HIV+ Subjects
Monica M. Calderon; Joseph A. Kovacs; Alice K. Pau; Maryellen McManus; Raul Alfaro; Parag Kumar; Scott R. Penzak
1National Institutes of Health (NIH), Bethesda, MD, US; 2National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 3University of North Texas System College of Pharmacy, Fort Worth, TX, US; 4US Food and Drug Administration (FDA), Silver Spring, MD, US

521 The Effect of Single and Multiple Dose Rifampin on the Pharmacokinetics of Doravirine
Ka Lai Yee; Sauzanne G. Khalilieh; Rachael Liu; Rosa Sanchez; Matt S. Anderson; Candice Smith-Bradley; Joan Buttton; Timothy Judge; Helen Manthos; John Brejda

522 Drug-Drug Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Dolutegravir
Wendy W. Yeh; Ted Manresco; Hwa-Ping Feng; Zifang Guo; Daria Stypinski; Lisa Ross; Ivy H. Song; Patricia James; Barbara Cook; Joan R. Button

523 HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR
Ishani Savant Landry; Xiaolu Tao; Jeffrey Anderson; Michael Hesney; Michele Stonier; Susan Lubin; Jian Wang; George J. Hanna; David W. Boulton
Bristol-Myers Squibb, Princeton, NJ, US

THURSDAY, FEBRUARY 26, 2015

Session P-H4 Poster Session
2:30 pm – 4:00 pm

Pharmacokinetics in Compartments and Reservoirs and of Novel Formulations

524 Local and Systemic Pharmacokinetic Profile of Dapivirine Vaginal Ring-004 When Used Continuously Over Various Periods up to Twelve Weeks
Annalene M. Nel; Wouter Haazen; Marisa Russell; Jeremy P. Nuttall; Neliette Van Nierkerk; Nicolien Treijtel
1International Partnership for Microbicides, Paarl, South Africa; 2SGS Life Science Services, Antwerp, Belgium; 3International Partnership for Microbicides, Silver Spring, MD, US; 4Kinesis Pharma BV, Breda, Netherlands

525 Steady-state TDF/FTC in Genital, Rectal, and Blood Compartments in Males vs Females
Sharon M. Seifert; Amie L. Meditz; Jose R. Castillo-Mancilla; Edward M. Gardner; Brandon Klein; Becky Kerr; L. Anthony Guida; Jia-Hua Zheng; Lane R. Bushman; Peter L. Anderson
1University of Colorado, Aurora, CO, US; 2Boulder Community Hospital, Boulder, CO, US; 3University of Colorado School of Medicine, Aurora, CO, US

526 Effects of Tenofovir/Emtricitabine on Endogenous Deoxyribonucleotide Pools in Vivo
Xinhui Chen; Kevin McAllister; Jia-Hua Zheng; Jose R. Castillo-Mancilla; Amie Meditz; Brandon Klein; Sharon M. Seifert; Lane Bushman; Peter L. Anderson
1University of Colorado Anschutz Medical Campus, Aurora, CO, US; 2Beacon Center of Infectious Diseases, Boulder, CO, US

527 Higher Cell Accumulation and Antiviral Activity of Lopinavir/Ritonavir Nanoparticles
Philip Martin; Tom O. McDonald; Marco Giardiello; Steven P. Rennard; Andrew Owen
1University of Liverpool, Liverpool, United Kingdom; 2University of Liverpool, Liverpool, United Kingdom

528 HIV reservoir targeted antiretroviral nanofabrication facilitates viral clearance
Pavan Puligujja; JoEllyn McMillian; Shantanu Balkundi; Prasanta K. Dash; James Hilaire; Santhi Gorantla; Larisa Poluekova; Xin-Ming Liu; Howard Gendelman
1University of Nebraska Medical Center, Omaha, NE, US; 2Kans University Innovation and Collaboration, Lawrence, KS, US

529 The Macrophage Proteome Defines the Long Acting Antiretroviral Therapy Cell Depot
Dongwei Guo; Mariluz Araínga; Jayme Horning; Pawel Ciborowski; Xin-Ming Liu; JoEllyn McMillan; Howard Gendelman
University of Nebraska Medical Center, Omaha, NE, US

530 Primary CD4 Subsets Are Similarly Loaded by Tenofovir Alafenamide (TAF)
Christian R. Frey; Yang Liu; Darius Babus; Adam Palazzo; Adrian S. Ray; Michael D. Miller; Kathryn M. Kiriinos; Christian Callebaut
Gilead Sciences, Inc., Foster City, CA, US

Session P-H5 Poster Session
2:30 pm – 4:00 pm

New Technologies in Assessing Drug Interactions and Systemic and Intracellular Pharmacology

531 Pharmacokinetic Interactions Between Antidiabetics and Efavirenz Using PBPK Modeling
Catia Marzolini; Rajith Rajoli; Luigia Ezzi; Manuel Battegay; David Back; Marco Siccardi
1University Hospital Basel, Basel, Switzerland; 2Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom

532 In Silico Simulation of Interaction Between Rifampicin and Boosted Darunavir
Marco Siccardi; Owain Roberts; Rajith Rajoli; Laura Dickinson; Saye Khoo; Andrew Owen; David Back
University of Liverpool, Liverpool, United Kingdom
**Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics**

Adeniyi Olagunju; Oluseye Bolajii; Alleu Amara; Laura Else; Ogechi Okafor; Ebunoluwa Adeyugbje; Oyigboha Johnson; David Back; Saye Khoo; Andrew Owen

1University of Liverpool, Liverpool, United Kingdom; 2Obafemi Awolowo University, Ille-Ife, Nigeria; 3Bishop Murray Medical Centre, Makurdi, Nigeria; 4Catholic Caritas Foundation of Nigeria, Makurdi, Nigeria

**Antiretroviral Drug Transporters and Metabolic Enzymes in Human Testicular Tissue**

Billy Huang; Md. Tozammel Hoque; Mohammad-Ali Jenabian; Kishanda Vyboh; Nancy Sheehan; Pierre Brassard; Maud Bélanger; Nicolas Chomont; Jean-Pierre Routy; Reina Bendayan

1University of Toronto, Toronto, Canada; 2McGill University, Montréal, Canada; 3Université du Québec à Montréal, Montréal, Canada; 4Metropolitan Centre of Plastic Surgery, Montréal, Canada; 5Vaccine and Gene Therapy Institute of Florida, Port St Lucie, FL, US

**Imaging the Spatial Distribution of Efavirenz in Intact HIV Tissue Reservoirs**

Elias P. Rosen; Corbin G. Thompson; Mark T. Bokhart; Craig Sykes; Yuri Fedoriv; Paul Luciw; David C. Muddiman; Angela D.M. Kashuba

1North Carolina State University, Raleigh, NC, US; 2University of North Carolina, Chapel Hill, NC, US; 3University of California Davis, Davis, CA, US

WEDNESDAY, FEBRUARY 25, 2015

**Session P-11 Poster Session**

**Poster Hall**

**Drug Development**

**Inhibition of HIV-1 Replication by a Novel A cylguanidine-Based Molecule**

Philip Mwimanzi; Ian Tietjen; Aniqa Shahid; Scott C. Miller; David Fedida; Zabrina L. Brumme; Mark Brockman

1Simon Fraser University, Burnaby, Canada; 2University of British Columbia, Vancouver, Canada

**4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EfDa) Has an Extremely High Genetic Barrier, Persistently Exerting Highly Potent Activity Against a Variety of HIV-1 Isolates Including EfDa-Selected HIV-1 Variants**

Kenji Maeda; Yuki Takamatsu; Satoru Kohgo; Nicole S. Delino; Simon B. Chang; Kazuhiro Haraguchi; Hiroaki Mitsuya

1National Institutes of Health (NIH), Bethesda, MD, US; 2National Center for Global Health and Medicine, Tokyo, Japan; 3Nihon Pharmaceutical University, Saitama, Japan

**Maturation Inhibitor Mechanistic Studies - Differential Inhibition of Gag Polymorphs**

Zeyu Lin; Joseph Cantone; Tricia ProJack; Dieter Drexler; Beata Nowicka-Sans; Yuan Tian; Zheng Liu; Mark Krystal; Alicia Ruequeiro-Ren; Ira B. Dicker


**Late-Stage Integrase-LEDGF Inhibitors Mode of Action and Acquisition of Resistance**

Richard Benarous; Erwann Le Rouzic; Nikki van der Velden; Damien Bonnard; Atze Das; Celine Amadori; Alessia Zamborlini; Stefano Emiliani; Ben Berkhourt

1Biodim Mutabilis, Romainville, France; 2Academic Medical centre, Amsterdam, Netherlands; 3Inserm CNRS, Paris, France; 4U944 UMR7212, Inserm CNRS, Paris, France

**BMS-986001: A Promising Candidate for HIV-2 Treatment**

Robert A. Smith; Dana Raugi; Kate Parker; Mariah Oakes; Papa Salif Sou; Selly Ba; Moussa Seydi; Geoffroy S. Gottlieb

On behalf of the University of Washington-Dakar HIV-2 Study Group

1University of Washington, Seattle, WA, US; 2CHU de Fann, Dakar, Senegal

**Dual Loaded Sustained Release Core-Shell Nanoparticles for Anti-HIV Therapy**

Hilliard L. Kutschler; Jessica L. Reynolds; Faithful Makita; Sara Difursi; Jacob Milling; Jesse Hanchett; Charles C. Maponga; Paras N. Prasad; Gene D. Morse

1University at Buffalo, Buffalo, NY, US; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe

**Chemical Facilitated Endosomal Storage of Long-Acting Antiretroviral Nanoparticles**

Dongwei Guo; Prasanta K. Dash; Gang Zhang; Mariluz Araingga; Jaclyn Knibbe; Jolynn McCmillan; Larisa Poluektova; Harris Gelbard; Santhi Gorantla; Howard Gendelman

University of Nebraska Medical Center, Omaha, NE, US

TUESDAY, FEBRUARY 24, 2015

**Session P-J1 Poster Session**

**Poster Hall**

**ART: Recent Perspectives**

**24-Weeks Virologic Efficacy of Fozivudine in ART-Naïve Patients From Africa**

Arne Kroidl; Tessa Lennemann; Frederic Ello; Jimson Mgaya; Raoul Moh; Lucas Maganga; Serge P. Holle; Pierre-Marie Girard; Friedrich von Massow; Christine Danel

1Medical Center of the University of Munich (LMU), Munich, Germany; 2CHU de Treichville, Abidjan, Côte d’Ivoire; 3NIMR–Mbeya Medical Research Center, Mbeya, United Republic of Tanzania; 4University Hospital Saint-Antoine, Paris, France; 5Institute for Life Sciences and Environment GmbH, Heidelberg, Germany; 6Programme PAC-CI, ANRS, Abidjan, Côte d’Ivoire
545 Attachment Inhibitor Prodrug BMS—663068 in ARV-Experienced Subjects: Week 48 Analysis
Melanie Thompson1; Jay Lalezari2; Richard Kaplan2; Yvette Pinedo2; Otto Sussman Pena2; Pedro Cahn1; David A. Stock1; Samit R. Joshi2; George J. Hanna1; Max Latatilade1
1AIDS Research Consortium of Atlanta, Atlanta, GA, US; 2Quest Clinical Research, San Francisco, CA, US; Desmond Tutu HIV Foundation, Cape Town, South Africa; 4Asociacion Civil Via Libre, Lima, Peru; 5Asistencia Cientifica de Alta Complejidad SAS, Bogotá, Colombia; 6Fundacion Huesped, Buenos Aires, Argentina; 7Bristol-Myers Squibb, Wallingford, CT, US; 8Bristol-Myers Squibb, Princeton, NJ, US

546 Delay in Antiretroviral Therapy Is Not Associated With Increased Virologic Failure
Ashita S. Batavia1; Patrice Severé1; Marc Antoine Jean Juste1; Rode Secours1; Daphne C. Bernard2; William J. Pape2; Daniel Fitzgerald1
1Weill Cornell Medical College, New York, NY, US; 2Gheskio Center, Port-au-Prince, Haiti

547 Effects of Quadruple First-Line ART on Mucosal Immunity
Sergio Serrano-Villar1; Tatia Sainz1; Surinder Mann1; Zhong-Min Ma1; Christopher Miller2; Netanya S. Utya1; Basile Siewe1; Tae-Wook-Chun1; Paolo Troia-Cancio1; David Asmuth1
1University Hospital Ramón y Cajal, Madrid, Spain; 2University Hospital Gregorio Marañón, Madrid, Spain; 3University of California Davis, Sacramento, CA, US; 4University of Texas, Galveston, TX, US; 5University Medical Center, Chicago, IL, US; 6National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

548 Maraviroc-Dependent Pharmacologic Effects on Viral Decay and Immune Recovery in GALT
Corbin Thompson1; Tae-Wook Chun1; Craig Sykes1; Zhong-Min Ma1; Christopher Miller1; Surinder Mann1; Richard Pollard1; Angela Kashuba1; David Asmuth1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2Division of AIDS, NIAID, NIH, Bethesda, MD, US; 3University of California Davis Medical Center, Davis, CA, US; 4University of California Davis, Davis, CA, US

549 Maraviroc Induces HIV Production in RCT and In Vitro, Potentially via the NFkB Pathway
Jori Symons1; Ward de Spiegelaere1; Annemarie Wensing1; Julia Drylevich1; Ananaa Middel1; Andy I. Hoepelman1; Kiki Tessaarla1; Limos Vandekerckhove1; Steven F. van Lelyveld1; Monique Nijnhujs1
1University Medical Center Utrecht, Utrecht, Netherlands; 2Ghent University, Ghent, Belgium; 3University Medical Center Utrecht, Utrecht, Netherlands; 4University Medical Center Utrecht, Utrecht, Netherlands

550 Consistency of Dolutegravir Treatment Difference in HIV+ Treatment Naives at Week 96
Catherine M. Granier1; Robert Cuffe2; Louise Martin-Carpenter2; Kimberly Y. Smith1; Clare Brennan1; Keith Pappap; Brian Wynne1; Steve Almond1; Naomi Givens1; Michael Aboud2
1GlaxoSmithKline, Uxbridge, United Kingdom; 2Viiv Healthcare, London, United Kingdom; 3Viiv Healthcare, Research Triangle Park, NC, US; 4GlaxoSmithKline, Research Triangle Park, NC, US; 5GlaxoSmithKline, Mississauga, Canada

551 Predictors of HIV RNA Suppression on Darunavir/ Ritonavir Monotherapy in the MONET and PROTEA Trials
Diego Ripamonti1; Ralph DelMasi1; Andrew M. Hill2; Ceyhun Bicer2; Christiane Moecklinghoff3
1Chelsea and Westminster Hospital, London, United Kingdom; 2A.O. Papa Giovanni XXIII, Bergamo, Italy; 3Janssen Pharmaceuticals, Inc., Titusville, NJ, US; 4Janssen Pharmaceuticals, Inc., Beese, Belgium; 5Janssen Pharmaceuticals, Inc., Neuss, Germany

552 Second-Line Treatment in Sub-Saharan Africa: Week 144 Follow-up of the EARNEST Trial
James G. Hakim1; Jennifer Thompson2; Cissy M. Kiryó1; Sarah Walker2; Joep van Oosterhout3; Anne Hoppe2; Andrew D. Kambu3; Peter Muyenyi4; Nicholas Paton4
1On behalf of the EARNEST Trial Team
2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3University College London, London, United Kingdom; 4Joint Clinical Research Centre, Kampala, Uganda; 5Infectious Disease Institute, Kampala, Uganda; 6National University of Singapore, Singapore, Singapore; 7AIRC Clinical Trials Unit at University College London, London, United Kingdom

553 Withdrawing Inactive NRTIs in Subjects With Suppressed Viremia: A Randomized Trial
Josep M. Llibre1; Hortensia Alvarez1; Antonio Antela2; Jessica Toro2; Juan González-Moreno2; M Jesús Perez-Elias2; Arkaiz Imaz2; Mar Masía2; Manel Crespo2; Bonaventura Clotet2
1Univ Hosp Germans Trias, Badalona, Spain; 2Hospital Clinico Universitario, Santiago de Compostela, Spain; 3Hospital Son Llàtzer, Mallorca, Spain; 4Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; 5Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain; 6Hospital Universitari d’Elche, Elche, Spain; 7Hospital Universitari Vell d’Hebrón, Barcelona, Spain; 8Complejo Universitario de Ferrol, A Coruña, Spain

554LB Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results
David A. Margolis1; Cynthia C. Brinson1; Graham H. Smith2; Jerome de Vente2; Debbie P. Hagins3; Sandy K. Griffith3; Marty H. St. Clair3; Kimberly Y. Smith1; Peter E. Williams1; William R. Spreen1
1GlaxoSmithKline, Durham, NC, US; 2Central Texas Clinical Research, Austin, TX, US; 3Maple Leaf Medical Clinic, Toronto, Canada; 4Living Hope Foundation, Long Beach, CA, US; 5Chatham County Health Department, Savannah, GA, US; 6Viiv Healthcare, Durham, NC, US; 7Janssen Pharmaceuticals, Inc, Beese, Belgium

Session P-K1 Poster Session
2:30 pm – 4:00 pm
ART: Adherence, Adherence, Adherence

555 Self-Reported Versus Blood-Tested ART Intake to Estimate ART Coverage in South Africa
Helena Huerga1; Gilles Van Cutsem2; Lubbe Wiesner3; Malika Bouhenia1; Jihane Ben Farhat1; Emmanuel Fajardo2; Ruggiero G. Giuliani1; David Maman1; Thomas Ellman2; Jean-François Etard2
1Epicentre, Paris, France; 2Médecins Sans Frontiéres, Cape Town, South Africa; 3University of Cape Town, Cape Town, South Africa
Session P-K2 Poster Session
Poster Hall
2:30 pm – 4:00 pm
ART: Monitoring and Biomarkers

561 New Marker of Standard-of-ART Care: Percentage of Time on cART With Suppressed HIV-RNA
Kamilla G. Laut; Leah C. Shepherd; Court Pedersen; Jürgen Rockstroh; Helen Sambatakou; Dzmitry Paduta; Jens D. Lundgren; Amanda Mocroft; Ole Kirk; EuroSIDA in EuroCoord on behalf of EuroSIDA in EuroCoord
1Righospitalet, University of Copenhagen, Copenhagen, Denmark; 2Odense University Hospital, Odense, Denmark; 3University Hospital Bonn, Bonn, Germany; 4University College London, London, United Kingdom; 5Hippokration General Hospital, University of Athens, Athens, Greece; 6Gomel Regional Centre for Hygiene, Gomel, Belarus

562 Viremia Copy Years and Its Impact on Risk of Clinical Progression According to Shape
Alessandro Cozzi-Lepri; Antonella Cingolani; Andrea Antinori; Andrea De Luca; Cristina Mussini; Stefano Rusconi; Carmela Pinnetti; Massimo Galli; Antonella Castagna; Antonella d’Arminio Monforte
1University College London, London, United Kingdom; 2Sacro Cuore University, Roma, Italy; 3INMI Spallanzani, Roma, Italy; 4University of Siena, Siena, Italy; 5University of Modena, Modena, Italy; 6Luigi Sacco University Hospital, Milano, Italy; 7S. Paolo Hospital, Milano, Italy; 8San Raffaele Scientific Institute, Milano, Italy

563 Monitoring and Switching of Antiretroviral Therapy in Sub-Saharan Africa
Andreas D. Haas; Olivia Keiser; François Dabiré; Mary-Ann Davies; Rosalind M. Parkes-Ratanshi; Steven J. Reynolds; Kara Wools-Kaloustian; Gilles Wandel; Matthias Egger
1ICREA East, West and Southern Africa; 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 3Université Bordeaux, Bordeaux, France; 4University of Cape Town, Cape Town, South Africa; 5Makere University College of Health Sciences, Makerere, Uganda; 6National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 7Indiana University, Indianapolis, IN, US

564 Virological Factors Associated With Outcome of Dual MVC/RAL Therapy (ANRS-157 Trial)
Cathia Soulie; Lambert Assoumou; Melanie Darty; Christophe Rodriguez; Gilles Petylavin; Marc-Antoine Valantin; Dominique Costagliola; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcellin
1Hôpital Pitié Salpêtrière, Paris, France; 2INSERM/UPMC, Paris, France; 3APHP Mondor, Creteil, France; 4APHP Bichat, Paris, France; 5Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

565 D-dimer Doesn’t Return to Pre-HIV Levels After Therapy and Is Linked With HANA Events
Matthew S. Freiberg; Ionut Bebu; Russell Tracy; Jason F. Okulicz; Anuradha Ganesan; Adam Armstrong; Thomas O’Bryan; Brian K. Agan
1IDCRP HIV Working Group; 2Uniformed Services University of the Health Sciences, North Bethesda, MD, US; 3Vanderbilt University Medical Center, Nashville, TN, US; 4University of Vermont College of Medicine, Burlington, VT, US; 5The George Washington University, Rockville, MD, US; 6US Naval Medical Research Unit No. 6, Peru, Lima, Peru
566 Virological Responses to Lamivudine and Emtricitabine in the Nationwide ATHENA Cohort
   Casper Roks1; Azzania Fibriani1; David A. van de Vijver1; Annelies Verbon1; Martin Schutten1; Luuk Gras2; Bart J. Rijnders1
   On behalf of the Dutch HIV Monitoring Foundation
   1Erasmus University Medical Center, Rotterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands

567 Prevalence and Risk Factors of Multiple Micronutrient Deficiencies Pre- and Post-ART
   Rupak Shivakoti1; Parul Christian1; Nikhil Gupta1; Cecilia Kanyama1; Sima Berendes2; Javier Llama3; Richard Semba3; Thomas Campbell3; Amita Gupta1
   NWCS 319 and PEARLS Study Team
   1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3University of North Carolina Project–Malawi, Lilongwe, Malawi; 4Malawi College of Medicine–Johns Hopkins University Research Project, Blantyre, Malawi; 5Association Civil Impacta Salud y Educacion, Lima, Peru; 6University of Colorado School of Medicine, Aurora, CO, US

568 Detection of HIV RNA and DNA in Anal Swabs of HIV Infected Men Having Sex With Men
   Julian Storm1; Jens Verheyen1; Eva Wolff1; Lewin Eisele1; Jeremias Wohlschläger1; Peter-Michael Rath1; Evelyn Heintschel von Heinegg1; Dirk Schadenkopf1; Stefan Esser1
   1University Hospital Essen, University Duisburg-Essen, Essen, Germany; 2University Hospital Essen, Germany

WEDNESDAY, FEBRUARY 25, 2015

Session P-K3 Poster Session
2:30 pm – 4:00 pm

ART: Immunologic Response—The Good and The Bad

569 Reference Curves for CD4 Response to Antiretroviral Treatment in HIV-1–Infected Naïve Patients
   Rodolphe Thiebaut
   On behalf of the Standard Reference Distribution of CD4 Working Group in COHERE in EuroCoord
   Bordeaux University, Bordeaux, France

570 Comparing Immunological Failure Definitions, Using Tanzanian National HIV Data
   Fiona Vanobbergen1; Bonita K. Kilama1; Alison Wringe1; Angela Ramadhani1; Basia Zaba1; Danon Mmbando1; Jim Todd1
   1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2National AIDS Control Program, Dar es Salaam, United Republic of Tanzania; 3Ministry of Health & Social Welfare, Dar es Salaam, United Republic of Tanzania

571 Delaying Second-Line Therapy After First-Line Failure: Moderating Effect of CD4 Count
   Julia K. Rohr1; Prudence Ive2; Rebecca H. Berhanu1; Kate Shearer1; Mhairi Maskew1; Lawrence Long1; Ian Sanne1; Matthew P. Fox1
   1Boston University School of Public Health, Boston, MA, US; 2University of Witswatersand, Johannesburg, South Africa; 3Right to Care, Johannesburg, South Africa

572 Rapid Progression Hinders the Recovery of CD4 + T Cells Following Initiation of cART
   Inma Jarrin
   On behalf of the CASCADE Collaboration within EUROCOORD
   Instituto de Salud Carlos III, Madrid, Spain

573 Increase in CD4 Counts at Presentation to ART Care Among Urban HIV Clinics in Uganda
   ELIZABETH K. NALINTYA1; Agnes N. Kiragga1; Esther Katunguka1; Henry W. Nabeta1; Joanita Kigozi1; Yukari Manabe1; David R. Boulware2; Jon Kaplan3; David B. Meya1
   1Infectious Diseases Institute, Kampala Uganda, Kampala, Uganda; 2University of Minnesota, Minneapolis, MN, US; 3CDC Center for Global Health, Division of Global AIDS/HIV, Atlanta, GA, US; 4Johns Hopkins University, Baltimore, MD, US

574 Implications of Poor CD4 Recovery During HIV Suppressive ART in Sub-Saharan Africa
   Marieke E. de pondert1; Tamara Sonia Boender1; Raph L. Hamers1; Kim Sigaloff1; Cissy M. Kityo1; Alani S. Akanmu1; Maureen Wellington1; Tobias F. Rinke de WIT2; Pascale Ondoa1
   Pan African Studies to Evaluate Resistance (PASER) studygroup
   1Amsterdam Institute for Global Health and Development, Brussels, Belgium; 2Joint Clinical Research Centre Kampala, Kampala, Uganda; 3Lagos University Teaching Hospital, Lagos, Nigeria; 4Newlands Clinic, Harare, Zimbabwe

575 Better CD4/CD8 Restoration in First-Line HIV-Infected CMV-Seronegative Patients
   Isabelle Poizot-Martin1; Clotilde Allavena1; Claudine Duvivier1; Carla E. Cano1; Francine Guillouet de Salvador1; David Rey1; Lise Cuzin1; Antoine Cheret1; Bruno Hoen2
   On behalf of the Dat’AIDS Group
   1Aix-Marseille Université, APHIM Hôpital Sainte-Marguerite, Marseille, France; 2CHU Hotel Dieu, Nantes, France; 3APHP–Hôpital Necker Université Paris Descartes–IHU Imagine, Paris, France; 4CHU Arche1, Nice, France; 5Hôpitaux Universitaires Strasbourg, Strasbourg, France; 6Research Coordination for HIV, Toulouse, France; 7Hospital Tourcoing, Tourcoing, France; 8University Medical Center of Guadeloupe, Guadeloupe, France; 9Dat’AIDS Group, Nice, France

576 CD4 Response in Treatment-Naïve HIV-2–Infected Patients: The ldeA West Africa Cohort
   Eric Balestre1; Koumavi K. Ekouevi1; Boris Tchounga2; Serge P. Eholié2; Eugène Messou1; Adrien Sawadogo1; Rodolphe Thiebaut1; Margaret T. May2; Jonathan A. Sterne2; François Dabis1
   1Univ Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France; 2APHP–Hôpital Necker Université Paris Descartes–IHU Imagine, Paris, France; 3Programme PAC-Cl, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; 4Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d’Ivoire; 5Centre de Prévention et de Recherche et de Formation, Hôpital Yopougon Attié, Abidjan, Côte d’Ivoire; 6Institut Supérieur des Sciences de la Santé, Université Polytechnique de Bobo-Dioulasso, Bobo-Dioulasso, Burkina Faso; 7School of Social and Community Medicine, Bristol University, Bristol, United Kingdom
Session P-K4 Poster Session
2:30 pm – 4:00 pm
ART: Mortality

577  Impact of Specific Antiretroviral Drugs on Non-AIDS Mortality; the D:A:D Study
Camilla I. Hatleberg1; Lene Ryom1; Andrew N. Phillips2; Amanda Mocroft3; Peter Reiss3; Matthew Law4; Rainer Weber4; François Dabis5; Jens D. Lundgren6; Colette Smith7
On behalf of the D:A:D Study group
1Righospitalet, University of Copenhagen, Copenhagen, Denmark; 2University College London, London, United Kingdom; 3Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 4University of New South Wales, Sydney, Australia; 5University Hospital Zurich, Zurich, Switzerland; 6University of Bordeaux, Bordeaux, France

578  Effect of ART on Mortality Generalized to Newly HIV-Diagnosed Persons in the USA
Catherine R. Lesko1; Stephen R. Cole1; H. Irene Hall1; Michael J. Mugavero7
1University of North Carolina, Chapel Hill, NC, US; 2University at Birmingham, Birmingham, AL, US; 3US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

579  Association of CD4:CD8 With Cause-Specific Mortality in Patients on Long-Term ART
Margaret T. May1; Adam Trickey1; Dominique Costagliola1; Peter Reiss2; Santiago Moreno3; John Gill4; Colette Smith5; Suzanne M. Ingle6; Jonathan A. Sterne7
On behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC)
1University of Bristol, Bristol, United Kingdom; 2University College London, London, United Kingdom; 3University of Calgary, Calgary, Canada; 4Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 5Hospital Ramón y Cajal, Madrid, Spain; 6UMR S 1136, Inserm et Sorbonne Universités, Université Pierre et Marie Curie, Paris, France

580  Outcomes of First ART in Latino Populations in North America and Latin America
Carina T. Cesar1; Mark J. Giganti2; Bryan E. Shepherd3; Richard Moore1; Keri N. Allthoff4; Sonia Napravnik5; Angel M. Mayor6; Catherine Mc Gowan7; Pedro E. Cahn8
1Fundacion Huésped, Buenos Aires, Argentina; 2Vanderbilt University, Nashville, TN, US; 3Johns Hopkins University, Baltimore, MD, US; 4University of North Carolina, Chapel Hill, NC, US; 5Retrovirus Research Center, Bayamón, PR, Puerto Rico

581  Gender Disparity in cART Initiation/Outcome: The South African Military Phidisa Cohort
Ming-Han Motloung1; Linda Mesani1; Selloane Pula1; Jing Wang1; Michael Proshan1; Matthew Dolan1
On behalf of the Phidisa Gender Disparity Group
1Henry Jackson Foundation, San Antonio, TX, US; 2Project Phidisa, Bloemfontein, South Africa; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US

Session P-L1 Poster Session
2:30 pm – 4:00 pm
HIV Drug Resistance: Mechanisms and Mutations

582  Structural Basis of Inhibition and Resistance Mechanism to Ef dA, a Highly Potent NRTI
Zhe Li1; Karen Kirby2; Bruno Marchand3; Michailidis Eleftherios4; Eiichi Kodama5; Hisao Mitsuya6; Michael Parniak7; Stefan Sarafianos8
1University of Missouri, Columbia, MO, US; 2Tohoku University, Sendai, Japan; 3National Institutes of Health, Division of AIDS, Bethesda, MD, US; 4University of Pittsburgh, Pittsburgh, PA, US

583  Structural Basis and Distal Effects of Gag Substrate Coevolution in Drug Resistance to HIV-1 Protease
Kuan-Hung Lin1; Celia A. Schiffer2
1University of Massachusetts Medical School, Worcester, MA, US

584  Influence of Codon Pair Usage in the Evolvability of HIV-1
Maria Nevot1; Cristina Andrés2; Mariona Parera3; Glòria Martrus1; Miguel Ángel Martinez1
1IrsiCaixa Institute for AIDS Research, Badalona, Spain
Poster Listings

588 Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide PI Susceptibility
Dana N. Raugi1; Robert A. Smith1; Matthew Coyne1; Julia Olson1; Kara Parker1; Sally Ba2; Papa Salif Sow3; Moussa Seydi4; Geoffrey S. Gottlieb5
University of Washington-Dakar HIV-2 Study Group
1University of Washington School of Medicine, Seattle, WA, US; 2Centre Hospitalier National Universitaire de Fann, Universite Cheikh Anta Diop de Dakar, Dakar, Senegal

589 Enhanced Neutralization of HIV-1 With Fusion Inhibitor Resistant Mutations
Muntasir Alam1; Takeo Kuwata2; Kristel P. Ramirez3; Yasuhiro Maruta4; Kazuki Tanaka5; Kazuya Shimura6; Shinya Oishi7; Nobutaka Fujii8; Masao Matsuoka9; Shuzo Matsushita10
1Kumamoto University, Kumamoto, Japan; 2Kyoto University, Kyoto, Japan

590 Mutations at the Bottom of the Phe43 Cavity Are Responsible for Cross-Resistance to NBD Analogues
Shigeyoshi Harada1; Yu Irahara2; Samatchaya Boonchawalit3; Mai Goryo4; Hirokazu Tamamura5; Tetsuro Matano6; Shuzo Matsushita7; Kazuha Yoshimura8
1National Institute of Infectious Diseases, Shinjuku, Japan; 2Tokyo Medical and Dental University, Chiyoda, Japan; 3Kumamoto University, Kumamoto, Japan

591 SIV<sub>mac239</sub> Integrase as a Model of HIV Drug Resistance Against Integrase Inhibitors
Said Hassounah1; Thibault Mesplede2; Maureen Oliveira3; Peter K. Quashe4; Daniela Moisi5; Paul A. Sandstrom6; Mark A. Wainberg7; Bluma Brenner8
1McGill University, Montreal, Canada; 2National HIV and Retrovirology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Ottawa, Canada

592 Within-Run Cross-Contamination in Deep Sequencing Applications on the Illumina MiSeq
Chanson J. Brumme1; Winnie Dong2; Celia K. Chui3; Richard Liang1; Art F. Poon1; Richard Harrigan1
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

593 Analysis of Resistance Haplotypes Using Primer IDs and Next Gen Sequencing of HIV RNA
Valerie E. Boltz1; Jason Rausch2; Wei Shao1; Charles Coomer1; John W. Mellors1; Mary Kearney1; John M. Coffin1
1National Institutes of Health (NIH), Frederick, MD, US; 2Leidos, Frederick, MD, US; 3University of Pittsburgh, Pittsburgh, PA, US; 4Tufts University, Boston, MA, US

Session P-L2 Poster Session
2:30 pm – 4:00 pm
HIV Subtypes and Resistance

594 HIV-1 Subtype Influences the Pathways of Genotypic Resistance to Integrase Inhibitors
Tomas J. Doyle1; David Dunn2; Rolf Kaiser3; Erasmus Smit4; Anne-Genevieve Marcellin5; Carmen de Mendoza6; Javier Martinez-Picado7; Federico Garcia8; Francesca Ceccherini-Silberstein9; Anna Maria Geretti10
CORONET study group
1King’s College London, London, United Kingdom; 2University of Liverpool, Liverpool, United Kingdom; 3University of Cologne, Cologne, Germany; 4University College London, London, United Kingdom; 5Hôpital Pitié Salpetrière, APHM, Paris, France; 6Hospital Carlos III, Madrid, Spain; 7University Hospital San Cecilia, Granada, Spain; 8University of Rome Tor Vergata, Rome, Italy; 9Institut de Recerca de la Sida, Barcelona, Spain; 10Birmingham Heartlands Hospital, Birmingham, United Kingdom

595 Differences in Resistance Mutations in Non-B Subtypes at First-Line Failure in Africa
Cissy M. Kityo1; Sarah Walker2; Immaculata Nankya3; Anne Hoppe4; Jennifer Thompson5; Silvia Bertagnolio6; Philippa Easterbrook7; Peter Mugyenyi8; Nicholas Paton9
On behalf of the EARNEST Trial Team
1Joint Clinical Research Centre, Kampala, Uganda; 2MRC Clinical Trials Unit at University College London, London, United Kingdom; 3World Health Organization, Geneva, Switzerland; 4Yong Loo Lin School of Medicine, Singapore, Singapore

596 K65R Detected More Frequently in HIV-1 Subtype C Viruses at Virological Failure
Erasmus Smit1; Ellen White2; Duncan Clark3; Duncan Churchill4; Hongyi Zhang5; Simon Collins6; Deenan Pillay7; Anna Tostevin8; David Dunn9
1UKHRED and UKCHIC
2Public Health England, Birmingham, United Kingdom; 3Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 4University of KwaZulu-Natal and University College London, London, United Kingdom; 5St Bartholomew’s and the London NHS Trust, London, United Kingdom; 6HIV i-Base, London, United Kingdom; 7Addenbrooke’s Hospital, Cambridge, United Kingdom; 8University College London, London, United Kingdom

597 Viral Failure and High K65R in Kenyan Patients on Tenofovir-Based First-Line Therapy
Katherine C. Brooks1; Lameck Diero1; Allison Delong2; Maya Balamane3; Marissa Reitsma4; Emmanuel Kemb05; Millicent Orido6; Mia Goetze7; Joseph Hogan8; Ram I2
1Mai University, Eldoret, Kenya; 2Brown University, Providence, RI, US; 3Academic Model Providing Access to Healthcare, Eldoret, Kenya

Session P-L3 Poster Session
2:30 pm – 4:00 pm
Transmitted HIV Drug Resistance: Assessing the Threat

598 Large NNRTI-Resistant Transmission Cluster in Injection Drug Users From Saskatchewan
Alexander Wong1; Jaspread Kambo1; Richard Harrigan1; Art F. Poon1; Jeffrey B. Joy1
1University of Saskatchewan, Regina, Canada; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
599 Transmitted Drug Resistance and Time of HIV Infection, New York State, 2006-2013
Zhengyan Wang; Emily Waites; Daniel E. Gordon; Bridget J. Anderson; Deepa Rajulu; Ling Wang; Lou C. Smith
1New York State Department of Health, Albany, NY, US; 2University at Albany, School of Public Health, Albany, NY, US

600 Transmitted HIV Drug Resistance Among Early Infected Persons in San Diego, California
Theppharit Panichsillapakit; David M. Smith; Joel Wertheim; Douglas D. Richman; Susan Little; Sanjay Mehta
1Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2University of California San Diego (UCSD), La Jolla, CA, US

601 HIV Molecular Epidemiology and Transmitted Drug Resistance in the Mesoamerican Region
Claudia Garcia-Morales; Santiago Avila-Rios; Daniela Tapia-Trejo; Carlos Mejia-Villatoro; Juan M Pascale; Guillermo Porras-Cortes; Ivette Lorenzana; Elsa Palou; Marvin Manzanero; Gustavo Reyes-Terán
1National Institute of Respiratory Disease, Mexico City, Mexico; 2Roosevelt Hospital, Guatemala City, Guatemala; 3Gorgas Memorial Institute for Health Studies, Panama City, Panama; 4Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; 5Vivian Pellas Metropolitan Hospital, Managua, Nicaragua; 6Ministry of Health, Belize City, Belize

602 Temporal Trends of Transmitted HIV Drug Resistance Following Seroconversion
Ashley Olson; Claudia Kucherer; Anders Sönnerborg; Carmen de Mendoza; Robert Zangerle; Maria Prins; John Gill; Anne-Marte Bakken Kran; Dimitrios Paraskeviss; Kholoud Porter
for CASCADE collaboration in EuroCoord
1University College London, London, United Kingdom; 2University of Calgary, Alberta Health Services, Calgary, Canada; 3Robert Koch Institute, Berlin, Germany; 4Karolinska Institutet, Stockholm, Sweden; 5Puerta de Hierro Research Institute and University Hospital, Madrid, Spain; 6Insbruck Medical University, Insbruck, Austria; 7Oslo University Hospital, Oslo, Norway; 8University of Athens, Athens, Greece; 9Public Health Service of Amsterdam, Amsterdam, Netherlands

603 Increase in HIV Primary Drug Resistance in a Demographic Surveillance Area in Rural KwaZulu-Natal South Africa
Justen Manasa; Siva Danaviah; Frank Tanser; Sureshnee Pillay; Hloniphile Mthiyane; Eduan Wilkinson; Deenan Pillay; Tulio de Oliveira
University of KwaZulu-Natal, Durban, South Africa

604 A Clinical Prediction Rule for PI Resistance in Resource-Limited Settings
Karen Cohen; Anemie Stewert; Andre P. Kengne; Rory F. Leisegang; Marla Coetse; Shavani Maharaj; Liesl Dunn; Graeme Meintjes; Gert U. van Zyl; Gary Maartens
1University of Cape Town, Cape Town, South Africa; 2Aid for AIDS Management (Pty) Ltd, Cape Town, South Africa; 3University of Stellenbosch, Cape Town, South Africa

605 Baseline Low-Frequency HIV-1 Variants Do Not Predict Virologic Failure to RPV/FTC/TDF
Danielle P. Porter; Martin Däumer; Alexander Thielien; Michael D. Miller; Kirsten L. White
1Gilead Sciences, Inc., Foster City, CA, US; 2Seq-IT GmbH & Co KG, Kaiserslautern, Germany

606 High Rates of Early Virologic Failure in a Cohort of Tanzanian HIV-Infected Adults
Claudia A. Hawkins; Nzovu Ulenga; Enju Liu; Said Aboud; Ferdinand Mugusi; Guerino Chalamilla; David Sando; Eric Aris; Wafaeie Fawzi
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Management and Development for Health, Dar es Salaam, United Republic of Tanzania; 3Harvard School of Public Health, Boston, MA, US; 4Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania

607 HIV Drug Resistance Surveillance in Honduras After 10 Years of Widespread ART
Claudia Garcia-Morales; Santiago Avila-Rios; Daniela Tapia-Trejo; Rita Meza; Sandra Nuñez-Rubio; Norma Flores; Wendy Murillo; Ivette Lorenzana; Elsa Palou; Gustavo Reyes-Terán
1National Institute of Respiratory Diseases, Mexico City, Mexico; 2Honduran HIV National Program and National Laboratory, Tegucigalpa, Honduras; 3Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras; 4Hospital Escuela Universitaria, Tegucigalpa, Honduras; 5Instituto Nacional Cardiopulmonar, Tegucigalpa, Honduras

608 High Prevalence of Genotypic Resistance to Integrase inhibitors of HIV-1 Strains in Taiwan
Sui-Yuan Chang; Chien-Ching Hung
1National Taiwan University, Taipei, Taiwan; 2National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

609 Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks
Cindy L. Vavro; Jenny Huang; Mounir Al-Khaled
GlaxoSmithKline, Research Triangle Park, NC, US

610 Discordant Predictions Could Impact Dolutegravir Use Upon Raltegravir Failure
Kristof Theys; Ana B. Abecasis; Pieter Libin; Perpétua Gomes; Joaquim Cabanas; Ricardo J. Camacho; Kristel Van Laethem
1the Portuguese HIV-1 Resistance Study Group
2University of Leuven, Leuven, Belgium; 3Universidade Nova de Lisboa, Lisbon, Portugal; 4Hospital Egas Moniz, Lisbon, Portugal

611 Integrase S119P Mutation Correlates With Disease Progression in HIV-1 Naïve Patients
Daniele Armenia; Maria Mercedes Santoro; Caterina Gori; Emanuele Nicastrì; Antonio Cristaudo; Massimo Andreoni; Andrea Antinori; Zeger Debyser; Carlo-Federico Perro; Francesca Ceccherini-Silberstein
1University of Rome Tor Vergata, Rome, Italy; 2L. Spallanzani Hospital, Rome, Italy; 3San Gallicano Dermatological Institute, Rome, Italy; 4University Hospital Tor Vergata, Rome, Italy; 5Katholieke Universiteit Leuven, Leuven, Belgium
TUESDAY, FEBRUARY 24, 2015

Session P-M1 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Nucleic-Acid–Based Detection of HIV

612 A Generalized Entropy Measure of Viral Diversity for Identifying Recent HIV-1 Infections
Julia W. Wu; Oscar Patterson-Lomba; Marcello Pagano
Harvard School of Public Health, Boston, MA, US

613 Acute Infections, Cost and Time to Reporting of HIV Test Results in US State Public Health Laboratories
Muazam Nasrullah¹; Laura G. Wesolowski¹; Steven F. Ethridge¹; Kevin Cranston²; Robert A. Myers²; James T. Rudrik³; Angela B. Hutchinson³; Barbara G. Werner³
¹US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; ²Massachusetts Department of Public Health, Boston, MA, US; ³Maryland Department of Health and Mental Hygiene, Baltimore, MD, US; ⁴Michigan Department of Community Health, Lansing, MI, US

614 The POC Alere q HIV-1/2 Detect Test for Detection and Quantification of HIV-2
Ming Chang¹; Katja Weimar¹; Dana N. Raugi¹; Robert A. Smith¹; Selby Ba²; Moussa Seydi³; Katrin Steinmetzer³; Robert W. Coombs¹; Geoffrey S. Gottlieb¹
¹UW-Dakar HIV-2 Study Group
²University of Washington, Seattle, WA, US; ³Alere Technologies GmbH, Jena, Germany; ⁴Service des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal

615 Performance of HIV Viral Load with Dried Blood Spots in Children on ART in Mozambique
Amina M. de Sousa Muhate¹; James C. Houston¹; Mariam Assane¹; Joy Chang³; Emilia Koumans¹; Ilesh V. Jani¹; Jennifer Sabatier¹; Paula M. Vaz³; Chunfu Yang³; Emilia Rivadeneira³
¹Ministry of Health, Mozambique, Mozambique; ²Centers for Disease Control and Prevention, Atlanta, GA, US; ³Fundação Ariel Glaser Contra o SIDA Pediatrica, Maputo, Mozambique

616 Cost-Effectiveness of Pooled PCR Testing of Dried Blood Spots for Infant HIV Diagnosis
Cari van Schalkwyk¹; Jean Maritiz¹; Alex Welte¹; Gert U. van Zyl¹; Wolfgang Preiser²
¹University of Stellenbosch, South Africa, Stellenbosch, South Africa; ²University of Stellenbosch, Tygerberg, South Africa

617 Evaluating Dried Blood Spot Performance in Assessing HIV Treatment Failure in Uganda
Allen Roberts¹; Herbert C. Duber¹; Ming Chang¹; Anne Gasasira¹; Gloria Iklezi¹; Jane Achau¹; Joan Dragavon¹; Glenda Daza¹; Emmanuela Gakidou¹; Robert W. Coombs¹
¹Makerere University College of Health Sciences, Kampala, Uganda

618 Comparison of Pooled RNA and 4th Generation Ag/Ab Testing to Identify Acute HIV Infection
Gary Murphy¹; Simon Carne¹; Bharati Patel¹; Elaine Mckinney¹; Samuel Moses¹; Noel Gill¹; John Parry¹; Jennifer Tosswill¹
¹Public Health England, London, United Kingdom

SESSION P-M2 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Comparison of HIV Incidence Assays

619 Improved Viral Load Monitoring Capacity With Rank-Based Algorithms for Pooled Assays
Tao Liu¹; Joseph Hogan¹; Renxia Huang¹; Rami Kantor¹
¹Brown University, Providence, RI, US; ²Miriam Hospital, Alpert Medical School, Brown University, Providence, RI, US; ³Fulcrum Analytics Inc, Fairfield, CT, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-M2 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Evaluation of Determine® HIV-1/2 Ag/Ab Combo in the Context of Acute HIV Screening
Sílvia Masciotta¹; S. Michele Owen¹; Wei Luo²; Emily Westheimer³; Stephanie Cohen²; Laura Hall²; Cindy L. Gay³; Philip J. Peters³

620 Performance of the Geenius HIV-1/HIV-2 Assay in the CDC HIV Testing Algorithm
Kevin P. Delaney; Steven Ethridge; Laura G. Wesolowski; Michele Owen; Bernard M. Branson
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

621 The Effect of HIV-1 Subtype A, C and D on Cross-Sectional Incidence Assay Performance
Andrew F. Longosz¹; Mary Grabowski¹; Charles S. Morrison¹; Ronald H. Gray²; Connie Celum²; Quarraisha Abdool Karim³; Hilmarie Brand³; Thomas C. Quinn¹; Susan H. Eshleman¹; Oliver B. Laeyendecker²
¹National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; ²Johns Hopkins University, Baltimore, MD, US; ³University of Washington, Seattle, WA, US; ⁴University of Washington, Seattle, WA, US; ⁵University of KwaZulu-Natal, Congella, South Africa; ⁶SACEMA, Stellenbosch University, Stellenbosch, South Africa

622 Avidity Assay for Cross-Sectional Incidence Based on a 4th-Generation Combo Ag/Ab EIA
Allison R. Kirkpatrick¹; Eshan U. Patel¹; Connie L. Celum²; Richard D. Moore²; Joel N. Blankson²; Shrutil Mehta³; Gregory D. Kirk³; Thomas C. Quinn¹; Susan H. Eshleman¹; Oliver B. Laeyendecker²
¹National Institutes of Health, Baltimore, MD, US; ²University of Washington, Seattle, WA, US; ³University of Washington, Seattle, WA, US; ⁴Johns Hopkins University School of Medicine, Baltimore, MD, US; ⁵Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; ⁶Johns Hopkins University School of Medicine, Baltimore, MD, US
Andrea A. Kim1; David Maman2; Harrison Fredrick Omondi3; Alex Morwabeb; Irene Mukui1; Valerie Opollo1; Beatrice Kirubi1; Jean-François Eta1; Martinus W. Borgdorff1; Clement Zeh1

625 False Recent Rates for Two Recent Infection Testing Algorithms, South Nyanza, Kenya
Clement Zeh1; David Maman2; Harrison Omondi3; Alex Morwabe3; Collins Odhiambo3; Beatrice Kirubi1; Irene Mukui1; Martinus W. Borgdorff1; Jean-François Eta1; Andrea A. Kim1

626 Viral Load is Critical in Limiting False-Recent Results From HIV Incidence Assays
Reshma Kassanjee1; Shelley Facente1; Sheila Keating1; Elaine McKinney1; Kara Marson2; Christopher D. Pilcher1; Michael Busch1; Gary Murphy1; Alex Welte1
The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)

627 Use of the Sample-to-Cutoff Ratio (S/CO) to Identify Recency of HIV-1 Infection
Eric M. Ramos; José Ortega; Glenda Daza; Yuree Namkung; Socorro Harb; Joan Dragavon; Robert W. Coombs
University of Washington, Seattle, WA, US

628 An Abbott Architect Combo Signal to Cut-Off Ratio With Adequate PPV to Confirm HIV
Tomas O. Jensen1; Peter Robertson2; Jeffrey J. Post1
1Prince of Wales Hospital, Randwick, Australia; 2South Eastern Area Laboratory Services, Prince of Wales Hospital, Sydney, Australia

629 Determining HIV Status of African Adults With Discordant HIV Rapid Tests
Jessica M. Fegel1; Estelle Piwowar-Manning1; Mark A. Marzinke1; William Clarke1; Michal Kulich1; Jessie K. Mbwayombo1; Linda Richter1; Glenda Gray1; Thomas J. Coates1; Susan H. Ehleman1
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Charles University, Prague, Czech Republic; 3Muhimbili University Teaching Hospital, Dar es Salaam, United Republic of Tanzania; 4Universities of the Witwatersrand and KwaZulu-Natal, Durban, South Africa; 5South African Medical Research Council, Cape Town, South Africa; 6David Geffen School of Medicine and University of California Los Angeles Health, Los Angeles, CA, US

Session P-M3 Poster Session
2:30 pm – 4:00 pm

630 Accuracy of POC CD4 testing using microtube capillary sampling in Botswana households
Sikhulile Moyo1; Lillian Okui1; Hermann Bussmann1; Simani Gaseitsiwe1; Erik van Widenfelt2; Molly P. Holme2; Joseph Makhema1; Shahin Lockman3; Vladimir Novitsky4; Max Essex1
1Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; 2Harvard School of Public Health, Boston, MA, US

631 Zyomyx MyT4 and BD FACS® Presto Comparison to the Pima CD4 Assay
Katie Tucker; Sehin Birhana; Larry Westerman
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

632LB Point-of-Care CD4 (Pima) Impact on Linkage to Care With Home-Based HIV Testing, Kenya
Mitesh A. Desai1; Duncan Okali1; Robert T. Chen2; Richard Ndivo2; Charles Lebaron3; Tiffany Williams4; Fred Otieno5; Charles Rose2; Taraz Samandari1; Clement Zeh1
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2Médecins Sans Frontières, Paris, France; 3Kenya Medical Research Institute, Kisumu, Kenya

633 Reliable Genotypic Tropism Tests for the Major HIV-1 Subtypes
Kieran Cashin1; Lachlan R. Gray1; Katherine L. Harvey1; Danielle Perez-Bercoff1; Guinevere Q. Lee2; Jasminka Sterjovski3; James F. Demarest4; Fraser Drummond5; Melissa J. Churchill6; Paul R. Gorry7
1Burnet Institute, Melbourne, Australia; 2Centre Recherche Public de la Santé, Strassen, Luxembourg; 3BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 4VIV Healthcare, Durham, NC, US

634 Accuracy of Re-Reading HIV Rapid Tests and the Effect of Prolonged High Temperature
Augustine T. Choko1; Deus Thindwa1; Peter MacPherson2; Rodrick Sambakunsi1; Aaron Molo1; Kondwani Chiimwemwe1; Owen Malema2; Simon Makombe3; Emily L. Webb1; Elizabeth L. Corbett4
1Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi; 2University of Liverpool, Liverpool, United Kingdom; 3Ministry of Health, Blantyre, Malawi; 4Ministry of Health, Lilongwe, Malawi; 5London School of Hygiene and Tropical Medicine, London, United Kingdom; 6London School of Hygiene and Tropical Medicine, London, United Kingdom

635 Analysis of False Negative HIV Tests Based on Oral Fluid in 3 Clinical Trials
Marcel E. Culin1; Michael T. Martin2; Wanna Leelawiwat3; Roman Gvetadze3; Charles Rose1; Sarika Pattanasin3; Richard Niska1; Timothy Holtz1; Kachit Choopanya3; Janet McNickoll3
1US Centers for Disease Control and Prevention, Apo, US; 2Thailand Ministry of Public Health—Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; 3Bangkok Tenofovir Study Group, Bangkok, Thailand
TUESDAY, FEBRUARY 24, 2015

Session P-N1 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Natural History and Prognosis of HCV Infection

636 Progression of Liver Disease in HLV/HCV Coinfected People According to Gender in Icona Cohort: Role of Age as Potential Different Exposure to Estrogens
Antonella Cingolani1; Paola Cicconì2; Gloria Taliani3; Alessandro D. Cozzi-Lepri4; Massimo Puoti5; Carmela Pinnetti6; Pier Luigi Viale7; Antonella d’Arminio Monforte1
for Icona Foundation Study Group
1Catholic University, Roma, Italy; 2University of Milano, Milano, Italy; 3University La Sapienza, Roma, Italy; 4University College London Medical School, Royal Free Campus, London, United Kingdom, London, United Kingdom; 5Niguarda Hospital, Milano, Italy; 6National Institute for Infectious Diseases L. Spallanzani, Roma, Italy; 7University of Bologna, Bologna, Italy

637 A Prognostic Score Estimating the Risk of Liver-Related Death Among HIV/HCV Coinfected Subjects
Daniel Grint1; Lars Peters2; Jürgen Rockstroh3; Karine Lacombe4; Andrezj Herban5; Irina Khromova4; Jose Gatell6; Antonella d’Arminio Monforte1; Jens D. Lundgren7; Amanda Mccroft8
on behalf of EuroSIDA in EuroCoord
1University College London, London, United Kingdom; 2University of Copenhagen, Copenhagen, Denmark; 3University Hospital Bonn, Bonn, Germany; 4Hospital Saint Antoine, Paris, France; 5Wojewodzki Szpital Zakazny, Warsaw, Poland; 6University of Barcelona, Barcelona, Spain; 7Clinica delle Malattie Infettive e Tropicali, Milan, Italy; 8Centre for HIV/AIDS & Infectious Diseases Prevention & Control, Kaliningrad, Russian Federation

638 Has Modern ART Reduced Endstage Liver Disease Risk in HIV-Hepatitis Coinfection?
Marina B. Klein1; Keri N. Althoff2; Yuezhou Jing3; Greg D. Kirk4; Michael Lo Re5; Nina Kim4; Mari Kitahata6; Chloé Thio7; Michael J. Silverberg8; Richard Moore9
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

639 Marijuana Use Does Not Accelerate Liver Fibrosis in HCV/HIV-Coinfected Women
Erin M. Kelly1; Jennifer L. Dodge2; Monika Sarkar3; Audrey French4; Phyllis Tien5; Marshall Glesby6; Elizabeth Golub7; Michael Augenbraun8; Michael Plankney9; Marion G. Peters10
WHIS

640 HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma
Fernando H. Aguiar1; Alejandro Forner2; Christian Manzardo3; Andres Valdivieso4; Mariano Blanes5; Rafael Barcena6; Antoni Rafecas7; Lluís Castells8; Antonio Rimola9; Jose M Miro10
1University of Barcelona, Barcelona, Barcelona, Spain; 2Hospital Clinic, IDIBAPS and El Centro de Investigacio Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 3Hospital Universitario de Cruces, Bilbao, Spain, Bilbao, Spain; 4Hospital University of La Fe, Valencia, Spain, Valencia, Spain; 5Hospital Universitario Ramón y Cajal, Madrid, Spain, Madrid, Spain; 6Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain

641 Rapid Progression to Cirrhosis and Death Among HCV-Infected Persons Who Inject Drugs in India
Shruti H. Mehta1; Suniti Solomon2; Allison M. McFall1; Aylur K. Srikrishnan3; Pachamuthu Balakrishnan4; Nandagopal P5; David L. Thomas6; Mark Sulkowski7; Sunil S. Solomon8
1Johns Hopkins University, Baltimore, MD, US; 2YR Gaitonde Centre for AIDS Research and Education, Chennai, India

642 Chronic Kidney Disease Progression After HCV Seroconversion
Adeel A. Butt
University of Pittsburgh/VA Pittsburgh Healthcare System, Pittsburgh, PA, US

Session P-N2 Poster Session  Poster Hall
2:30 pm – 4:00 pm
HCV Therapy: Observations From Cohort Studies

643 Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons
Adeel A. Butt1; Peng Yan2; Obaid Shaikh3; Shari Rogal1

644 Sofosbuvir, Simeprevir, +/- Ribavirin in HCV Protease Inhibitor-Experienced Patients
Kristen M. Marks1; Ethan M. Weinberg; Sonal Kumar; Carrie Down; Ype P. de Jong; Leah A. Burke; Mary C. Olson; Ira M. Jacobson
Weill Cornell Medical College, New York, NY, US

645 Effectiveness of Sofosbuvir/Simeprevir for HIV/HCV Patients in Clinical Practice
Jody Gilmore1; Kenneth Lynn3; Delisha Breen1; Stacey Trooskin3; Jihad Slim2; Nancy Scangarelo1; Alvin Kingcade2; Katie Hunyh3; Vincent Lo Re1; Jay R. Kostman1
1Perelman School of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3St Michael’s Medical Center, Newark, NJ, US; 4Philadelphia Health Management Corporation, Philadelphia, PA, US
646 German Cohort on Sofosbuvir-Based Therapy for HIV/HCV and HCV Infection (GECOSO)
Stefan Christensen1; Ingiliz Patrick1; Dietrich Hueppe2; Thomas Lutz3; Karl Georg Simon3; Knud Schewe4; Heiner Busch5; Axel Baumgarten5; Guenther Schmutz1; Stefan Mauss1
1Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 2CIM Infectious Diseases, Muenster, Germany; 3Medizinisches Infektiologie Zentrum Berlin, Berlin, Germany; 4Infektiologikum, Frankfurt, Germany; 5Infektsmedizinisches Centrum Hamburg, Hamburg, Germany; 6Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7Practice for Gastroenterology Herne, Herne, Germany

647 Real-World Data on HIV-Positive Patients With HCV Treated With Sofosbuvir and/or Simeprevir
David Del Bello1; Kian Bichoupan1; Calley Levine1; Agnes Cha1; David Perlman1; Nadim H. Salomon1; Donald Kotler1; Daniel Fierer1; Douglas Dieterich1; Andrea D. Branch1
1Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 2CIM Infectious Diseases, Muenster, Germany; 3Medizinisches Infektiologie Zentrum Berlin, Berlin, Germany; 4Infektiologikum, Frankfurt, Germany; 5Infektsmedizinisches Centrum Hamburg, Hamburg, Germany; 6Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7Practice for Gastroenterology Herne, Herne, Germany

648 Simeprevir and Sofosbuvir Regimens for Hepatitis C: Decompensation and Serious AEs
Ponni V. Perumalswami1; Kian Bichoupan1; Lawrence Ku1; Neal M. Patel1; Rachana Yadavanchil1; Thomas Schiano1; Mark Woodward1; Douglas Dieterich1; Andrea A. Branch1
1Mount Sinai Health System, New York City, NY, US; 2Brooklyn Medical Center, New York City, NY, US

649 Successful HCV Treatment With Direct Acting Antivirals in HIV/HCV Patients
Jennifer L. Grant1; Valentina Stosor2; Frank J. Palella1; Richard M. Greer1; Guajira Thomas1; Donna V. McGregor1; Milena M. McLaughlin1; Sudhir Penugonda1; Michael Angarone1; Claudia Hawkins1
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2University of Miami, Miami, FL, US

650 Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis
Alissa Nava1; Francine Guillouet de Salvador; Isabelle Perbost; Brigitte Dunais; Aline Joulié; Rodolphe Garraffo; Pascal Pugliese; Jacques Durant; Pierre Marie Roger; Eric Rosenthal
Centre Hospitalier Universitaire de Nice, Nice, France

651 Majority of HIV/HCV Patients Need to Switch ART to Accommodate Simeprevir
Rebecca Cope1; Aaron Pickering1; Thomas Glow1a; Samantha Faulds1; Peter Velkidkamp1; Ramakrishna Prasad1
1University of Pittsburgh, Pittsburgh, PA, US; 2University of Maryland, Glen Burnie, MD, US

Session P-N3 Poster Session
2:30 pm – 4:00 pm
Treatment of HCV with DAAs: Short-Term Costs and Long-Term Benefits

652 Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis
Jacob A. Langness1; David Tabano2; Sarah Tise3; Lindsay Pratt4; Lauren Ayres5; Amanda Wieland5; Sonia Lin5; Vahram Ghushchyan5; Kavita Nair6; Greg Everson1
1University of Colorado, Arvada, CO, US; 2Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, US; 3University of Colorado, Aurora, CO, US

653 SVR Durability: HCV Patients Treated With IFN-Free DAA Regimens
Aurielle M. Thomas1; Sarah Kattakuzhy2; Sarah Jones3; Anita Kohli3; Wilson Eleanor4; Angie Price4; Rachel Silk5; Zayani Sims5; Anu Osenusi5; Shyam Kottili1
1The National Institutes of Health, Bethesda, MD, US; 2Leidos Biomedical Research, Inc., Bethesda, MD, US; 3Institute of Human Virology, University of Maryland, Baltimore, MD, US

654 Five-Year Risk of Late Relapse or Reinfection With Hepatitis C After Sustained Virological Response: Meta-analysis of 49 Studies in 8534 Patients
Andrew M. Hill1; Bryony Simmons2; Jawaad Saleem2; Graham Cooke2
1Chelsea and Westminster Hospital, London, United Kingdom; 2St Mary’s Hospital – Imperial College Healthcare NHS Trust, London, United Kingdom

655 Incidence of Extrahepatic Complications in HIV/HCV Patients Who Achieved SVR
Sebastiano Leone1; Mattia Prosperi1; Silvia Costarelli1; Francesco Castelli1; Franco Maggiolo1; Simona Di Giambenedetto1; Annalisa Saracino1; Massimo Di Pietro1; Fabio Zacchi2; Andrea Gori1
1“San Gerardo Hospital”, University of Milano-Bicocca, Monza, Italy; 2University of Manchester, Manchester, United Kingdom; 3University of Brescia, Brescia, Italy; 4Ospedali Riuniti, Bergamo, Italy; 5Policlinico Gemelli, Rome, Italy; 6Policlinico di Bari, Bari, Italy; 7S.M Annunziata Hospital, Firenze, Italy; 8Istituti Ospedalieri di Cremona, Cremona, Italy

656 Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV Patients
Janet Tate1; E. John Wherry2; Jay R. Kostman3; Debika Bhattacharya4; Guadalupe Garcia-Tsao3; Cynthia Gibert3; Joseph K. Lim3; David Rimland1; Amy Justice4; Vincent Lo Re4
1VA Connecticute Health System, West Haven, CT, US; 2University of Pennsylvania, Philadelphia, PA, US; 3Atlanta VA HealthCare System, Atlanta, GA, US; 4VA Greater Los Angeles, Los Angeles, CA, US; 5Yale University School of Medicine, New Haven, CT, US; 6Washington DC VA Medical Center, Washington, DC, US

657 Portal Pressure Changes After HCV Eradication in HIV/HCV+ Patients With Cirrhosis
Matilde Sánchez-Conde; Leire Pérez-Latorre; Diego Rincón; Pilar Miralles; Maria Vega Catalina; Juan Carlos López; Rafael Bañares; Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
Session P-N5 Poster Session     Poster Hall
2:30 pm – 4:00 pm
HCV: Epidemiology and Case Detection

662  Hepatitis C and B Testing Among HIV-Infected Individuals in England
Sam Lattimore; Sarah Collins; Celia Pennman; Lukasz Cieply; Sema Mandal
Sentinel Surveillance of Blood-Borne Virus Testing
Public Health England, London, United Kingdom

WEDNESDAY, FEBRUARY 25, 2015

Session P-N6 Poster Session     Poster Hall
2:30 pm – 4:00 pm
Acute HCV Infection

669  SVR12 Results After 12w Boceprevir + P/R in the Dutch Acute Hepatitis C in HIV Study
Sebastiaan J. Hullegie; Mark A. Claassen; Guido E. van den Berk; Jan T. van der Meer; Joep E. Arends; Clemens Richter; Dirk Posthouwer; Peter P. Koopmans; Fannya N. Lauw; Bart J. Rijnders
1Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 2Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 3Academic Medical Center, Amsterdam, Netherlands; 4Maastricht University Medical Center, Maastricht, Netherlands; 5Rijnstate Ziekenhuis, Arnhem, Netherlands; 6Radboud University Medical Center, Nijmegen, Netherlands; 7Slotervaart Ziekenhuis, Amsterdam, Netherlands; 8Erasmus University Medical Center, Rotterdam, Netherlands

668  Impact of Integrating EMR HCV Testing Prompts in a Difficult to Navigate EMR System
Stephanie Tzarnas; Monique Allen; Allison Brodsky; Gregory Johnson; Lora Magaldi; Carolyn Moy; Nancy Tursi; Steven Zivich; Stacey Trooskin
1Drexel University College of Medicine, Philadelphia, PA, US; 2Drexel University College of Medicine, Philadelphia, PA, US; 3Drexel University College of Medicine, Philadelphia, PA, US

667  Evaluation of CDC Recommendations for HCV Testing in an Urban Emergency Department
Yu-Hsiang Hsieh; Richard Rothman; Oliver B. Laeyendecker; Gabor Kelen; Ama Avornu; Eshun U. Patel; Jim Kim; Risha Irvin; David L. Thomas; Thomas C. Quinn
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2National Institutes of Health (NIH), Bethesda, MD, US; 3National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 4Johns Hopkins University School of Medicine, Baltimore, MD, US

666  Low HCV Screening Uptake of the Current Birth Cohort Testing Guidelines
Alexander G. Geboy; Hyun A. Cha; Idene E. Perez; Matthew T. Bell; Sandeep Mahajan; Adesina O. Ayodele; Dawn A. Fishbein
1MedStar Health Research Institute, Hyattsville, MD, US; 2MedStar Washington Hospital Center, Washington, DC, US

665  High HCV Prevalence Among Baby Boomers in Surveillance-Identified High HIV Risk Areas
Irene Kuo; Meriam Mikre; A. Toni Young; Geoffrey Maugham; Amanda D. Castel
1George Washington University, Washington, DC, US; 2Community Education Group, Washington, DC, US

664  HCV 2k/1b Recombinant Form among Hepatitis C–Infected Genotype 2 Patients in Georgia
Marika Karchava; Jesper Waldenstrom; Monica M. Parker; Renee Hallack; Lali Sharvadze; Lana Gatserelia; Nikoloz Chkhartishvili; Nata Dvali; Helen Norder; Tengiz Tsertsvadze
1Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia; 2Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; 3Wadsworth Center, Albany, NY, US

663  WITHDRAWN
670  Does the Availability of New DAs Influence Treatment Uptake in Acute Hepatitis C in HIV Coinfection?  
Christoph Boesecke 1; Mark Nelson 1; Patrick Ingliz 2; Thomas Lutz 3; Stefan H. Scholten 3; Christoph D. Spinner 4; Michael Rausch 5; Thomas Reiberger 6; Stefan Mauss 7; Jürgen Rockstroh 1  
1Bonn University Hospital, Bonn, Germany; 2Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 3Infektiologikum, Frankfurt/Main, Germany; 4Praxis Hohenstaufenring, Cologne, Germany; 5MIB, Berlin, Germany; 6Interdisciplinary HIV Centre (IZAR), University Hospital Klinikum Rechts der Isar, Munich, Germany; 7Medical University of Vienna, Vienna, Austria; "Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; "Aetzezentrum Nollendorfplatz, Berlin, Germany

671  Long-Term Follow-Up of HIV-Positive Men Who Have Sex With Men (MSM) With Acute Hepatitis C Virus (HCV) Infection: High Rates of Treatment and Low Rates of Liver-Related Complications  
Patrick Ingliz 1; Anders C. Boyd 2; Katharina Steininger 3; Andreas Carganico 3; Stephan Duple 4; Ivanka Krznaric 1; Marcel Schuetze 1; Stefan Neifer 1; Martin J. Obermeier 1; Axel Baumgarten 1  
1Medical Center for Infectious Diseases, Berlin, Germany; 2National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

672  Hepatitis C in Men Who Have Sex With Men With New HIV Diagnoses in Los Angeles  
Kara W. Chew 1; Marjan Javanbakht 1; Laurel Clare 1; Lorelei Bornfleth 2; Debika Bhattacharya 1; Pamina Gorbach 1; Martha L. Blum 1  
1David Geffen School of Medicine at UCLA, Los Angeles, CA, US; 2UCLA Fielding School of Public Health, Los Angeles, CA, US; "Community Hospital of the Monterey Peninsula, Monterey, CA, US

673  Development and Comparison of Hepatitis C Cross-Sectional Incidence Testing Methods  
Eshan U. Patel 1; Andrea Cox 2; Shruti H. Mehta 3; Caroline E. Mullis 1; Jeffrey Quinn 1; Gregory D. Kirk 3; Thomas C. Quinn 1; Oliver B. Laeyendecker 1  
1National Institute of Allergy and Infectious Diseases (NIAID), Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of North Carolina, Chapel Hill, NC, US

674  Risk Factors for Transmission of HCV Among HIV-Infected MSM: A Case-Control Study  
Joost W. Vanhommeg 1; Femke A. Lambers 1; Andrea Cox 2; Shany N. Lauw 4; Kees Brinkman 5; Luuk Gras 6; Bart J. Rijnbergs 1; Jan T. van der Meer 7; Maria Prins 8  
1GGD Amsterdam, Amsterdam, Netherlands; 2University Medical Center Utrecht, Utrecht, Netherlands; 3Utrecht University Hospital, Amsterdam, Netherlands; 4Radboud University Medical Center, Nijmegen, Netherlands; 5Erasmus University Medical Center, Rotterdam, Netherlands; 6Academic Medical Center, Amsterdam, Netherlands

675  Behavioural and Treatment Interventions to Reduce HCV Transmissions in HIV+ MSM  
Luisa Salazar-Vizcaya 1; Roger Kouyos 2; Cindy Zahnd 1; Manuel Battegay 1; Katharine Darling 1; Alexandra Calmy 1; Pietro L. Vernazza 6; Olivia Keiser 1; Andri Rauch 1  
1On behalf of the Swiss HIV Cohort Study; 2University of Bern, Bern, Switzerland; 3University Hospital Zurich, Zurich, Switzerland; 4University Hospital Basel, Basel, Switzerland; 5Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 6Geneva University Hospitals, Geneva, Switzerland; 7Kantonsspital St Gallen, St Gallen, Switzerland; 8University Hospital Bern, Inselspital, Bern, Switzerland

676  Macrophage Activation and Hepatitis C (HCV) Disease Progression in HIV-Infected Women Participating in the Women's Interagency HIV Study (WHIS)  
Audrey L. French 1; Charlesmina Evans 2; Marion G. Peters 1; Mary A. Young 2; Mark Kuniholm 2; Michael Augenbraun 2; Seema N. Desai 1  
1CORE Center/Strayer Hospital of Cook County, Chicago, IL, US; 2University of California San Francisco, San Francisco, CA, US; "Northwestern University, Chicago, IL, US; "Georgetown University, Washington, DC, US; 3Rush University Medical Center, Chicago, IL, US; "Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US; "State University of New York Downstate, Brooklyn, NY, US

677  HIV/HCV Co-Infection Accelerated Liver Disease is Associated With Induction of M2-Like Macrophages  
Moses T. Bility 1; Feng Li 1; Junichi Nunoya 1; Guangming Li 1; Eoin Feeney 1; Raymond Chung 2; Lishan Su 1  
1University of North Carolina, Chapel Hill, NC, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

678  HIV Infection Is Associated With an Impaired Anti-HCV Activity of NK-Like T Cells  
Pavlos Kokordelis 1; Benjamin Krämer 1; Christoph Boesecke 1; Esther Voigt 1; Patrick Ingliz 2; Andreas Glässner 3; Franziska Wolter 1; Ulrich Spengler 1; Jürgen K. Rockstroh 2; Jacob Nattermann 1  
1University of Bonn, Bonn, Germany; 2Medical Center for Infectious Diseases, Berlin, Germany

679  Dys-Regulated Cross Talk Between CD4+ T Cells and NK Cells in HIV/HCV Coinfection  
Benjamin Krämer 1; Andreas Glässner 1; Claudia Zwanck 1; Felix Goese 1; Christoph Boesecke 1; Patrick Ingliz 2; Christian P. Strassburg 3; Ulrich Spengler 1; Jürgen Rockstroh 2; Jacob Nattermann 1  
1University of Bonn, Bonn, Germany; 2Medical Center for Infectious Diseases, Berlin, Germany

680  HIV/HCV Coinfection Is Associated With Significant Alterations of the NK Cell Pool  
Dominik J. Kaczmarek 1; Pavlos Kokordelis 1; Benjamin Krämer 1; Andreas Glässner 1; Franziska Wolter 1; Patrick Ingliz 2; Christian P. Strassburg 3; Ulrich Spengler 1; Jürgen Rockstroh 2; Jacob Nattermann 1  
1University of Bonn, Bonn, Germany; 2Medical Center for Infectious Diseases, Berlin, Germany
Dynamic Changes of CXCL10 Isoforms and DPP4 During IFN-Free Treatment for HCV
Eric G. Meissner1; Jeremie Decalf2; Armanda Casrouge3; Henry Masur4; Shyam Kotttili1; Darragh Duffy5; Matthew L. Albert1
1Medical University of South Carolina, Charleston, SC, US; 2Institut Pasteur, Paris, France; 3National Institutes of Health (NIH), Bethesda, MD, US; 4University of Maryland School of Medicine, Baltimore, MD, US

Mx1 and OAS1-2 SNPs Are Related With Severity of Liver Disease in HIV/HCV Coinfection
Mónica García-Álvarez1; Juan Berenguer2; Daniel Pineda-Tenorio2; Maria Ángeles Jiménez-Sousa3; Maria Guzmán-Fulgenceo4; Ana Carrero5; Teresa Aldamiz-Echevarría6; Francisca Tejerina7; Cristina Diez8; Salvador Resino9
1Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain; 2Hospital General Universitario Gregorio Marañón, Madrid, Spain

Treatment With DCV Plus ASV Reduces Immune Activation in HIV/HCV Coinfected Patients
Eleanor M. Wilson1; Anita Kohli2; Julia B. Purdy3; Louisa Howard4; Sabrina Mangat5; Gebeeyehu Teferi6; John Hogan7; Henry Masur8; Shyam Kotttili9
1National Institutes of Health (NIH), Bethesda, MD, US; 2Leidos Biomedical Research, Inc, Bethesda, MD, US

Innate Immune Activation Pathways Overlap, Yet Are Distinct in HCV and HIV Infection
Lenche Kostadinova; Benigno Rodriguez; Donald Anthony Case Western Reserve University, Cleveland, OH, US

A Novel Mechanism of Resistance to Multiple bNAbs Revealed by Natural Variation in Panel of 199 HCVpp
Ramy El-Diwany1; Lisa Wasilewski2; Madeleine Mankowski3; Stuart C. Ray4; Justin R. Bailey5
1Johns Hopkins University School of Medicine, Baltimore, MD, US

Single-Variant Sequencing Revealed Rapid HCV Evolution in HIV Immune Reconstitution
Lin Liu1; David Nardo2; Eric Li3; Gary Wang4
1University of Florida, Gainesville, FL, US
<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N9 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>Mental Health and Treatment Adherence with Direct-Antiviral Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>694</td>
<td>Impact of Baseline Mental Health on Adherence to Interferon-Free HCV Therapy</td>
<td>Jack Masur; Lydia Tang; Amy Nelson; Anu Osinusi; Anita Kohli; Rachel Silk; Chloe Gross; Sarah Kattakuzhy; Michael Polis; Shyam Kotttili</td>
<td>1University of Maryland, Baltimore, MD, US; 2National Institutes of Health, Bethesda, MD, US; 3Leidos Biomedical Research, Inc, Frederick, MD, US; 4Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 5Institute of Human Virology, University of Maryland, Baltimore, MD, US</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N10 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>HCV: Resistance to Antiviral Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>696</td>
<td>Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors</td>
<td>Jennifer Cook; Owen Solberg; Alicia Newton; Suqin Cai; Arne Frantzell; Jacqueline Reeves; Christos J Petropoulos; Jonathan Toma; Wei Huang</td>
<td>Monogram Biosciences, South San Francisco, CA, US</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N11 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>Other Hepatitis Viruses: HBV, HDV, HEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>700</td>
<td>Revaccinating HIV+ Adults With Double vs Standard HBV Regimen: ANRS B-BOOST Trial</td>
<td>David Rey; Cécile Dufour; Marie-Josée Wendling; Patrick Mialhès; Philippe Sogni; Georges Haour; Marie-Louise Michel; Lionel Pirioth; Odile Launay; Fabrice Carrat</td>
<td>1University Hospital Strasbourg, Strasbourg, France; 2Université Pierre et Marie Curie, Strasbourg, France; 3Hôpitaux Universitaires Strasbourg, Strasbourg, France; 4University Hospital of Lyon, Lyon, France; 5CIC Vaccinologie, Paris, France; 6University Hospital of Dijon, Dijon, France; 7Institut Pasteur, Paris, France; 8Cochin Hospital, Paris, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N12 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>Complex HCV Quasispecies Affects Immunogenicity in Acute Hepatitis B Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>702</td>
<td>Higher Rate of Hepatitis B Antigen and Anti-HBV Antibody Seroconversion Among HIV/Chronic Hepatitis B Coinfection Initiating HIV Active HAART From Thailand</td>
<td>Anchealee Avihingsanon; Ossip Putcharoen; Salyavit Chittmittrapap; Tanakorn Apompong; Vorapat Sapsirisavat; Sasiwimalubolym; Stephen J. Kerr; Kiat Ruxrungtham</td>
<td>On behalf of the HIV-NAT 105 Study Team</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N13 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>698</td>
<td>Compensatory Mutations in HCV NSSA/B Coevolve in Patients Failing NS3 Inhibitors</td>
<td>Velia Chiara Di Maio; Valeria Cento; Daniela Di Paolo; Sergio Babudieri; Gloria Taliani; Giustino Parruti; Giuliano Rizzardini; Mario Angelico; Carlo Federico Perno; Francesca Ceccherini-Silberstein</td>
<td>1University of Rome Tor Vergata, Rome, Italy; 2University Hospital of Rome Tor Vergata, Rome, Italy; 3University of Sassari, Sassari, Italy; 4University of Rome La Sapienza, Rome, Italy; 5Hospital Sacco of Milan, Milan, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N14 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>698</td>
<td>Compensatory Mutations in HCV NSSA/B Coevolve in Patients Failing NS3 Inhibitors</td>
<td>Velia Chiara Di Maio; Valeria Cento; Daniela Di Paolo; Sergio Babudieri; Gloria Taliani; Giustino Parruti; Giuliano Rizzardini; Mario Angelico; Carlo Federico Perno; Francesca Ceccherini-Silberstein</td>
<td>1University of Rome Tor Vergata, Rome, Italy; 2University Hospital of Rome Tor Vergata, Rome, Italy; 3University of Sassari, Sassari, Italy; 4University of Rome La Sapienza, Rome, Italy; 5Hospital Sacco of Milan, Milan, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Hall</th>
<th>Session P-N15 Poster Session</th>
<th>2:30 pm – 4:00 pm</th>
<th>HCVNS3 Variants in HIV/HCV Coinfected Patients Before-After PegIFN/Ribavirin</th>
</tr>
</thead>
<tbody>
<tr>
<td>698</td>
<td>Compensatory Mutations in HCV NSSA/B Coevolve in Patients Failing NS3 Inhibitors</td>
<td>Velia Chiara Di Maio; Valeria Cento; Daniela Di Paolo; Sergio Babudieri; Gloria Taliani; Giustino Parruti; Giuliano Rizzardini; Mario Angelico; Carlo Federico Perno; Francesca Ceccherini-Silberstein</td>
<td>1University of Rome Tor Vergata, Rome, Italy; 2University Hospital of Rome Tor Vergata, Rome, Italy; 3University of Sassari, Sassari, Italy; 4University of Rome La Sapienza, Rome, Italy; 5Hospital Sacco of Milan, Milan, Italy</td>
</tr>
</tbody>
</table>
TUESDAY, FEBRUARY 24, 2015

Session P-01 Poster Session
Poster Hall
2:30 pm – 4:00 pm

HPV Infections and Cancers

710 Factors Associated With Extensive Cervical Lesions Among HIV-Infected Women Screening for AIDS Clinical Trials Group (ACTG) Protocol A5282
Timothy J. Wilkin1; Roy Matining2; Vikrant Sahasrabuddhe3; Catherine Godfrey4; Thandie Lungu5; Mulindi Mwanahamuntu6; Ramesh Bhosale7; Scott Evans8; Robert W. Coombs5; Cynthia Finnhaber9
1Weill Cornell Medical College, New York, NY, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Cambridge, MA, US; 3Division of AIDS (DAIDS), NIAID, NIH, Bethesda, MD, US; 4University of North Carolina Project–Malawi, Lilongwe, Malawi; 5University Teaching Hospital, Lusaka, Zambia; 6Byramjee Jeejeebhoy Medical College, Pune, India; 7University of Washington, Seattle, WA, US; 8University of Witwatersand, Johannesburg, South Africa

711 HIV Infection and Survival Among Women With Cervical Cancer in Botswana
Scott Dryden-Peterson1; Memory Bvocora-Nsingo2; Heluf Medhin3; Gita Suneja4; Aida Asmelash5; Malebogo Pusoentsi6; Anthony Russell7; Jason Esfantihou8; Bruce Chabner8; Shahn Lockman9

712 Potential Cost-Effectiveness of Cervical Cancer Screening of HIV-Positive Kenyan Women
Marita Mann1; Joseph Babigumira; Louis Garrison; Michael Chung
1University of Washington, Seattle, WA, US

713 Anal High-Risk Human Papillomavirus (HPV) Infection Among HIV-Infected MSM in the SUN Study, 2004-2011
Pragna Patel1; Tim Bush2; Ema Kojic3; Lois Conley4; Elizabeth Unger5; Teresa Darragh6; Keith Henry7; John Hammer8; Nur Oner9; Joel Palefsky10
1CDC, Atlanta, GA, US; 2Brown University, Providence, RI, US; 3University of California San Francisco, San Francisco, CA, US; 4University of Minnesota, Minneapolis, MN, US; 5Denver Infectious Diseases Consultants, Denver, CO, US; 6Washington University School of Medicine, St. Louis, MO, US

714 Long-Term Effectiveness of Electrocautery Ablation of HGAIN in HIV-Infected MSM
Joaquín Burgos1; Adria Curran2; Natalia Tallada3; Ana Guelar4; Jordi Navarro5; Stefania Landolfi6; Judith Villar7; Manel Crespo8; Estève Ribera9; Vicenç Falco10
1University Hospital Vall d’Hebron, Barcelona, Spain; 2University Hospital del Mar, Barcelona, Spain

715 Survival and Treatment Trends for Squamous Cell Carcinoma of the Anus in HIV Infection
Robert A. Pitts1; Stephen Goldstone2; Keith Sigel3; Michael M. Gaisa4; Carlie Sigel5; Juan Wintsjes6

704 Occult HBV/HIV Coinfection and Validation of Cost-Effective NAT Pooling PCR
Shanmugam Saravanan1; Janardhanan Mohanakrishnan1; Thongadi Ramesh Dinesha2; Jayaseelan Boobalan2; Pachamuthu Balakrishnan2; Kailapuri G Murugavel1; Sunil S Solomon1; Suniti Solomon1; Davey M. Smith1
1YRG Centre for AIDS Research and Education, Chennai, India; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3University of California, San Diego, San Diego, CA, US

705 Invariant Natural Killer T-Cells in HIV-HEV Coinfection
Matteo Basilissi1; Camilla Tincati1; Esther Merlini1; Elisabetta Sinigaglia2; Javier Sanchez-Martinez3; Giovanni Carpani4; Antonella d’Arminio Monforte1; Laura Milazzo1; Giulia Marchetti1
1University of Milan, Milan, Italy; 2San Paolo Hospital, Milan, Italy

706 Effect of Immunosuppression and Antivirals on Intracellular HBV Replication in HIV-HEV Coinfection
Anders C. Boyd1; Karine Laccombe1; Fabien Lavocat1; Sarah Maylin1; Patrick Mailhe2; Caroline Lascoux-Combe1; Constance Delaugerre1; Pierre-Marie Girard1; Fabien Zoulim1
1Inserm UMR_S1136, Paris, France; 2Inserm U1052, Lyon, France; 2Hopital Saint-Louis AP-HP, Paris, France

707 Prevalence of HDV in a Midwestern HIV-HEV Coinfected Population
Sanam Razeghi1; Susan Rouster1; Kenneth E. Sherman
1University of Cincinnati, Cincinnati, OH, US

708LB Oral Prenylation Inhibition With Lonafarnib in Chronic Hepatitis D Infection: A Randomized, Double-Blinded, Placebo-Controlled Proof-of-Concept Study
Christopher Koh1; Laetitia Canini1; Harel Dahari1; David Cory1; Ingrid Choong1; David Kleiner1; Stewart Cooper1; Mark A. Winters1; Jeffrey Glenn1; Theo Heller1
1National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, US; 2Loyola University Medical Center, Maywood, IL, US; 3Eiger BioPharmaceuticals, San Carlos, CA, US; 4National Cancer Institute, Bethesda, MD, US; 5Stanford University, Stanford, CA, US; 6California Pacific Medical Center, Palo Alto, CA, US; 7University of Edinburgh, Edinburgh, United Kingdom

709 Incidence of Hepatitis E Virus in HIV-Infected Patients: A Longitudinal Prospective Study
Antonio Rivero-Juarez1; Loreto Martinez-Dueñas1; Antonio Martinez-Peinado1; Angela Camacho1; Celia Cifuentes1; Ana Gordon1; Mario Frias1; Julian Torre-Cisneros1; Juan A. Pineda1; Antonio Rivero1
1Instituto Maimonides de Investigación Biomédica de Córdoba, Cordoba, Spain; 2Instituto Maimonides de Investigación Biomédica de Córdoba, Cordoba, Spain; 3Hospital Universitario de Valme, Seville, Spain
716 Oral HPV Shedding and Warts After Starting Antiretroviral Therapy: ACTG Protocol A5272
Caroline H. Shiboski1; Anthony Lee2; Jennifer Webster-Cyriaque3; Huichao Chen4; Malcolm John5; Raphael J. Landovitz6; Mark Jacobson1
Oral HIV Research Alliance and the AIDS Clinical Trial Group

717 Incidence and Outcomes of HIV-Associated Lymphomas in Botswana
Michael G. Milligan1; Elizabeth Bigger1; Musimar Zola2; Mukendi Kayembe2; Heluf Medhin3; Gita Suneja4; Shahin Lockman5; Jeremy Abramson6; Bruce Chabner7; Scott Dryden-Peterson2
1Harvard Medical School, Brookline, MA, US; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4University of Utah, Salt Lake City, UT, US; 5Botsswana Ministry of Health, Gaborone, Botswana; 6Botsswana National Health Laboratory, Gaborone, Botswana; 7Princess Marina Hospital, Gaborone, Botswana

718 CHOP Is Feasible for HIV-Associated Lymphoma in the ART Era in Malawi
Satish Gopal1; Yuri Fedoriw1; Agnes Moses2; Nathan Montgomery1; Wongani Kaimila3; Coccily Kampani3; Robert Kryskiak3; Kristy Richards1; Thomas Shea1; George Liomba6
1University of North Carolina, Chapel Hill, NC, US; 2University of North Carolina Project–Malawi, Lilongwe, Malawi; 3Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; 4University of the Witwatersrand, Johannesburg, South Africa; 5Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; 6University of Bern, Bern, Switzerland

719 Chronic Hepatitis B and C Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients
Heiner C. Bucher
On behalf of the Collaboration of Observational HIV Epidemiological Research Group (COHERE) in EuroCoord
University Hospital Basel, Basel, Switzerland

720 High Mobility Group Box 1 (HMGB1) and HIV-Associated Kaposi Sarcoma in Africa
Helen Byakwaga1; Peter W. Hunt1; Miriam O. Laker-Oketta2; Albert R. Davalos3; Conrad Muzoora4; David V. Glidden4; A. Rain Mocello5; David R. Bangsberg6; Edward Mbidde7; Jeffrey N. Martin1
1Mbarara University of Science and Technology, Mbarara, Uganda; 2Infectious Diseases Institute, Kampala, Uganda; 3University of California San Francisco, San Francisco, CA, US; 4Massachusetts General Hospital, Center for Global Health, Harvard Medical School, Boston, MA, US; 5Uganda Virus Research Institute, Entebbe, Uganda; 6Buck Institute for Research on Aging, Novato, CA, US

721 The CXCL12/CXCR4-CXCR7 Pathway, a Trio Implicated in Kaposi Sarcoma Pathogenesis
Aude Desnoyer2; Francoise Gaudin2; Agnes Carlotti3; Nicolas Dupin3; Valérie Martinez-Pourcher1
1Hospital Pitie-Salpetriere, Paris, France; 2Inserm, Univ Paris-Sud, LABEX LERMIT, UMR_S996, Clamart, France; 3Dermatology, Paris, France

THURSDAY, FEBRUARY 26, 2015

722 Cancer in HIV-Infected Children: Record Linkage Study in South Africa
Julia Bohlius1; Nicky Maxwell2; Brian Eley3; Hans Prozesky4; Shobna Sawry5; Karl-Günter Technau6; Alan Davidson1; Cristina Stefan1; Matthias Egger2
On behalf of the IeDEA Southern Africa collaboration
1University of the Witwatersrand, Johannesburg, South Africa; 2University of Cape Town, Cape Town, South Africa; 3Red Cross War Memorial Children’s Hospital, Cape Town, South Africa; 4University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; 5Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa; 6University of Bern, Bern, Switzerland

723 Smoking Outweighs HIV-Related Risk Factors for Non-AIDS-Defining Cancers
Keri N. Althoff1; Stephen J. Gange2; Chad Achenbach3; Lisa P. Jacobson4; Angel M. Mayor2; Michael J. Silverberg5; Amy Justice2; Richard Moore4; Yuezhou Jing2; Kelly Gebo3
On behalf of the North American AIDS Cohort Collaboration on Research and Design
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3Universidad Central del Caribe, Bayamon, US; 4Kaiser Permanente Northern California, Oakland, CA, US; 5Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, CT, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US
727  **High Frequency of Early Lung Cancer Diagnosis With Chest CT in HIV-Infected Smokers**  
Alain Makinson1; Sabrina Eymard-Duverney2; François Raffi1; Fabrice Bonnet3; Laurence Thirard4; Pierre Tattevin5; Sophie Abgrall1; Jacques Reynes1; Vincent Le Moing1  
on behalf of the ANRS EP48 HIV CHEST Study Team  
1University Hospital Montpellier, UMI233, Montpellier, France; 2UMI 233, IRD, University Montpellier 1, Montpellier, France; 3Nantes University Hospital, Nantes, France; 4University Hospital Bordeaux, Inserm U897, Bordeaux, France; 5Tourcoing University Hospital, Tourcoing, France; 6Pontchaillou University Hospital, Rennes, France; 7University Hospital Avicenne, Bobigny, France; 8ANRS, Paris, France

728  **CD4 Measures as Predictors of Lung Cancer Risk and Prognosis in HIV Infection**  
Keith Sigel1; Kristina Crothers2; Kirsha Gordon3; Sheldon Brown4; David Rimland5; Maria Rodriguez-Barradas2; Cynthia Gibert1; Matthew B. Goetz2; Roger Bedimo1; Robert Dubrow1  
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2University of Washington School of Medicine, Seattle, WA, US; 3VA Connecticut Healthcare System and Yale University Schools of Medicine and Public Health, New Haven, CT, US; 4James J. Peters VA Medical Center, Bronx, NY, US; 5Atlanta VA Medical Center, Atlanta, GA, US; 6Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, US; 7Washington DC Veterans Affairs Medical Center, Washington, DC, US; 8Los Angeles VA Medical Center, Los Angeles, CA, US; 9Veterans Affairs North Texas Health Care System, Dallas, TX, US; 10Yale University School of Public Health, New Haven, CT, US

**TUESDAY, FEBRUARY 24, 2015**

**Session P-P1 Poster Session**  
2:30 pm – 4:00 pm  
Poster Hall

**Cardiovascular Disease Outcomes**

729  **Cardiovascular Disease Mortality Among HIV-Infected Persons, New York City, 2001—2012**  
David B. Hanna1; Chitra Ramaswamy2; Robert C. Kaplan1; Regina Zimmerman1; Sarah L. Braunstein1  
1Albert Einstein College of Medicine, Bronx, NY, US; 2New York City Department of Health and Mental Hygiene, Long Island City, NY, US

730  **Angiographic Restenosis After PTCA in HIV-Infected Patients: Incidence and Predictors**  
Dominik Pronny1; Christoph D. Spinner1; Salvatore Cassese1; Isabell Bernlochner1; Christian Bradaric1; Karl-Ludwig Laugwitz1; Adnan Kastrati2; Simon Schneider1  
1University Hospital Klinikum Rechts der Isar, Munich, Germany; 2Deutsches Herzzentrum Muenchen, Munich, Germany; 3University Hospital Klinikum Rechts der Isar, Munich, Germany

**WEDNESDAY, FEBRUARY 25, 2015**

**Session P-P2 Poster Session**  
2:30 pm – 4:00 pm  
Poster Hall

**Dyslipidemia: Mediators and Treatment**

731  **PCSK9 Is Elevated in HIV+ Patients and May Mediate HIV-Associated Dyslipidemia**  
Payal Kohli1; Peter Ganz1; Yi Fei Ma1; Rebecca Scherer1; Kristinalisa Maka1; Scott Wasserman2; Rob Scott1; Priscilla Hsu1  

732  **Enhanced, Not Inhibited Monocyte Cholesterol Efflux Characteristics Untreated HIV**  
Jane A. O’Halloran1; Therese Herlihy2; Alan Macken3; Louise Rainford1; John S. Lambert1; Gerard J. Sheehan1; Niall G. Mahon1; Leo P. Lawler1; Patrick W. Mallon2  
1University College Dublin, Dublin, Ireland; 2University College Dublin, Dublin, Ireland; 3University College Dublin, Dublin, Ireland; 4University College Dublin, Dublin, Ireland; 5University College Dublin, Dublin, Ireland

733  **Rosuvastatin vs Protease Inhibitor Switch for Hypercholesterolemia: Randomised Trial**  
Frederick J. Lee1; Polyania Monteiro1; David Baker1; Mark Bloch1; Robert Finlayson1; Richard Moore1; Norman Roth1; Jennifer F. Hoy1; Esteban Martinez1; Andrew Carr1  
1East Sydney Doctors, Sydney, Australia; 2Holdsworth House Medical Practice, Sydney, Australia; 3Hospital Clinic, University of Barcelona, Barcelona, Spain; 4Monash University/Alfred Hospital, Melbourne, Australia; 5Northside Clinic, Melbourne, Australia; 6Prahran Market Clinic, Melbourne, Australia; 7St. Vincent’s Hospital, Sydney, Australia; 8Taylor Square Private Clinic, Sydney, Australia

734  **Application of New ACC/AHA Cholesterol Guidelines to an HIV Clinical Care Cohort**  
Mosepele Mosepele1; Susan Regan1; James B. Meigs1; Steven Grinspoon1; Virginia A. Triant1  
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4Harvard School of Public Health, Boston, MA, US

**Session P-P3 Poster Session**  
2:30 pm – 4:00 pm  
Poster Hall

**ART: Cardiovascular Risk and Hypertension**

735  **ICAM-1 Overexpression Induced by Abacavir is Mediated by P2X, Receptors**  
Carmen de Pablo1; Victor Collado-Diaz1; Samuel Orden1; Cesar Rios-Navarro1; Juan Esplugues2; Angeles Alvarez1  
1University of Valencia, Valencia, Spain

736  **Changes in Platelet Function Following Abacavir Administration: A Pilot Study**  
Janine M. Trevillyan1; Elizabeth E. Gardiner1; Jane F. Arthur2; Jing Jing1; Robert K. Andrews1; Jennifer F. Hoy1  
1Monash University, Melbourne, Australia; 2Monash University, Melbourne, Australia
737  An RCT of Rilpivirine vs Efavirenz on Cardiovascular Risk in Healthy Volunteers
Samir K. Gupta1; James E. Slaven; Ziyue Liu1
1Indiana University School of Medicine, Indianapolis, IN, US; 2Indiana University, School of Medicine, Indianapolis, IN, US

738  Elvitegravir Reduces Monocyte Activation and Vasculitis Inflammation More Than Efavirenz
Corri Lynn O. Hileman1; Bruce Kinley1; Valeska Scharen-Guivel1; Kathy Melbourne1; Javier Szwarcbarg1; Janet Robinson1; Michael M Lederman1; Grace A. McComsey1
1Case Western Reserve University, Cleveland, OH, US; 2Gilead Sciences, Inc., Foster City, CA, US

739  Impact of Antiretroviral Drugs on Hypertension in HIV-Positive Persons: D:A:D Study
Camilla L. Hatleberg1; Lene Ryom1; Antonella d’Arminio Monforte2; Eric Fontas1; Peter Reiss1; Ole Kirk1; Wafaa M. El-Sadr5; Stéphane De Wit4; Jens D. Lundgren1; Caroline Sabin1
On behalf of the D:A:D Study group
1Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2San Paolo University Hospital, Milan, Italy; 3Nice University Hospital, Nice, France; 4Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 5Division of Nephrology, Mount Sinai School of Medicine, New York, New York, NY, US; 6Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 7Nephrology department, Public Health department, CHU Nice, Nice, France; 8University College London, London, United Kingdom; 9University of Bordeaux, INSERM U 897, CHU de Bordeaux, Bordeaux, France

740  Population-Based Assessment of Hypertension Among HIV Patients in Rural Uganda
Dalsone Kwarisiima1; Prashant Kotwani1; Norton Sang1; Florence Mwangva1; Vivek Jain1; Dathan Byonanebye2; James Ayiekoh1; Laura Balzer2; Diane Havlir3; Moses R. Kamya3
1Makerere University Joint AIDS Program, Kampala, Uganda; 2Infectious Disease Research Collaboration, Kampala, Uganda; 3University of California San Francisco, San Francisco, CA, US; 4Research Care Training Program, Kenya Medical Research Institute, Nairobi, Kenya; 5University of California San Francisco, San Francisco, CA, US; 6Makerere University College of Health Sciences, Kampala, Uganda

TUESDAY, FEBRUARY 24, 2015

Session P-P4 Poster Session
2:30 pm – 4:00 pm
What Predicts Risk for CVD in HIV?

741  CD4/CD8 Ratio, Age, and Serious Noninfectious Outcomes in HIV-Infected Adults
Jessica L. Castilho1; Megan Turner; Sally Bebawy; Bryan E. Shepherd; Timothy Sterling
Vanderbilt University School of Medicine, Nashville, TN, US

742  Relationship Between Confirmed eGFR and Cardiovascular Disease in HIV-Positive Persons
Lene Ryom1; Jens D. Lundgren; Peter Reiss; Michael Ross; Christoph Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Caroline Sabin; Amanda McComsey
On behalf of the D:A:D Study Group
1CHIP, Department of Infectious Diseases and Rheumatology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; 2Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; 3Division of Nephrology, Mount Sinai School of Medicine, New York, New York, NY, US; 4Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland; 7Nephrology department, Public Health department, CHU Nice, Nice, France; 8University College London, London, United Kingdom; 9University of Bordeaux, INSERM U 897, CHU de Bordeaux, Bordeaux, France

743  Smoking, Other Substance Use and Coronary Atherosclerosis Among HIV-Infected and Uninfected Men
Sean G. Kelly1; Michael Plankey1; Wendy Post2; Xiuhong Li; Ron Stall3; Lisa P. Jacobson1; Mallory Witt1; Lawrence Kingsley3; Christopher Cox2; Frank J. Palella1
1Northwestern University, Chicago, IL, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Georgetown University, Washington, DC, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5University of California Los Angeles, Los Angeles, CA, US

744  Pericardial Fat Density: A Novel Marker of Cardiometabolic Risk in HIV Infection
Chris T. Longenecker1; Mark Schluter; Yiyong Liu; Grace A. McComsey1
Case Western Reserve University, Cleveland, OH, US

745  The Effect of Physical Activity on Cardiometabolic Health and Inflammation in HIV
Saheera Dirajal-Fargo1; Allison R. Webel1; Bruce Kinley1; Danielle Labbato1; Ying Jiang1; Sara M. Debanne1; Grace A. McComsey1
1Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, US; 2Frances Payne Bolton School of Nursing Case Western Reserve University, Cleveland, OH, US; 3University Hospitals Case Medical Center, Cleveland, OH, US; 4Case Western Reserve University, Cleveland, OH, US

WEDNESDAY, FEBRUARY 25, 2015

Session P-P5 Poster Session
2:30 pm – 4:00 pm
Cardiovascular Risk Prediction

746  Cumulative HIV Care Measures Highly Associated With Acute Myocardial Infarction
Jorge L. Salinas1; Christopher T. Rentsch1; Vincent C. Marconi1; Janet Tate1; Adeel A. Butt2; Matthew S. Freiberg; Matthew B. Goetz3; Maria Rodriguez-Barradas4; Amy Justice1; David Rimland1
1Emory University, Atlanta, GA, US; 2Atlanta VA Hospital, Decatur, GA, US; 3Yale University, New Haven, CT, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US; 6Baylor College of Medicine, Houston, TX, US
747 Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS)
Angela M. Thompson-Paul; Kenneth A. Lichtenstein; Carl Armon; Kate Buchacz; Rachel Debes; Joan S. Chmiel; Frank J. Palella; Stanley C. Weil; Jacke Skarbinski; John T. Brooks
1US Centers for Disease Control and Prevention, Atlanta, GA, US; 2National Jewish Health, Denver, CO, US; 3Cerner Corporation, Vienna, VA, US; 4Northwestern University, Feinberg School of Medicine, Chicago, IL, US

748 Incidence and Risk of Myocardial Infarction (MI) by Type in the NA-ACCORD
Daniel R. Droz; Mari M. Kitahata; Keri N. Althoff; Jinbing Zhang; Susan R. Heckbert; Matthew J. Budoff; Frank J. Palella; Daniel B. Klein; Richard D. Moore; Heidi M. Crane

749LB Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD
Frank J. Palella; Keri N. Althoff; Richard Moore; Jinbing Zhang; Mari Kitahata; Stephen J. Gange; Heidi M. Crane; Daniel R. Drozd; John T. Brooks; Richard Eliot

750 HIV-Infected Veterans and the New ACC/AHA Cholesterol Guidelines: Got Statins?
Meredith E. Clement; Lawrence Park; Ann Marie Navar-Boggan; Nwora O. Oker; Michael Pancina; Pamela Douglas; Susan Naggie
1Duke University, Durham, NC, US; 2Duke University, Durham, NC, US; 3Duke University, Durham, NC, US

751 Evaluation of the ACC/AHA CVD Risk Prediction Algorithm Among HIV-Infected Patients
Susan Regan; James B. Meigs; Joseph Massaro; Ralph B. D'Agostino; Steven Grinspoon; Virginia A. Triant
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Boston University, Boston, MA, US; 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

TUESDAY, FEBRUARY 24, 2015

Session P-P6 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Biomarkers and Atherosclerosis

752 IL-6 and CD8 Senescence Independently Associate With Atherosclerosis in Treated HIV
Denise C. Hsu; Zhonghi Hu; Courtney Carroll; Kristinлица Maka; Adam Rupert; Steven Deeks; S. C. Kalaputs; Priscilla Hse; Irini Sereti
1National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2University of California San Francisco, San Francisco, CA, US; 3Leidos Biomedical Research, Inc, Frederick, MD, US

753 sCD163 Correlates With IMT and Macrophages in Aorta and Heart With HIV Infection
Joshua A. Walker; Graham A. Beck; Andrew D. Miller; Tricia H. Burdo; Kenneth C. Williams
1Boston College, Chestnut Hill, MA, US; 2Cornell University, Ithaca, NY, US

754 Non-Classical Monocytes Predict Progression of Carotid Intima-Media Thickness
Dominic C. Chow; Jamie M. Kagihara; Guangxiang G. Zhang; Scott A. Souza; Brooks I. Mitchell; Beau K. Nakamoto; Kalpana J. Kallianpur; Robert J. Matyas; Lishomwa C. Ndihlovu; Cecilia M. Shikuma
1University of Hawaii, Honolulu, HI, US; 2Kaiser Permanente, Honolulu, HI, US

755 TMAO and HIV-Associated Atherosclerosis
Arjun Sinha; Yifei Ma; Rebecca Scherer; Courtney Carroll; Steven Deeks; Peter Ganz; Priscilla Hse
1San Francisco General Hospital, San Francisco, CA, US; 2San Francisco VA Medical Center, San Francisco, CA, US; 3University of California San Francisco, San Francisco, CA, US

756 Impaired Cardiac Strain and Biomarkers of Immune Activation in HIV
Colleen Hadigan; Julia Purdy; Diana Thiara; Louisa Howard; Chia-Ying Liu; Fabio Raman; Sabrina Mangat; Christopher Sibley; David Bluemke
1National Institutes of Health (NIH), Bethesda, MD, US; 2Oregon Health and Sciences University, Portland, OR, US

Session P-P7 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Endothelial Functions and Cerebral Vasoreactivity

757 Role of Angiopoietin 1, Angiopoietin 2, and Endothelial Function in HIV
Mark L. Dela Cruz; Yifei Ma; Rebecca Scherer; Alan Wu; Kristinлицa Maka; Steven Deeks; Peter Ganz; Priscilla Hse

758 HIV-Infected Persons With Type 2 Diabetes Have Evidence of Endothelial Dysfunction
Malene Hove; Julie C. Gaardb; Hedda Hoel; Lillian Kolte; Allan Vaag; Jan Gerstoft; Henrik Ullum; Marius Troseid; Susanne D. Poulsen
1Righospitalet, University Hospital of Copenhagen, Copenhagen, Denmark; 2Hvidovre Hospital, University Hospital of Copenhagen, Hvidovre, Denmark; 3Oslo University Hospital, Ullevål, Norway

759 Unique Circulating MicroRNA Profiles and Endothelial Function in HIV Infection
Venkata A. Narla; Nirav Bhakta; Jane E. Freedman; Kaharman Tanriverdi; Kristinлица Maka; Steven Deeks; Peter Ganz; Priscilla Hse
1San Francisco General Hospital, University of California San Francisco, San Francisco, CA, US; 2University of California San Francisco, San Francisco, CA, US; 3University of Massachusetts Medical School, Worcester, MA, US
760  Cerebral Vasoreactivity Is Impaired in Virally Suppressed HIV-Infected Individuals
Felicia C. Chow1; Claire Mills3; Nerissa Ko1; Courtney Carroll1; Richard Price1; Steven Deeks1; Farzaneh A. Sorond2; Priscilla Y. Hsue1
1University of California San Francisco, San Francisco, CA, US; 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

Session P-Q1 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Inflammation: Biomarkers and Relationship to Outcomes

761  IL-6 Is a Stronger Predictor of Clinical Events Than hsCRP or D-Dimer in HIV Disease
Álvaro H. Borges1; Jemma L. O’Connor3; Andrew N. Phillips2; James D. Neaton1; Birgit Grund4; Jacqueline Neuhaus1; Michael Vjecha1; Alexandra Calmy5; Kersten K. Koelsch6; Jens D. Lundgren7
INSIGHT SMART and ESPRIT Study Groups
1Righshospitalet, University of Copenhagen, Copenhagen, Denmark; 2University College London, London, United Kingdom; 3University of Minnesota, Minneapolis, MN, US; 4University of Minnesota, Minneapolis, MN, US; 5Geneva University Hospitals, Geneva, Switzerland; 6University of New South Wales, Sydney, Australia; 7Veterans Affairs Medical Center, Washington, DC, US

762  Persistent Inflammation on ART Is Associated With Poor Nutritional Recovery in Zambia
George Praygod1; Meridith Blevins1; Susannah Woodd1; Andrea Rehan1; Jeremiah Kidola1; Henrik Friis2; Paul Kelly1; Douglas Heimburer1; Suzanne Filteau1; John Koethe1
1Vanderbilt University, Nashville, TN, US; 2National Institute of Medical Research, Mwanza, United Republic of Tanzania; 3University of Hygiene & Tropical Medicine, London, United Kingdom; 4University of Copenhagen, Copenhagen, Denmark; 5University Teaching Hospital, Lusaka, Zambia

763  Smoking and Obesity May Partially Explain the Inflammation and Morbidity Association
Supriya Krishnan1; Ronald Bosch2; Benigno Rodriguez3; Peter W. Hunt2; Cara C. Wilson3; Steven Deeks1; Michael M Lederman2; Alan Landay1; Carey Lumeng1; Allan Tenorio1
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 2Division of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, US; 3Positive Health Program, Dept of Medicine, San Francisco General Hospital, San Francisco, CA, US; 4Division of Infectious Diseases, Univ of Colorado Hospital, Aurora, CO, US; 5Department of Immunology and Microbiology, Rush Univ Medical Center, Chicago, IL, US; 6Univ of Michigan Medical School, Department of Pediatrics, Ann Arbor, MI, US; 7Department of Medicine, Rush University Medical Center, Chicago, IL, US

764  Infectious and Noninfectious Multimorbidity Among HIV Clinic Clients in the African Cohort Study
Julie Ake1; Jonah Maswai3; Francis Kiwewa5; Lucas Maganga2; Milton Omendi1; Babajide Keshinro4; Lindsay Hughes1; Victor G. Valcour7; Christina Polya1
RV 329 AFRICOS Study Team
1US Military HIV Research Program, Bethesda, MD, US; 2KEMRI/Walter Reed Project, Kericho, Kenya; 3Makerere University Walter Reed Project, Kampala, Uganda; 4Mbeya Medical Research Centre, Mbeya, United Republic of Tanzania; 5KEMRI/Walter Reed Project, Kisumu, Kenya; 6Walter Reed Program – Nigeria, Abuja, Nigeria; 7University of California San Francisco (UCSF), San Francisco, CA, US

Session P-Q2 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Bone Metabolism and ART: Mechanisms and Outcomes

765  Bone Metabolism and Tenofovir: Evidence of Direct Effect on Calcium-Sensing Receptor
Paolo Bonfanti1; Caterina Brasacchio2; Chiara Molteni1; Barbara Menzagli3; Laura Soldati4; Tiziana Quirino1; Stefano Mora1
1Busto Arziso Hospital, Busto Arziso, Italy; 2A. Manzoni Lecco Hospital, Lecco, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4San Raffaele Scientific Institute, Milan, Italy

766  Bone Turnover on DRV/r + Either RAL or TDF/FTC as First-Line ART: NEAT 001 / ANRS 143
Jose I Bernardino1; Amanda Mocroft2; Laura Richert1; Abdel Babiker6; Antonio Buño1; Antonella Castagna4; Pierre-Marie Girard1; Genevieve Chene1; Jose R Arribas2; François Raffi1
1Hospital Universitario La Paz. IdiPAZ, Madrid, Spain; 2University College London, London, United Kingdom; 3University of Bordeaux, Bordeaux, France; 4MRC Clinical Trials Unit at University College London, London, United Kingdom; 5San Raffaele Scientific Institute, Milan, Italy; 6Hospital St Antoine and Inserm, Paris, France; 7Université Nantes, Nantes, France

767  Tenofovir Replacement in Patients With Osteoporosis Increased Sclerostin Levels
Eugenia NEGREDO1; Adolfo Diez-Perez2; Pere Domingo3; Nuria Perez-Alvarez1; Mar Gutierrez1; Gracia Mateos1; Jordi Puig1; Patricia Echeverria1; Anna Bonjoch1; Bonaventura Clotet1
1Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autonna de Barcelona, Barcelona, Spain; 2Hospital del Mar-IMIM, Universitat Autonna de Barcelona and RETICEF, Instituto Carlos III Madrid, Barcelona, Spain; 3Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autonna de Barcelona, Universitat de Vic—Universitat Central de Catalunya, Barcelona, Spain; 4Santa Creu i Sant Pau Hospital, Universitat Autonna de Barcelona, Barcelona, Spain; 5Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autonna de Barcelona, Llister Institute Foundation, Germans Trias i Pujol University Hospital, Barcelona, Spain; 6Lluita Contra la Sida Foundation, Germans Trias i Pujol University Hospital, Universitat Autonna de Barcelona, Statistics and Operations Research Department, Universitat Politècnica de Catalunya, Barcelona, Spain
768  Relationship Between Phosphate Reabsorption, Age, Tenofovir and Bone Mineral Density
Lisa Hamzah; Amanda Samarakwickrama; Karen Walker-Bone; Yvonne Gilleece; Martin Fisher; Frank A. Post
1Brighton and Sussex Medical School, London, United Kingdom; 2King's College London, London, United Kingdom; 3University of Southhampton, Southampton, United Kingdom; 4Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 5King's College Hospital NHS Foundation Trust, London, United Kingdom

769LB Less Bone Loss With a Maraviroc Regimen in HIV-Infected Treatment-Naïve Subjects
Babafemi Taiwo; Ellen Chan; Carl Fichtenbaum; Heather Ribaudo; Athe Tsibris; Karin Klingman; Joseph J. Eron; Baiba Berzins; Todd T. Brown
ACTG A5303 Study Team
1Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 2Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA, US; 3University of Cincinnati, Cincinnati, OH, US; 4Bingham and Women's Hospital, Harvard Medical School, Boston, MA, US; 5National Institutes of Health, Bethesda, MD, US; 6University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 7Johns Hopkins University School of Medicine, Baltimore, MD, US

Session P-Q3 Poster Session  Poster Hall
2:30 pm – 4:00 pm  Bone Disease: Mechanisms of Bone Loss and Fracture Risk

770  Association of Adipokines With Bone Mineral Density in HIV+ and HIV- Women
Anjali Sharma; Yiifei Ma; Rebecca Scherzer; Amber L. Wheeler; Mardge Cohen; Deborah Gustafson; Michael T Yin
1Albert Einstein College of Medicine, Bronx, NY, US; 2University of California San Francisco, San Francisco, CA, US; 3John H. Stroger Jr. Hospital of Cook County, Chicago, IL, US; 4State University of New York Downstate Medical Center, Brooklyn, NY, US; 5College of Physicians and Surgeons, Columbia University, New York, NY, US

771  Long-Term Changes in Bone Mineral Density and Insulin Resistance on Statins in HIV
Kristine M. Erlandson; Ying Jiang; Sara M. Debanne; Grace A. McComsey
1University of Colorado, Aurora, CO, US; 2Case Western Reserve University, Cleveland, OH, US

772  Immunologic Predictors of Bone Loss in a Contemporary HIV Cohort
Edgar T. Overton; Katherine H. Hullsiek; Gerome Escota; Kenneth A. Lichtenstein; Lois Conley; Pragana Patel; John T. Brooks; Irini Sereti; Jason V. Baker
the CDC SUN (Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy) Investigators
1University of Alabama at Birmingham, Birmingham, AL, US; 2University of Minnesota, Minneapolis, MN, US; 3Washington University School of Medicine, St. Louis, MO, US; 4National Jewish Health, Denver, CO, US; 5Division of HIV/AIDS Prevention, Atlanta, GA, US; 6National Institute of Allergy and Infectious Disease (NIAID), Bethesda, MD, US

773  RANKL Predicts 96-Week BMD Changes in ATV/r Monotherapy: A MODAt Trial Sub-Study
Vincenzo Spagnuolo; Marco Borderi; Giuseppina Musumeci; Laura Galli; Camilla Tincati; Stefano Rusconi; Giovanni Guaraldi; Alba Bigoloni; Adriano Lazarini; Antonella Castagna
1San Raffaele Scientific Institute, Milan, Italy; 2Aldo Mater Studiorum University of Bologna, Bologna, Italy; 3University of Milan, Milan, Italy; 4University of Modena and Reggio Emilia, Modena, Italy

774  Predictors of Longitudinal Change in Bone Mineral Density in a Cohort of HIV Positive and Negative Subjects
Willard Tinagco; Aoife Cotter; Caroline Sabin; Alan Macken; Eoin Kavanagh; Jennifer Brady; Geraldine McCarthy; Juliet Compston; Patrick W. Mallon
HIV UPBEAT Study Group
1University College Dublin, Dublin, Ireland; 2Research Department of Infection and Paululation Health, London, United Kingdom; 3Mater Misericordiae University Hospital, Dublin, Ireland; 4Mater Misericordiae University Hospital, Dublin, Ireland; 5Mater Misericordiae University Hospital, Dublin, Ireland; 6University of Cambridge, London, United Kingdom

775  Fracture Incidence Is Increased in Aging HIV-Infected Women
Anjali Sharma; Qiuju Shi; Donald R. Hoover; Kathryn Anastas; Phyllis C. Tien; Mary A. Young; Mardge Cohen; Deborah Gustafson; Michael T Yin

Session P-Q4 Poster Session  Poster Hall
2:30 pm – 4:00 pm  Measuring Bone Density

776  Heel Quantitative Ultrasound to Cut Down on DXA Costs in HIV-infected Patients
Marilia R. Pinzone; Maria Gussio; Daniela Canestrino; Adriana Di Gregorio; Benedetto M. Celesia; Bruno Capocaccia; Giuseppe Nuninari
1St. Michael's Hospital, Toronto, Canada; 2Toronto General Research Institute, Toronto, Canada; 3University Health Network, Toronto, Canada; 4Centre for Excellence in Skeletal Health Assessment, Toronto, Canada

777  Novel Radiographic Measures HRpQCT and HSA as Correlates of HIV-Associated Fractures
Darrell H. Tan; Janet Raboud; Leah Szadkowski; Eva Szabo; Hanxian Hu; Queenie Wong; Angela Cheung; Sharon Walsmsley
1St. Michael's Hospital, Toronto, Canada; 2Toronto General Research Institute, Toronto, Canada; 3University Health Network, Toronto, Canada; 4Centre for Excellence in Skeletal Health Assessment, Toronto, Canada
WEDNESDAY, FEBRUARY 25, 2015

Session P-Q5 Poster Session
2:30 pm – 4:00 pm
Fat Without Borders: Metabolic Complications in Resource-Limited Settings

778 Obesity and Inflammation in Resource-Diverse Settings of ART Initiation
Kristine M. Erlandson1; Nikhil Gupta2; Javier R. Lama3; Patcharaphan Sugandhavesa4; Thando Mwelase5; Ashwin Balagopalan6; David Asmuth7; Thomas B. Campbell1; Amrita Gupta2
On behalf of the AST75 and NWCS319 study team
1University of Colorado, Aurora, CO, US; 2Johns Hopkins University, Baltimore, MD, US; 3University of New Mexico, Albuquerque, NM, US; 4University of the Witwatersrand, Johannesburg, South Africa; 5University of California Davis, Sacramento, CA, US

779 Body Composition Outcomes at 96 Weeks in the SECOND-LINE RCT DXA Substudy
Mark A. Boyd1; Janaki Amin2; Patrick W. Mallon3; Jennifer F. Hoy1; Samuel Ferret; Waido Belloso4; Praphan Phanuphak5; Sean Emery1; David A. Cooper1
SECOND-LINE study group
1University of New South Wales Australia, Sydney, Australia; 2University College Dublin, Dublin, Ireland; 3Monash University/Alfred Hospital, Melbourne, Australia; 4Hospital Italiano, Buenos Aires, Argentina; 5Tha Red Cross AIDS Research Centre, Bangkok, Thailand

780 Bone Quality by Quantitative Ultrasound at the Radius Does Not Differ in ART-Naive HIV+ and HIV- Rwandan Women
Eugene Mutimura1; Qiuhu Shi2; Donald R. Hoover2; Kathryn Anastos3; Emmanual Rudakemwa4; Jean Claude Dusingize2; Jean D’Amour5; Sinayobye1; Michael T. Yin4
1Regional Alliance for Sustainable Development, Kigali, Rwanda; 2School of Health Sciences and Practice, New York Medical College, New York, NY, US; 3State University of New Jersey, New Brunswick, NJ, US; 4Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, US; 5FMSB/University Y aounde 1, Y aounde, Cameroon

781 Predictors and Outcomes of Incident High Cholesterol in Adults on ART in South Africa
Denise Evans1; Alana T. Brennan2; Faith Moyo3; David Spencer4; Kay Mahomed3; Mhairi Maskew5; Lawrence Long1; Sydney Rosen1; Matt P. Fox2
1University of the Witwatersrand, Johannesburg, South Africa; 2Boston University, Boston, MA, US; 3Hight to Care, Johannesburg, South Africa

782 Metabolic Changes and Second-Line ART in Africa (2LADY/ANRS 12169 Trial)
Amandine Cournil1; Assane Diouf2; Sabrina Eymard-Duvernay3; Adrien Sawadogo; Liliane Ayangma; Louise Fortes-Deguenonvo1; Jean-Marc Mben2; Eric Delaporte3; Laura Ciaffi4; Sinata Koulla-Shiro5
1IRD/UM 1, Montpellier, France; 2CHU Souro Sanou, Bobo Dioulasso, Burkina Faso; 3CRCF, Dakar, Senegal; 4Yaounde Military Hospital, Yaounde, Cameroon; 5FMSB/University Yaounde 1, Yaounde, Cameroon; 6ANRS Research Center, Yaounde, Cameroon

TUESDAY, FEBRUARY 24, 2015

Session P-Q6 Poster Session
2:30 pm – 4:00 pm

783 Novel Mechanisms of Nucleoside Analog Associated Mitochondrial DNA Mutation
Kristian Gardner; Patrick F. Chinnery; Brendan A. Payne
Newcastle University, Newcastle-upon-Tyne, United Kingdom

784 Balance Confidence Predicts Falls Better Than Physical Function Testing in HIV+ Men
Todd T. Brown1; Xiuhong Li2; Lisa P. Jacobson2; Jennifer Schrack2; Frank J. Palella1; Lawrence Kingsley3; Joseph B. Margolick1; Adrian Dobs4; Jordan Lake4; Keri N. Althoff5
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3University of Alabama at Birmingham, Birmingham, AL, US; 4University of Pennsylvania, Philadelphia, PA, US; 5University of California Davis, Sacramento, CA, US

785 Aging: Frailty, Telomeres, and mtDNA
Todd T. Brown1; Abimereki D. Muzaale2; Shruti H. Mehta3; Ryan P. Westergaard2; Todd T. Brown1; Kusang V. Patel4; Sean X. Leng5; Gregory D. Kirk1
1Johns Hopkins University, Baltimore, MD, US; 2University of Wisconsin, Madison, WI, US; 3University of Washington, Seattle, WA, US

Session P-Q7 Poster Session
2:30 pm – 4:00 pm
Diabetes and Other Endocrine Disorders

787 Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation
Todd T. Brown1; Ellen Chan2; Edgar T. Overton3; Pablo Tebas4; Kathy Melbourne5; Royce Hardin; Heather Ribaudo; Michael T. Yin7
ACTG
788 First-Line NRTIs and Risk of New Onset Diabetes in HIV-Infected Adults in Thailand  
Prakit Riyaten¹; Nicolas Salvadori¹; Patrimee Traisathit¹; Nicole Ngo-Giang-Huong¹; Rapeepan Suaysod²; Guttiga Halve¹; Naruepon Yutthakasemsunt¹; Apichat Chutanunta¹; Jacqueline Capeau⁵; Gonzague Jourdain²  
¹Chiang Mai University, Chiang Mai, Thailand; ²Institut de Recherche pour le Développement UMI 174-PHPT, Chiang Mai, Thailand; ³Phayao Provincial Hospital, Phayao, Thailand; ⁴Nong Khai Hospital, Nong Khai, Thailand; ⁵Samutsakhon Hospital, Samutsakhon, Thailand; ⁶Sorbonne University, Paris, France

789 Diabetes Mellitus Among HIV-Infected Adults in Care in the United States, 2009–2010  
Alfonso C. Hernandez-Romieu  
Emory University Rollins School of Public Health, Decatur, GA, US

790 Functional Vitamin D Deficiency With Initiation of Tenofovir-Based ART?  
Evelyn Hsieh¹; Liana Frankel¹; Weibo Xia¹; Yang Han¹; Michael T Yin¹; Karl Insogna¹; Ting Zhu¹; Taisheng Li²  
¹Yale University School of Medicine, New Haven, CT, US; ²Peking Union Medical College Hospital, Beijing, China; ³Columbia University Medical Center, New York, NY, US; ⁴Yale University School of Medicine, New Haven, CT, US

791 Determinants of Parathyroid Hormone Levels in HIV-positive Tenofovir-treated Patients with Normal Renal Function  
Letizia Marinaro, Andrea Calcagno; Jessica Cusato; Elisabetta Scarvaglieri; Marco Simiele; Maria Cristina Tettoni; Laura Trentini; Antonio D’Avolio; Giovanni Di Perri; Stefano Bonora  
Unit of Infectious Diseases, Turin, Italy

THURSDAY, FEBRUARY 26, 2015

Session P-Q8 Poster Session  
2:30 pm – 4:00 pm

Renal Dysfunction: ART and Biomarkers

792 Elevated Tenofovir Exposure via Intensive PK Monitoring Is Associated With Progressive Kidney Function Decline  
Sanjiv M. Baxi¹; Rebecca Scherer¹; Ruth M. Greenblatt¹; Howard Minkoff¹; Kathryn Anastos¹; Mardge H. Cohen¹; Mary A. Young¹; Monica Gandhi¹; Michael G. Shlipak¹  
¹University of California San Francisco, San Francisco, CA, US; ²State University of New York Downstate Medical Center, Brooklyn, NY, US; ³Georgetown University, Washington, DC, US; ⁴John Stroger (formerly Cook County) Hospital, Chicago, IL, US; ⁵Montefiore Medical Center, University Hospital for Albert Einstein College of Medicine, Bronx, NY, US

793 Impact of TDF + PI/r on Renal Function in Sub-Saharan Africa: 2LADY/ANRS 12169 Trial  
Arsene Hema¹; Amandaine Couriël¹; Laura Ciaffi¹; Sabrina Eymard-Duverney¹; Assane Diouf¹; Nestor Marga³; Vincent Le Moing¹; Jacques Reyes²; Sinata Koula-Shiro¹; Eric Delaporte²  
¹CHU Sourou Sanou, Bobo Dioulasso, Burkina Faso; ²IRD/UM 1, Montpellier, France; ³Le Centre Régional de Recherche et de Formation à la Prise en Charge Clinique de Fann, Dakar, Senegal; ⁴Yaounde Military Hospital, Yaounde, Cameroon; ⁵FMSB/University Yaounde 1, Yaounde, Cameroon

794 Renal Tubular Disease and the Relationship With Tenofovir and Atazanavir Exposure  
Lisa Hamzah¹; John Booth¹; Catherine Horsfield¹; Rachael Jones¹; Jeremy Levy¹; Deborah Williams; Nadia Khattib¹; Rachel Hilton¹; John Connolly¹; Frank A. Post¹  
¹King’s College London, London, United Kingdom; ²University College London, London, United Kingdom; ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; ⁴Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; ⁵Imperial College London, London, United Kingdom; ⁶Brighton and Sussex Hospitals NHS Trust, London, United Kingdom; ⁷Heart of England NHS Foundation Trust, Birmingham, United Kingdom; ⁸King’s College Hospital NHS Foundation Trust, London, United Kingdom

795 Safety of Tenofovir Alafenamide in Renal Impairment  
Anton Pozniak¹; Jose R Arribas¹; Samir K. Gupta¹; Frank A. Post¹; Anchalee Avihingsanon¹; Gordon Crofoot¹; Kenneth A. Lichtenstein¹; Moti Ramgopal¹; Ploenchan Chetchotisakd¹; Marshall W. Fordye¹  
¹Gilead Sciences Inc, Foster City, CA, US; ²Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; ³Hospital Universitario La Paz, Madrid, Spain; ⁴Indiana University School of Medicine, Indianapolis, IN, US; ⁵King’s College Hospital NHS Foundation Trust, London, United Kingdom; ⁶HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ⁷Crofoot Research, Houston, TX, US; ⁸National Jewish Health, Denver, CO, US; ⁹Midway Research Center, Ft. Pierce, FL, US; ¹⁰Khon Kaen University, Khon Kaen, Thailand

796 Elevated Nonclassical Monocytes and Urinary Fibrotic Markers in HIV Albuminuria  
Brooks I. Mitchell¹; Mary Margeret Byron; Roland C. Ng; Dominic C. Chow; Pichaya O-charoen; Lishomwa C. Ndhlovu; Cecilia M. Shikuma  
¹University of Hawaii, Honolulu, HI, US

797 Kidney Dysfunction and Markers of Inflammation in the Multicenter AIDS Cohort Study  
Alison G. Abraham¹; Annie Darlay¹; Heather McKay¹; Joseph B. Margolick¹; Michelle M. Estrella³; Frank J. Palella⁴; Robert Bolan⁵; Charles R. Rinaldo⁶; Lisa P. Jacobson¹  
¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; ²AstraZeneca, Gaithersburg, MD, US; ³Yale University School of Medicine, Baltimore, MD, US; ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, US; ⁵Los Angeles LGBT Center, Los Angeles, CA, US; ⁶University of Pittsburgh, Pittsburgh, PA, US
Program and Agenda

Poster Listings

Session P-Q9 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Renal Transplantation: Long-Term Outcomes

798  Risk Factors for Acute Allograft Rejection in HIV Positive Kidney Transplant Recipients
Esther N. Gathogo; Mark Harber; Sanjay R. Bhagani; Joanne Baxter; Vincent Lee; Jeremy Levy; Rachael Jones; Rachel Hilton; Graham Davies; Frank A. Post
1King’s College London, London, United Kingdom; 2Royal Free London NHS Foundation Trust, London, United Kingdom; 3North Manchester General Hospital, Manchester, United Kingdom; 4Central Manchester University Hospitals, Manchester, United Kingdom; 5Imperial College Healthcare NHS Trust, London, United Kingdom; 6Chelsea and Westminster Hospital, NHS Foundation Trust, London, United Kingdom; 7Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

799  Survival in HIV-Positive Transplant Recipients Compared to Matched Registry Controls
Michelle E. Roland; Burc Barin; Shirish Huprikar; Michael Wong; Emily Blumberg; David Simon; Margaret Ragni; Don Stablein; Peter Stock
1HIV-TR Study Team
1University of California San Francisco, San Francisco, CA, US; 2EMMES Corporation, Rockville, MD, US; 3Mount Sinai School of Medicine, New York, NY, US; 4Beth Israel Deaconess Medical Center, Boston, MA, US; 5University of Pennsylvania, Philadelphia, PA, US; 6Rush University Medical Center, Chicago, IL, US; 7University of Pittsburgh, Pittsburgh, PA, US

Session P-Q10 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Pulmonary Disease

800  Risk Factors for Airflow Obstruction Among HIV+ Individuals in Nairobi, Kenya
Engi F. Attia; Elizabeth Maleche-Obimbo; Nelly Yatich; Lillian Nduke; Julia Njoroge; Sameh Sakr; Neveen El Antouney; Fr. Mena Attwa; Kristina Crothers; Michael Chung
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Coptic Hope Center for Infectious Diseases, Nairobi, Kenya

801  Pulmonary Complications of HIV-1 in Youth: The PHACS AMP Study
William T. Shearer; Erin Leister; George Siberry; Denise L. Jacobson; Russell B. Van Dyke; Hannah H. Peavy; Suzanne Siminski; Meyer Kattan; Laurie Butler; Andrew Colin
1Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, US; 2Harvard School of Public Health, Boston, MA, US; 3National Institutes of Health (NIH), Bethesda, MD, US; 4Tulane University Health Sciences Center, New Orleans, LA, US; 5National Heart, Lung, and Blood Institute, Bethesda, MD, US; 6Frontier Science and Technology Research Foundation, Amherst, NY, US; 7Columbia University Medical Center, New York, NY, US; 8University of Miami Health System Batchelor Research Institute, Miami, FL, US

802  Distinct Airway Methylation and Gene Expression Profiles in HIV-Associated COPD
Janice M. Leung; Emily Vucic; Joseph C. Liu; David Ngan; Tawimas Shaiapanich; Julio Montaner; Stephen Lam; Don Sin; Wan Lam; S. F. Paul Man
1Centre for Heart Lung Innovation, Vancouver, Canada; 2BC Cancer Research Center, Vancouver, Canada; 3St. Paul’s Hospital, Vancouver, Canada; 4BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

Session P-Q11 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Body Composition and Risk Factors for Abnormalities

803  Altered Body Composition and Inflammation in HIV Infection With Type 2 Diabetes
Malene Hove; Julie Abildgaard; Julie C. Gaardbo; Allan Vaag; Jan Gerstoft; Bente Klarlund Pedersen; Birgitte Lindegaard; Susanne D. Poulsen
Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark

804  Alcohol, Substance Use, and Smoking Associations With Lipodystrophy and Lipohypertrophy
Marisela Noorhasan; Daniel R. Drozd; Aaron Blashill; Greer Burkholder; Karen Cropsey; Matthew Mimiga; Katerina Christopoulos; Carl Grunfeld; Heidi M. Crane
Centers for AIDS Research Network of Integrated Clinical Systems

Session P-Q12 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Complications: Liver Disease Without Viral Hepatitis

805  Antiretroviral Drugs Associated With Chronic ALT Elevations in Persons Without HCV and HBV Infection
Helen Kovari; Caroline Sabin; Bruno Ledegerber; Lene Ryom; Antonella d’Arminio Monforte; Matthew G. Law; Stéphane De Wit; Andrew N. Phillips; Jens D. Lundgren; Rainer Weber
on behalf of the D:A:D Study Group
1University Hospital Zurich, Zurich, Switzerland; 2University College London, London, United Kingdom; 3University of Copenhagen, Copenhagen, Denmark; 4University of Milan, Milan, Italy; 5University of New South Wales, Sydney, Australia; 6St Pierre University Hospital, Brussels, Belgium

806  APRI and FIB4: Associated With D-Drug Exposure, Low CD4 Count and Monocyte Activation
Katherine W. Kooij; Rosan van Zoest; Ferdinand W. Wit; Judith Schouten; Neeltje Kootstra; Ineke G. Stolte; Maria Prins; Peter Reiss; Marc van der Valk
AGEhIV Cohort Study Group
1Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3Public Health Service of Amsterdam, Amsterdam, Netherlands
807 HIV and Liver Fibrosis Among Prison Inmates: The iDEA West Africa Collaboration
Antoine Jaquet1; Gilles Wandel2; Judicael Tine3; Claver Dagnan4; Alain Attia5; Akouda Patassi5; Abdoulaye Ndiaye3; Kounavki K. Ekouevi5; Moussa Seydi6; François Dabis7
1Inserm U897, ISPED, Université de Bordeaux, Bordeaux, France; 2Département of Infectious Diseases, Bern University Hospital, Bern, Switzerland; 3Service de Maladies Infectieuses et Tropicales, CRF, CHU de Fann, Dakar, Senegal; 4Service de Virologie, BIOLIM, Université de Lomé, Lomé, Togo; 5Service de Hépato-Gastroentérologie, CHU de Yopougon, Abidjan, Côte d’Ivoire; 6Service de Maladies Infectieuses et Tropicales, CHU Sylvanus Olympio, Lomé, Togo; 7Service de Médecine Interne, CHU Aristide Le Dantec, Dakar, Senegal; 8Département de Santé Publique, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo.

808 Clinical Correlates of Alcohol Use Disorders Among HIV-Infected Adults in Zambia
Michael J. Vinikoor1; Masumba Masananga2; Carolyn Bolton Moore3; Virginia Munamunungu4; Alice Siyunda5; Lloyd Mulenga6; Matthias Egger7; Benjamin H. Chi8; Gilles Wandel9
1University of North Carolina, Lusaka, Zambia; 2Lusaka District Health Management Team, Lusaka, Zambia; 3University of North Carolina, Chapel Hill, NC, US; 4Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 5University of Zambia, Lusaka, Zambia; 6Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; 7Imperial College London, London, South Africa; 8Département de Santé Publique, Faculté des Sciences de la Santé, Université de Lomé, Lomé, Togo.

809 Depression and Treatment Outcomes Among Tanzanian Adults Initiating HAART
Christopher R. Sudfeld1; Sylvia Kaaya1; Nilupa S. Gunaratna1; Wafae Fawzi1; Ferdinand Mugusi1; Mary C. Smith Fawzi1
1Harvard School of Public Health, Roxbury Crossing, MA, US; 2Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania; 3Harvard Medical School, Boston, MA, US.

TUESDAY, FEBRUARY 24, 2015

810 Discordant Early Immune Responses Distinguish TB IRIS and Death in HIV/TB Coinfection
Shruthi Ravimohan1; Neo Tamuhi1; Andrew Steenhoff2; Rona Letlhohile1; Kebatshablele Ntanyana1; Tunelo Rantleru1; Robert Gross3; Drew Weissman2; Gregory P. Bisson1
1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, US; 2Botswana University of Pennsylvania Partnership, Gaborone, Botswana.

811 MMPs and Immunopathology in TB Immune Reconstitution Inflammatory Syndrome
Naomi F. Walker1; Katalin A. Wilkinson2; Graeme Meintjes3; Rene Goliath4; Janique Peyper4; Robert J. Wilkinson5; Jon S. Friedland6; Paul T. Elkinson7
1Imperial College London, Cape Town, South Africa; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, South Africa; 4University of Southampton, Southampton, United Kingdom.

812 Exuberant Pathogen-Specific Th1 CD4+ T-Cell Responses in MAC-IRIS in HIV Infection
Kimberly F. Faldetta1; Denise C. Hsu1; Virginia Sheikh1; Gregg Roby2; Kenneth Olivier3; Irini Sereti4
1National Institutes of Health (NIH), Rockville, MD, US; 2National Institutes of Health (NIH), Bethesda, MD, US.

813 A Paradoxical Treatment of Mycobacterial Immune Reconstitution Inflammatory Syndrome
Denise C. Hsu1; Kimberly F. Faldetta1; Luxin Pei1; Delmyra Turpin; Virginia Sheikh1; Irini Sereti4
1National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US.

814 CD8 T Cells in Lesions of PML-IRIS Express CCR5: Rationale for the Use of Maraviroc
Guillaume Martin-Blondeau1; Jan Bauer1; Emmanuel Uro-Coste2; Hervé Dumas1; Hans Lassmann3; David Brassat2; Pierre Delobel1; Roland Blab1; Bruno Marchou1
1University of Vienna, Vienna, Austria; 2Toulouse University Hospital, Toulouse, France; 3Inserm, Toulouse, France.

815 Monocyte Immune Responses in Cryptococcal Immune Reconstitution Inflammatory Syndrome
David B. Meya1; Godfrey Ziziwa1; Samuel Okurut1; Stephen Cole2; Paul Bohjanen2; Sharon Wahl3; David R. Boulware4; Yuka Manabe5; Edward N. Janoff6
1Makerere University College of Health Sciences, Kampala, Uganda; 2Makerere University Walter Reed Project, Kampala, Uganda; 3Medical Research Council, Kampala, Uganda; 4University of Minnesota, Minneapolis, MN, US; 5National Institute for Dental and Craniofacial Research, Bethesda, MD, US; 6Johns Hopkins University School of Medicine, Baltimore, MD, US; 7University of Colorado, Denver, CO, US.

816LB Does HIV Infection Reduce the Probability of Transmission of Pulmonary Tuberculosis?
Judith R. Glynn1; José Afonso Guerra-Assunção2; Rein M. Houben3; Thembza Mzembe4; Lifted Sichali5; Palwasha Y. Khan6; Ruth McNerney7; Julian Parkhill8; Taane G. Clark1; Amelia C. Crampin1
1Inserm U897, UPR 977, INSERM, Avenue du Colonel Roche, Bordeaux, France; 2University of North Carolina, Lusaka, Zambia; 3National Institute for Dental and Craniofacial Research, Bethesda, MD, US; 4Department of Infectious Diseases, University of Lusaka, Lusaka, Zambia; 5Institutes of Health (NIH), Bethesda, MD, US; 6Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland; 7Imperial College London, Cape Town, South Africa; 8University of Bordeaux, Bordeaux, France.

Session P-Q13 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Depression and Alcohol Use Disorders

Session P-R1 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Immune Reconstitution Inflammatory Syndrome in Opportunistic Infections
Poster Hall

Program and Agenda

Poster Listings

Session P-R2 Poster Session
Poster Hall
2:30 pm – 4:00 pm
T-Cell Responses to Tuberculosis Infection

817  The Relationship Between T-Regulatory Cells and Latent Tuberculosis Infection in Household Contacts Exposed to Pulmonary Tuberculosis Infection in Kampala, Uganda
Rhoda Namakula1; Irene A. Odanga2; Josephine Kasolo2; Ekii A. Abuo1
1Makerere University–Johns Hopkins Research Collaboration, Kampala, Uganda; 2Makerere University College of Health Sciences, Kampala, Uganda; 3Medical Research Council (Uganda Virus Research Institute), Entebbe, Uganda

818  Antiretroviral Therapy Fails to Restore Mycobacterium Tuberculosis-specific Th1 and Th17 CD4 Responses
Lyle W. Murray1; Dominique Goedhals1; Iman Satti1; Rodney Phillips1; Helen McShane1; John Frater1
1Phillips/ Frater
1University of Oxford, Oxford, United Kingdom; 2University of the Free State, Bloemfontein, South Africa

819  Treg/Th17 and T-Cell Effector Responses in Tuberculosis Patients Infected with HIV
Christine Lacabaratz1; Aurelie Wiedemann1; Celine Manier1; Laure Bourdery1; Mathieu Surenaud1; Jean-Daniel Lelièvre2; Giovanna Melica1; Yves Lévy3
1INSERM U955, Université Paris-Est Créteil, Vaccine Research Institute, Créteil, France; 2Inserm U955, Université Paris-Est Créteil, Vaccine Research Institute, CHU H. Mondor-A. Chenevier, Créteil, France; 3CHU H. Mondor-A. Chenevier, Créteil, France

820  HIV-Tuberculosis Coinfection Leads to Increased Turnover of Late-Senescent CD8+ T Cells
Shankar Esaki Muthu1; Chong Yee Kien1; Alireza Saedid1; Adeeba Kamarulzaman1; Vijayakumar Velu1; Marie Larsson1
1University of Malaya, Kuala Lumpur, Malaysia; 2Emory University, Atlanta, GA, US; 3Linkoping University, Linkoping, Sweden

821  CD8 T-Cell Terminal Differentiation and Its Regulation by DHEA in HIV-TB Coinfection
Guadalupe V. Suarez1; Matias T. Angerami1; Maria B. Vecchione1; Omar Sued1; Horacio Salomon1; Maria F. Quiroga1
1INIBIS (UBA-CONICET), Buenos Aires, Argentina; 2Fundacion Huesped, Buenos Aires, Argentina

Session P-R3 Poster Session
Poster Hall
2:30 pm – 4:00 pm
TB Diagnostic Challenges

822  Unsuspected Prevalent TB among HIV-Infected Pregnant Women, South Africa
Jennifer D. Hoffmann1; Silvia E. Cohn1; Fildah Mashabela1; Ziyaad Waja2; Christopher J. Hoffmann2; Neil Martinson2; Richard E. Chaisson1
1Tshepiro Study Team
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa

823  Evaluation of WHO 4-Symptom Tool to Rule Out TB: Data From the XPHACTOR Study
Yasmeen Hanifa1; Katherine Fielding1; Violet Chihota2; Nontobeko Ndlou2; Alan Karstaedt3; Lungiswa Adonis4; Linda Erasmus4; Mark Nicol4; Gavin Churchyard1; Alison Grant1
1London School of Hygiene & Tropical Medicine, London, United Kingdom; 2Aurum Institute for Health Research, Johannesburg, South Africa; 3Chris Hani Baragwanath Hospital, Johannesburg, South Africa; 4Mamelodi Hospital, Pretoria, South Africa; 5National Health Laboratory Service, Johannesburg, South Africa

824  Xpert MTB/RIF Versus AFB Smear to Determine Respiratory Isolation of US TB Suspects
Anne Luetkemeier1; Cynthia Finnhaber1; Michelle Kendall1; Xingye Wu1; Debra Benator1; Gerald Mazurek1; Diane Havlir1; Beatrix Grinsztejn1; David Alland1
on behalf of the ACTG A5295/TBTC 34 Study Teams
1San Francisco General Hospital, University of California San Francisco, San Francisco, CA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Washington DC Veterans Affairs Medical Center, Washington, DC, US; 4US Centers for Disease Control and Prevention, Atlanta, GA, US; 5Instituto de Pesquisas Clínicas Evandro Chagas, Rio de Janeiro, Brazil; 6Rutgers New Jersey Medical School, Newark, NJ, US; 7University of Witwatersrand, Johannesburg, South Africa; 8ACTG A5295/TBTC 34 Study Teams, N/a, MA, US

825  Needle Autopsies Highlight Challenges in Defining HIV+ TB Deaths Using Verbal Autopsy
Aaron Karat1; Mpho Tlali1; Salome Charalambous1; Kerrigan McCarthy2; Violet Chihota1; Gavin Churchyard1; Katherine Fielding1; Kathleen Kahn1; Tanvier Omar1; Alison Grant1
1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2The Aurum Institute, Johannesburg, South Africa; 3University of the Witwatersrand, Johannesburg, South Africa; 4National Health Laboratory Service, Wits School of Public Health, Johannesburg, South Africa

826  Delta-Like 1 Protein, Vitamin D Binding Protein, and Fetuin Measurement in Cerebrospinal Fluid for Detection of Mycobacterium tuberculosis Meningitis
Nathan C. Bahr1; Ryan Halupnick; Grace Linder; Reuben Kiggundu1; Henry W. Nabeta2; Darlisha Williams3; Srinand Srevatsan1; Joshua Rhein1; David B. Meya1; David R. Boulware1
1University of Minnesota, Minneapolis, MN, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 4US Centers for Disease Control and Prevention, Athens, GA, US; 5National Health Laboratory Service, Wits School of Public Health, Johannesburg, South Africa

827LB Adherence to Once-Weekly Self-Administered INH and Rifapentine for Latent TB: iAdhere
Robert Belknap1; Andrey Borisov1; David Holland1; Pei-Jean Feng1; Joan-Pau Millet1; Neil Martinson1; Alicia Wright1; Michael Chen1; Joan Cayla1; Jose M. Mida1
and the Tuberculosis Trials Consortium (TBTC)
1Denver Health and Hospital Authority, Denver, CO, US; 2US Centers for Disease Control and Prevention, Atlanta, GA, US; 3Emory University, Atlanta, GA, US; 4Tuberculosis Investigation Unit of Barcelona, Barcelona, Spain; 5University of the Witwatersrand, Johannesburg, South Africa; 6Vanderbilt University, Nashville, TN, US; 7Hospital Clinic–IDIBAPS, University of Barcelona, Barcelona, Spain
829 **Severe Adverse Events in Outpatient Drug-Resistant TB Treatment in South Africa**
Rebecca H. Berhanu1; Kathryn Schnippel; Andrew Black; Erika Mohr; Busi Mnucube; Ian Sanne

1Health Economics and Epidemiology Research Organisation, Johannesburg, South Africa; Right to Care, Johannesburg, South Africa; Reproductive Health Institute, University of Witswatersrand, Johannesburg, South Africa; Médecins Sans Frontieres, Cape Town, South Africa

830 **Decreased TB Recurrence After Introduction of ART in Durban, South Africa**
Yuri I. van der Heijden1; Farina Karim2; Gary Parker3; Tilagavathy Chinappa4; Grace Muafamadi5; Linda Zako6; Bryan E. Shepherd7; Timothy Sterling8; Alexander Pym9

1Vanderbilt University, Nashville, TN, US; 2St. Augustine's Hospital, Durban, South Africa; 3KwaZulu Natal Research Institute for TB and HIV (K-RITH), Durban, South Africa; 4Ethekwini Municipality, Durban, South Africa

831 **Incidence of Active Tuberculosis in HIV-Infected Adults and Mortality in Thailand**
Nicolas Salvadori1; Suwali Chalermpantmetagul1; Julie Figoni1; Suchart Thongpaen2; Aampaipith Nilmanat3; Patinun Chirawatthanaparan4; Pramual Thaingamsilp5; Tim R. Cressey6; Nicole Ngo-Giang-Huong7; Gonzague Jourdain8

1Institut de Recherche Pour le Développement UMI 174-PHPT, Chiang Mai, Thailand; 2Mahasarakham Hospital, Mahasarakham, Thailand; 3Hat Yai Hospital, Hat Yai, Thailand; 4Phaholpolpayuhasena Hospital, Kanchanaburi, Thailand; 5Kalasin Hospital, Kalasin, Thailand

832 **Antiretroviral Scale-up and Tuberculosis Mortality in High-Burden Countries**
Eline Korenromp1; Eran Bendavid; Isabel Yan1

1Stanford University, Stanford, CA, US; 2Futures Institute, Glastonbury, CT, US

833 **Culture-Negative TB Is Associated With Increased Mortality in HIV-Infected Persons**
Timothy Sterling1; Cathy Jenkins1; Karu Jayathilake1; Eduardo Gotuzzo2; Valdilea Veloso3; Claudia P. Cortes2; Denis Padgett5; Brenda Crabtree-Ramirez2; Bryan E. Shepherd1; Catherine McGowan1

1Vanderbilt University, Nashville, TN, US; 2Universidad Peruana Cayetano Heredia, Lima, Peru; 3Instituto Peruano Evandro Chagas, Rio de Janeiro, Brazil; 4University of Chile, Santiago, Chile; 5Instituto Hondureno de Seguridad Social, Tegucigalpa, Honduras; 6Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

**THURSDAY, FEBRUARY 26, 2015**

**Session P-R5 Poster Session**
2:30 pm – 4:00 pm

**Poster Hall**

**Cryptococcal Meningitis: Host Response, Treatment, and Outcomes**

834 **Local and Systemic Humoral Responses to Cryptococcal Meningitis in Patients With AIDS**
Erin E. Finn1; Jordan Janoff2; Jeremy Rahkola3; David B. Meya4; Samuel Okurut5; Andrew D. Kambugu6; Paul Bohjanen7; Kirsten Nielsen7; David R. Boulware8; Edward N. Janoff9

1Mucosal and Vaccine Research Colorado, Aurora, CO, US; 2Makerere University College of Health Sciences, Kampala, Uganda; 3University of Minnesota, Minneapolis, MN, US

835 **Antiretroviral Therapy Alters the CSF Immune Response in Cryptococcal Meningitis**
James E. Scriver1; Britta Urban1; Lisa Graham2; Charlotte Schutz2; Robert J. Wilkinson1; David R. Boulware3; David Laloo4; Graeme Meintjes1

1Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 2University of Cape Town, Cape Town, South Africa; 3Imperial College London, London, United Kingdom; 4University of Minnesota, Minneapolis, MN, US

836 **Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation**
Joshua Rhein1; Katherine H. Hullisek1; Nathan C. Bahr1; Reuben Kiggundu2; Darlisha Williams2; Henry W. Nabeta3; Abdou Musibire2; David B. Meya4; David R. Boulware1

1University of Minnesota, Minneapolis, MN, US; 2University of Minnesota, Minneapolis, MN, US; 3Makerere University College of Health Sciences, Kampala, Uganda

837 **Impact of ART on Mortality in Cryptococcal Meningitis Patients: High-Income Settings**
Suzanne M. Ingle1; Jose M. Miro2; Hansjakob Furrer3; Amy Justice4; Michael S. Saag1; Christian Manzando2; Anna Esteve3; Laureen E. Cain4; Jonathan A. Sterne5; Margaret T. May6

1University of Bristol, Bristol, United Kingdom; 2Harvard School of Public Health, Boston, MA, US; 3University of Minnesota, Minneapolis, MN, US; 4University of Minnesota, Minneapolis, MN, US; 5University of Alabama at Birmingham, Birmingham, AL, US; 6Centre d’Estudis Epidemiològics Sobre ITS/VIH/SIDA de Catalunya, Barcelona, Spain

838 **Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis**
Joshua Rhein1; Katherine H. Hullisek2; Bozena Morawski2; Kyle Smith2; Ali Al-Hadab1; Abdou Musibire2; Darlisha Williams2; Kristen Nielsen3; David B. Meya4; David R. Boulware1

1University of Minnesota, Minneapolis, MN, US; 2Makerere University College of Health Sciences, Kampala, Uganda
TUESDAY, FEBRUARY 24, 2015

Session P-R6 Poster Session
2:30 pm – 4:00 pm
Syphilis and HIV Coinfection

839
Infection With HIV Among Individuals With Primary and Secondary Syphilis: USA, 2013
John R. Su; Akbar A. Zaidi; Elizabeth A. Torrone; Hillard S. Weinstock
US Centers for Disease Control and Prevention, Atlanta, GA, US

840
Risk Factors for Asymptomatic and Symptomatic Neurosyphilis Differ in HIV-Infected Patients With Syphilis
Christina Marra; Trudy Jones; Shelia Dunaway; Emily Ho; Abigail Crooks; Lauren Tantalo; Sharon Sahi
University of Washington, Seattle, WA, US

841
High Incidence of Syphilis Among Thai MSM Who Started ART Therapy During Acute HIV Infection
Donn J. Colby; Suteeporn Pinyakorn; Frits van Griensven; Eugene Kroon; Naphassanan Lopraynak; Robert O’Connell; Nelson L. Michael; Praphan Phanuphak; Jintanat Ananworanich; Nittaya Phanuphak
1Thai Red Cross AIDS Research Center, Bangkok, Thailand; 2US Military HIV Research Program, Bethesda, MD, US

Session P-R7 Poster Session
2:30 pm – 4:00 pm
Opportunistic Infections: Odds and End Organs

843
The Exposure and Geospatial Risk Factors for AIDS-Associated Penicilliosis in Vietnam
Thuy Le; Brian Jonat; Ngo T. Cuc; Nguyen T. Thanh; Dang T. Bich; Cecilia Shikuma; Jeremy Day; Heiman Wertheim; Jeremy Farrar; Marcel Wolbers
1Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; 2New York-Presbyterian University Hospital of Columbia and Cornell, New York City, NY, US; 3Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; 4National Hospital for Tropical Diseases, Hanoi, Vietnam; 5Hawaii Center for AIDS, University of Hawaii, Ho Chi Minh, Vietnam

844
AS265 Clinical Trial: Gentian Violet for Oral Candidiasis is as Effective as Nystatin
Pranab K. Mukherjee; Lauren Patton; James Hakim; Huichao Chen; Mai T. Pho; Kenneth A. Freedberg; Caroline Shiboldski; Mahmoud A. Ghannoum; Robert A. Salata
Oral HIV/AIDS Research Alliance (OHARA)/ACTG
1Case Western Reserve University, Cleveland, OH, US; 2University of North Carolina, Chapel Hill, NC, US; 3Harvard School of Public Health, Boston, MA, US; 4University of Zimbabwe - Parirenyatwa, Harare, Zimbabwe; 5University of Chicago, Chicago, IL, US; 6Harvard Medical School, Boston, MA, US; 7University of California San Francisco (UCSF), San Francisco, CA, US

Session P-S1 Poster Session
THURSDAY, FEBRUARY 26, 2015

Session P-S1 Poster Session
2:30 pm – 4:00 pm
Access and Engagement

850
Wade Ivy; Gabriela Paz-Bailey
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US
851  Engagement in the HIV Care Continuum Among Female Sex Workers in Lilongwe, Malawi
Kathryn E. Lancaster1; Thandile Lungu1; Mina C. Hosseinipour1; Katy Chadwick2; Zoe Dibb2; Vivian F. Go3; Brian W. Pence3; Kimberly A. Powers1; Irving F. Hoffman1; William C. Miller1
1University of North Carolina, Chapel Hill, NC, US; 2Theatre for a Change, Lilongwe, Malawi; 3University of North Carolina Project—Malawi, Lilongwe, Malawi

852  New HIV Cases and ARV Retention in Pretoria: A Gender Project for High-Risk Women
Wendee M. Wechsberg1; William A. Zule1; Irene A. Doherty1; Tracy L. Kline1; Jacqueline Ndirangu1; Charles M. van der Horst1
1RTI International, Research Triangle Park, NC, US; 2University of North Carolina, Chapel Hill, NC, US

853  Intimate Partner Violence and Antiretroviral Adherence in HIV-Positive Women in Kenya
Kate S. Wilson1; Krista Yuhas1; Ruth Deya1; Barbra Richardson1; Linnet Masese1; Jane Simoni1; Walter Jaoko1; R Scott McClelland1
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya

854  Re-engagement in Care Leads to Sustained Engagement and Viral Suppression
Brittani D. Saafir-Callaway1; Amanda D. Castel1; Lena Lago1; Christie Oliejemeh1; Garret Lum1; Lawrence Frison1; Michael Kharchen1
1District of Columbia Department of Health, Washington, DC, US; 2University of Nairobi, Nairobi, Kenya

TUESDAY, FEBRUARY 24, 2015

Session P-S2 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Cervical Sampling, Shedding, and Outcomes

855  Symptoms and Genital HSV-2 and HIV-1 in Coinfected Women, Chiang Rai, Thailand
Eileen F. Dunne1; Brooke E. Hoots1; Janet McNicholl1; Sara Whitehead2; Thomas A. Peterman2; Lauri E. Markowitz2; Wanna Leelawiwat3; Tammy Evans-Strickfaden4; Cheng Chen5
1US Centers for Disease Control and Prevention, Bangkok, Thailand; 2US Centers for Disease Control and Prevention, Atlanta, GA, US; 3Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand

856  High-Risk HPV Clustering and Cervical Outcomes in HIV-Infected Women in Rio de Janeiro, Brazil
Jessica L. Castilho1; José Eduardo Levi1; Paula M. Luz1; Mary Catherine Cambou2; Tazio Vanni2; Angela de Andrade2; Monica Derrico2; Valdirea Veloso2; Beatriz Grinsztejn2; Ruth Friedman2
1Vanderbilt University School of Medicine, Nashville, TN, US; 2Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 3University of California Los Angeles, Los Angeles, CA, US; 4United Nations, Lyons, France

857  Comparison of Three Female Genital Tract Sampling Techniques for HIV RNA Recovery
Catherine S. Todd1; Shameem Jaumdally2; Heidi E. Jones3; Hoyam Gamieldien1; Nontokozo Langwenya1; Landon Myer1; Donald R. Hoover1; Jo-Ann Passmore1
1FH360, Bangkok, Thailand; 2University of Cape Town, Cape Town, South Africa; 3Hunter College, CUNY School of Public Health, New York, NY, US; 4University of Cape Town, Cape Town, South Africa; 5Rutgers New Jersey Medical School, Piscataway, NJ, US

THURSDAY, FEBRUARY 26, 2015

Session P-S3 Poster Session  Poster Hall
2:30 pm – 4:00 pm
Hormonal Contraception

858  CCR5 Expression in HIV-Uninfected Women Receiving Hormonal Contraception
Athe Tsbris1; Gaia Sciaranghella2; Cuwei Wang3; Kerry Murphy4; Zaher Mehris5; Ruth M. Greenblatt6; Margde Cohen7; Elizabeth Golub7; Heather Watts8; Mary A. Young4
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3Georgetown University Medical Center, Washington, DC, US; 4Albert Einstein College of Medicine, Bronx, NY, US; 5University of Vermont College of Medicine, Burlington, VT, US; 6University of California San Francisco, San Francisco, CA, US; 7Streger Hospital and Rush University and CORE Center, Chicago, IL, US; 8Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 9The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US

859  Estrogen Replacement in Healthy Postmenopausal Women Reduces %CCR5+ CD4+ T Cells
Amie Meditz1; Samantha MaWhinney1; Kerrie Moreau1; Kelsey Melander2; Joy Folkvord1; Wendy Kohrt1; Margaret Wieman1; Elizabeth Connick1
1Boulder Community Health, Boulder, CO, US; 2University of Colorado Anschutz Medical Campus, Aurora, CO, US

860  Progesterone Increases Are Associated With HIV Susceptibility Factors in Women
Alison Y. Swaims1; Tammy Evans-Strickfaden1; L Davis Lupo2; Alfredo Aguirre3; Anandi Sheth3; Igbo Ofotokun3; Clyde E. Hart4; Richard E. Haaland5
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Emory University School of Medicine, Atlanta, GA, US

861  Changes in Vaginal Microbiota and Cytokines in HIV-1-Seronegative Women Initiating DMPA
Alison C. Roxby1; David N. Fredricks1; Katherine Odem-Davis1; Kristjana H. Ásbjörnsdóttir1; Linnet Masese1; Tina L. Fiedler2; Walter Jaoko3; James N. Kiarie3; Julie M. Overbaugh4; R Scott McClelland5
1Vanderbilt University School of Medicine, Nashville, TN, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya
862  A Thinned Vaginal Stratum Corneum Is a Susceptibility Factor for SHIV Acquisition  
Ellen Kersh: Jana Ritter; Katherine Butler; Sharon Dietz Ostergaard; Debra Hanson; Sherif Zaki; Janet McNicholl  
US Centers for Disease Control and Prevention, Atlanta, GA, US

863  Specific Effects of ZDV, 3TC and LPV/r on HIV-1 RNA Viral Load During Pregnancy  
Patumrat Sripan; Sophie Le Coeur; Lily Ingsrisawang; Tim R. Cressey; Jean-Marc Tréhuyer; Naïm Bouazza; Frantz Foissac; Gonzague Jourdain; Marc G. Lallemand; Saïk Urien  
1ED420, University of Paris Sud 11, Paris Descartes, Paris, France/PHPT-IRD U174, Chiang Mai, Thailand/Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 2Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 3PHPT-IRD U174, Faculty of Associated Medical Sciences, Chiang Mai University/Harvard School of Public Health, Chiang Mai, Thailand; 4EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-Hôpital Tarnier, Paris, France; 5Institut d’Etudes Démographiques, Institut de Recherche Pour le Développement (UMR 1ED420, University of Paris Sud 11, Paris Descartes, Paris, France/PHPT-IRD U174, Chiang Mai, Thailand/Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand; 6AP-HP , Hôpital Necker-Enfants Malades, University Paris 7, Paris, France; 7, Colombes, France; 8University Paris 7, Paris, France; 9University Paris 7, Paris, France

864  Viral Suppression After Antiretroviral Therapy Initiation in Pregnancy in South Africa  
Landon Myer; Tamsin Phillips; Nei-Yuan Hisao; Allison Zerbe; Jo Ramjith; Linda-Gail Bekker; James A. McIntyre; Elaine J. Abrams  
1University of Cape Town, Cape Town, South Africa; 2National Health Laboratory Services/University of Cape Town, Cape Town, South Africa; 3ICAP at Columbia University, New York, NY, US; 4Anova Health Institute, Hôpital Tarnier, CIC-0901 Inserm, Cochin-Necker, Paris, France

865  Maternal Viral Load in the Context of PMTCT B+ Within the Kabeho Study in Kigali  
Emily A. Bobrow; Placidie Mgwevanga; Gilles F. Ndjayisaba; Dieudonne Ndmatama; Michelle Gill; Heather J. Hoffman; Cyprien Baribwira; Laura Guay; Anita Asimwe  
Kabeho Study Team  
1Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, US; 2Ministry of Health, Kigali, Rwanda; 3Elizabeth Glaser Pediatric AIDS Foundation, Kigali, Rwanda; 4George Washington University Milken Institute School of Public Health, Washington, DC, US; 5University of Maryland, School of Medicine, Kigali, Rwanda; 6Rwanda University Teaching Hospitals, Kigali, Rwanda

866  ART Response Among Pregnant and Postpartum Women With Acute Versus Chronic HIV-1  
Alison L. Drake; John Kinuthia; Daniel Matembo; Barbra Richardson; Michael Chung; James N. Kiarie; Sandy Emery; Julie M. Overbaugh; Grace John-Stewart  
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Fred Hutchinson Cancer Research Center, Seattle, WA, US

867  No Perinatal Transmission of HIV-1 in Women Efficiently Treated Since Conception  
Laurent Mandelbrot; Roland Tubiana; Jérome Le Chenadec; Catherine Dolfius; Albert Faye; Christine Rouzioux; Anais Perilhou; Josiane Warszawski; Stéphane Blanche  
The ANRS-EPF (C01/C010/C011) Study Group  

868  Predictors of Perinatal HIV Transmission in the BAN Study  
Sascha R. Ellington; Athena P. Kourtis; Ali Fokar; Charles S. Chasela; Dumbani Kayira; Gerald Tegha; Denise J. Jamieson; Charles M. van der Horst  
The BAN Study Team  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2University of North Carolina, Chapel Hill, NC, US; 3University of North Carolina Project Lilongwe, Lilongwe, Malawi; 4University of Witwatersrand, Johannesburg, South Africa

869  High Rate of HIV Superinfection After Delivery: Secondary Analysis of the PEPI Trial  
Andrew D. Redd; Sarah Wendel; Andrew Longosz; Jessica M. Fogel; Newton Kumwenda; Sufia Dadabhi; Susan H. Eshleman; Stephen Porcella; Thomas C. Quinn; Taha Taha  
1National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2Johns Hopkins University School of Medicine, Baltimore, MD, US; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 4National Institute of Allergy and Infectious Diseases (NIAID), Hamilton, MT, US

870  Decline in Early Mother-to-Child HIV Transmission (MTCT) Risk Over Time in Botswana  
Kathleen M. Powis; Gbolahan Aijibola; Jean Leidner; Kara Bennett; Florence Chilisa; Keabetwe Bedi; Chipo Petlo; Michael D. Hughes; Roger Shapiro; Shahin Lockman  
871 Impact of Maternal Antiretroviral Regimen on Six-Month HIV-Free Survival in Botswana
Rebecca Zash¹; Sahjir Souda²; Chazha Hick³; Kelebogile Binde⁴; Sikuhiile Moyo⁵; Erik van Widenfeld⁶; Jean Leidner⁷; Joseph Makhema⁸; Mompati Mmalane⁹; Roger Shapiro¹
¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; ²University of Botswana, Gaborone, Botswana; ³Botswana Harvard AIDS Institute, Gaborone, Botswana; ⁴Harvard School of Public Health, Boston, MA, US

872 Infant Outcomes Among a Cohort of HIV-Infected Pregnant Women With and Without TB in South Africa: The Tshepiso Study
Jennifer D. Hoffmann¹; Silvia E. Cohn¹; Nicole M. Salazar-Austin²; Filidah Mashabela³; Ziyaad Waja³; Christopher J. Hoffmann¹; Sanjay Lal⁴; Richard E. Chaisson⁴; Neil A. Martinson⁴
¹Johns Hopkins University School of Medicine, Baltimore, MD, US; ²Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa; ³Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Session P-T3 Poster Session
2:30 pm – 4:00 pm
Option B+: Retention and Transmission

873 Early HIV Infection Rate Trends in Exposed Infants Pre- and Post-Option B+ in Mozambique
Thresia Sebastian; Serena Brusamento; Laurence Ahoua; Dario Aly; Stephen M. Arpadi; Chloe A. Teasdale; Fatima Tsiouris; Elaine J. Abrams ICAP at Columbia University, New York, NY, US

874 Option B+ Scale Up and Comprehensive PMTCT Service Delivery in Central Malawi
Michael E. Herce¹; Tiwonge Mtande²; Frank Chimbwandira³; Innocent Mofolo²; Christine Chingondole; Nora Rosenberg⁴; Kathryn Lancaster⁴; Mina C. Hosseinipour⁵; Charles M. van der Horst¹
Safeguard the Family—Malawi Ministry of Health Partnership ¹University of North Carolina, Lusaka, Zambia; ²UNC Project-Malawi, Lilongwe, Malawi; ³Malawi Ministry of Health, Lilongwe, Malawi; ⁴University of North Carolina, Chapel Hill, NC, US

875 Retention Amongst HIV-Infected Pregnant Women Initiating Lifelong Antiretroviral Treatment (Option B+) in Haiti
Jean W. Domercant¹; Nancy Puttkammer¹; Lydia Lu¹; Kesner Francois²; Olbég Desinor³; Reginald Jean_Louis⁴; Michelle Adler⁵; Barbara Marston⁶; Reynold Grand_Pierre⁷

THURSDAY, FEBRUARY 26, 2015

876 Malnutrition Among HIV-Exposed Uninfected Children in Botswana
Kathleen M. Powis¹; Quanhong Lei¹; Yvonne Chinyanga¹; Esther Turnbare¹; Nealia Khan¹; Jacinta Sibila¹; Erik van Widenfeld¹; Joseph Makhema²; Roger Shapiro³
¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; ²Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; ³Botswana Ministry of Health, Gaborone, Botswana; ⁴Elizabeth Glaser Pediatric AIDS Foundation, Harare, Zimbabwe; ⁵Harvard School of Public Health, Boston, MA, US; ⁶Botswana Harvard AIDS Institute, Gaborone, Botswana; ⁷Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US

877 Hospitalizations Among Uninfected Children Exposed or Unexposed to HIV — A Nationwide Cohort Study
Ellen M. Larsen¹; Marie Helleberg²; Sannie Nordly³; Nina Weis³; Vibeke Rosenfeldt³; Merete Storgaard³; Gitte Pedersen³; Isik S. Johansen; Suzanne Lunding⁴; Terese L. Katzenstein⁴
¹Nordsjællands Hospital, Hillerød, Denmark; ²Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; ³Copenhagen University Hospital, Hvidovre Hospital, Hvidovre, Denmark; ⁴Aarhus University Hospital, Skejby, Aarhus, Denmark; ⁵Aalborg University Hospital, Aalborg, Denmark; ⁶Odense University Hospital, Odense, Denmark

878 Reassuring Birth Outcomes Data With Atripla Used for PMTCT in Botswana
Rebecca Zash¹; Jennifer Y. Chen¹; Sahjir Souda¹; Scott Dryden-Peterson¹; Shahin Lockman¹; Mompati Mmalane¹; Joseph Makhema¹; Max Essex¹; Roger Shapiro¹
¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; ³Botswana Harvard AIDS Institute, Gaborone, Botswana; ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; ⁵Harvard School of Public Health, Boston, MA, US

879 Growth and Bone Markers in Malawian Infants Pre- and Postnatally Exposed to Tenofovir
Giuseppe Liotta¹; Marco Floridia¹; Mauro Andreotti¹; Haswell Jere¹; Clementina Galluzzo¹; Sandro Mancinelli¹; Maria Cristina Marazza¹; Stefano Vella¹; Marina Giuliano¹; Leonardo Palombi¹
¹Istituto Superiore di Sanità, Rome, Italy; ²University of Tor Vergata, Rome, Italy; ³Community of S.Egidio, Blantyre, Malawi; ⁴Lumsa University, Rome, Italy
Lower Insulin, Acylcarnitines, and Branch-Chain Amino Acids in HIV-Exposed Infants
Jennifer Jao; Brian Kirmse; Chunli Yu; Fanny Epie; Emmanuel Nshom; Rhoda Sperring; Elaine J. Abrams; Derek LeRoith; Mitchell Geffner; Irwin Kurland
1Icahn School of Medicine at Mount Sinai, New York, NY, US; 2Children’s National Health System, Washington, DC, US; 3Icahn School of Medicine at Mount Sinai, New York, NY, US; 4Cameron Baptist Convention Health Services, Bamenda, Cameroon; 5Icahn School of Medicine at Mount Sinai, New York, NY, US; 6ICAP at Columbia University, New York, NY, US; 7Icahn School of Medicine at Mount Sinai, New York, NY, US; 8Keck School of Medicine at University of Southern California, Los Angeles, CA, US; 9Albert Einstein College of Medicine, New York, NY, US

No Effect of Maternal HIV and In-Utero cART on Infant Leukocyte Telomere Length
Abhinav Ajaykumar; Hugo Soudeyns; Fatima Kakkar; Jason Brophy; Ari Bitnurt; Ariane Alimenti; Deborah Money; Arianne Albert; Hélène C. Côté
On behalf of the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)
1University of British Columbia, Vancouver, Canada; 2Université de Montréal, Montreal, Canada; 3University of Ottawa, Ottawa, Canada; 4University of Toronto, Toronto, Canada; 5Women’s Health Research Institute, Vancouver, Canada

Long-Term Effects of In Utero ARV Exposure on Cardiac Function in HIV-Exposed Uninfected Youth
Vitor C. Guerra; Erin Leister; Paige L. Williams; Steven E. Lipshultz; Russell Van Dyke; Rohan Hazra; Steven D. Colan
1 Tulane University, New Orleans, LA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Wayne State University School of Medicine, Detroit, MI, US; 4Emunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 5Boston Children’s Hospital, Harvard Medical School, Boston, MA, US

Is the Prevalence of M. tuberculosis Infection Higher in HIV-Exposed Children?
Palwasha Y. Khan; Katherine L. Fielding; Dominic Mulawa; Regina Chiuyaya; Thembu Mzembe; Olivier Koole; Judith R. Glynn; Amelia C. Crampin
1 London School of Hygiene and Tropical Medicine, London, United Kingdom; 2Karonga Prevention Study, Karonga, Malawi

TUESDAY, FEBRUARY 24, 2015

Session P-T6 Poster Session
Poster Hall
2:30 pm – 4:00 pm

ART Adherence, Adverse Effects, and Retention Among Pregnant Women and Infants

ARV Adherence Associated with Reduced Breastmilk HIV Viral Load and HIV Transmission
Nicole L. Davis; William C. Miller; Michael G. Hudgens; Charles S. Chasela; Dorothy Sichiali; Julie A. Nelson; Joseph Rigidor; Sascha R. Ellington; Athena P. Kourtis; Charles M. van der Horst
1BAN study team
2University of Witwatersrand, Johannesburg, South Africa; 3UNC Project-Malawi, Lilongwe, Malawi; 4US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 5University of North Carolina, Chapel Hill, NC, US

Peripartum Hair Levels of Antiretrovirals Predict Viral Suppression in Ugandan Women
Catherine A. Koss; Peter Bacchetti; Deborah Cohan; Paul Natureeba; Howard Horng; Tamara Clark; Edwin Charlebois; Moses R. Kamya; Diane Havlir; Monica Gandhi
1University of California San Francisco, San Francisco, CA, US; 2Makerere University College of Health Sciences, Kampala, Uganda

Side Effects and Treatment Adherence After ART Initiation in Pregnancy in South Africa
Tamsin Phillips; Allison V. Zerbe; Agnes Ronan; Claude A. Mellins; Robert H. Remien; James A. McIntyre; Greg Petro; Elaine J. Abrams; Landon Myers
1University of Cape Town, Cape Town, South Africa; 2ICAP at Columbia University, New York, NY, US; 3New York State Psychiatric Institute and Columbia University, New York, NY, US; 4Anova Health Institute, Johannesburg, South Africa

Efficacy of Mobile Phone Use on Adherence to Nevirapine Prophylaxis and Retention in Care Among HIV-Exposed Infants
Lilian M. Kebaya; Dalton Wamalwa; Nyambura Kariuki; Bashir Admani; Ruth W. Nduati
1University of Nairobi, Nairobi, Kenya

HIV Care Continuum for Postpartum Women in Philadelphia: Barriers and Facilitators
Joella W. Adams; Kathleen Brady; Yvonne Michael; Baligh R. Yehia; Florence Momplaisir
Session P-T7 Poster Session  
2:30 pm – 4:00 pm  
Pharmacokinetics and Safety of ART During Pregnancy

891  
Raltegravir Plasma Concentrations on HIV-1 Infected Pregnant Women  
Emilie Belissa; Amine Benchik; Charlotte Charpentier; Morgane Valentin; Agnes Bourgeois-Moine; Sylvie Lariven; Florence Damond; Yazdan Yazdanpanah; Sophie Matheron; Gilles Peytavin  
APHP Bichat-Claude Bernard Hospital, Paris, France

892  
Etravirine Pharmacokinetics During Pregnancy and Postpartum  
Brookie M. Best; Angela Colbers; Jiajia Wang; Graham Taylor; Alice Stek; Marjo van Kasteren; Mark Mirochnick; David Burger  
On behalf of the IMPAACT P1026s Protocol Team and the PANNA Network

1 University of California San Diego, San Diego, CA, US; 2 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; 3 Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US; 4 Imperial College Healthcare NHS Trust, London, United Kingdom; 5 University of Southern California School of Medicine, Los Angeles, CA, US; 6 St. Elisabeth Hospital, Tilburg, Netherlands; 7 Boston University School of Medicine, Boston, MA, US

893  
Pharmacokinetics of Etravirine in HIV-1–Infected Pregnant Women  
M Ramgopal; O Osyemni; C Zorrilla; HM Crauwels; R Ryan; K Brown; V Hillewaert; B Baugh  
1 Midway Immunology and Research Center, Fort Pierce, FL, US; 2 Triple O Research Institute PA, West Palm Beach, FL, US; 3 University of Puerto Rico School of Medicine, San Juan, US; 4 Janssen Infectious Diseases, Beese, Belgium; 5 Janssen Research & Development, Titusville, NJ, US; 6 Janssen Therapeutics, Titusville, NJ, US; 7 Janssen Research & Development, Beese, Belgium

894  
Pharmacokinetics of Rilpivirine in HIV-Infected Women During Pregnancy and Postpartum  
Mark Mirochnick; Brookie M. Best; Alice Stek; Regis Kretchmann; Jiajia Wang; David Shapiro; Elizabeth Smith; Lynne Mofenson; Tim R. Cressey; Edmund Capparelli  
1 Boston University School of Medicine, Hingham, MA, US; 2 University of California San Diego, San Diego, CA, US; 3 University of Southern California, Los Angeles, CA, US; 4 Harvard School of Public Health, Boston, MA, US; 5 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 6 Emunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 7 Harvard School of Public Health/Chiang Mai University, Chiang Mai, Thailand; 8 Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil

Session P-T8 Poster Session  
2:30 pm – 4:00 pm  
Planning and Preventing Pregnancy

895  
Safer Conception Delayed by Lack of HIV Viral Suppression  
Sheree R. Schwartz; Rebecca Phofo; Nonpumelelo Yende; Jean Bassett; Nora West; Ian Sanne; Annelies Van Rie  
1 University of North Carolina, Chapel Hill, NC, US; 2 Witkoppen Health and Welfare Centre, Johannesburg, South Africa; 3 University of the Witwatersrand, Johannesburg, South Africa

896  
Preventing Unintended Pregnancy and HIV: The HIV Treatment Cascade and Contraceptive Choices  
Julia Raifman; Terusha Cheety; Frank Tanser; Tinofa Mutevedzi; Philippa Matthews; Kobus Herbst; Deenan Pillay; Till Barnighausen  
1 Harvard School of Public Health, Washington, DC, US; 2 Africa Centre for Health and Population Studies, Mtubatuba, South Africa

THURSDAY, FEBRUARY 26, 2015

Session P-T9 Poster Session  
2:30 pm – 4:00 pm  
Mechanisms of MTCT and Maternal/Infant Health

897  
HIV Target Cells and Altered Microbiome Associated With Mixed Feeding in South Africa  
Lianna F. Wood; Cosette LeCiel; Heather Jaspan; Donald Sodora  

898  
Role of Type 1 IFNs in the Control of HIV-1 Infection at the Feto-Maternal Interface  
Erica L. Johnson; Sahithi Boggavarapu; Elan S. Johnson; Asim A. Lal; Siddhartha Bhaumik; Murali-Krishna Kaja; Rana Chakraborty  
Emory University School of Medicine, Atlanta, GA, US

899  
Immune Activation During Pregnancy and Postpartum Period in Treated HIV+ Ugandans  
Peter W. Hunt; Helen Byakwaga; Yap Boum; Lynn T. Matthews; Tricia H. Burdo; Yong Huang; Annet Kembabazi; Angela Kaida; David R. Bangsberg; Jeffrey Martin  
1 University of California San Francisco, San Francisco, CA, US; 2 Mbarara University of Science and Technology, Mbarara, Uganda; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4 Boston College, Boston, MA, US; 5 Simon Fraser University, Vancouver, Canada

900  
T-Cell Activation and Exhaustion in HIV-Infected and HIV-Uninfected Pregnant Women  
Christina Fiske; Vlad Melekhin; Fernanda Maruri; Cindy Hager; Louise Barnett; Timothy Sterling; Spyros Kalams  
Vanderbilt University School of Medicine, Nashville, TN, US

901  
HIV and Smoking Associated with Shorter Telomere Length in a Cohort of Pregnant Women  
Sara Saberi; Beheroze Sattha; Evelyn Maan; Julie Van Schalkwyk; Deborah Money; Hélène Côté  
On behalf of the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA)  
1 University of British Columbia, Vancouver, Canada; 2 BC Women’s Hospital and Health Centre, Vancouver, Canada; 3 Women’s Health Research Institute, Vancouver, Canada

902  
Low Prolactin and High 20α-HSD May Contribute to cART-Induced P4 Deficits in Pregnancy  
Eszer Papp; Lena Serghides  
AAPH Team  
Toronto General Research Institute, Toronto, Canada
TUESDAY, FEBRUARY 24, 2015

Session P-T10 Poster Session  
2:30 pm – 4:00 pm  
**Poster Hall**

**Immune Mechanisms in MTCT**

**Poster Listings**

903  Generating HIV Neutralization in Milk With Neutralizing IgG/dIgA Antibodies Infusion  
_Genevieve Fouad_; Josh Eudailey; Erika Kunz; Joshua Amos; Jonathan Himes; Lisa Colvin; Xinyue Wang; Keith Reimann; Barton Haynes; Sallie Pernmar  
1Duke University, Durham, NC, US; 2University of Massachusetts Medical School, Boston, MA, US

904  Specificity of V3-specific Neutralizing Responses in HIV-1 Infected Women  
_David R. Martinez_; Genevieve Fouad; Nathan Vandergriff; Celia LaBranch; David Montefiori; Xiaoying Shen; Thomas Denny; Georgia Tomaras; Sallie Pernmar  
Duke Human Vaccine Institute, Durham, NC, US

905  Broad, Highly Avid Vaccine-Elicited Anti-V1V2 IgG Responses in HIV-Exposed Infants  
_Genevieve Fouad_; Coleen Cunningham; Elizabeth McFarland; Bill Borkowsky; Nicole Yates; Erin McGuire; Hua-Xin Liao; Barton Haynes; Georgia Tomaras; Sallie Pernmar  
1Duke University, Durham, NC, US; 2University of Colorado, Aurora, CO, US; 3New York University, New York, NY, US

906  Maternal Neutralization Escape Virus Variants Do Not Predict Infant HIV Infection Risk  
_Caitlin Milligan_; Maxwel Omenda; Vasha Chohan; Katherine Odem-Davis; Barbra A. Richardson 1; Ruth W. Nduati; Julie M. Overbaugh  
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya

Session P-T11 Poster Session  
2:30 pm – 4:00 pm  
**Poster Hall**

**PMTCT-Associated Drug Resistance in Women and Infants**

907  ART Failure and Resistance Among Pregnant and Post-Partum Women in South Africa  
_Chris Hoffmann_; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; _Kelly E. Dooley_; Richard E. Chaisson; Neil Martinson  
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Perinatal HIV Research Unit (PHRU), Johannesburg, South Africa

_Johanna Ledwaba_; Anna Salimo; Karl Technau; Simon Travers; Lynn Morris; Gillian Hunt; Louise Kuhn  
1National Institute for Communicable Diseases, National Health Laboratory Service, Sandringham, South Africa; 2Columbia University, New York, NY, US; 3University of the Western Cape, Middedorp, South Africa; 4University of the Witwatersrand, Johannesburg, South Africa

WEDNESDAY, FEBRUARY 25, 2015

Session P-U1 Poster Session  
2:30 pm – 4:00 pm  
**Poster Hall**

**HIV Diagnosis in Infants and Children**

910  Birth HIV PCR Testing in South Africa: Diagnostic Challenges and Risk Factor Analysis  
_Karl-Günter Technau_; Louise Kuhn; Lucia Hans; Sergio Carmona; Ashraf Coovadia; Gayle Sherman  
1University of the Witwatersrand, Johannesburg, South Africa; 2Columbia University, New York, NY, US; 3National Health Laboratory Service, Johannesburg, South Africa; 4National Institute for Communicable Diseases, Johannesburg, South Africa

911  System Gaps Result in Late Diagnosis and Treatment of Children With HIV in Hospital  
_Irene N. Njuguna_; Anjuli D. Wagner; Vincent Otieno; Lisa Cranmer; Judy Adhiambo; Sarah Benki-Nugent; Elizabeth Maleche-Obimbo; Jennifer A. Slyker; Dalton Wamalwa; Grace John-Stewart  
1University of Washington, Seattle, Kenya; Emory University School of Medicine, Atlanta, GA, US; 2University of Nairobi, Nairobi, Kenya

Session P-U2 Poster Session  
2:30 pm – 4:00 pm  
**Poster Hall**

**Early ART and HIV Persistence**

912  Early Infant Antiretroviral Therapy Reduces Transcriptionally Active HIV Persistence  
_Gert U. van Zyl_; Margaret A. Bedison; Anita Janse van Rensburg; Barbara Laughton; Mark F. Cottin; John W. Mellors  
1Stellenbosch University and National Health Laboratory Service, Parow, South Africa; 2University of Pittsburgh, Pittsburgh, PA, US; 3Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa

913  Immunodeficiency at the Start of ART in Children: A Global View  
_Klea Panayidou_; Ali Judd  
On behalf of the iDeA Collaboration and the COHERE Collaboration  
1University of Bern, Bern, Switzerland; 2University of Copenhagen, Copenhagen, Denmark; 3University College London, London, United Kingdom
914 Immune Recovery at 5 Years on ART in HIV+ Children From Four African Countries
Chloe A. Teasdale; Ruby Fayrose; Zenebe Melaku; Duncan Chege; Catarina Casalini; Thresia Sebastian; Elaine J. Abrams
ICAP at Columbia University, New York, NY, US

915 Antiretroviral Therapy in Severely Malnourished, HIV-Infected Children in Asia
David C. Boettiger; Linda Aurpibul; Dina Mukiatti; Siew Fong; Pagakrong Lumbigano; Saphonn Vonthanak; Nguyen Van Lam; Rawiwan Hansudewechakul; Azar Kariminia
On behalf of TREAT Asia Pediatric HIV Observational Database
1University of New South Wales, Sydney, Australia; 2Chiang Mai University, Chiang Mai, Thailand; 3Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 4Hospital Likas, Kota Kinabalu, Malaysia; 5Khon Kaen University, Khon Kaen, Thailand; 6National Centre for HIV/AIDS Dermatology and STDs, Phnom Penh, Cambodia; 7National Hospital of Pediatrics, Hanoi, Vietnam; 8Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand

916 Pubertal Development in HIV-Infected African Children on First-Line Antiretroviral Therapy
Mutsa F. Bwakura Dangarembizi
On behalf of the ARROW Trial Team
University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe

917 Mortality of HIV-Infected Youth in the Combination Antiretroviral Therapy (cART) Era
Gayatri Mirani; Paige L. Williams; Miriam Chernoff; Mark Abzug; Myron Levin; James Oleske; George Seage; Rohan Hazra; Russell B. Van Dyke
On behalf of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network P1074 Study Team
1Tulane University Health Sciences Center, New Orleans, LA, US; 2Center for Biostatistics in AIDS Research Harvard School of Public Health, Boston, MA, US; 3University of Colorado Anschutz Medical Campus, Aurora, CO, US; 4Division of Pediatrics Allergy, Immunology & Infectious Diseases, Newark, NJ, US; 5Emory University, Atlanta, GA, US; 6University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, US; 7IMPAACT Operations Center FHI 360, Durham, NC, US

918 Transition to Adult Units: Situation and Evolution of Vertically HIV Infected Youths in Spain
Talia Sainz; Carolina Fernandez McPhee; Santiago Jimenez de Ory; Maria Isabel Gonzalez-Tome; Rafael Rubio; Jose I Bernadino; Santiago Moreno; Jose Antonio Inbarren; Belen Alejos; Marisa Navarro
On behalf of the Spanish Cohort of AIDS Research (CORIS) and the Pediatric Spanish Cohort of HIV-infected Children (CoRISpe)
1Hospital Universitario Gregorio Marañon, Madrid, Spain; 2Hospital Universitario Ramon y Cajal, Madrid, Spain; 312 de Octubre Hospital, Madrid, Spain; 4La Paz University Hospital, Madrid, Spain; 5Hospital de Donostia, San Sebastian, Spain; 6Centro Nacional de Epidemiologia, ISCIII, Madrid, Spain; 7Hospital Gregorio Marañon, Madrid, Spain

Session P-U4 Poster Session
2:30 pm – 4:00 pm
Treatment and Monitoring Strategies in Children

919 Long-Term Consequences of Planned Treatment Interruption in HIV—1—Infected Children
Riccardo Freguia; Hahah Poulsou; Paola Del Bianco; Alexandre Compagnucci; Yacine Saidi; Carlo Giaquinto; Lynya Harper; Diana M. Ghib; Nigel J. Klein; Anita De Rossi
1I AIDS Reference Center, Section of Oncology and Immunology, Padova, Italy; 2Institute of Child Health, London, United Kingdom; 3Istituto Oncologico Veneto—IRCCS, Padova, Italy; 4Inserm SC10, Paris, France; 5Department of Mother and Child Health, Padova, Italy; 6Medical Research Council, London, United Kingdom

920 Can CD4 Monitoring in Virologically Suppressed Children be Reduced or Stopped?
Mary-Ann Davies; Helena Rabie; Geoff Fatti; Kathryn Stinson; Karl-Günter Technau; Shobna Sawry; Brian Eley; Lynne Mofenson; Andrew Boullie; JeDEA Southern Africa
1University of Cape Town, Cape Town, South Africa; 2University of Stellenbosch, Cape Town, South Africa; 3Keth’s Impala, Cape Town, South Africa; 4University of the Witwatersrand, Johannesburg, South Africa; 5University of Witwatersrand, Johannesburg, South Africa; 6University of Cape Town, Cape Town, South Africa; 7Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 8University of Cape Town and University of Bern, Cape Town, South Africa

TUESDAY, FEBRUARY 24, 2015
Session P-U5 Poster Session
2:30 pm – 4:00 pm
Determinants of Disease Progression in Children

921 Impact of Sex Differences on Disease Outcome in Pediatric HIV in South Africa
Masahiko Mori; Emily Adland; Alice Swordy; Maximilian Muenchhoff; Nora Lavandier; Jacob Hurst; Thumbi Ndung’u; Andy Prendergast; Philip J. Goulder; Pieter Jooste
1University of Oxford, Oxford, United Kingdom; 2University of KwaZulu-Natal, Durban, South Africa; 3Queen Mary University of London, London, United Kingdom; 4Kimberley Hospital, Durban, South Africa

922 CD31 Expression on CD4 Cells Predicts Clinical Outcome of HIV in a Perinatally HIV-Infected Cohort
Ramia Zakhour; Gilhen Rodriguez; Cynthia Bell; Guenet Degaffa; Laura Benjamins; Gabriela DelBianco; Elizabeth Donnachie; Tran Dat; Gloria P. Heresi; James R. Murphy
1University of Texas, Houston, TX, US; 2UHealth Medical School, Houston, TX, US

923 Premature Aging and Immune Senescence in HIV-1-Infected Children
Ketty Giaнесin; Antoni Noquera-Julian; Marisa Zanchetta; Osvalda Rampon; Claudia Fortuny; Mineia Camoś; Carlo Giaquinto; Anita De Rossi
1University of Padova, Padova, Italy; 2Hospital Sant Joan de Déu—Universitat de Barcelona, Barcelona, Spain; 3Istituto Oncologico Veneto—IRCCS, Padova, Italy
Tuesday, February 24, 2015

Session P-U6 Poster Session
2:00 pm – 4:00 pm
Complications of HIV and ART: Pulmonary and Cardiovascular Outcomes

924 KIR/HLA Alleles Alter CD4+ Lymphocyte Count and Viral Load in HIV-Infected Children
Kumud Singh; Min Qin; Sean Brummel; Konstantia Angelidou; Rodney Trout; Terrence Fenton; Stephen Spector
1University of California San Diego, La Jolla, CA, US; 2Harvard School of Public Health, Boston, MA, US

925 Arterial Stiffness in HIV+ Youth and Associations With HIV-Related Variables
Allison R. Eckard; Julia C. Rosebush; Mary Ann O’Riordan; Christopher T. Longenecker; Bridget Wynn; Monika Uribe Leitz; Danielle Labbato; Norma Storer; Bruce Kinley; Grace A. McCamsey
1Emory University School of Medicine, Atlanta, GA, US; 2Case Western Reserve University, Cleveland, OH, US

926 Does Early ART Normalize Pulse-Wave Velocity in Children? Evidence From CHER Cohort
Steve Innes; Zukiswa Magogotya; Philip Herbst; Mark F. Cotton; Barbara Laughton; Sara Browne; Richard Haubrich
1Stellenbosch University, Cape Town, South Africa; 2University of California San Diego, San Diego, CA, US

927 The Impact of HIV and ART on Markers of Inflammation, Vascular Injury and Disordered Thrombogenesis in Children
Julia M. Kenny; Sarah Walker; Adrian Cook; Victor Musiime; Priscilla Wavamunno; Florence Odongo; Grace Mirembe; Dorica Masaku; Diana M. Gibb; Nigel J. Klein
1University College London, London, United Kingdom; 2Joint Clinical Research Centre, Kampala, Uganda; 3University Teaching Hospital, Lusaka, Zambia

928 T-Cell Activation and E-Selectin Associated With Coronary Plaque in HIV-Infected Youth
Julia B. Purdy; Aylin Unsal; Khaled Abd-Elmoniem; Adam Rupert; Joseph A. Kovacs; Rohan Hazra; Ahmed Gharib; Colleen Hadigan
1National Institutes of Health, Bethesda, MD, US

929 High Prevalence of Dyslipidemia and Insulin Resistance in African Children on ART
Steve Innes; Kameelah L. Abdullah; Richard Haubrich; Sara Browne; Mark F. Cotton
1Stellenbosch University, Cape Town, South Africa; 2University of California San Diego, San Diego, CA, US

930 Growth and Lipid Profiles in a South African Cohort of HIV+ Children and HIV Controls
Sarah Ramteke; Stephanie Shiau; Marc Foca; Renate Strehlau; Francoise Pinillos; Faezah Patel; Ayy Violari; Aafaq Liberty; Stephen M. Arpadi; Louise Kuhn
1Columbia University, New York, NY, US; 2University of the Witwatersrand, Johannesburg, South Africa; 3University of Witwatersrand, Johannesburg, South Africa

Thursday, February 26, 2015

Session P-U7 Poster Session
2:30 pm – 4:00 pm
Complications of HIV and ART: Bones, Brains, and Kidneys

931 Vitamin D Status and Bone Outcomes in Perinatally HIV-Infected Children
Denise L. Jacobson; Mitchell Geffner; Charles B. Stephens; Rohan Hazra; Kunjal Patel; Tracie L. Miller; Russell B. Van Dyke; Angela Ellis; Linda A. DiMeglio
For the Pediatric HIV/AIDS Cohort Study
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 2Children’s Hospital Los Angeles, Keck School of Medicine, Los Angeles, CA, US; 3USDA, Davis, CA, US; 4Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, US; 5University of Miami, Miami, FL, US; 6Tulane University School of Medicine, New Orleans, LA, US; 7Indiana University, School of Medicine, Indianapolis, IN, US; 8Harvard School of Public Health, Boston, MA, US; 9Frontier Science and Research Foundation, Amherst, NY, US

932 Bone Quality by Ultrasoundometry in South African HIV+ Children and HIV- Controls
Stephen M. Arpadi; Stephanie Shiau; Renate Strehlau; Francoise Pinillos; Faezah Patel; Louise Kuhn; Ashraf Coovadia; Sarah Ramteke; Jonathan Kaufman; Michael T. Yin
1Columbia University, New York, NY, US; 2University of the Witwatersrand, Johannesburg, South Africa; 3Mount Sinai School of Medicine, New York, NY, US

933 APOL1 Gene Variants and Chronic Kidney Disease in Perinatally HIV-Infected Youth
Murri Purswani; Kunjal Patel; Cheryl Winkler; Stephen Spector; Rohan Hazra; George Seage; Lynne Mofenson; Gwendolyn Scott; Russell Van Dyke; Jeffrey Kopf
For the Pediatric HIV/AIDS Cohort Study (PHACS)
1Albert Einstein College of Medicine, Bronx, NY, US; 2Harvard School of Public Health, Boston, MA, US; 3National Cancer Institute (NCI), Bethesda, MD, US; 4University of California San Diego, San Diego, CA, US; 5Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, US; 6University of Miami, Miami, FL, US; 7Tulane University, New Orleans, LA, US; 8National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, US

934 Cystatin C Is a Marker for Both Inflammation and Renal Function in HIV+ Children
Angela Deyà-Martínez; Claudia Fortuny; Pere Soler-Palacin; Olaf Neth; Emilia Sánchez; Andrea Martín-Nalda; Lola Falcón-Neyra; Anna Villa; Anna Valls; Antoni Noguera-Julian
1Hospital Sant Joan de Déu, Esplugues, Spain; 2Hospital Vall d’Hebron, Barcelona, Spain; 3Hospital Virgen del Rocío, Sevilla, Spain; 4Universitat Ramon Llull, Barcelona, Spain

935 Cognitive Performance and Intracerebral Findings in Perinatally HIV-Infected Children
Sophie Cohen; Matthan W. Caan; Jacqueline A. ter Steege; Henriette J. Scherbier; Taco W. Kuipers; Peter Reiss; Gerrit J. Geurtsen; Charles B. Majoe; Ben Schmand; Dasja Pajkrt
1Emma Children’s Hospital AMC, Amsterdam, Netherlands; 2Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 3Academic Medical Center University of Amsterdam, Amsterdam, Netherlands; 4Emma Children’s Hospital, Amsterdam, Netherlands
936 Executive Functions Among Perinatally HIV-Exposed and HIV-Infected Youth
Sharon L. Nichols; Miriam Chernoff; Kathleen M. Malee; Patricia A. Sirois; Paige L. Williams; Betsy L. Kammerer
the Memory Substudy Team of the Pediatric HIV/AIDS Cohort Study (PHACS)
1University of California, San Diego, La Jolla, CA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Northwestern University Feinberg School of Medicine, Chicago, IL, US; 4Tulane University School of Medicine, New Orleans, LA, US; 5Children’s Hospital Boston, Boston, MA, US

937 Sleep Disturbances in a Cohort of HIV-Infected Children and Adolescents on Antiretroviral Treatment: NeuroCoRISpeS
Cristina García-Navarro; Santiago Jiménez de Ory; María Luisa Navarro-Gomez; José Tomás Ramos Amador; María Jose Mellado; Luis Prieto; Pablo Rojo Conejo; Esmeralda Nuñez; María Isabel González-Tomé
On behalf of the CoRISpeS, AMadrid Cohort
1Hospital Universitario 12 de Octubre, Madrid, Spain; 2Hospital Universitario Gregorio Marañón, Madrid, Spain; 3Hospital Universitario La Paz, Madrid, Spain; 4Hospital Regional Universitario Carlos Haya, Málaga, Spain; 5Hospital Universitario de Getafe, Getafe, Spain; 6Hospital Universitario Clínico San Carlos, Madrid, Spain; 7Madrid, Madrid, Spain

938 Tuberculosis Among Children on Antiretroviral Therapy in Swaziland, 2004-2012
Melissa A. Briggs; Andrew Auld; Harrison Kamuru; Harriet Nuwagaba-Birinconwha; Velephi Okello; George Bicugo; Andrew L. Baughman; Simon Agolory; Todd V. Ellerbrock; Peter Ehrenkranz
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Mailman School of Public Health, New York, NY, US; 3Swaziland Ministry of Health, Mbabane, Swaziland; 4US Centers for Disease Control and Prevention (CDC), Mbabane, Swaziland

939 Mycobacterium TB Disease in HIV-Infected Children Receiving LPV/r or NVP-Based ART
Mohemdran Archary; Linda Barlow-Mosha; Avy Volari; Jane Lindsey; Lynne Mofenson; Patrick Jean-Philippe; Bonnie Zimmer; Paul E Palumbo
1University of KwaZulu-Natal, Durban, South Africa; 2MUJHU Care Ltd/ MUJHU Research Collaboration, Kampala, Uganda; 3Perinatal HIV Research Unit, Johannesburg, South Africa; 4Frontier Science, Amherst, NY, US; 5Geisel School of Medicine at Dartmouth, Lebanon, NH, US

940 Safety of Rifabutin in HIV/TB-Coinfected Children on Protease Inhibitor-Based ART
Holly E. Rawizza; Kristin M. Darin; Kimberly K. Scarsi; Biobele Brown; Regina Oladosun; Nikiru David; Sulaimon Akanmu; Oluremi Olaitan; Prosper Okonkwo; Phyllis Kanki
On behalf of the APIN PEPFAR Team
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2Northwestern University, Feinberg School of Medicine, Chicago, IL, US; 3University of Nebraska Medical Center, Omaha, NE, US; 4University College Hospital, Ibadan, Nigeria; 5National Institute of Medical Research, Lagos, Nigeria; 6Lagos University Teaching Hospital, Lagos, Nigeria; 7AIDS Prevention Initiative in Nigeria, Abuja, Nigeria; 8Harvard School of Public Health, Boston, MA, US

941 Skin Complaints in African Children Randomized to Stop or Continue Cotrimoxazole
Andrew Prendergast; Mutsa F. Bwakura Dangarembizi; Peter Muyenyi; Joseph Lutaakome; Adeo Adeleke; Diana M. Gibb; Sarah Walker
On behalf of the ARROW Trial Team
1Queen Mary University of London, London, United Kingdom; 2University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; 3ICRC, Kampala, Uganda; 4MRC/UUVI Uganda Research Unit on AIDS, Entebbe, Uganda; 5Baylor Uganda, Kampala, Uganda; 6MRC Clinical Trials Unit at University College London, London, United Kingdom

942 Disease Progression and Response to Treatment in Vertically HIV/HVC Co-infected Patients
Talia Sainz; Carolina Fernández McPhee; Santiago Jiménez de Ory; Pablo Rojo; María del Carmen Otero; Milagros Garcia Lopez-Hortelano; Olaf Neith; José Beceiro; Maribel González Tomé; María Luisa Navarro
On behalf of the Spanish Cohort of HIV-Infected Children and Adolescents (CoRISpe)
1Hospital Universitario Gregorio Marañón, Madrid, Spain; 2Hospital Ramón y Cajal, SEIM-Gesida, Madrid, Spain; 3Hospital 12 de Octubre, Madrid, Spain; 4Hospital La Fe, Valencia, Spain; 5Hospital La Paz, Madrid, Spain; 6Hospital Gregorio Marañón, Madrid, Spain; 7Hospital Virgen del Rocio, Sevilla, Spain; 8Hospital de Alcalá, Alcalá de Henares, Spain

943 Human Papillomavirus and Cervical Cytology in Perinatally Infected Asian Adolescents
Annette H. Soha; Stephen J. Kerr; Rawiwan Hansudewechakul; Wasana Prasitsuebsai; Kulanya Chokephahibulkit; Truong V. Nguyen; Thoa P. Le; Thida Singtoroj; Nittaya Phanuphak; HPV in Adolescents Study
1TREAT Asia/amfAR – The Foundation for AIDS Research, Bangkok, Thailand; 2HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; 4Siriraj Hospital, Mahidol University, Bangkok, Thailand; 5Hung Yoon Hospital, Ho Chi Minh City, Viet Nam; 6Children’s Hospital 1, Ho Chi Minh City, Viet Nam; 7SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand
944  Sexually Transmitted Infections in Youth With Controlled and Uncontrolled HIV
Andres F. Camacho-Gonzalez; Miriam C. Chernoff; Paige L. Williams; Ann Chahroudi; James M. Oleske; Rana Chakraborty; Shirley Traite; Murli U. Purwani; Mark J. Abzug
On behalf of the IMPACT P1074 Study Team
1Emory University School of Medicine, Atlanta, GA, US; 2Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, US; 3Rutgers New Jersey Medical School, Newark, NJ, US; 4Albert Einstein College of Medicine, Division of Pediatric Infectious Diseases, Bronx Lebanon Hospital Center, Bronx, NY, US; 5University of Colorado School of Medicine, Division of Pediatric Infectious Diseases, Aurora, CO, US; 6International Maternal Pediatric Adolescent AIDS Clinical Trials, Durham, NC, US

TUESDAY, FEBRUARY 24, 2015

Session P-U9 Poster Session  Poster Hall
2:30 pm – 4:00 pm Responses to Vaccines in Children

945  Sustained Responses to Measles Revaccination in HIV-Infected Children on ART in Kenya
Laura Newman; Anne Njoroge; Bhavna Chohan; Amalia Magaret; Jonathan Gorstein; Julie M. Overbaugh; Dalton Wamalwa; Elizabeth M. Obimbo; Ruth W. Nduati; Carey Farquhar
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3University of Nairobi, Nairobi, Kenya

946  T-Cell Anergy and Activation Are Associated With Suboptimal Humoral Responses to Measles Revaccination in HIV-Infected Children on Antiretroviral Therapy in Nairobi, Kenya
Matthew B. Buechler; Laura Newman; Bhavna Chohan; Anne Njorge; Dalton Wamalwa; Carey Farquhar
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US; 3University of Washington, Seattle, WA, US; 4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 5Kenyatta National Hospital, Nairobi, Kenya; 6University of Nairobi, Nairobi, Kenya

947  Molecular Profiles of CXCR5+ CD4 Memory T Cells Associated With Flu Vaccine Response
Lesley R. de Armas; Nicola Cotugno; Suresh Pallikkuth; Alberto Cagigi; Paolo Palma; Paolo Rossi; Savita Pahwa
1University of Miami Miller School of Medicine, Miami, FL, US; 2Children's Hospital Bambino Gesu, Rome, Italy; 3Children's Hospital Bambino Gesu, Rome, Italy

948  The Potential of BCG and HIV-TB Vaccines to Exacerbate HIV-1 Pathogenesis in Infants
Kara Jensen; Koen K. Van Rompay; William R. Jacobs; Glenn Fennessy; Katie Mollan; Michael G. Hudgens; Mike Piatak; Michelle H. Larsen; Kristina De Paris
1University of North Carolina, Chapel Hill, NC, US; 2California National Primate Research Center, University of California, Davis, CA, US; 3Albert Einstein College of Medicine, New York, NY, US; 4Frederick National Laboratory, Frederick, MD, US

Session P-U10 Poster Session  Poster Hall
2:30 pm – 4:00 pm Pharmacokinetics, Safety, and Efficacy of ART in Children and Youth

949  Prediction of ARV Drug Clearance in Children
Frantz Feissac; Naim Bouazza; Elodie Valade; Majils De Sousa; Floris Fauchet; Sihem Benaboud; Deborah Hirt; Stéphane Blanche; Saik Urien; Jean-Marc Treluyer
EA 08 Université Paris Descartes, Sorbonne Paris Cité, Unité de Recherche Clinique, AP-HP; Hôpital Tarnier, Paris, France, Paris, France

950  Use of Maraviroc in HIV-1-Infected Paediatric Patients in Clinical Practice
Claudia Palladino; Maria Luisa Navarro Gomez; Pere Soler-Palacin; Maria Isabel Gonzalez-Tome; Santiago Jimenez de Ory; Maria Espiau; Juan Antonio León-Leal; Claudia Fortuny; Verónica Briz
CoRISpe working group
1University of Lisbon, Lisbon, Portugal; 2National Center for Microbiology, Madrid, Spain; 3Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain; 4Hospital Infantil Universitario Virgen del Rocío, Seville, Spain; 5Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6Hospital General Universitario Gregorio Marañón, Madrid, Spain; 7Hospital Universitario Doce de Octubre, Madrid, Spain

951  Safety and Pharmacokinetics of Elvitegravir in HIV-1 Infected Pediatric Subjects
Joseph M. Custodio; Víctor Musiime; Aditya Gaur; Elizabeth McFarland; Wasana Prasitsuebsai; Lize Hellstrom; Xuelian Wei; Rebecca Begley; Srinivasan Ramanathan; Sean R. Bennett
1Gilead Sciences, Inc., Foster City, CA, US; 2Joint Clinical Research Centre, Kampala, Uganda; 3STUDE Children’s Research Hospital, Memphis, TN, US; 4University of Colorado Denver, Aurora, CO, US; 5HIV - NAT, Bangkok, Thailand; 6Be Part Yoluntu Centre, Cape Town, South Africa

952  Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs
Danielle P. Porter; Sean R. Bennett; Erin Quirk; Michael D. Miller; Kirsten L. White
Gilead Sciences, Inc., Foster City, CA, US

953  Week-24 Data From a Phase 3 Clinical Trial of E/C/F/TAF in HIV-Infected Adolescents
Hilda Kizito; Aditya Gaur; Wasana Prasitsuebsai; Natella Rakhmanina; Eileen Lawson; Yongwu Shao; Sean R. Bennett; Andrew Cheng; Erin Quirk
1Gilead Sciences, Inc., Foster City, CA, US; 2Joint Clinical Research Centre, Kampala, Uganda; 3STUDE Children’s Research Hospital, Memphis, TN, US; 4HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand; 5Children’s National Health System, Washington, DC, US

954  Efficacy and Safety of Long-Term Tenofovir DF (TDF) Therapy in HIV-Infected Children
Xavier Saez-Llorens; Jaime G. Deville; Ayisha Mirza; Janet S. Chen; Aditya Gaur; Moebeen Rathore; Dana Hardin; Ya-Pei Liu; Erin Quirk
GS-US-104-0352 Study Team
1Gilead Sciences, Inc., Foster City, CA, US; 2Hospital del Niño, Panama City, Panama; 3University of California Los Angeles, Los Angeles, CA, US; 4University of Florida, Jacksonville, FL, US; 5Drexel University College of Medicine, Philadelphia, PA, US; 6STUDE Children’s Research Hospital, Memphis, TN, US; 7Eli Lilly, Indianapolis, IN, US
955  Acceptability of Lopinavir/r Minitabs, Tablets and Syrups in HIV-Infected Children
  Adeodata Kekitiiwaa
  CHAPAS-2
  Baylor College of Medicine Children's Foundation Uganda, Kampala, Uganda

956  Therapeutic Drug Monitoring of Lopinavir in HIV-Infected Children on Second-Line ART
  Linda Auripibul1; Wasana Prasitsuebsai2; Tavitiny Sujaatrakul1; Pope Kosalaraks1; Nia Kurniati3; Khanh Huu Truong3; Viet Chau Do4; Sirimaya Teeraananchai4; Stephen J. Kerr4
  the TASER-Pediatrics Study Group
  1Research Institute for Health Sciences, Chaing Mai University, Chiang Mai, Thailand; 2The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 3Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; 5Children's Hospital 1, Ho Chi Minh City, Viet Nam; 6Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 7Children's Hospital 2, Ho Chi Minh City, Viet Nam

WEDNESDAY, FEBRUARY 25, 2015

Session P-V1 Poster Session
2:30 pm – 4:00 pm
Poster Hall

957  Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis
  Surasak Wiboonchutikul1; Varaporn Thientong1; Patama Sutha1; Boonchai KowdasaiBurana2; Weerasawat Manosuthi1
  1Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand; 2Bangkok Hospital, Bangkok, Thailand

958  Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis
  Rosalind Foster1; John McAllister1; Tim R. Read1; Anna Pierce1; Robyn Richardson1; Anna McNulty1; Andrew Carr2
  On behalf of the EPEP Study Researchers
  1Sydney Sexual Health Centre, Sydney, Australia; 2St Vincent's Centre for Applied Medical Research, Sydney, Australia; 3Melbourne Sexual Health Centre, Melbourne, Australia; 4The Alfred Hospital, Melbourne, Australia

959  Tenofovir/Emtricitabine Plus LPV/r vs MCV or Raltegravir for PEP: 2 Randomized Trials
  Lorna Leal1; Agathe Leon2; Berta Torres; Alexey Inciarte; Constanza Lucero; Josep Mallolas; Maria Martinez-Rebollar; Ana Gonzalez-Cordón; Jose M. Gatell; Felipe Garcia
  Hospital Clinic Barcelona, Barcelona, Spain

960  Effects of Three Regimens of PEP on the Immune System of HIV-Seronegative Individuals
  Alberto C. Guardo1; Lorna Leal2; Agathe Leon; Cristina Rodriguez de Miguel3; Manel E. Bargallo; Cristina Rovira; Josep Llach; Jose M. Gatell; Felipe Garcia; Montserrat Plana1
  1L’Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; 2Hospital Clinic, Barcelona, Spain

961  Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learnt
  Goli Haidari1; Naomi Fitzgerald2; Sonia Raffe3; Nneka Nwokolo2; Olamide Dosekun; Mark D. Lawton1; Nickie Mackie1; Julie Fox4; Martin Fisher4; Sarah Fidler1
  1St Mary's Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom; 2Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 4Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; 5The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 6St Mary's Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom; 7Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; 8Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 9St Mary's Hospital—Imperial College Healthcare NHS Trust, London, United Kingdom

THURSDAY, FEBRUARY 26, 2015

Session P-V2 Poster Session
2:30 pm – 4:00 pm
Poster Hall

962  FTC/TDF Prevents SHIV Infection in C trachomatis and T vaginalis-Infected Macaques
  Jessica Radzio; Tara Henning; James Mitchell; Angela Holder; Debra Hanson; Janet McNicholl; Waldid Heneine; John Papp; Ellen Kesh; Gerardo Garcia-Lerma
  US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

963  Impact of Sexually Transmitted Infections on the Efficacy of Tenofovir Vaginal Gel in Macaques
  Natalia Makarova; Tara Henning; Andrew Taylor; Chuong Dinh; Carol Farshy; Janet McNicholl; John Papp; Waldid Heneine; Ellen Kesh; Charles W. Dobard
  US Centers for Disease Control and Prevention, Atlanta, GA, US

964  Oral Single-Dose Maraviroc Does Not Prevent Ex Vivo HIV Infection of Rectal Mucosa in Healthy HIV-1—Negative Human Volunteers in Tissue Explants.
  Josep Coll1; José Multí2; Jaume Boix3; Laura Ese3; Elisabet García1; Roger Paredes1; David Back4; Bonaventura Clotet1; Cecilia Cabrera1
  1Institut de Recerca de la Sida IRISCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 2Fundació Lluita Contra la SIDA, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain; 3Unidad de Endoscopia Digestiva. Hospital Universitario Germans Trias i Pujol, Barcelona, Spain; 4Pharmacology Research Laboratories, Liverpool, United Kingdom; 5Fundació Lluita Contra la SIDA-IRISCaixa, VIC-UC (Universitat de Vic-Universitat Central de Catalunya), Barcelona, Spain

965  CCR5 Blockade With Maraviroc Does Not Prevent SIVmac Oral Transmission to Macaques
  Egidio Brocca-Cofano1; Cuiling Xu; Dongzhu Ma3; Benjamin Policicchio; Kevin Raehz; Tammy Dunsmore; George Richter-Harelt; Brandon F. Keele2; Ivona Pandrea; Cristian Apelei1
  1University of Pittsburgh, Pittsburgh, PA, US; 2National Cancer Institute (NCI), Frederick, MD, US
966LB  Correlation of In Vivo Cabotegravir Concentration and Prevention of SIV in Macaques
William R. Spreen1; Anabel Lowry2; Ranajit Pal3; Yun Lan Yueh4; Susan Ford5; Nicola Richardson-Harman1; Jim A. Turpin5; Fulvia Veronesi1; James E. Cummins1
ABL/BIOQUAL NHP Team

967  MZC Gel Inhibits Ex Vivo HIV-1 and HSV-2 Infection in Human Cervical Mucosa
Guilermo Villegas1; Giulia Calenda; Patrick Barnable; Keith Levendosky; Michael Cooney; José Fernández-Romero; Thomas Zydowsky; Natalia Teleshova
Population Council, New York, NY, US

968  GRFT/Carrageenan Gel Inhibits SHIV-RT and HSV-2 Infection in Macaque Vaginal Mucosa
Giulia Calenda1; Patrick Barnable1; Keith Levendosky5; Kyle Kleinbeck1; Agegenehu Gettie4; James Blanchard3; José Fernández-Romero1; Barry O'Keefe1; Thomas Zydowsky5; Natalia Teleshova1

971  Preliminary Follow-up of Injecting Drug Users Receiving PrEP
Michael T. Martin1; Suphak Vanichseni2; Pravan Suntharasamai3; Udomsak Sangkum2; Philip Mock3; Mano Leethochawalit4; Sithisat Chiamwongpaet5; Somyot Kittimunkong1; Marcel Curalin4; Kachit Choopanya1
1US Centers for Disease Control and Prevention (CDC), Nonthaburi, Thailand; 2Bangkok Tenofovir Study Group, Bangkok, Thailand; 3Bangkok Metropolitan Administration, Bangkok, Thailand; 4Ministry of Public Health, Nonthaburi, Thailand

972  Recent Increases in PrEP Utilization at a Boston Community Health Center Among Men Who Have Sex With Men, 2011-2014: Transition From Research to Clinical Practice
Kenneth H. Mayer1; Kenneth Levine1; Chris Grasso1; Douglas S. Krakower2; Matthew Mimiaga3
1Boston Medical Center, Boston, MA, US; 2Boston University School of Medicine, Boston, MA, US; 3Harvard School of Public Health, Boston, MA, US

973  Barriers to Effective Prevention: Applying a PrEP Care Continuum to a US Cohort of Black and White MSM
Colleen F. Kelley1; Erin M. Kahlb; Aaron Siegler; Carlos del Rio; Travis Sanchez; Patrick Sullivan; Eli S. Rosenberg
Emory University, Atlanta, GA, US

974  Provider Prescription of PrEP
Shikha Garg; John Weiser; Linda Beer; Jacek Skarbinski
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

TUESDAY, FEBRUARY 24, 2015

Session P-V3 Poster Session  Poster Hall
2:30 pm – 4:00 pm
PrEP: Uptake

Renee Heffron1; Kenneth Figure2; Nulu Bulya Semiyaga3; Josephine Odoyo1; Edna Tindimwebwa4; Jennifer Morton4; Lara Kidoguchi5; Mark A. Marzinke6; Connie Celum6; Jared Baeten1
Partners Demonstration Project Team
1University of Washington, Seattle, WA, US; 2Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya; 3Makerere University College of Health Sciences, Kampala, Uganda; 4Kenya Medical Research Institute, Nairobi, Kenya; 5Kabwohe Clinic Research Center, Kabwohe, Uganda; 6Johns Hopkins University School of Medicine, Baltimore, MD, US

970  PrEP Engagement for HIV Prevention: Results From the iPrEx Open Label Extension (OLE)
David V. Glidden1; Susan P. Buchbinder2; Peter L. Anderson2; Vanessa McMahan3; K. Rivet Amico4; Albert Liu5; Sybil Hosek5; Megha Mehrotra5; Robert M. Grant6
iPrEx Investigators

975  Urine Assay for Tenofovir to Monitor Adherence to Tenofovir-Etricitabine as PrEP
Helen C. Koenig1; Karam Mouner2; Giffin W. Daughtridge3; Caroline E. Sloan1; Linden Lalley-Chareczok5; Ganesh Moorthy1; S. Caitlin Coneyingham1; Elizabeth Ketner1; Luis J. Montaner3; Pablo Tetas3

976  Comparison of Adherence Measures in a Clinical Trial of Preexposure Prophylaxis
Davis C. Munganzi1; Jessica Haberer2; Yap Boum3; Nicholas Musinguzi4; Allan Ronald5; Connie Celum6; Jared Baeten6; David R. Bangsberg1
1Mbarara University of Science and Technology, Kampala, Uganda; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3University of Washington, Seattle, WA, US; 4University of Manitoba, Winnipeg, Canada

977  Self-Reported Recent PrEP Use Has Strong Relation to Drug Detection in iPrEx OLE
Rivet Amico; Vanessa McMahan; Megha Mehrotra; Peter L. Anderson; Juan Guanina; Valdilea Veloso; Robert M. Grant
iPrEx study team
1University of Michigan, Ann Arbor, MI, US; 2Gladstone Institute, San Francisco, CA, US
Linda-Gail Bekker; James Hughes; Rivet Amico; Surita Roux; Craig Hendrix; Peter L. Anderson; Bonnie Dye; Vanessa Elharrar; Michael J. Stirrat; Robert Grant  
1Dept of Medicine and Institute of Infectious Disease and Molecular Medicine, Cape Town, South Africa; 2HIV Prevention Trials Network, Seattle, WA, US; 3The Desmond Tutu HIV Centre, Cape Town, South Africa; 4University of Michigan, Ann Arbor, MI, US; 5Johns Hopkins University, Baltimore, MD, US; 6University of Colorado, Aurora, CO, US; 7FH360, Durham, NC, US; 8PSP/DAIDS/NIADDK, Bethesda, MD, US; 9Center for Mental Health Research on AIDS, Bethesda, MD, US; 10University of California, San Francisco, CA, US

979  **Correlates of Early Adherence in VOICE PrEP Trial Differ Between Oral and Vaginal Products**  
Ariane van der Straten; Elizabeth R. Brown; James Dai; Craig Hendrix; Karen Liu; Cynthia Grossman; Z M. Chirenje; Jeanne Marrazzo  
1RTI, San Francisco, CA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3Johns Hopkins School of Medicine, Baltimore, MD, US; 4National Institute of Mental Health (NIMH), Bethesda, MD, US; 5University of Zimbabwe—University of California San Francisco Research Collaboration, Harare, Zimbabwe; 6University of Washington, Seattle, WA, US

980  **Intimate Partner Violence Is Associated With Low PrEP Adherence in African Women**  
Sarah T. Roberts; Connie Celum; Nelly Mugo; Jessica Haberer; Craig R. Cohen; Elizabeth Iru growa; James N. Kiarie; Edwin Were; Jared Baeten  
On behalf of the Partners PrEP Study Team  
1University of Washington, Seattle, WA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Kenya Medical Research Institute, Nairobi, Kenya; 4University of California San Francisco, San Francisco, CA, US; 5Kenya National Hospital, Nairobi, Kenya; 6University of Nairobi, Nairobi, Kenya; 7Moi University, Eldoret, Kenya

**WEDNESDAY, FEBRUARY 25, 2015**

**Session P-V5 Poster Session**  
**Poster Hall**  
**2:30 pm – 4:00 pm**  
**PrEP: Evaluating Potential Harm**

981  **Reversibility of Kidney Function Decline in HIV-1–Uninfected Men and Women Using Preexposure Prophylaxis**  
Kenneth K. Mugwanya; Christina Wyatt; Connie Celum; Deborah Donnell; Nelly Mugo; James N. Kiarie; Allan Ronald; Jared Baeten  
On behalf of the Partners PrEP Study Team  
1University of Washington, Seattle, WA, US; 2Mount Sinai School of Medicine, New York, NY, US; 3Fred Hutchinson Cancer Research Center, Seattle, WA, US; 4Kenya Medical Research Institute, Nairobi, Kenya; 5University of Nairobi, Nairobi, Kenya; 6University of Manitoba, Winnipeg, Canada

982  **Minor Drug-Resistant Variants Infrequently Detected in Seroconverters From MTN 003 (VOICE)**  
Constantinos Panousis; Elias K. Halvas; Clifford Kelly; Jeanne Marrazzo; Z M. Chirenje; John W. Mellors; Urvi M. Parikh  
On behalf of the MTN 003 Protocol Team  

983  **PrEP-Selected Drug Resistance Fades by Six Months Following Drug Cessation**  
Julie F. Weiss; Jared Baeten; Ruth Kanthula; Connor McCoy; Lisa Frenkel; Nelly Mugo; Frederick Matsen; Julie M. Overbaugh; Connie Celum; Dana A. Lehman  

984  **Randomized Controlled Trial on ART Outcomes in Tenofovir Gel Trial Seroconvertors**  
Anushka Naidoo; Nivashee Naicker; Lise Werner; Nigel Garrett; Sarah Dlamini; Villeshni Asari; Nelsile Majola; Cheryl Baxter; Quarraisha Abdool Karim; Salim S. Abdool Karim  
Center for the AIDS Program of Research in South Africa, Durban, South Africa

985  **Frequent Dapivirine Cross-Resistance of HIV from 1st-line ART Failures in S. Africa**  
Kerri J. Penrose; Kristen A. Hamanishi; Kelly C. Gordon; Raquel V. Viana; Carole L. Wallis; John W. Mellors; Urvi M. Parikh  
1University of Pittsburgh, Pittsburgh, PA, US; 2Lancet Laboratories, Johannesburg, South Africa; 3Lancet Laboratories/BARC-SA, Johannesburg, South Africa

986  **Effect of TDF Monotherapy PrEP on Immune Function in Seroconverting Individuals**  
Marcel E. Curlin; Michael T. Martin; Punneeporn Wasinrapee; Wanna Leelawiwat; Boonyos Raengsakulrach; Janet McNicholl; Pravan Suntharasamai; Udomsak Sangkum; Suphak Vanichseni; Kachit Choopanya  
1US Centers for Disease Control and Prevention (CDC), Apo, US; 2Thailand Ministry of Public Health–Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; 3Bangkok Tenofovir Study Group, Bangkok, Thailand

987  **The Impact of Preexposure Prophylaxis on Antibody Maturation in HIV-Infected Women**  
Oliver B. Laeyendecker; Andrew D. Redd; Martha Nason; Andrew Longosz; Quarriasha Abdool Karim; Vivek Naranhbhai; Nigel Garrett; Salim S. Abdool Karim; Thomas C. Quinn  
1National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 3National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
**Session P-V6 Poster Session**

**Poster Hall**

**HIV Prevention, Miscellaneous**

988 Medication Sharing Among African HIV Serodiscordant Couples Enrolled in a PrEP Trial  
Kerry A. Thomson1; Jessica Haberer2; Connie Celum1; Andrew Mujugira1; Patrick Ndase2; Craig Hendrix1; Mark A. Marzinke1; Allan Ronald1; David Bangsberg3; Jared Baeten1  
On behalf of the Partners PrEP Study Team  
1University of Washington, Seattle, WA, US; 2Johns Hopkins University, Baltimore, MD, US; 3University of Manitoba, Winnipeg, Canada; 4Massachusetts General Hospital, Boston, MA, US

994 CHARM-01, a Phase 1 Rectal Safety, Acceptability, PK/PD Study of 3 Tenofovir Gels  
Ian McGowan1; Kathy Duffill2; Charlene Dezutto1; Nicola Richardson-Harman2; Mark A. Marzinke1; Ross D. Cranston1; Lisa Rohan4; Craig W. Hendrix1; Julie Elliott3; Peter Anton1  
1University of Pittsburgh, Pittsburgh, PA, US; 2Magee-Womens Research Institute, Pittsburgh, PA, US; 3Alpha StatConsult LLC, Damascus, MD, US; 4Johns Hopkins University School of Medicine, Baltimore, MD, US; 5David Geffer School of Medicine at University of California Los Angeles, Los Angeles, CA, US

995 Female Condom Functionality in the Presence of a Vaginal Ring  
Annalene M. Nel1; Milide Leuvennink1; Neliette Van Niekerk1; Terri Walsh2; Ron Frezieres2  
1International Partnership for Microbicides, Paarl, South Africa; 2California Family Health Council Inc, Los Angeles, CA, US

**THURSDAY, FEBRUARY 26, 2015**

**Session P-V6 Poster Session**

**Poster Hall**

**HIV Prevention, Miscellaneous**

989 HIV-1 Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy  
Andrew Mujugira1; Katherine Thomas1; Connie Celum1; Deborah Donnelly2; Carey Farquhar3; Elizabeth Bukusi4; Jared Baeten5  
On behalf of the Partners PrEP Study Team  
1University of Washington, Seattle, WA, US; 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 3Kenya Medical Research Institute, Nairobi, Kenya

990 Long-Term ART Outcomes in Botswana Encouraging Treatment as Prevention Approach  
Hermann Bussmann1; William C. Wester2; Ernest Fetogang3; Tony Chebani2; Sihkulluie Moyo2; Naledi M. Mlaudzi2; Erik V. Widenfelt1; Joseph Makhema1; Max Essex3; Richard Marlink4  
1Vanderbilt University School of Medicine, Nashville, TN, US; 2Botswana Medical Research Institute Partnership for HIV Research and Education, Gaborone, Botswana; 3Botswana Harvard AIDS Institute Partnership for HIV Research and Education, Gaborone, Botswana; 4Harvard School of Public Health, Boston, MA, US

991LB Use of Population Viral Load to Predict HIV-Incidence in a Hyperendemic Population in Rural KwaZulu-Natal, South Africa  
Frank Tanser1; Julio de Oliveira2; Till Barnighausen1; Deenan Pillay1  
1University College London, London, United Kingdom; 2Harvard School of Public Health, Boston, MA, US; 3University of KwaZulu-Natal, Mtubatuba, South Africa

**TUESDAY, FEBRUARY 24, 2015**

**Session P-W1 Poster Session**

**Poster Hall**

**HIV Testing and the Continuum of Care in the Industrialized World**

996 Continuous Retention Predicts Viral Suppression Across the US and Canada  
Peter F. Rebeiro1; Baligh R. Yehia2; Kelly Gebo1; Bryan Lau1; Kenneth H. Mayer2; Michael A. Horberg3; Mari Kitahata4; John Gill5; Timothy Sterling6; Stephen J. Gange1  
1North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD); 2Vanderbilt University, Nashville, TN, US; 3University of Pennsylvania, Philadelphia, PA, US; 4Johns Hopkins University, Baltimore, MD, US; 5Harvard University, Boston, MA, US; 6Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, MD, US; 7University of Washington, Seattle, WA, US; 8University of Calgary, Alberta Health Services, Calgary, Canada

997 Disparities in HIV Viral-Load Suppression Among MSM, the HIV Outpatient Study, 2013  
Kate Buchacz1; Carl Armon2; Ellen Tedaldi3; Frank J. Palella4; Richard Novak5; Doug Ward6; Benjamin Young7; Rachel Debes8; Marcus Durham9; John T. Brooks1  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Cerner Corporation, Vienna, VA, US; 3Temple University School of Medicine, Philadelphia, PA, US; 4Northwestern University, Chicago, IL, US; 5University of Illinois at Chicago, Chicago, IL, US; 6University of Nebraska Medical College, Omaha, NE, US; 7Northwestern University, Chicago, IL, US; 8University of Michigan, Ann Arbor, MI, US; 9University of Nebraska Medical College, Omaha, NE, US

998 Early Linkage to HIV Care and Antiretroviral Therapy Use Among People Who Inject Drugs: 20 US Cities, 2009 and 2012  
Brooke Hoots1; Teresa Finlayson; Dita Broz; Gabriela Paz-Bailey2  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2Magee-Womens Research Institute, Pittsburgh, PA, US
999 Late HIV Diagnosis in Metropolitan Areas of the United States and Puerto Rico
H. Irene Hall1; Tian Tang2; Lorena Espinoza3
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2ICF International, Atlanta, GA, US

1000 HIV Care During the Last Year of Life
H. Irene Hall1; Lorena Espinoza2; Shericka Harris3; Jing Shi2
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2ICF International, Atlanta, GA, US

1001 Reductions in the Time From HIV Infection to ART Initiation in New York City
Sarah L. Braunstein1; McKaylee Robertson1; Julie Myers1; Bisrat Abraham1; Denis Nash1
1New York City Department of Health and Mental Hygiene, Queens, NY, US; 2City University of New York, New York, NY, US; 3Weill Cornell Medical College, New York, NY, US; 4City University of New York School of Public Health, New York, NY, US

1002 Return to HIV-Related Medical Care After a Hiatus of ≥1 Year, New York State, 2013
Carol-Ann Swain1; Daniel Gordon1; Jessica L. Simpson1; Bridget J. Anderson1; Bruce D. Agins1; Lou C. Smith1

1003 Care-Cascade Status of Partners of Persons With New HIV Infections in North Carolina
Anna B. Cope1; Lisa Hightow-Weidman1; JoAnn D. Kuruc1; Jenni Marmorino1; Steve Beagie1; Philip J. Peters1; Cynthia L. Gay1
1University of North Carolina, Chapel Hill, NC, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1004 The Role of HIV Status Disclosure in Retention in Care and Viral-Load Suppression
Latesha E. Elopre1; Andrew Westfall1; Michael J. Mugavero2; Anne Zinski2; Greer Burkholder1; Edward Hook1; Nicholas Van Wagoner1 University of Alabama at Birmingham, Birmingham, AL, US

1005 Alcohol and Substance Use and Timing of Presentation to HIV Care Across the United States
Jesse Abbott Klafter1; Daniel R. Drozd1; Michael J. Mugavero1; Katerina Christopoulos1; Christopher W. Mathews1; Joseph J. Eron1; Kenneth H. Mayer1; Henry M. Crane1

1006 Marijuana Use and Its Nuanced Relationship With HIV Treatment Continuum Metrics
John A. Schneider1; Ethan Morgan1; Stuart Michaels2; Britt Skaathun1; Lindsay Young3; Robert W. Coombs1; Phil Schumm1; Dexter Voisin1; Sam Friedman1

1007 “Test-and-Treat” in the Netherlands
Ard van Sighem1; Luuk Gras1; Elise Op de Coul1; Daniela Bezemer1; Michiel van Agtmael1; Godelieve de Bree1; Peter Reis3
1On behalf of the ATHENA National Observational HIV Cohort 2Stichting HIV Monitoring, Amsterdam, Netherlands; 3National Institute for Public Health and the Environment, Bilthoven, Netherlands; 4VU University Medical Centre, Amsterdam, Netherlands; 5Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands

1008 Estimates of HIV Prevalence, Proportion of Diagnosed Patients and Quality of Treatment in Switzerland Philipp Kohler1; Axel J. Schmidt2; Bruno Ledergerber1; Pietro L. Vernazza3
1Cantonal Hospital St. Gallen, St. Gallen, Switzerland; 2Universitätsspital Zürich, Zurich, Switzerland; 3Federal Office of Public Health, Bern, Switzerland

1009 Medical Care Interruptions in HIV-infected Patients: Characteristics and Consequences
Lise Cuzin1; Pierre Dellamonica1; Yazdan Yazdanpanah1; Sabelline Bouchez1; David Rey1; Bruno Hoen1; André Cabié1
1Toulouse University Hospital, Toulouse, France; 2University Hospital, Nice, Nice, France; 3University Hospital, Nantes, France; 4University Hospital, Fort de France, France; 5University Hospital, Pointe à Pitre, France; 6University Hospital, Strasbourg, France; 7Hôpital Bichat-Claude Bernard, APHM, Paris, France

1010 Blood Donor Test-Seeking Motivation and Prior HIV Testing Experiences in São Paulo
Hong-Ha M. Truong1; Paula Blatyta2; Sandra Montebello3; Sandra Esposti4; Fatima Hangai5; Nanci Salles6; Alfredo Mendrone6; Ester C. Sabino6; Willi McFarland6; Thelma T. Gonzalez6
1University of California San Francisco, San Francisco, CA, US; 2Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil; 3University of São Paulo, São Paulo, Brazil; 4Blood Systems Research Institute/University of California San Francisco, San Francisco, CA, US

Session P-W2 Poster Session
2:30 pm – 4:00 pm
HIV Testing and the Continuum of Care in the Developing World

1011 Treatment Interruptions in ART Programmes in Resource-Limited Settings: 2003 to 2013
Gail B. Cross1; Tim Spelman1; Daniel P. O’Brien2; Nathan Ford3; Jane Greig4; James H. McMahon1
1Monash University/Alfred Hospital, Prahan, Australia; 2Burnet Institute, Melbourne, Australia; 3World Health Organization (WHO), Geneva, Switzerland; 4Médecins Sans Frontières, London, United Kingdom
1012 Time to ART Qualification and Retention Among Patients With Early HIV in Haiti
Rita T. Dadaile; Serena P. Koengi; Kelley Henessey; Ellie Cooper; Pierre Cremieux; William J. Pape
Analysis Group; Les Centers GHSKID IT Team
1Gheskio Centers, Port au Prince, Haiti; 2Analysis Group, Boston, MA, US

1013 Awareness of HIV Diagnosis in the Swaziland HIV Incidence Measurement Survey
Tanya M. Ellman; Ruth Emerson; Deborah Donnell; Neena M. Philip; Rejoice Nkambule; Naomi Bock; Peter Ehrenkranz; George Bicego; Jessica E. Justman
1ICAP at Columbia University, New York, NY, US; 2Ministry of Health, Mbabane, Swaziland; 3US Centers for Disease Control and Prevention, Atlanta, GA, US; 4Fred Hutchinson Cancer Research Center, Seattle, WA, US; 5Centers for Disease Control and Prevention, Mbabane, Swaziland

1014 Who Is at Risk of Being Untested and Unaware of HIV-Positive Status in KwaZulu-Natal?
Helena Huerga; Gilles Van Cutsem; Jihane Ben Farhat; Malika Bouhenia; Matthew Reid; David Maman; Jean-François Etard; Thomas Ellman
1San Francisco Department of Public Health, San Francisco, CA, US; 2University of California San Francisco, San Francisco, CA, US; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4University of Victoria, Victoria, Canada; 5University of California San Diego, San Diego, CA, US

1015 Impact of Unplanned Care Interruption on Immune Recovery After ART Initiation in Nigeria
Aimalohi A. Ahonkhai; Juliet Adedola; Bolanle Banigbe; Ifeyinwa Onwuselu; Ingrid V. Bassett; Elena Losina; Kenneth A. Freedberg; Prosper Okonkwo; Susan Regan
1Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 2AIDS Prevention Initiative Nigeria, Jabi District, Nigeria; 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US

1016 Linkage to HIV Care Among Men Who Have Sex With Men and Drug Users in India: Getting to 90
Sunil S. Solomon; Allison M. McFall; Aylur K. Srikrishnan; Gregory M. Lucas; Canjeeveram K. Vasudevan; David D. Celentano; Muniratnam S. Kumar; Sunithi Solomon; Shruti H. Mehta

1017 Sex Pro: A Personalized HIV Risk Assessment Tool for Men Who Have Sex With Men
Hyman Scott; Eric Vittinghoff; Risha Irving; Albert Liu; Sheldon D. Fields; Manya Magnus; Darrell P. Wheeler; Kenneth H. Mayer; Beryl A. Koblin; Susan P. Buchbinder

1018 Unreported Sexual Risk Behavior Among MSM Newly Diagnosed With HIV Infection
Hsiu Wu; Lisa B. Hightow-Weidman; Cindy L. Gay; Tonyka Jackson; Emily Pike; Jenni Marmorino; Steve Beagle; Laura Hall; Philip J. Peters

1019LB HIV Transmission in Male Serodiscordant Couples in Australia, Thailand and Brazil
Andrew E. Grulich; Benjamin R. Bavinton; Fengyi Jin; Garrett Prestage; Iryna B. Zablotska; Beatriz Grinsztejn; Nittaya Phanuphak; Richard Moore; Kersten K. Koelsch
1University of New South Wales, Sydney, Australia; 2Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 3Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 4Northside Clinic, Melbourne, Australia

1020 Seminal Shedding of CMV and HIV Transmission Among Men Who Have Sex With Men
Sara Gianella Weibel; Konrad Scheffler; Sanjay Mehta; Susan J. Little; Lorri Freitas; Sheldon R. Morris; David M. Smith
1University of California San Diego, La Jolla, CA, US; 2University of California San Diego, La Jolla, CA, US

Martin Hoenigl; Christy M. Anderson; Sanjay Mehta; Nella L. Green; Davey M. Smith; Susan Little
1University of California San Diego, San Diego, CA, US

1022 Influence of Voluntary Repeat HIV Testing on Sexual Risk Behavior Among MSM
Martin Hoenigl; Davey M. Smith; Christy M. Anderson; Nella L. Green; Sanjay Mehta; Susan J. Little
1University of California San Diego, San Diego, CA, US

1023 HIV-Positive MSM With Unsuppressed Viral Load Are More Likely to Engage in Risky Sex: Vancouver, Canada
David Moore; Zishan Cui; Nathan J. Lachowsky; Henry F. Raymond; Eric Roth; Asheligh Rich; Paul Sereda; Julie Montaner; Mark Gilbert; Robert Hogg
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2San Francisco Department of Public Health, San Francisco, CA, US; 3University of Victoria, Victoria, Canada; 4BC Centre for Disease Control, Vancouver, Canada

1024 Substance Use, Mental Health, and HIV Risk Behavior Among MSM in Vancouver, Canada
Nathan J. Lachowsky; Zishan Cui; Asheligh Rich; Paul Sereda; Thomas L. Patterson; Trevor Cornell; Mark Gilbert; Eric Roth; Robert Hogg; David Moore
1University of British Columbia, Vancouver, Canada; 2BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3University of California San Diego, San Diego, CA, US; 4Ontario HIV Treatment Network, Toronto, Canada; 5University of Victoria, Victoria, Canada; 6Simon Fraser University, Burnaby, Canada
1025  **Electronic and Online Innovations in Respondent-Driven Sampling Methodology**  
Nathan J. Lachowsky1; Allan Lal2; Zishan Cui3; Ashleigh Rich4; Paul Sereda1; Henry Fisher Raymond3; Jamie I. Forrest4; Eric Roth4; Robert Hogg5; David Moore6  
1University of British Columbia, Vancouver, Canada; 2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3University of California San Francisco, San Francisco, CA, US; 4University of Victoria, Victoria, Canada

1026  **Incident Symptomatic Gonorrhea Infection Among Men Who Have Sex With Men, Thailand**  
Marcel E. Curn1; Sarika Pattanasin2; Pikunchai Luechai3; Anuwat Sriporn1; Jaray Tongtroyai1; Eileen F. Dunne4; Wichuda Sukwicha5; Oranuch Kongpechsa6; Pachara Sirivongrangscon7; Timothy Holt8  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2University of British Columbia, Vancouver, Canada; 3University of Washington, Seattle, WA, US; 4University of Pittsburgh, Pittsburgh, PA, US; 5CDC Central America Region, Guatemala City, Guatemala; 6HIV Unit of the Witwatersrand, Johannesburg, South Africa; 7Medical Research Council, Durban, South Africa; 8The Aurum Institute, Klerksdorp, South Africa; 9University of California Los Angeles, Los Angeles, CA, US; 10University of Pittsburgh, Pittsburgh, PA, US

Session P-W4 Poster Session  
Poster Hall  
2:30 pm – 4:00 pm  
Transmission Through Needles and Heterosexual Contact

1027  **Occupationally Acquired HIV Infection by Healthcare Personnel—United States, 1985-2013**  
M Patricia Joyce1; David Kuhar2; John T. Brooks3  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1028  **Analyzing Trends in HIV Risks for Injection Drug Users by Respondent-Driven Sampling**  
Kathleen A. Brady1; Tannber N. Bassau2; Jennifer Shinefield3; Catherine Mezzacappa4  
1Philadelphia Department of Public Health, Philadelphia, PA, US

1029  **Sexual Transmission of HIV and Possible Underreporting of Drug Use in Kazakhstan**  
Anna Deryabina1; Padmaja Patnaik1; Charon Gwynn1; Wafaa M. El-Sadr2  
1ICAP at Columbia University, Almaty, Kazakhstan

1030  **Can We Trust Self-Reported Condom Use? Association Between Reporting Bias and STIs**  
Hongjie Liu1; Tami A. Nazario2; Jennifer Shinefield3; Catherine Mezzacappa4  
1Philadelphia Department of Public Health, Philadelphia, PA, US

1031  **Prevalence and Correlates of Exchange Sex Among Low-Income Heterosexual Women in 21 US Cities**  
Catlinn Sionean1; Rashunda Lewis1; Lina M. Nerlander2; Gabriela Paz-Bailey3  
1On behalf of the NHBS Study Group  
2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1032  **HIV and STIs Among Transgendered Populations: Four Country Survey From Central America**  
David Ham1; Sanny Y. Northbrook2; Sonia Morales-Miranda3; Maria Elena Guadarr4; Mary Kamb5  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2CDC Central America Region, Guatemala City, Guatemala; 3HIV Unit of Center for Health Studies, Del Valle University of Guatemala, Guatemala; 4TEPHINET/ The Taskforce for Global Health Inc., Guatemala City, Guatemala

1033  **Incidence of Curable Sexually Transmitted Infections Among South African Women Recently Infected With HIV**  
Jennifer E. Balkus1; Marla E. Husnik1; Thesla Palanee-Phillips2; Ravindre Panchia3; Ifshana Barkoo4; Anebel Hadler5; Vanessa Goveder6; Marthinetta Taljard7; Pamina Gorbach7; Sharon Riddler8  
1Fred Hutchinson Cancer Research Center, Seattle, WA, US; 2University of the Witwatersrand, Johannesburg, South Africa; 3Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa; 4CAPRISA/University of KwaZulu-Natal, Durban, South Africa; 5Medical Research Council, Durban, South Africa; 6The Aurum Institute, Klerksdorp, South Africa; 7University of California Los Angeles, Los Angeles, CA, US; 8University of Pittsburgh, Pittsburgh, PA, US

1034  **Population Mobility, Sexual Behavior and Risk of HIV Infection in Sub-Saharan Africa**  
Laurence Palk1; Sally Blower2  
1On behalf of the Center for Biomedical Modeling  
2David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

1035  **HIV Transmission Linkage Among Seroconverting Partners in HIV-Discordant Relationships in Kenya**  
Bhavna H. Chohan1; Brandon L. Guthrie2; Brian Khasimwa6; Stephanie Rainwater3; Barbara Loman-Payne2; Rose Bosire2; Romel D. Mackelprang2; Julie M. Overbaugh2; Carey Farquhar2  
1Canada Medical Research Institute, Nairobi, Kenya; 2University of Washington, Seattle, WA, US; 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 4University of Nairobi, Nairobi, Kenya

1036  **Rising School Enrollment & Declining HIV Risk, 15-19y, Rakai, Uganda, 1994-2013**  
John Santelli1; Sanyukta Mathur1; Xiaoyu Song2; Tzu-Jung Huang3; Ying Wei4; Tom Lutalo5; Fred Halugoda6; Ronald H. Gay7; David Serwadda8  

1037  **Alcohol Use and HIV Risk Factors: Results From the 2011 Uganda AIDS Indicator Survey**  
George Aluzimbi1  
1CDC Center for Global Health, Division of Global AIDS/HIV, Kampala, Uganda

1038  **Population Attributable Fraction of HIV Due to Alcohol in Fishing Communities, Uganda**  
Noah Kiwanuka1; Ismail Sekandi1; Ali Ssealta2; Annet Nalutaaya3; Juliet Mpendo4; Paul K. Kitandwe5; Jan D. Bont6; Pontiano Kaleebu7; Nelson K. Sewankambo8  
1Makerere University College of Health Sciences, Kampala, Uganda; 2UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda; 3International AIDS Vaccine Initiative, New York, NY, US; 4MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 5Makerere University College of Health Sciences, Kampala, Uganda
1039 **Risky Sexual Behavior and HIV Infection Among Fisher Folk: Lake Kyoga Region, Uganda**

Rose Apondi1; Rhoda Wanyenze2; Herbert S. Kinyingi3; Abu-Maliki Muyinda4; Elizabeth Meassick4; Joy Kusima4; David Serwadda4

1CDC Center for Global Health, Division of Global AIDS/HIV, Kampala, Uganda; 4Makerere University School of Public Health, Kampala, Uganda

**THURSDAY, FEBRUARY 26, 2015**

**Session P-W6 Poster Session**

2:30 pm – 4:00 pm


Laurie Linley5; Gian An6; Kristen Mahle Gray7; Alexandra Oster8; Angela L. Hernandez7

US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

**Differences in Acute Retroviral Syndrome by HIV 1 Subtype in a Multicentre Cohort Study in Africa**

Eduard J. Sanders1; Kimberly A. Powers2; Etienne Karita3; Anatoli Kamali4; William Kilimben2; Susan Allen4; Eric Hunter3; Omu Anzala3; Pat Fast1; Matthew Price1


**Using GPS Data to Construct a Spatial Map of the HIV Epidemic in Malawi**

Danielle E. Robbins1; Brian J. Coburn1; Sally Blower1

1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

**HIV Incidence in Rural Malawi During Widespread Antiretroviral Treatment Availability**

Alison Price1; Menard Chihana2; Ndolive Kayum1; Amelia C. Crampin1; Milly Marston1; Basia Zaba1; Estelle McLean1; Olivier Koole2; Moffat Nyirenda3

1London School of Hygiene and Tropical Medicine, Chilumba, Malawi; 2Karonga Prevention Study, Chilumba, Malawi

**HIV-1 Incidence Among Adult STI Clinic Patients in Blantyre, Malawi**

Fatima Zulu1; Isaac Singini1; Newton I. Kumwenda1; Johnstone Kumwenda1; Safia Dadabh2

1Johns Hopkins University Research Project, Blantyre, Malawi; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

**IL-6 Partially Mediates the Effect of HIV Status on Survival**

Kaku So-Armah1; Amy Justice2; David Rimland3; Maria Rodriguez-Barradas4; Adeel A. Butt5; David Leaf1; Russell Tracy1; Mohammad Sajadi1; Cynthia Gibert1; Matthew S. Freiberg6

1Yale University School of Medicine, New Haven, CT, US; 2VA Connecticut Healthcare System, West Haven, CT, US; 3Veterans Affairs Medical Center, Atlanta, GA, US; 4Veterans Affairs Medical Center, Houston, TX, US; 5Sheik Khalifa Medical City, Abu Dhabi, United Arab Emirates; 6Veterans Affairs Medical Center, Greater Los Angeles, CA, US; 7University of Vermont, Burlington, VT, US; 8Veterans Affairs Medical Center, Baltimore, MD, US; 9Veterans Affairs Medical Center, Washington, DC, US; 10Vanderbilt University School of Medicine, Nashville, TN, US

**Persistently Elevated Macrophage Activation in HIV+ Women Reporting Heavy Alcohol Use**

Seema N. Desai1; Kathleen M. Weber2; Jane Burke-Miller2; Audrey L. French3; Monica Gandhi4; Mark H. Kuniholm4; Elizabeth T. Golub5; Kendall Bryant1; Alan Landay6; Marjorie Cohen7

1VA Connecticut Healthcare System, West Haven, CT, US; 2VA Connecticut Healthcare System, West Haven, CT, US; 3Veterans Affairs Medical Center, Baltimore, MD, US; 4Johns Hopkins School of Medicine, Baltimore, MD, US; 5Vanderbilt University School of Medicine, Nashville, TN, US; 6University of Vermont, Burlington, VT, US; 7National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, US; 8Veterans Affairs Medical Center, Oakland, CA, US; 9Veterans Affairs Medical Center, Washington, DC, US; 10Yale University School of Medicine, New Haven, CT, US; 11University of California School of Medicine, San Francisco, CA, US; 12Albert Einstein College of Medicine, Bronx, NY, US; 13Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 14National Institutes of Health/National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, US; 15Stroger Hospital of Cook County, Chicago, IL, US
1051 Is Survival Following HIV Seroconversion Still Improving, 17 Years After the Introduction of cART?  
Ashley Olson1; Caroline Sabin2; Maria Prins1; Laurence Meyer1; Julia del Amo3; Genevieve Chene1; Osamah Hamouda1; Giota Touloumi1; Khouloud Porter1  
On behalf of the CASCADE Collaboration in EuroCoord
1University College London, London, United Kingdom; 2Public Health Service of Amsterdam, Amsterdam, Netherlands; 3Inserm, Paris, France; 4Instituto de Salud Carlos III, Madrid, Spain; 5Inserm, Bordeaux, France; 6Robert Koch Institute, Berlin, Germany; 7University of Athens, Athens, Greece

1052 National Estimates of Life Expectancy After HIV Diagnosis: US HIV Surveillance Data  
Azfar-e-Alam Siddiqi1; H. Irene Hall1; Xiaohong Hu2; Ruiguang Song3  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1053 Age-Related Morbidities Among HIV-Infected Adults From 2000 to 2010  
Cherise Wong1; Stephen J. Gange2; Michael A. Horberg3; Gregory D. Kirk4; Anita Rachlis5; John Gill6; Jennifer E. Thorne1; Robert Hogg7; James G. Goedert1; Keri N. Althoff1  
1Johns Hopkins University, Baltimore, MD, US; 2Mid-Atlantic Permanente Research Institute, Rockville, MD, US; 3University of Toronto Sunnybrook Research Institute, Toronto, Canada; 4University of Calgary, Alberta Health Services, Calgary, Canada; 5British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 6National Cancer Institute (NCI), Rockville, MD, US

1054 A Retrospective Population-Based Examination of Prescription Drug Usage Prior to HIV Diagnosis Among HIV Cases and Their Controls: The Missed Opportunity for Diagnoses Epidemiological Study (MODES)  
Souaredu Y. Shaw1; Laurie Ireland1; Tara Carnochan2; Nancy Yu1; Carla Ens1; Yoav Keynan1; Ken Kasper2; Marissa Becker1  
On behalf of the MODES Manitoba Team
1University of Manitoba, Winnipeg, Canada; 2Nine Circles Community Health Centre, Winnipeg, Canada; 3Manitoba Health, Winnipeg, Canada; 4Manitoba HIV Program, Winnipeg, Canada

1055 Elevated Rates of Injury Among HIV-Positive Individuals in British Columbia  
Hasina Samji1; Dmitry Shopin1; Wendy Zhang1; Oghenowede Eyawo1; Guillaume Colley1; Mark Hull2; Julio Montaner2; Robert Hogg1  
On behalf of the COAST Study
1BC Centre for Excellence in HIV/AIDS, Vancouver, Canada; 2Simon Fraser University, Burnaby, Canada; 3University of British Columbia, Vancouver, Canada

1056 Higher Economic Well-Being Among Virally Suppressed HIV-Infected Adults With CD4>500  
Harsha Thirumurthy1; Aleksandra Jakubowski1; James G. Kahn1; Norton Sang2; Tamara Clark1; Edwin Charlebois1; Maya Petersen1; Moses R. Kamya3; Diane Havlir2  
SEARCH Collaboration
1University of North Carolina at Chapel Hill, Chapel Hill, NC, US; 2University of California San Francisco, San Francisco, CA, US; 3University of California Berkeley School of Public Health, Berkeley, CA, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5KEMRI, Kisumu, Kenya

Session P-W8 Poster Session
Poster Hall
2:30 pm – 4:00 pm
Serosorting and Seroadapative Behavior: What’s Your Position?

1057 Internalized Stigma in a Population-Based Sample of US HIV-Infected Adults in Care  
Amy R. Baugher1; Linda Beer2; Jennifer L. Fagan3; Christine L. Mattson3; Mark Freedman4; Jacek Skarbinski5  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

Alexandra B. Balaji1; Justin C. Smith2; Kristina Bowles2; Gabriela Paz-Bailey2  
US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1059 Has Antiretroviral Treatment Scale-Up in Sub-Saharan Africa Reduced HIV-Related Stigma in the General Population? A Cross-Country Analysis  
Brian T. Chan1; Alexander Tsai2; Mark Siedner3  
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

Session P-W7 Poster Session
Poster Hall
2:30 pm – 4:00 pm
HIV Stigma

1060 Trends in Sexual Behaviors Among Men Who Have Sex With Men in the United States, the Role of Antiretroviral Therapy and Seroadaptive Strategies  
Gabriela Paz-Bailey1; Maria Mendoza1; Binh Le1; Charles E. Rose1; Teresa Finlayson1; Cyprian Wejnert1; Henry F. Raymond1; Joseph Prejean1  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2San Francisco Department of Public Health, San Francisco, CA, US

1061 Changes in Condomless Sex and Serosorting Among MSM After HIV Diagnosis  
Christine M. Khosropour1; Julia C. Dombrowski2; David A. Katz2; Matthew R. Golden1  
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US

1062 Serosorting and Sexual Risk Behavior Influenced by Perceived HIV Serostatus Among MSM  
Kathleen A. Brady1; Jennifer Shinefeld1; Catherine Mezzacappa1  
1Philadelphia Department of Public Health, Philadelphia, PA, US
TUESDAY, FEBRUARY 24, 2015

Session P-X1 Poster Session
2:30 pm – 4:00 pm

Paying for Care

1063 Use of the Seroadaptive Strategies of Sexual Positioning and Serosorting by MSM in Nigeria
Cristina M. Rodriguez-Hart1; Hongjie Liu; Iheanyi K. Orazulike1; Sam Zorowitz2; Sylvia Adebaioj3; Lindsay Hughes4; Stefan Baral5; Merlin L. Robb6; William Blattner7; Manhattan Charurat8
1University of Maryland School of Medicine, Baltimore, MD, US; 2University of Maryland School of Public Health, College Park, MD, US; 3International Center on Advocacy and Rights to Health, Abuja, Nigeria; 4Massachusetts General Hospital and Harvard Medical School, Boston, MA, US; 5Population Council, Abuja, Nigeria; 6US Military HIV Research Program, Bethesda, MD, US; 7Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

1064 Ryan White HIV/AIDS Program Assistance and HIV Treatment Outcomes in the United States
Heather Bradley1; Abighail V. Hall2; Pascale M. Wortley3; Antigone Dempsey4; Heather Hauck5; Jack Skarbinski6
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2US Health Resources and Services Administration, Rockville, MD, US

1065 Combining Multisite Payor Data With Clinical Data to Quantify Medicaid Payments for HIV Care
Anne Monroe1; Cindy Voss2; Richard Moore3; Kelly Gebo4; Allison Agwu5; Richard Rutstein6; Victoria Sharp7; Stephen Boswell8; John Fleishman9

1066 Proportionately More Gay Men in Seattle Insured Following the Affordable Care Act
Julia E. Hood1; Susan E. Buskin1; Elizabeth A. Barash1; Julia C. Dombrowski2; Matthew R. Golden3
1Public Health–Seattle & King County, Seattle, WA, US; 2University of Washington, Seattle, WA, US

1067 Characteristics and Outcomes of Patients Seeking Care at a New “Co-Pay” Convenience Clinic Established to Explore Sustainable Funding Models in Uganda
Rosalind M. Parkes-Ratanshi1; Sylvia Adebajo2; Lindsay Hughes3; Stefan Baral4; Merlin L. Robb5; William Blattner6; Manhattan Charurat7
1University of Maryland School of Medicine, Baltimore, MD, US; 2University of Maryland School of Public Health, College Park, MD, US; 3International Center on Advocacy and Rights to Health, Abuja, Nigeria; 4Massachusetts General Hospital and Harvard Medical School, Boston, MA, US; 5Population Council, Abuja, Nigeria; 6US Military HIV Research Program, Bethesda, MD, US; 7Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US

Wednesday, February 25, 2015

Session P-X2 Poster Session
2:30 pm – 4:00 pm

Linkage to and Retention in Care

1068 A Longitudinal Approach to Retention and Virologic Suppression Across the HIV Care Continuum
Jonathan Colasanti; Carlos del Rio; Wendy Armstrong
Emory University School of Medicine, Atlanta, GA, US

1069 A High Proportion of Persons Diagnosed With Acute HIV Achieve Viral Suppression
Emily Westheimer1; Philip J. Peters2; Rebekkah Robbins3; Sarah L. Braunstein4
1New York City Department of Health and Mental Hygiene, Queens, NY, US; 2US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 3New York City Department of Health and Mental Hygiene, Queens, NY, US

1070 Drivers of HIV Treatment Success Among a Population-Based Sample of Younger Black MSM
John A. Schneider1; Britt Skaathun2; Stuart Michaels3; Lindsay Young4; Keith Green5; Ethan Morgan6; Robert W. Coombs7; Sam Friedman8; Edward Laumann9
On behalf of UConnect Study Team 1University of Chicago, Chicago, IL, US; 2NORC, Chicago, IL, US; 3University of Washington, Seattle, WA, US; 4National Development Research Institute, New York, NY, US

1071 Population-Level HIV RNA and CD4+ Distribution in a Rural Ugandan Community With Widespread Community HIV Testing and Universal ART Access
Vivek Jain1; Gabriel Chamie1; Gideon Amanyire2; Dalsone Kwarisima3; Jane Kabami4; Maya L. Petersen5; Tamara Clark6; Edwin D. Charlebois7; Moses R. Kamya8; Diane Havlin9
1University of California San Francisco, San Francisco, CA, US; 2Makerere University–University of California San Francisco Research Collaboration, Kampala, Uganda; 3University of California Berkeley School of Public Health, Berkeley, CA, US

1072 Facility-Level Factors Influencing Retention in HIV Care in East Africa
Beth Rachlis1; Giorgos Bakoyannis2; Philippa Easterbrook3; R. Scott Braithwaite4; Craig R. Cohen5; Elizabeth Bukusi6; Andrew D. Kambugu7; Mwebesa Bosco Bwana8; Elvin H. Geng9; Paula Bratstein1
1Academic Model Providing Access to Health Care program, Eldoret, Kenya; 2Indian University, School of Medicine, Indianapolis, IN, US; 3Infectious Diseases Institute, Kampala, Uganda; 4New York University, New York City, NY, US; 5University of California San Francisco (UCSF), San Francisco, CA, US; 6Kenya Medical Research Institute, Nairobi, Kenya; 7Mbarara University, Mbarara, Uganda

1073 Patient Retention in HIV Care Is Related to Point of Diagnosis in Western Kenya
Becky L. Genberg1; Hana Lee1; Fatma Some2; Joseph Hogan3; Paula Bratstein4
1Brown University, Providence, RI, US; 2Moi University School of Medicine, Eldoret, Kenya; 3Indiana University School of Medicine, Indianapolis, IN, US
1074 Successful Down-Referral Even Among Patients With Virologic Failure in South Africa
Jonathan Colasanti1; Darius McDaniel2; Brent Johnson2; Henry Sunpath1; Carlos del Rio1; Vincent C. Marconi1
1Emory University School of Medicine, Atlanta, GA, US; 2Emory University Rollins School of Public Health, Atlanta, GA, US; 3Emory University Rollins School of Public Health, Atlanta, GA, US; 4Mc Cord Hospital, Durban, South Africa

1075 Retention in a Decentralized HIV Care and Treatment Program in North Central Nigeria
Patricia Agaba1; Becky L. Genberg2; Solomon Sagay3; Oche Agbaji4; Nancin Dadem1; Grace Kolawole5; Prosper Okonkwo5; Seema Meloni4; Phyllis Kanki5; Norma C. Ware1
1University of Jos, Jos, Nigeria; 2Brown University, Providence, RI, US; 3AIDS Prevention Initiative, Abuja, Nigeria; 4Harvard School of Public Health, Boston, MA, US; 5Harvard Medical School, Boston, MA, US

Bonita K. Kilama1; Candida Moshiro2; Jim Todd3; Angela Ramadhani1; Donan Mmbando1
1National AIDS Control Program, Dar es Salaam, United Republic of Tanzania; 2Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania; 3Ministry of Health Of Social Welfare, Dar es Salaam, United Republic of Tanzania; 4London School of Hygiene and Tropical Medicine, London, United Kingdom

1077 Impact of the Ebola Outbreak on the Quality of Care of People Living With HIV Taking Antiretroviral Treatment at Donka National Hospital in Conakry, Guinea
Mohamed Cisse1; Mohamadou Saliou Diallo2; Cheick Tidiane Tidiane3; Cece Kpamou4; Justeau Dimitri5; Eric Dortenzio1; Jacques D. Ndawinz1
1Solthis International NGO, Paris, France; 2Hôpital National de Donka, Conakry, Guinea; 3Ministère de la Santé et de l’Hygiène Publique, Conakry, Guinea; 4Solthis NGO, Conakry, Guinea

Helena Kwaka1; Rahab Wahome; Oumar H. Gaye; Natasha Z. Mvula1
Philadelphia Department of Public Health, Philadelphia, PA, US

THURSDAY, FEBRUARY 26, 2015
Session P-X3 Poster Session
2:30 pm – 4:00 pm
Guidelines and Their Implementation

1079 Starting ART at 500 CD4 in Southern Africa: What Is the Impact on ART Eligibility?
Helena Huerga1; David Maman2; Gilles Van Cutsem3; Beatrice Kirubi2; Charles Masiku4; Ruggiero G. Giuliani5; Irene Mukui3; Benson Chilima4; Elisabeth Zoumili6; Jean-François Etaf1
1Epicentre, Paris, France; 2Médecins Sans Frontières, Cape Town, South Africa; 3Médecins Sans Frontières, Nairobi, Kenya; 4Médecins Sans Frontières, Lilingwe, Malawi; 5National AIDS and STDS Control Program, Nairobi, Kenya; 6Ministry of Health, Lilingwe, Malawi

1080 Impact of South Africa’s HIV Treatment Guidelines on Early Losses: A Cohort Analysis
Ingrid T. Kata1; Richard Kaplan2; Garrett Fitzmaurice3; Dominick Leone4; David R. Bangsberg4; Linda-Gail Bekker5; Catherine Orrell1
1Harvard Medical School, Cambridge, MA, US; 2Desmond Tutu HIV Foundation, Cape Town, South Africa; 3Boston University School of Medicine, Boston, MA, US; 4Harvard School of Public Health, Boston, MA, US

1081 Mortality Across Two ART Trials Enrolling at ≤200 vs ≤350 CD4 cells/ul in Kenya
Rachel A. Silverman1; Michael Chung1; James N. Kiarie1; Nelly Yatich1; Julia Njoroge1; Katherine Kiptiness1; Samah Saks1; Grace John-Stewart1; Lisa Frenkel1
1University of Washington, Seattle, WA, US; 2University of Nairobi, Nairobi, Kenya; 3Coptic Hospital, Nairobi, Kenya

1082 HIV Testing of Persons Aged 15–65 Years at Visits to US Physician Offices, 2009–2010
Karen Hoover; Shirley Lecher; Roman Gvetadze; Philip Peters
US Centers for Disease Control and Prevention, Atlanta, GA, US

1083 Frontline Practices With HIV Prevention: A Survey of US Infectious Disease Physicians
Douglas S. Krakower1; Susan E. Beekmann2; Philip M. Polgreen3; Kenneth H. Mayer4
1Emerging Infections Network
2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US; 3University of Iowa, Iowa City, IA, US

Session P-Y1 Poster Session
2:30 pm – 4:00 pm
Male Circumcision: Risk, Innovation, and Scale-Up

1084 HSV-2 Shedding From Male Circumcision Wounds Among HIV-Infected Men
Mary K. Grabowski1; Godfrey Kigozi2; Ronald H. Gray3; Jordyn L. Manucci1; David Servadda4; Eshan U. Patel4; Fred Nalugoda5; Maria J. Wawer1; Thomas C. Quinn4; Aaron A. Tobian4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 2Rakai Health Sciences Program, Kalisizo, Uganda; 3Johns Hopkins University School of Medicine, Baltimore, MD, US; 4Makerere University College of Health Sciences, Kampala, Uganda; 5National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US
1085  **Association Between Foreskin Microbiota and Local Cytokines in Men From Rakai, Uganda**  
Cindy M. Liu1; Aaron A. Tobian1; Jessica Proder2; David Serwadda3; Godfrey Kigozi3; Fred Nalugoda3; Maria J. Wawer3; Lance Price4; Rupert Kaul1; Ronald H. Gray5  
1Johns Hopkins University School of Medicine, Baltimore, MD, US; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Rakai Health Sciences Program, Rakai, Uganda; 4Translational Genomics Research Institute, Flagstaff, AZ, US; 5University of Toronto, Toronto, Canada  

1086  **Mobile VMMC Teams in Tanzania See Older Clients and Have Higher Followup Rates**  
Augustino M. Hellar1; Dorica Boyée1; Hally Mahler1; Marya Plotkin1; Touma Ng’wanakila1; Kelly Curran1; Tsigitu Ashengo1; Hawa Mziray1; Erick Mlanga1; Sifuni Koshuma1  
1Jhpiego, Dar es Salaam, United Republic of Tanzania; 2Jhpiego, Baltimore, MD, US; 3US Agency for International Development, Dar es Salaam, United Republic of Tanzania; 4Ministry of Health and Social Welfare, Iringa, United Republic of Tanzania  

1087  **High Acceptability of PrePex™ Device in Routine Programmatic Settings in Rwanda**  
Eugene Rugwizangoga1; Beata Mukarugwino1; Jovite Sinzahera1; Alphonse Mutabarakwa2; Glorioso Abayisenga2; J.D. Nitakikirabose2; Ngeruka Leon1; Eugene Zimuлина1; Kelly Curran2; Tsigitu Ashengo2  
1Jhpiego/Rwanda, Kigali, Rwanda; 2Jhpiego, an Affiliate of Johns Hopkins University, Washington, DC, US; 3US Department of Defense, Rwanda, Kigali, Rwanda; 4Rwanda Military Hospital, Kigali, Rwanda  

1088  **Self-Selection of Circumcision Acceptors, Risk Compensation and Effectiveness of Circumcision Among Service Recipients, Rakai, Uganda**  
Joseph Kagaayi1; Xiangrong Kong1; Godfrey Kigozi1; Fred Nalugoda1; Steven J. Reynolds1; David Serwadda1; Nelson K. Sewankambo1; Maria J. Wawer1; Ronald H. Gray5  
1Rakai Health Sciences Program, Entebbe, Uganda; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, US; 3Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, US; 4Makerere University School of Public Health, Kampala, Uganda; 5University College of Health Sciences, Kampala, Uganda  

1089  **Potential Protection From HIV Transmission by Penile Cuttings in Papua New Guinea**  
Ivy H. Shih1; Lester Asugeni2; Matthew David3; Paul Horwood3; Parana Hewage Mangalasir1; David Mc Laren1; Rachael Tommbe1; Andrew Vallely1; Arnold Wayne4; Stuart G. Turville1  
1The Kirby Institute, Sydney, Australia; 2Pacific Adventist University, Port Moresby, Papua New Guinea; 3James Cook University, Cairns, Australia; 4University of Papua New Guinea, Port Moresby, Papua New Guinea; 5Papua New Guinea Institute of Medical Health, Goroka, Papua New Guinea  

WEDNESDAY, FEBRUARY 25, 2015  
Session P-Y2 Poster Session  
2:30 pm – 4:00 pm  
Linkage to Care and ART Initiation  

1090  **Linkage to HIV Care Following Home-Based Testing and CD4 in Rural Malawi**  
Sophie Masson1; Lihane Ben Farhat1; Charles Masiku1; Benson Chilima1; Elisabeth Szumilin1; Leon Salumu1; Jean-François Etard1; David Maman1  
1Epicentre/Médecins Sans Frontières, Paris, France; 2Ministry of Health, Lilongwe, Malawi; 3Médecins Sans Frontières, Paris, France; 4Médecins Sans Frontières Malawi, Lilongwe, Malawi  

1091  **Rapid ART Initiation Reduces Loss Between HIV Testing and Treatment: The RapIT Trial**  
Sydney Rosen1; Mhairi Maskew1; Matt P. Fox1; Cynthia Nyoni2; Constance Mongwenyana1; Given Malete1; Ian Sanne2; Julia K. Rohr3; Lawrence Long2  
1Boston University, Boston, MA, US; 2University of the Witwatersrand, Johannesburg, South Africa  

1092  **Outcomes of a Clinic-Health Department “Data to Care” Relinkage Intervention**  
Joanna M. Bove1; Matthew R. Golden1; Shireesha Dhanireddy1; Robert Harrington2; Julie Dombrowski3  

1093  **HIV Partner Services Can Achieve Near-Universal Linkage to HIV Care**  
David A. Katz1; Julia C. Dombrowski1; Susan E. Buskin1; Amy Bennett1; Elizabeth A. Barash1; Matthew R. Golden1  
1University of Washington, Seattle, WA, US; 2University of Washington, Seattle, WA, US; 3Public Health – Seattle & King County, Seattle, WA, US  

1094  **Immunodeficiency at the Start of ART: A Global View**  
Klea Panayidou1; Ole Kirk1  
On behalf of the iDeA Collaboration and the COHERE Collaboration  
1University of Bern, Bern, Switzerland; 2Université Victor Segalen Bordeaux 2, Bordeaux cedex, France; 3University of Copenhagen, Copenhagen, Denmark  

1095  **Providers’ Attitudes and Practices Related to ART Use for HIV Care and Prevention**  
Kate Buchacz1; Jennifer Farrior1; Gheetha Beauchamp1; Laura McKirnstry1; Ann Kurther1; Barry S. Zingman1; Fred Gordin1; Deborah Donnell1; Wafa M. El-Sadri1; Bernard M. Branson1  
1US Centers for Disease Control and Prevention (CDC), Atlanta, GA, US; 2FH360, Durham, NC, US; 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 4New York University School of Medicine, New York, NY, US; 5Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, US; 6Veterans Affairs Medical Center and George Washington University, Washington, DC, US; 7Columbia University and Harlem Hospital, New York, NY, US
**Session P-Y3 Poster Session**

**Poster Hall**

**2:30 pm – 4:00 pm**

**HIV Testing: Innovations and Scale-Up**

1096 Availability and Quality of Online HIV Self-Test Kits in China and the United States

Fengying Liu1; Larry Han1; Weiming Tang2; Shujie Huang2; Ligang Yang2; Heiping Zheng3; Bin Yang4; Joseph Tucker1

1University of North Carolina, Guangzhou, China; 2Guangdong Provincial STD Control Center, Guangzhou, China; 3University of North Carolina, Chapel Hill, NC, US

1097 Home HIV Testing and Medical Care: Doing the Right Thing

Charulata J. Sabharwal1; Sharmila Shah2; Chi-Chi N. Udeagu3

New York City Department of Health and Mental Hygiene, Queens, NY, US

1098 Using Grindr™, a Social-Media—Based Application, to Increase HIV Self Testing Among High-Risk Men Who Have Sex With Men in Los Angeles, California, 2014

Alexandra Medline1; Emily Huang2; Robert Marlin3; Sean D’Young4; Justin Kwok5; Jeffrey D. Klausner6

1McGill University, Toronto, Canada; 2David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, US

1099 Sexually Transmitted Disease Partner Services Increase HIV Testing Among Men Who Have Sex With Men

Matthew R. Golden1; David A. Katz2; David Kern3; David Heal4; Roxanne Kerani5; Julia C. Dombrowski6


1100 Expanding HIV Testing in Hospital Emergency Departments and Inpatient Admissions

Polyanna R. Chavez1; Elizabeth Greene2; Kate Buchacz3; Theresa Gamble4; Steven F. Ettridge5; Laura McKinstry6; Gheetta Beauchamp7; Matthew Connor8; Wafa M. El-Sadr9; Bernard M. Branson10


1101 Universal HIV Testing Using a “Hybrid” Approach in East Africa in the SEARCH Trial

Gabriel Chamie1; Tamara Clark2; Jane Kabami3; Kevin Kadeed4; Dalsone Kwaisirima2; Norton Sanyi5; Maya Petersen6; Moses R. Kamya7; Diane Havlir8; Edwin Charlebois9

1University of California San Francisco, San Francisco, CA, US; 2Kenyan Medical Research Institute (KEMRI), Nairobi, Kenya; 3Makerere University - University of California Research Collaboration, Kampala, Uganda; 4University of California Berkeley School of Public Health, Berkeley, CA, US; 5University of California San Francisco (UCSF), San Francisco, CA, US

1102 A Household Food Voucher Increases Consent to Home-Based HIV Testing in Rural KwaZulu-Natal

Mark McGovern1; David Canning2; Frank Tanser3; Kobus Herbst4; Dickman Gareta5; Tinofa Mutvedzi6; Deenan Pillay7; Till Barnighausen8

1Harvard University, Cambridge, MA, US; 2Welcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, KwaZulu-Natal, South Africa

1103 Acceptability and Uptake of Home-Based HIV Self-Testing in Lesotho

Allison V. Zerbe1; Abby L. DiCarlo2; Joanne E. Mantell1; Robert H. Remien3; Danielle D. Morris4; Koen Frederix5; Blanche Pitt4; Zachary J. Peters6; Wafa M. El-Sadr1


**TUESDAY, FEBRUARY 24, 2015**

**Session P-Z1 Poster Session**

**Poster Hall**

**2:30 pm – 4:00 pm**

**Costs and Cost Effectiveness**

1104 The Lifetime Medical Cost Savings From Preventing HIV in the United States

Bruce R. Schackman1; John Fleishman2; Amanda Su3; Richard Moore4; Rochelle Walensky5; David Paltiel4; Milton Weinstein6; Kenneth Freedberg7; Kelly Gebo8; Elena Losina9

1Weill Cornell Medical College, New York, NY, US; 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Harvard School of Public Health, Boston, MA, US; 5Johns Hopkins University School of Medicine, Baltimore, MD, US; 6Agency for Healthcare Research and Quality, Rockville, MD, US

1105 Online Partner Notification: A Cost-Effective Tool to Reduce HIV-1 Epidemic Among MSM

Brooke E. Nichols1; Hannelore M. Götz2; Eric C. van Gorp3; Annelies Verbon4; Casper Rokx5; Charles Boucher6; David A. van de Vijver7

1Erasmus University Medical Center, Rotterdam, Netherlands; 2Public Health Service Rotterdam-Rijnmond, Rotterdam, Netherlands; 3Erasmus Medical Center, Rotterdam, Netherlands

1106 Cost-Effectiveness of Preexposure Prophylaxis for High-Risk HIV-Discordant Couples

Roger Ying1; Renee Heffron2; Jared Baeten3; Connie Celum4; Elly Katahira5; Nulu Bulya6; Ruane V. Barnabas7

1University of Washington, Bellevue, WA, US; 2Makerere University College of Health Sciences, Kampala, Uganda

1107 Multipurpose Prevention Technologies for HIV and Pregnancy Prevention

Rebecca Geary; Jennifer Smith; Nidhi Khurana; Ide Cremin; Timothy Hallett

Imperial College London, London, United Kingdom

1108 Cost-Effectiveness of Isoniazid Preventative Therapy for HIV-Infected Pregnant Women in India

Sunaina Kapoor; Natasha Chida; Amita Gupta; Maunank Shah

Johns Hopkins University School of Medicine, Baltimore, MD, US

1109 Epidemiologic Benefits and Cost-Effectiveness of Improving Rwanda’s HIV Care Cascade

Eran Bendavid1; Edward Mills2; Steve Kanter3; Sabin Nsanzimana4

1Stanford University, Stanford, CA, US; 2University of Ottawa, Ottawa, Canada; 3Rwanda Biomedical Center, Kigali, Rwanda
1110 The Cost-Effectiveness of Early ART Initiation in South Africa: A Quasi-Experiment
Jacob Bor; Ellen Moscoe; Natsayi Chimbindi; Kobus Herbst; Kevindra K. Naidu; Frank Tanser; Deenan Pillay; Till Barnighausen
1Boston University School of Public Health, Boston, MA, US; 2Harvard School of Public Health, Boston, MA, US; 3Wellcome Trust Africa Centre for Health and Population Studies, Samkelo, South Africa

1111 Community-Based Strategies to Strengthen the Continuum of HIV Care Are Cost-Effective
Jennifer A. Smith; Monisha Sharma; Carol Levin; Jared Baeten; Heidi van Rooyen; Connie Celum; Timothy Hallett; Ruanne V. Barnabas
1Imperial College London, London, United Kingdom; 2University of Washington, Seattle, WA, US; 3National Institutes of Health, Bethesda, MD, US

1112 The Cost-Effectiveness of CD4 Cell Count Versus HIV RNA Viral Load for ART Initiation
Roger Ying; Brian Williams; Ruanne V. Barnabas; Reuben Granich
1University of Washington, Bellevue, WA, US; 2Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland; 3Stellenbosch University, Stellenbosch, South Africa

1113 Costs of Expanded HIV Testing in 4 EDs: Results From HPTN 065
Bruce R. Schackman; Ashley A. Eggman; Jared A. Leff; Megan Braunlin; Bernard M. Brandeau; Fumiyo Nakagawa
1Weill Cornell Medical College, New York, NY, US; 2U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, US

1114 Global Fund Cost Projections for Implementing WHO 2013 Guidelines
Obinna Onyekwena; Ade Fakoya; Michael Johnson; Michael Olszak-Olszewski; Mark Dybul; John Stanecki; Sandro Galea

1117 Decreasing Number of Undiagnosed HIV Infections in the Netherlands
Ard van Sighem; Fumiyo Nakagawa; Daniela De Angelis; Chantal Quinten; Daniela Bezemer; Eline Op de Coul; Matthias Egger; Frank de Wolf; Christophe Fraser; Andrew N. Phillips
1Stichting HIV Monitoring, Amsterdam, Netherlands; 2National Institute for Public Health and the Environment, Bilthoven, Netherlands; 3University College London, London, United Kingdom; 4MRC Biostatistics Unit, Cambridge, United Kingdom; 5European Centre for Disease Prevention and Control, Stockholm, Sweden; 6Imperial College London, London, United Kingdom; 7Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland

THURSDAY, FEBRUARY 26, 2015
Session P-Z3 Poster Session 2:30 pm – 4:00 pm
Modeling the Impact of HIV Interventions

1118 Predicted Impact of Antiretroviral Treatment on Preventing New HIV Infections in 53 Low- and Middle-Income Countries With Large HIV Epidemics
Andrew M. Hill; Anton Pozniak; Katherine Heath; Alice Raymond; Mary Mahy; Nathan Ford
1Chelsea and Westminster Hospital, London, United Kingdom; 2St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 3Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland; 4World Health Organization, Geneva, Switzerland

1119 Survival Benefits Attributable to the Brazilian National ART Policy
Paula M. Luz; Michael P. Giraud; Beatriz Grinsztejn; Kenneth Freedberg; Valdevira Veloso; Elena Losina; Claudio Struchiner; Robert Parker; David Paltiel; Rochelle Walensky
1Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 2Massachusetts General Hospital, Boston, MA, US; 3Yale School of Public Health, New Haven, CT, US; 4Brigham and Women’s Hospital, Boston, MA, US

1120 A Predictive Risk Model for First-Line Treatment Failure in South Africa
Julia K. Rohr; Prudence Ives; Rebecca H. Berhanu; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P. Fox
1Stanford University, Stanford, CA, US; 2VA Palo Alto Health Care System, Palo Alto, CA, US

1121 U.S. Population Benefits of HIV Preexposure Prophylaxis for Injection Drug Users
Cora Bernard; Margaret L. Brandeau; Douglas K. Owens; Keith Humphreys; Eran Bendavid; Mark Holodniy; Christopher Yewant; Jeremy D. Goldhaber-Fiebert
1Stanford University, Stanford, CA, US; 2VA Palo Alto Health Care System, Palo Alto, CA, US
1122  Procreation in HIV-Serodiscordant Couples: TasP, PrEP, or Assisted Reproduction?
Guillaume Mabileau1; Michaël Schwarzinger1; Juan Flores1; Catherine Patrat1; Dominique Luton1; Sylvie Épelboin1; Laurent Mandelbrot1; Sophie Matheron1; Yazdan Yazdanpanah1
On behalf of ANRS 12008
1Inserm, Paris, France; 2AP-HP, Bichat-Claude Bernard Hospital, Paris, France; 3Louis Mourier Hospital, Colombes, France
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td></td>
<td>Plenary: PreP for HIV Prevention: What We Know and What We Need to Know for Implementation Room 6AB</td>
<td>Plenary: Preventing Pediatric HIV and Managing HIV-Infected Children: Where Are We Now and Where Are We Going? Room 6AB</td>
<td>Plenary: Cardiovascular Disease in HIV Patients: An Emerging Paradigm and Call to Action Room 6AB</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Workshop for New Investigators and Trainees Room 6E</td>
<td>Plenary: Specific HIV Integration Sites Linked to Clonal Expansion and Persistence of Cells Room 6D</td>
<td>Plenary: Directing Chronic Virus Infection Through Viral Regulation of Innate Immune Defenses Room 6AB</td>
<td>Plenary: The Price of Selling Sex: HIV Among Female Sex Workers—The Context and the Public Health Response Room 6AB</td>
</tr>
<tr>
<td>9:30 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td>ORAL ABSTRACT CONCURRENT SESSIONS 10:00 AM to 12:15 PM</td>
<td>ORAL ABSTRACT CONCURRENT SESSIONS 10:00 AM to 12:15 PM</td>
<td>ORAL ABSTRACT CONCURRENT SESSIONS 10:00 AM to 12:15 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-1: Preventing HIV and HSV-2: What Will It Take? Room 6AB</td>
<td>0-6: Intracellular and Clinical Pharmacology, Drug Interactions, and Adherence Room 615</td>
<td>0-11: Cardiovascular, Bone, and Kidney Health Room 6C</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-2: Prevention, Diagnosis, and Treatment of Pediatric HIV Infection Room 613</td>
<td>0-7: KS and Cervical/Anal Dysplasia: Tale of 2 Tumors, and TB and Other OIs Room 613</td>
<td>0-12: Curing HCV: Mission Accomplished Room 6AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-3: Cellular Dynamics, Sensing, and Viral Restriction Room 615</td>
<td>0-8: Factors Affecting HIV Care and Outcome: Global Perspective Room 6E (ends at 12:30 PM)</td>
<td>0-13: Reaching Populations: Demonstrating Impact Room 6D</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0-4: New Discoveries in HIV Pathogenesis Room 6D</td>
<td>0-9: New Insights Into HIV Persistence, Latency Reversal, and Viremia Rebound Room 6D</td>
<td>0-14: Immune Mechanisms: The Road to Protection Room 613</td>
</tr>
<tr>
<td>12:15 PM</td>
<td></td>
<td>LUNCH 12:15 PM to 1:30 PM</td>
<td>LUNCH 12:15 PM to 1:30 PM</td>
<td>LUNCH 12:15 PM to 1:30 PM</td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
<td>Martin Delaney Presentation Room 6E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td></td>
<td>THEMED DISCUSSION CONCURRENT SESSIONS 1:30 PM to 2:30 PM</td>
<td>THEMED DISCUSSION CONCURRENT SESSIONS 1:30 PM to 2:30 PM</td>
<td>THEMED DISCUSSION CONCURRENT SESSIONS 1:30 PM to 2:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TD-B: Next Generation of Next-Generation Sequencing Room 615</td>
<td>TD-A: Interferon: Triggers and Effectors Room 615</td>
<td>TD-M: Identifying Recent Infections: Issues of False Recency Room 615</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TD-C: HIV/CMV Interactions in Transmission and Pathogenesis Room 613</td>
<td>TD-H: New Technologies in Assessing Drug Interactions and Systemic and Intracellular Pharmacology Room 613</td>
<td>TD-N: Next-Generation HCV Therapeutics: From Clinical Trials to the Clinic Room 6AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TD-F: Leaky Latency Room 6D</td>
<td>TD-Q: Cancers in Young and Old, and Lung Cancer in HIV Room 6D</td>
<td>TD-P: Cardiovascular Risk Prediction: Can We Do Better? Room 6AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TD-I: Circumcision: Evolving Knowledge and Practice Room 6E</td>
<td>TD-Z: Economic Implications of ART Room 6C</td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td></td>
<td>CONCURRENT WORKSHOPS 2:30 PM to 4:30 PM</td>
<td>CONCURRENT WORKSHOPS 2:30 PM to 4:30 PM</td>
<td>CONCURRENT WORKSHOPS 2:30 PM to 4:30 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clinical Trial Design and Analysis Room 6D</td>
<td>CONCURRENT SYMPOSIAS 4:00 PM to 6:00 PM</td>
<td>CONCURRENT SYMPOSIAS 4:00 PM to 6:00 PM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frontiers in Laboratory Science Room 6D</td>
<td>0-1: Harnessing Antibodies for Prevention and Therapeutics Room 6C</td>
<td>0-4: Making Sense of Sensing: Innate Immunity and HIV Infection Room 613</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatitis C Care in the Interferon-Free Era Room 613</td>
<td>0-2: Current Issues in HIV-Related Malignancies Room 6D</td>
<td>0-5: Advancing HIV Prevention: Lessons From Biology, Medicine, and Public Health Law Room 6D</td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td>0-3: Current Imperatives in HIV Prevention and Treatment Room 6AB</td>
<td>0-6: Tuberculosi: Magic Bullets and Moving Targets Room 6E</td>
</tr>
<tr>
<td>4:30 PM</td>
<td></td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td>ORAL ABSTRACT SESSION (ends at 6:15 PM)</td>
<td>S-5: Scale-Up of Interventions Room 6D</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Opening Session 5:00 PM to 7:00 PM</td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td>O-10: New Antiretroviral Agents, Strategies, and HIV Drug Resistance Room 6C</td>
<td>S-9: HCV: New Frontiers and Controversies Room 6E</td>
</tr>
<tr>
<td></td>
<td>Bernard Fields Lecture: Hepatitis C: Light at the End of the Tunnel</td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N’Galy-Mann Lecture: Antiretroviral Therapy: Past, Present, and Future Room 6D</td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Welcome Reception 6:30 PM to 7:30 PM</td>
<td>ORAL ABSTRACT SESSION Room 6D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30 PM</td>
<td></td>
<td>SPECIAL SESSION 6:30 PM to 7:30 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td></td>
<td>Ebola Virus Disease: Responding to the Challenge Room 6E</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>